UNITED STATES OF AMERICA FEDERAL TRADE COMMISSION

In the Matter of

Altria Group, Inc., a corporation,

And

JUUL Labs, Inc., a corporation,

Respondents.

The Honorable D. Michael Chappell Docket No. 9393

MOTION OF NON-PARTY TURNING POINT BRANDS, INC. FOR IN CAMERA TREATMENT OF PROPOSED TRIAL EXHIBITS

Pursuant to Rule 3.45 of the Federal Trade Commission's Rules of Practice, 16 C.F.R. § 3.45(b), non-party Turning Point Brands, Inc. ("Turning Point") respectfully moves for in camera treatment of certain proposed trial exhibits in the above-captioned case. Each proposed trial exhibit (collectively, the "Confidential Documents") contains Turning Point's sensitive, nonpublic business information, the disclosure of which would cause Turning Point serious competitive harm by unfairly advantaging Turning Point's competitors and by providing Turning Point's customers with leverage over Turning Point in negotiations. In support of its motion, Turning Point provides the accompanying declaration of Frank Vignone, Vice President of Sales at Turning Point ("Vignone Declaration" or "Vignone Decl."). A copy of each Confidential Document is attached to the Vignone Declaration.¹

¹ Certain of the Confidential Documents were produced with redactions, which are indicated on the Confidential Documents with the reason for the redaction. If a redaction does not have an explanation, the redacted information is information for which Turning Point seeks in camera treatment.

I. **BACKGROUND**

Turning Point is a manufacturer, marketer, and distributor of products in the smoking accessories and other tobacco products industry, including the RipTide pod-based vaping system, which competes with the pod-based system manufactured by JUUL Labs, Inc. ("JUUL"). Vignone Decl. ¶ 4. Turning Point is not a party to the above-captioned action but, in response to subpoenas issued by JUUL and the FTC, Turning Point produced nearly 1,500 pages of documents. In addition, Turning Point's CEO, Larry Wexler, provided deposition testimony. Turning Point requested confidential treatment for its production and Mr. Wexler's deposition transcript under the Protective Order entered in the above-captioned action. Turning Point provided documents to its attorneys for production in a secure manner to ensure that they were accessible only to the intended recipients. The FTC and Respondents designated five of the documents produced by Turning Point as trial exhibits, along with Mr. Wexler's deposition transcript and declarations submitted by Mr. Wexler and Turning Point's General Counsel, Brittani Cushman. Turning Point requests in camera treatment for limited portions of only three of the documents it produced, the entirety of just one document, and excerpts constituting about two pages of Mr. Wexler's deposition transcript.

FTC does not oppose this motion. Respondents are still considering their position with respect to Turning Point's motion.²

II. LEGAL STANDARD

Evidence is entitled to *in camera* treatment pursuant to Rule § 3.45 (b) if the evidence's "public disclosure will likely result in a clearly defined, serious injury to the ... corporation

² Respondents have requested that a limited number of in-house counsel responsible for this matter have access to in camera sessions in which confidential Turning Point material is discussed and filings related to that material. Respondents and Turning Point continue to discuss that request.

requesting in camera treatment." The FTC recognizes that "[t]he likely loss of business advantages is a good example of a clearly defined, serious injury," In re Hoechst Marion Roussel, Inc., 2000 FTC LEXIS 138, at *6 (Sept. 19, 2000) (internal quotation marks omitted), so courts attempt "to protect confidential business information from unnecessary airing," In re H.P. Hood & Sons, Inc., 1961 FTC LEXIS 368, *12 (Mar. 14, 1961). ALJs have broad discretion in determining what is entitled to in camera treatment. In re Gen. Foods Corp., 95 FTC. 352, 1980 WL 338997, at *2 (Mar. 10, 1980).

To determine whether "disclosure would result in a serious competitive injury, the FTC considers whether the information is "sufficiently secret and sufficiently material ... that disclosure would result in a serious competitive injury." Id. at *4; In re Bristol-Myers Co., 90 FTC 455, 1977 WL 189054, at *1-2, (Nov. 11, 1977). Three of the factors consider the degree to which the materials in question are kept secret (the "Secrecy Factors"): (1) the extent to which the information is known outside of movant's business; (2) the extent to which the information is known by employees and others involved in movant's business; and (3) the extent of measures taken by movant to guard the secrecy of the information. Id. at *2. The other three factors consider the materiality of the information (the "Materiality Factors"): (4) the value of the information to movant and its competitors; (5) the amount of effort or money expended by movant in developing the information; and (6) the ease or difficulty with which the information could be properly acquired or duplicated by others. Id.

The FTC treats requests for *in camera* treatment by non-parties with "special solicitude." In re Kaiser Aluminum & Chem. Corp., 103 FTC. 500, 1984 WL 565325, at *1 (May 25, 1984); In re The Crown Cork & Seal Co., 71 FTC. 1714, 1967 WL 94017, at *1 (1967) ("[P]etitioner's plea warrants special solicitude coming as it does from a third party bystander in no way involved



in the proceedings whose records, if in camera treatment is denied, will be open to the scrutiny of its competitors.").

THE CONFIDENTIAL DOCUMENTS MERIT IN CAMERA TREATMENT III.

Turning Point seeks in camera treatment for the information set forth in the following chart:

In Camera Exhibit Number	Exhibit No.	Document Description	Bates Range	Locations Containing Confidential Information
A-1	PX3133 RX1790	Riptide Product Launch: Sales Training Brand Overview	TPB-JLI-FTC000000108- 154	TPB-JLI-FTC000000130- 135; TPB-JLI-FTC000000138- 141
A-2	PX3134 RX1791	National Account Review 10/23/19	TPB-JLI-FTC000000226- 272	TPB-JLI-FTC000000228; TPB-JLI-FTC000000231; TPB-JLI-FTC000000233; TPB-JLI-FTC000000235 TPB-JLI-FTC000000238; TPB-JLI-FTC000000241; TPB-JLI-FTC000000244- 245; TPB-JLI-FTC000000248- 249; TPB-JLI-FTC000000252- 253; TPB-JLI-FTC000000252- 253; TPB-JLI-FTC000000259; TPB-JLI-FTC000000259; TPB-JLI-FTC000000261- 263; TPB-JLI-FTC0000000265- 272
A-3	PX3135	Playing to Win Highlights	TPB-JLI-FTC000000294- 313	Entire Document
A-4	PX3145	September 2019 IVG Business Presentation	TPB-JLI-FTC000000040- 054	TPB-JLI-FTC000000041- 042
A-5	PX7030 RX0133	Deposition of Larry Wexler	PX7030-001-094	25:10 to 26:15; 152:21 to 153:11

For PX3133/RX1790, PX3134/RX1791, and PX3145, Turning Point seeks in camera treatment only for those slides associated with the Bates numbers or ranges in the right column above. For PX7030/RX0133, Turning Point seeks in camera treatment only for the portions of the transcript identified in the right column above. Each document or portion of a document set forth above contains information that is "sufficiently secret and sufficiently material to [Turning Point's] business that disclosure would result in serious competitive injury" and warrants in camera treatment." See In re Gen. Foods, 1980 WL 338997, at *4.

The Secrecy Factors Support Granting The Confidential Documents In Camera Treatment

The Confidential Documents are sufficiently secret to merit in camera treatment. They are kept confidential in the ordinary course of Turning Point's business and are not disclosed to the public.³ Vignone Decl. ¶¶ 6-9, 11. The information in PX3133/RX1790, PX3134/RX1791, and PX3135 is also not generally available to Turning Point employees; they are saved in a folder on an individual computer and they are not kept on Turning Point's server. Id. ¶ 10. Turning Point has also taken steps to keep the documents confidential in connection with this litigation, designating them confidential under the Protective Order and providing them to Turning Point's attorneys in a secure manner.

Turning Point has strict rules about employee access to and dissemination of sensitive or proprietary information. Turning Point's employees are bound by Turning Point's Code of Business Conduct and Ethics, which they sign upon hiring and which prohibits them from disclosing confidential and proprietary information outside of Turning Point Id. ¶ 12. Similarly, Turning Point's Employee Handbook, which new hires are also required to review, prohibits the

³ PX3133/RX1790 is marked "For Internal Use Only" on each page. Vignone Decl. ¶ 6.



disclosure of "secret, proprietary, [or] confidential" information" to employees without a need to know the information. Id. ¶ 13. These rules apply to the Confidential Documents. Id. ¶ 14.

B. The Materiality Factors Also Support Granting The Confidential Documents In Camera Treatment

All of the documents and information for which Turning Point seeks in camera treatment are highly material to Turning Point, its competitors, and, in some cases, its customers. Disclosure of this information would result in the "loss of business advantages" to Turning Point and is therefore entitled to in camera treatment. In re Hoechst, 2000 FTC LEXIS 138, at *6.

1. PX3133/RX1790

PX3133/RX1790, entitled "Riptide Product Launch: Sales Training Brand Overview" is a PowerPoint presentation developed in 2019 to train Turning Point's sales force to more effectively Vignone Decl. ¶ 6. Pages TPB-JLI-FTC000000130-135 and TPB-JLImarket RipTide. FTC000000138-141 describe detailed short- and long-term marketing plans for the placement of RipTide, including goals for Turning Point's sales force, specific strategies and messaging, and sample prices and discounts. *Id*.

If this information on these pages were disclosed to the public, it would provide competitors with insight into what Turning Point views as the strengths and weaknesses of RipTide compared to its competitors, brand positioning, and pricing, giving an unfair advantage to Turning Point's competitors, who could use this information to tailor their marketing strategies to counter Turning Point's. It would also give customers leverage in negotiations with Turning Point by informing them of Turning Point's specific promotional pricing and sales strategies. See In re Mcwane, Inc., & Star Pipe Prods., Ltd., 2012 WL 5879803, at *1 (FTC Nov. 8, 2012) (granting non-party's motion for in camera treatment of "strategic planning" documents); See In re Polypore

Int'l, Inc., 2009 WL 1499350, at *5 (FTC May 13, 2009) (granting in camera treatment for documents containing "business plans and strategies").

2. PX3134/RX1791

PX3134/RX1791, entitled "National Account Review 10/23/19" is a PowerPoint providing an overview of Turning Point's National Account performance in 2019. Vignone Decl. ¶ 7. There is highly material information throughout this document, which provides, at the retailer level, information about the distribution levels of various Turning Point products (not limited to RipTide), promotional programs that Turning Point is running, upcoming plans, analysis of how Turning Point's programs are performing, and strategies for improving Turning Point's performance, as well as detailed granular data about retailer-specific performance. Id.⁴

This information is highly valuable to Turning Point, its competitors, and its customers. If it were disclosed to the public, it would provide an unfair advantage to Turning Point's competitors because they would be able to understand how Turning Point's products perform at particular chain stores and Turning Point's specific strategies and promotions designed to improve Turning Point's performance, giving them the opportunity to undercut Turning Point in the deals they offer Turning Point's customers. See In re Polypore, 2009 WL 1499350, at *5 (granting in camera treatment for "customer-specific documents" and "documents containing "pricing strategy" and "market analysis"). It would also provide Turning Point's customers with leverage in negotiations with Turning Point because Turning Point's customers would be able to see all the promotions that Turning Point offers other chain stores.

JLI-FTC000000256-257, TPB-JLI-FTC000000259, TPB-JLI-FTC000000261-263, and TPB-JLI-FTC000000265-

This information is located on the slides with the Bates numbers TPB-JLI-FTC000000228, TPB-JLI-FTC000000241, TPB-JLI-FTC000000244-245, TPB-JLI-FTC000000248-249, TPB-JLI-FTC000000252-253, TPB-

3. PX3135

PX3135 is a "Playing to Win" Highlights Document from March 2019, which documents develops in Turning Point's relationships with specific customers. Vignone Decl. ¶ 8. This document is material to Turning Point, its competitors, and its customers because it contains the names and locations of specific retail stores that carry Turning Point's products as well as detailed, granular information about the performance of specific Turning Point products at specific stores, documents changes to the Turning Point products carried by these specific retail stores, and describes meetings between representatives of Turning Point and the retailers at TPB-JLI-FTC000000294-296 and TPB-JLI-FTC000000301-313. Id. If disclosed, this information would advantage Turning Point's competitors in their dealings with these retailers by informing them how Turning Point was performing at particular retailers and about changes to Turning Point's relationships with these retailers. It would provide Turning Point's customers with unfair leverage in negotiations with Turning Point because they would know how Turning Point's products perform at similar retailers as well as promotions or offers Turning Point is providing other retailers. See re Polypore, 2009 WL 1499350, at *5 (granting in camera treatment for "customerspecific documents")

4. PX3145

PX3145 is an example of a presentation, delivered periodically to management, concerning Turning Point's vapor distribution and direct-to-consumer vapor businesses (known as "IVG") and addressing developments in the vapor industry and other information that is relevant to understanding vapor products, including those manufactured and/or distributed by Turning Point. Vignone Decl. ¶ 9. TPB-JLI-FTC000000041-042 contains detailed information about IVG's financial performance, comparing its actual performance to its budget and analyzing, at a granular level, its SG&A expenses, and highly sensitive profits and margin data.



This information is material to Turning Point, its competitors, and its customers because public disclosure of this information would provide Turning Point's competitors with an unfair advantage over Turning Point by allowing them to understand nonpublic information about Turning Point's financial performance, including Turning Point's costs, expenses, and margins. Id. ¶ 9. See In re Polypore, 2009 WL 1499350, at *5 (granting in camera treatment for documents containing "costing data" and "sales and financial information").

5. PX7030-001-094

During his deposition, Mr. Wexler twice referred to plans of Turning Point that are the subject of ongoing and anticipated litigation at 25:10 to 26:15 and 152:21 to 153:11. The information contained in these statements is material and, if disclosed, could harm Turning Point's relationships with business partners and provide competitors with an unfair advantage. Vignone Decl. ¶ 11.

IV. TURNING POINT'S NON-PARTY STATUS WEIGHS IN FAVOR OF **GRANTING IN CAMERA STATUS**

Turning Point's status as a non-party further strengthens its claim for *in camera* treatment of the Confidential Documents. As a non-party, its request deserves "special solicitude." See In re Kaiser Aluminum, 1984 WL 565325, at *1. As the FTC has previously recognized, granting "special solicitude" to third-party requests for in camera treatment "encourages cooperation with future adjudicative discovery requests." Id.

V. **DURATION**

Turning Point seeks in camera treatment for the Confidential Documents for a period of five years. Five years is necessary to protect Turning Point from suffering the competitive injuries it would suffer if the highly sensitive information contained in the Confidential Documents were disclosed. If this information is disclosed sooner, Turning Point will lose the advantages it has

gained from the confidentiality of the information contained in the Confidential Documents. In re

Otto Bock Healthcare N. Am., Inc., 2018 FTC LEXIS 111, at *11 (July 6, 2018) (granting in

camera treatment for five years from time of order to non-party's ordinary business records,

including documents containing product level sales data and pricing information); In re 1-800

Contacts, 2017 FTC LEXIS 55, at *8-10 (Apr. 4, 2017).

VI. CONCLUSION

For the forgoing reasons, Turning Point respectfully requests that the Court grant in camera

treatment of the Confidential Documents for at least five years.

Date: May 7, 2021

Respectfully submitted,

/s/ Mark A. Ford

Mark A. Ford

Katherine V. Mackey

Gary B. Howell-Walton

WILMER CUTLER PICKERING

HALE AND DORR LLP

60 State Street

Boston, MA 02109

(617) 526-6000

mark.ford@wilmerhale.com

katherine.mackey@wilmerhale.com

gary.howell-walton@wilmerhale.com

Counsel for Turning Point Brands, Inc.

10

UNITED STATES OF AMERICA FEDERAL TRADE COMMISSION OFFICE OF ADMINISTRATIVE LAW JUDGES

In the Matter of

Altria Group, Inc., a corporation,

Docket No. 9393

And

JUUL Labs, Inc., a corporation

Respondents.

[PROPOSED] ORDER GRANTING MOTION OF NON-PARTY TURNING POINT BRANDS FOR IN CAMERA TREATMENT OF PROPOSED TRIAL EXHIBITS

On May 7, 2021, non-party Turning Point Brands, Inc. ("Turning Point") moved for in camera treatment of certain proposed trial exhibits. Upon consideration, the Motion is GRANTED and it is hereby ORDERED that the following documents are provided with in camera treatment under 16 C.F.R. § 3.45(b) for five years from the date of this order.

Exhibit No.	Document Description	Bates Range	Locations Containing Confidential Information
PX3133	Riptide	TPB-JLI-FTC000000108-154	TPB-JLI-FTC000000130-135;
RX1790	Product		TPB-JLI-FTC000000138-141
	Launch: Sales		
	Training Brand		
DX/2124	Overview	TDD H I FTC000000227 272	TDD 11 1 ETC000000229
PX3134	National	TPB-JLI-FTC000000226-272	TPB-JLI-FTC000000228 TPB-JLI-FTC000000231;
RX1791	Account		TPB-JLI-FTC000000231;
	Review 10/23/19		TPB-JLI-FTC000000235
	10/23/19		TPB-JLI-FTC000000238;
			TPB-JLI-FTC000000241;
			TPB-JLI-FTC000000244-245;
			TPB-JLI-FTC000000248-249;
			TPB-JLI-FTC000000252-253;
			TPB-JLI-FTC000000256-257;
			TPB-JLI-FTC000000259;

			TPB-JLI-FTC000000261-263; TPB-JLI-FTC000000265-272
PX3135	Playing to Win Highlights	TPB-JLI-FTC000000294-313	Entire Document
PX3145	September 2019 IVG Business Presentation	TPB-JLI-FTC000000040-054	TPB-JLI-FTC000000041-042
PX7030 RX0133	Deposition of Larry Wexler	PX7030-001-094	25:10 to 26:15; 152:21 to 153:11

O	R]	D'	Εl	R1	E	D	:

The Honorable D. Michael Chappell Chief Administrative Law Judge

Date: May [], 2021



UNITED STATES OF AMERICA FEDERAL TRADE COMMISSION

In the Matter of

Altria Group, Inc., a corporation,

And

JUUL Labs, Inc., a corporation,

Respondents.

The Honorable D. Michael Chappell

Docket No. 9393

PROOF OF SERVICE OF PUBLIC FILING AND CERTIFICATION PURSUANT TO 16 C.F.R. § 4.2

I, Mark A. Ford, hereby certify that on May 7, 2021, I served a copy of Non-Party Turning Point Brands, Inc.'s Motion for In Camera Treatment, supporting declaration of Frank Vignone, and Proposed Order electronically via email and the Office of the Secretary's electronic filing system to:

April Tabor Acting Secretary Federal Trade Commission 600 Pennsylvania Avenue, NW, Room H-113 Washington, DC 20580 secretary@ftc.gov

And pursuant to ¶ 1 of the Scheduling Order in the above-captioned matter by email to:

The Honorable D. Michael Chappell Chief Administrative Law Judge Office of Administrative Law Judges 600 Pennsylvania Avenue, NW, Room H-110 Washington, DC 20580

And pursuant to ¶ 2 of the Scheduling Order in the above-captioned matter by email to Complaint Counsel and counsel of record for the Respondents:

James Abell jabell@ftc.gov Dominic Vote dvote@ftc.gov Peggy Bayer Femenella pbayer@ftc.gov

Erik Herron eherron@ftc.gov

Joonsuk Lee ilee4@ftc.gov Meredith Levert

mlevert@ftc.gov Kristian Rogers

krogers@ftc.gov **David Morris**

dmorris1@ftc.gov Michael Blevins

mblevins@ftc.gov Michael Lovinger

mlovinger@ftc.gov Frances Anne Johnson

fjohnson@ftc gov

Jennifer Milici

imilici@ftc.gov Nicole J. Lindquist

nlindquist@ftc.gov

Jeanine K. Balbach jbalbach@ftc.gov

Federal Trade Commission 600 Pennsylvania Avenue, NW

Washington, DC 20580

Complaint Counsel

David Gelfand dgelfand@cgsh.com

Jeremy Calsyn

icalsyn@cgsh.com

Jessica Hollis

jhollis@cgsh.com

Matthew Bachrack

mbachrack@cgsh.com

Linden Bernhardt

lbrenhardt@cgsh.com

Cleary Gottlieb Steen & Hamilton LLP

2112 Pennsylvania Avenue NW

Washington, DC 20037

Counsel for Respondent Juul Labs, Inc.

Debbie Feinstein

debbie.feinstein@arnoldporter.com

Robert Katerberg

robert.katerberg@arnoldporter.com

Justin Hedge

justin.hedge@arnoldporter.com

Francesca Pisano

francesca.pisano@arnoldporter.com

Le-Tanya Freeman

tanya.freeman@arnoldporter.com

Adam Pergament

adam.pergament@arnoldporter.com

David Kouba

david.kouba@arnoldporter.com

Arnold & Porter Kaye Scholer LLP

601 Massachusetts Avenue NW

Washington, DC 20011

Marc Wolinsky

MWolinsky@wlrk.com

Jonathan Moses

JMMoses@wlrk.com

Kevin Schwartz

KSchwartz@wlrk.com

Adam Goodman

ALGoodman@wlrk.com

Wachtell, Lipton, Rosen & Katz

51 West 52nd Street

New York, NY 10019

Beth Wilkinson bwilkinson@wilkinsonstekloff.com James Rosenthal jrosenthal@wilkinsonstekloff.com J.J. Snidow jsnidow@wilkinsonstekloff.com Wilkinson Stekloff LLP 2001 M Street NW, 10th Floor Washington, DC 20036

Moira Penza mpenza@wilkinsonstekloff.com Wilkinson Stekloff LLP 130 W 42nd Street, 24th Floor New York, NY 10036

Counsel for Respondent Altria Group, Inc.

/s/ Mark A. Ford

UNITED STATES OF AMERICA FEDERAL TRADE COMMISSION

In the Matter of

Altria Group, Inc., a corporation,

And

JUUL Labs, Inc., a corporation,

Respondents.

The Honorable D. Michael Chappell

Docket No. 9393

DECLARATION OF FRANK VIGNONE IN SUPPORT OF NON-PARTY TURNING POINT BRANDS, INC.'S MOTION FOR IN CAMERA TREATMENT OF PROPOSED TRIAL EXHIBITS

- 1. I am Vice President of Sales at Turning Point Brands, Inc. ("Turning Point"), nonparty in the above-captioned proceeding. In this role I am responsible for the strategic development, direction and execution of Turning Point's sales organization including field sales, retail and wholesale national accounts, trade marketing, and customer service. I have worked at Turning Point since January 2018 and prior my current position I was the Senior Director of National Accounts, responsible for developing and leading go to market strategies, training, development and advancement for our national accounts team.
- 2. I am familiar with the documents forming the subject of the instant motion (the "Confidential Documents"). Turning Point produced these documents in response to subpoenas issued by the FTC and JUUL Labs, Inc. in the above-captioned proceedings. True and Correct copies of the Confidential Documents are attached as Exhibits A1-A5.



- 3. I have personal knowledge of the following facts, with the exception of the facts contained in Paragraphs 12 and 13, which I believe to be true on information and belief based on my investigation.
- 4. Turning Point is a manufacturer, marketer, and distributor of products in the smoking accessories and other tobacco products ("OTP") industry. The OTP industry consists of non-cigarette products, and Turning Point has three focus segments in this industry: the Zig-Zag® Products segment, which primarily includes rolling papers and cigarette wraps; the Stoker's® Products segment, which includes moist snuff and chewing tobacco; and the NewGen Products segment, which includes a Turning Point subsidiary dedicated to alternative products (including CBD and nutraceuticals), Turning Point's vape distribution business, and certain hemp and cannabis products. Among Turning Point's NewGen products is the RipTide pod-based vaping system, which competes with JUUL.
- 5. Turning Point's primary competitors are significantly larger and have more resources, and impose continuing competitive pressure on Turning Point. Turning Point must therefore compete aggressively to ensure that its products are available to consumers and are competitively priced. I know from my experience at Turning Point that information about Turning Point's customers, sales strategies, marketing plans, and finances is highly valuable both to Turning Point's competitors and its customers, and the disclosure of such information would unfairly advantage Turning Point's competitors and would provide Turning Point's customers with leverage over Turning Point in negotiations.
- 6. PX3133/RX1790 is a PowerPoint presentation that was developed in 2019 to train Turning Point's sales force to more effectively market RipTide. This document is kept confidential in the ordinary course of Turning Point's business and is marked "For Internal Use Only" on each

page. It has not been disclosed to the public. This document provides an overview of RipTide's distinguishing features, pricing, competitors, and sales and marketing plans. In particular, the pages numbered TPB-JLI-FTC000000130-135 and TPB-JLI-FTC000000138-141 describe detailed short- and long-term marketing plans for the placement of RipTide in independent retail stores. These slides describe goals for Turning Point's sales force, detail specific strategies and messaging, and provide sample pricing for RipTide products, including discounts. Although these plans were introduced to the sales force in 2019, they are similar to the plans that Turning Point uses today. If information on these pages were disclosed to the public, it would provide an unfair advantage to Turning Point's competitors, who could alter their marketing strategies, pricing, and messaging to specifically counter Turning Point. Moreover, insight into Turning Point's specific promotional pricing and sales strategies would give customers leverage in negotiations with Turning Point.

7. PX3134/RX1791 is a PowerPoint that provides an overview of Turning Point's National Account performance in 2019. It is kept confidential in the ordinary course of business and has not been disclosed to the public. It provides information about the distribution levels of various Turning Point products at each retailer, promotional programs that Turning Point is running with each retailer, upcoming plans for each retailer, analysis of how Turning Point's programs are performing at each retailer, and strategies for improving Turning Point's performance with each retailer. This information is contained on the slides with the Bates numbers TPB-JLI-FTC000000228, TPB-JLI-FTC000000231, TPB-JLI-FTC000000233, TPB-JLI-FTC000000235, TPB-JLI-FTC000000238, TPB-JLI-FTC000000241, TPB-JLI-FTC000000244-245, TPB-JLI-FTC000000248-249, TPB-JLI-FTC000000252-253, TPB-JLI-FTC000000256-257, TPB-JLI-FTC000000259, and TPB-JLI-FTC000000261-263. The presentation also contains

detailed, granular data analyzing how Turning Point's different products have performed with each retailer at TPB-JLI-FTC000000265-272. If this information were disclosed to the public, it would provide an unfair advantage to Turning Point's competitors because they would be able to understand how Turning Point's specific products perform at specific chain stores and Turning Point's specific strategies and promotions designed to improve Turning Point's performance, giving them the opportunity to undercut Turning Point in the deals they offer Turning Point's customers. It would also provide Turning Point's customers with leverage in negotiations with Turning Point because Turning Point's customers would be able to see all the promotions that Turning Point offers other chain stores that sell Turning Point's products.

8. PX3135 is a "Playing to Win" Highlights Document from March 2019. Turning Point creates these documents periodically to document customer-specific developments. It is kept confidential in the ordinary course of business and has not been disclosed to the public. It contains the names and locations of specific retail stores that carry Turning Point's products, documents changes to the Turning Point products carried by these specific retail stores, and describes meetings between representatives of Turning Point and the retailers at TPB-JLI-FTC000000294-296 and TPB-JLI-FTC000000301-313. It also contains detailed, granular information about the performance of specific Turning Point products at specific stores at TPB-JLI-FTC000000297-300. The information in this document, if disclosed to the public, would provide Turning Point's competitors with an unfair advantage over Turning Point by providing them with granular information about Turning Point's performance at particular retailers and incremental improvements that Turning Point has made at these retailers over time. It would provide retailers with leverage in negotiations with Turning Point because it would inform them of how Turning

Point's products perform at other, similar retailers, and would give them information about promotions that Turning Point is offering to other retailers.

- 9. PX3145 is a presentation concerning Turning Point's vapor distribution and directto-consumer vapor businesses (referred to internally as "IVG"). These presentations are delivered periodically to Turning Point's management and inform management of developments in the vapor industry and the performance of Turning Point's vapor business and provide other information that is relevant to understanding vapor products, including those manufactured and/or distributed by Turning Point. These presentations are kept confidential in the ordinary course of business and have not been disclosed to the public. This presentation contains detailed information about IVG's financial performance, comparing its actual performance to its budget and analyzing, at a granular level, its SG&A expenses, and highly sensitive profits and margin data at TPB-JLI-FTC000000041-042. Public disclosure of this information would provide Turning Point's competitors with an unfair advantage over Turning Point because it would allow them to understand nonpublic information about Turning Point's financial performance, including Turning Point's costs, expenses, and margins.
- 10. I keep PX3133/RX1790, PX3134/RX1791, and PX3135 saved to my computer. They are not saved on Turning Point's server or otherwise made generally available to the employees of Turning Point.
- I have reviewed portions of the deposition of Larry Wexler, Turning Point's 11. President and Chief Executive Officer. In the portion of the deposition from 25:10 to 26:15 and 152:21 to 153:11, Mr. Wexler testifies about specific but significant non-public strategic plans. These plans have no bearing on the issues in this case but are nevertheless highly sensitive. If those specific plans become public, it may significantly impact Turning Point's relationships with

business partners and provide competitors unfair competitive advantage. Turning Point has kept the plans described in this portion of Mr. Wexler's transcript highly confidential—they are not publicly disclosed and they are only communicated to Turning Point employees on a strict "need to know" basis.

- 12. The importance of not disclosing confidential information is emphasized within Turning Point. When hired, it is my understanding that it is standard practice for new Turning Point employees to sign Turning Point's Code of Business Conduct and Ethics, which prohibits employees from disclosing confidential or proprietary information outside of Turning Point. This prohibition extends to "all non-public information that might be of use to competitors or harmful to [Turning Point] or its customers, if disclosed, as well as "information that suppliers and customers have entrusted [Turning Point]" and "information about [Turning Point's] financial condition, prospects or plans, its marketing and sales programs and research and development information."
- 13. It is my understanding that it is also standard practice for newly hired Turning Point employees to sign an acknowledgement that they have read Turning Point's Employee Handbook, which provides that "secret, proprietary, confidential, or attorney-client privileged information will not be disclosed to external parties or employees without a 'need to know.' Such information includes, but is not limited to, business information related to our clients and information regarding the development of systems, processes, products, know how, technology, or other internal business-related communications."
- 14. The portions of the documents and transcript described above are each considered confidential and proprietary and are subject to these confidentiality restrictions spelled out in the Code of Business Conduct and Employee Handbook.

I declare under penalty of perjury that the foregoing is true and correct. Executed on April 30, 2021.

FEDERAL TRADE COMMISSION | OFFICE OF THE SECRETARY | FILED 05/07/2021 | Document No. 601358 | PAGE < Page 0F23 *Public* DocuSign Envelope ID: 70050AE0-BBAE-4894-B39B-7CFA4EB6C11D

Docusigned by:
Frank Vignore
435225ED69FF4DB...

Frank Vignone

PUBLIC EXHIBITA-1 PX3133 RX1790







FIDE TIAL - FT Docket o. 9393

Next Generation Nicotine Experience

RipTide®, powered by NicTech™, is an innovative and intensely satisfying nicotine experience, providing cleaner, crisper flavor, and a smoother-than-salt draw.

What is NicTech™

Breakthrough Nicotine Technology

A proprietary breakthrough in nicotine technology, NictechTM provides heightened nicotine satisfaction and a neutral taste palate, free of organic, lactic and benzoic acids (nic salts).

What is a RipStick™

A proprietary device / battery designed to maximize the RipTide $^{\rm @}$ POD experience.

FOR INTERNAL USE ONLY ©2019

Riptide PRODUCT LAUNCH - SALES TRAINING & BRAND OVERVIEW

FIDENONIAL - FT Docket No. 99

				1	
NCTECH	TBD NG / ML	SMOOTH	ON	ON	th less
SALT NICOTINE	2 NG / ML	HARSH	YES	YES	ves more wi
TRADITIONAL VAPOR NICOTINE	1 NG / ML	HARSH	ON	YES	Nictech achieves more with less
COMBUSTIBLE	5 NG / ML	HARSH	YES	YES	KTA: N
	NICOTINE IMPACT IN FIRST MINUTE	SMOOTHNESS	BENZOIC ACID (NICOTINE SALT)	TOBACCO BASED NICOTINE	



Riptide Flavors

All of our e-liquids are powered by NicTech, and designed to work optimally with the RipStick. These pods have a large, 1.4ml capacity, and are available in 2.4% and 5.0% NicTech Strengths.



A crisp, clean, and incredibly refreshing blend of hearty tobacco notes accented with the perfect touch of cooling menthol.

Experience all of the bold, face-puckering flavor of the world's most elusive fruit: the beautiful blue raspberry. Experience the best part of Saturday morning with this tart-andtangy mixed fruit cereal inspired masterpiece.

A daiquiri inspired blend of fresh coconut, ripe Georgia peaches, and supremely scrumptious strawberries.

KTA: 5 great flavors; mango in the works





Riptide PRODUCT LAUNCH - SALES TRAINING & BRAND OVERVIEW

Riptide Pods




KTA: 5 styles; 2 nic strengths

Riptide PRODUCT LAUNCH - SALES TRAINING & BRAND OVERVIEW

NICTECH

FIDENMIAL - FT Docket No. 9393





TPB-JLI-FT





Point of Sale Materials







KTA: POS is available now.

FOR INTERNAL USE ONLY ©2019

Riptide PRODUCT LAUNCH — SALES TRAINING & BRAND OVERVIEW

FIDENOIAL - FT Docket No. 9393

Point of Sale Materials









3 Tier Display

Trial Tips



KTA: More POS to come

FOR INTERNAL USE ONLY ©2019

Riptide PRODUCT LAUNCH - SALES TRAINING & BRAND OVERVIEW



Merchandising



KTA: Solutions to meet retailer needs

16-3/4"

11-1/4"

5-3/4"

2-1/8"

13-5/8"

8-1/8"

N/A

10″

10″

9 3/4"

Depth (front - back)

Height with Header

Height w/o header

10″

19"

FOR INTERNAL USE ONLY © 2019

Riptide PRODUCT LAUNCH - SALES TRAINING & BRAND OVERVIEW

ONFIDENTIAL - FT Docket No. 9393

FEDERAL TRADE COMMISSION | OFFICE OF THE SECRETARY | FILED 05/07/2021 | Document No. 601358 | PAGE < Page 6125 *Public*



List Pricing

SSS		LBS		LBS	4.15 LBS	LBS	4.15 LBS	LBS		4.15 LBS	LBS	4.15 LBS	LBS	4.15 LBS
GROSS		5.41 LBS		4.15 LBS	4.15	4.15 LBS	4.15	4.15 LBS		4.15	4.15 LBS	4.15	4.15 LBS	4.15
CASE		10/5's		20/2 _S	20/2 _S	20/2 _S	20/2 _S	20/2 _S		20/2 _S	20/2 _S	20/2 _S	20/2:S	20/5'S
UNIT		\$7.00		\$1.85	\$1.85	\$1.85	\$1.85	\$1.85		\$1.85	\$1.85	\$1.85	\$1.85	\$1.85
CARTON		\$35.00		\$9.25	\$9.25	\$9.25	\$9.25	\$9.25		\$9.25	\$9.25	\$9.25	\$9.25	\$9.25
CASE		\$350.00		\$185.00	\$185.00	\$185.00	\$185.00	\$185.00		\$185.00	\$185.00	\$185.00	\$185.00	\$185.00
UNIT UPC		9 0059		6181 7	61848	61879	6193 0	6199 2		6229 6	6232 6	6235 7	62418	6247 0
CARTON		6502 0		6182 4	6185 5	6188 6	6194 7	6200 5		6230 2	6233 3	6236 4	6242 5	6248 7
CASE		6504 1		61838	61869	6189 0	6195 1	6201 9		6231 6	6234 7	6237 8	6243 9	6249 1
PKG IND & MFG's UPC		1 08 404391		1 08 404391	1 08 404391	1 08 404391	1 08 404391	1 08 404391		1 08 404391	1 08 404391	1 08 404391	1 08 404391	1 08 404391
PRODUCT	RIPTIDE® TFN VAPOR POD SYSTEM BATTERY	RIPTIDE® RIPSTICK TFN BLACK BATTERY KIT	RIPTIDE® TFN VAPOR PODS 2.4%	RIPTIDE® TFN POD BRIGHT LEAF TOBACCO 2.4%	RIPTIDE® TFN POD MINT 2.4%	RIPTIDE® TFN POD BLUE RASPBERRY 2.4%	RIPTIDE® TFN POD BERRY CRUNCH 2.4%	RIPTIDE® TFN POD TROPICAL 2.4%	RIPTIDE® TFN VAPOR PODS 5.0%	RIPTIDE® TFN POD BRIGHT LEAF TOBACCO 5.0%	RIPTIDE® TFN POD MINT 5.0%	RIPTIDE® TFN POD BLUE RASPBERRY 5.0%	RIPTIDE® TFN POD BERRY CRUNCH 5.0%	RIPTIDE® TEN POD TROPICAL 5.0%
ITEM#	RIPTIDE®	16504	RIPTIDE® T	16183	16186	16189	16195	16201	RIPTIDE® T	16231	16234	16237	16243	16249

POD System Typical Consumer Retail Pricing

Consumer Pricing \$10.98+ tax * Currently, only known \$.99 Intro pricing being \$9.99 \$0.99 **ACE DEVICE INTRO PRICING*** Consumer Pricing NJOY ACE ACE Device Kit (device only) ACE 2pk 1.9ml POD ACE Device Kit Intro Price Net Consumer Trial Price(with Pod Pk Purchase) offered in WAWA stores.

	RIPTIDE RIPSTICK (device only)	\$12.99
	RIPTIDE 1pk 1.4ml POD	\$3.99
-	RIPSTICK DEVICE INTRO PRICING*	RICING*
J ,≅	RIPSTICK Device Intro Price	\$0.99
STICK	Net Consumer Trial Price(with Pod Pk Purchase)	\$4.98+ tax
리된	* Intro offer for all Chains/Independents with	ents with
	relevant Juul/ E-Category volume.	
	Innf	
	Consumer Pricing-Varied by Store/Market	tore/Market
	JUUL Starter Kit (device w/ 4 pods)	\$29.99 - \$59.99
	JUUL Device Kit (battery only)	\$17.99 - \$19.99
	JUUL 4pk .7ml POD	\$14.99 - \$17.99
	JUUL 2pk .7ml POD	\$9.99
	JUUL INTRO PRICING*	6 *
	JUUL Starter Kit TPR	\$29.99
	Not Consumer Trial Drice/with	

\$9.99-\$19.99

My Blu Starter Kit (device w/ 4 pods)

My Blu Device Kit (battery only)

Consumer Pricing-Varied by Store/Market

My BLU

\$8.99-\$9.99

My Blu 2pk 1.5ml POD

MY BLU INTRO PRICING*

Net Consumer Trial Price (with

Pod Pk Purchase)

couponing for discounted device.

LEAP

			-					_	
Juul	Consumer Pricing-Varied by Store/Market	JUUL Starter Kit (device w/ 4 pods) \$29.99 - \$59.99	JUUL Device Kit (battery only) \$17.99 - \$19.99	JUUL 4pk.7ml POD \$14.99 - \$17.99	JUUL 2pk .7ml POD \$9.99	JUUL INTRO PRICING*	JUUL Starter Kit TPR \$29.99	Net Consumer Trial Price(with \$29.99+ tax Pod Pk Purchase)	* \$29.99 Starter Kit reflective of JUUL Kit Buydown. Everyday pricing ranging \$39.99-\$59.99 FOR INTERNAL USE ONLY

VUSE ALTO

RIPTIDE


Consumer Pricing

ALTO KIT (device w/ 1 pod)	\$19.99-\$29.99
ALTO 2pk 1.8ml POD	\$13.49
ALTO INTRO PRICING*	NG*
ALTO Kit Intro Price	\$19.99
Net Consumer Trial Price(with Pod Pk Purchase)	\$19.99+ tax
* Currently seeing kit in chains at \$19.99, potential \$10.00 buydown. No known other current store intro, but rumored RAI direct to consumer	\$19.99, potential er current store onsumer

		10000
	Consumer Pricing-Varied by Store/Market	store/Market
	LEAP Starter Kit (device w/ 1 pod)	\$12.69-\$19.99
	LEAP 2pk 1.5ml POD	\$6.89-\$7.99
ì		
	LEAP INTRO PRICING*	NG*
-	LEAP Starter Kit	\$12.69 - \$19.99
	Net Consumer Trial Price(with Pod Pk Purchase)	\$12.69-\$19.99
ī	* Given current entrance to market, no current	et, no current
	information on potential intro offering for LEAP.	fering for LEAP.
	Anticipate some form of deep TPR near future.	R near future.

Q3-Q4 2018. Currently seeing regular retail pricing to * Known \$.99 My BLU ran in random retail locations

consumers at retail. (\$19.99 Kit price)



FIDENOIML - FT Docket No. 9 9

TPB-JLI-FT

Riptide-In Store Offering

Below is breakdown of Riptide Allowances.

				M JA
Details	10 Free \$.99 sniped Battery Trial Offer Units to Store. \$30.00 Display Merch Payment. Store Must Take 30 POD Packs at full list with Placement of RT Display. (goal 3 of each flavor/nic strenght)	10 Free \$.99 sniped Battery Trial Offer Units to Store. \$15.00 Display Merch Payment. Store Must Take min 20 POD Packs at full list with Placement of RT Display.	5 Free \$.99 sniped Battery Trial Offer Units to Store. \$10.00 Display Merch Payment. Store Must Take min 20 POD Packs at full list with Placement of RT Display.	\$2.00 Off Battery Carton, \$1.00 Off Pod Cartons. \$5.00 Display Allowance
Max Promo Allowance Type	Full Deal	Half Deal	Mini Deal	Distribution Allowance
Store Type	Selling 10+ Juul Pod Packs/E-Cat Total Units 50+ PW	Selling 5+ Juul Pod Packs/E-Cat Total Units 25+ PW	Selling Juul Pods at less that 5 4pks PW	Selling E-Cat 10+ Total Units PW

FEDERAL TRADE COMMISSION | OFFICE OF THE SECRETARY | FILED 05/07/2021 | Document No. 601358 | PAGE < Page 0+23 C *Public*

Riptide in Store Offering/Execution

The Merchandising/Display Credit can be found in the Riptide
Category on the distribution screen, at the bottom of the list. To enter
a Credit, click RETURNS next to this item under the Sales column:

	Sales	✓ Returns
	>	
	No	
IPTIDE -	ISPLAY/MERCHANDISING	CREDIT

ALY

TPB-JLI-FT

NAL USE ONLY

ONFIDENTIAL - FT Docket No. 9 9

- 1. Retailer reception to RipTide device and liquid? 1-4
- (1 = No, 2 = Interested but not at this time, 3 = Hesitant but eventually accepted, 4 = No objections, happy to accept)
- 2. Additional Comments
- 3. Any consumer feedback observed while in store?
- 4. Greatest objection to overcome?
- 5. If you overcame, how did you do so?
- 6. Which distribution deal did you use, if any? (None, Full, Half, Mini, Distribution Allowance)

FOR INTERNAL USE ONLY

Retail Profit Calculator

		\$30.00 Full Deal \$98.52 Profit	Total Potential \$63.98 Half Deal Profit	Total Potential \$10.00 Mini \$54.03 Deal Profit	allowance
	Frofit 5 Margin % Mark Up % \$5.29 40.72% 68.70% \$1.95 48.97% 95.97%	Potential Display Merchandis e Payment	Potential Display Merchandis e Payment	Potential Display Merchandis e Payment	\$2.00 off Rip Stick Carton and \$1.00 off Pod Cartons. \$5.00 Display allowance
<u> </u>	Margin % 40.72% 48.97%	\$9.90	\$9.90	\$4.95	Cartons.
RIP TIDE	Profit \$ \$5.29 \$1.95	Rip Stick Profit (10 @\$0.99)	Rip Stick Profit (10 @\$0.99)	Rip Stick Profit (5 @\$0.99)	.00 off Pod
坖	\$12.99 \$3.99	\$58.62	\$39.08	\$39.08	ton and \$1.
	Cost/pk \$7.70 \$2.04	Potential Pod Profit	Potential Pod Profit	Potential Pod Profit	p Stick Car
	Cost/ctn Cost/pk \$38.50 \$7.70 \$10.18 \$2.04	\$61.08	\$40.72	\$40.72	:2.00 off Ri
	Cost/ctn RIP STICK (Battery Pac \$38.50 PODS \$10.18	Initial Investment Full Deal = 6 ctns of different pods at full price	Initial Investment Half Deal = 4 ctns of different pods at full price	Initial Investment Mini Deal = 4 ctns of different pods at full price	Distribution allowance \$

FEDERAL TRADE COMMISSION | OFFICE OF THE SECRETARY | FILED 05/07/2021 | Document No. 601358 | PAGE < Page 01-28 > *Public*

B2B Trade Samples

TSMs Only - TSMs may expense a Ripstick & Individual Pods from their van stock for B2B purposes. Max 1 Ripstick & 2 Individual Pods per decision maker.

	Q	(a)	>
2/23/2019		Expense Type: Samples-Trade Riptide REMEMBER TO CHANGE PAYMENT TYPE Notes:	Cash / Personal Credit Card ☑ 0.00
Expense Date:*	Customer.:	Expense Type:* REMEMBER TO CHA	Payment Type: Reimbursable: Amount:

FOR INTERNAL USE ONLY

FIDENOIAL - FT Docket No. 9393

- What Makes Riptide Different
- Powerful battery-> What does a higher MAH(milliamp hours) battery mean?
- Simply put, the higher the MAH's the more usage a customer has with the battery before they need to recharge it.
- Each time a user puff's, the same amount of battery power is used to create vapor. With a stronger battery the user gets more puff's out of that battery before needing to charge.
- ٠ Our Ripsticks and PODS have been designed specifically to generate the perfect amount of vapor with each puff of Riptide
- Flavor Assortment-> Adult consumers enjoy vaping both traditional tobacco/mint flavors as well as a variety
- We engage with 1000's of verified adult consumers on our strictly age gated websites daily, and flavor availability are an important factor to them as they look for an alternative to combustible cigarettes.
- By offering quality tobacco, mint and other flavors we provide the best opportunity for cigarette consumers to try a vape
- Simply put, adult consumers want a liquid that tastes good. For some that is a tradition tobacco taste, for others it is a flavor.
 - Retailers offering a selection of traditional and flavored POD's allows them to meet the full share of requirements of the adult consumers entering their store looking for cigarette alternative.
- Nictech-> Consumers are looking for vape products that satisfy. Brands such as Juul grew by offering product that understood and delivered what consumers wanted. Riptide takes that to a new level:
- process to accomplish a cleaner, crisper flavor experience without creating the harshness a consumer gets from vaping nicotine salts. (like Coke or KFC's 11 herbs and spices we cant tell you what that trade secret is, but it is just a simple change Simply put, Nictech is our proprietary process developed for our e-liquid to maximize the products overall satisfaction. Unlike competitors using nicotine salts (the addition of Benzoic or other Acids to their liquid), we have just created a simple to make our liquid superior
- Nictech provides the consumer with a higher level of satisfaction using less nicotine. This is why we offer both a 5% and 2.4% nic strength. Many consumers using a competitor's 5%+ e-liquid will find that they only need to use our 2.4% to

FOR INTERNAL USE ONLY

Tobacco Derived Nicotine

- Tobacco derived nicotine, as the name implies, is extracted from tobacco by one of several methods including extractions with either water, organic solvents, or supercritical fluids or some combination thereof. The tobacco is placed into one of these liquids and the cellulose, chlorophyll and other plant materials are removed. The resulting material is then processed and distilled prior to purification to obtain USP grade nicotine. All of these methods allow for some of the minor tobacco constituents, e.g. nitrosamines, to be carried into the final product, albeit at trace levels.
- The resulting USP nicotine is then used for tobacco products, e.g. vapor products, and pharmaceutical nicotine replacement products.

Synthetic Nicotine

- Synthetic nicotine is chemically the same molecule as tobacco derived nicotine but it is not obtained from a biological source like tobacco. Synthetic nicotine is made from chemically derived raw materials and is produced in a manufacturing plant similar to the production of pharmaceuticals. Raw materials are sourced from reliable suppliers and a series of chemical reactions occur in a controlled environment to create the product. One of the major advantages of synthetic nicotine is that it is free of the other tobacco constituents that are present in tobacco derived nicotine. Synthetic nicotine is also made to the USP standard.
- It is important to note that nicotine, whether tobacco derived or synthetic, has the same chemical and physical properties.

FEDERAL TRADE COMMISSION | OFFICE OF THE SECRETARY | FILED 05/07/2021 | Document No. 601358 | PAGE CAUCHY Public*

Key Riptide Selling Points/Simple Answers

- What Makes Riptide Different
- Nictech is not about synthetic (tobacco free) nicotine
- The use of Tobacco Free Nicotine in our Riptide liquid is not a selling attribute to the product since nicotine is nicotine regardless of where it comes from
- Why we use Tobacco Free Nicotine verse Tobacco Based?
- Innovation
- Nicotine in its purest form
- No agricultural by-products
- No nitrosamines
- More expensive, but worth every penny more
 - Privileged

FOR INTERNAL USE ONLY

TPB-JLI-FT

Key Riptide Selling Points/Simple Answers

What Makes Riptide Different

- Lower Cost of consumer entry for Riptide, More transactions and Higher **GM%** for retailer
- Unlike many other products on the market where a consumer has to spend upward of \$30.00 to purchase a kit and try a POD system, we understand that making Riptide less cost prohibitive to a customer is important to both the consumer and the retailer.
- By having an aggressive list price driving a highly competitive retail price for the consumer, we allow a consumer to engage with Riptide without having to break the bank.
 - Even with our lower list, our SRP gives the retailer an higher GM% than competitors. To be successful retailers need to understand that not only is Riptide an excellent value for consumers, our \$3.99 PODS allow them to make 48%+ on each sale. Every consumer that switched from a pack of cigarettes to a Riptide POD increases the penny profit for that
- Since we sell our POD's in single units, we are increasing the number of times a consumer enters a retailer to purchase them. This not only brings a customer into their store for Riptide, but also for other items they buy at that store.

How should I present Riptide?-Pre call Planning

- Do your pre-call homework:
- What is the volume of the store you are calling on? Is it a Full Deal, Half Deal etc store.
- In your van, pre-pack the type of display you are presenting. Load it up with the right mix of POD's(both nic strengths) and \$.99 Trial Batteries based on store type.(put the \$.99 stickers on the batteries in van)
- of the investment will be as/more important than even the attributes of the product. Our top volume retailers will be able to bring in a full complement of Riptide with trial batteries for as low as \$31.00. This is for a retail value in product of over \$129.00 and penny profit in excess of \$58.00. Make sure you know the cost of the display and revenue/margin the store will be making off the display. Use the retail profit calculator to determine. For many retailers, what they make
- Make sure you have the POS items in hand you want to sell in with the product. This should
- Trial offer danglers(2- one for display and a second for transaction counter)
 - Stryene sign to use as a secondary zone 2 interruption item
- Counter mat for transaction counter(and DOB calendar when avail)
- At least one type of window/door item
- Larger exterior sign(coreplast/ballard)

FOR INTERNAL USE ONLY

- How should I present Riptide?-Selling in the Store
- First, do your overall store audit. They will see the display, which may open up questions on their part but more importantly you should be asking them questions about how the category is performing in their store.
- What are their top sellers and why?
- Do they have Juul?
- If so do they still have Juul flavors?
- One question/rebuttal they will most likely have is where will the display fit? If they don't have Juul flavors what did losing them do to their business?
- Part of your audit is to assess the stores back-bar situation and look for the recommendation of where Riptide display should go BEFORE presenting to the retailer.
- This may require some re-setting of the store to maximize visibility. When auditing determine where the ideal space for the display is, and what steps/merchandising solution you may need to perform to make that happen.
- Once you determine all the above, when you present Riptide also present the merchandising solution at the same time. This will help both answer that rebuttal prior to them asking and allow you to quickly move to execution of the product once accepted.

J

- How should I present Riptide?-Selling in the Store
- Sell using all the Riptide financial and product info. Keep it simple:
- Let the retailer see a device and hold it.
- Go ahead and let them try the device. Especially let them try if the buyer or another associate working is a smoker or vapor. (you can expense a carton of batteries and some pods as needed for in store trial)
- Talk to them about what makes Riptide different:
 - Nictech versus Salt nicotine liquid
- Our Flavors
- **Battery Strength**
- Marketing support
- Talk to them about the \$'s that Riptide represents to them

- High Margin, more consumer interaction with single pods
- Tell them we are so optimistic about what Riptide will do that we are going to give them the batteries for free Explain to them why we are offering trial batteries to help them quickly build a consumer base to drive that consumer trial
- Sell in the display and POS with the product. Why it is necessary, where you want it to go and how it will help make them \$5...
- Speak to them about their lower cost to invest in Riptide.
- Use the merchandising payment to close the deal when needed. Make sure they know that payment is for keeping the display up in the agreed upon location.

J

FOR INTERNAL USE ONLY

How should I present Riptide?-Selling in the Store

- Close the deal
- Once they say yes, create the invoice.
- You will be selling in the trial batteries at full price, then discounting each to zero.
- If they are taking the merchandising payment, select return on the Riptide merchandising payment item on the distribution tab and then enter in the payment amount on the cash sales tab. (similar to how we do the Stoker's can trial at retail)
- If a retailer wants to purchase some additional PODS try and pre-book them first thru their direct account. This will push out quicker wholesale engaged shipments.
- Merchandise the display
- Discuss with the retailer re-order options for the product, telling them they need to keep an eye on demand as trial increases. Tell them to order future product directly from their wholesaler.
- Again, if they want more product get that second pre-book written and begin them pulling from their wholesaler right away.
- Place the POS
- Think like a consumer, where will our pieces have the greatest impact.
- Where is competitive POS, can we show value of moving to Riptide with placement

FOR INTERNAL USE ONLY

TPB-II I-FT

Notable points

- B2C web sales....1,000 Ripsticks in 4-hours when posted online @ \$.99; shut down site
- One point was brought up about the rubber pieces on the pod's that need to be removed before using is not in the instructions. That is being addressed on the next production run.
- Question of Warranty- 100% guaranteed. If a consumer has an issue they just need to return to store level.
- 99c sticker & danglers need to add to soop |or | requisition via rsm & ship from SDF?



PUBLIC EXHIBIT A-2 PX3134 RX1791

FEDERAL TRADE COMMISSION | OFFICE OF THE SECRETARY | FILED 05/07/2021 | Document No. 601358 | PAGE < Public*



TURNING POIN'

National Account Review 10.23.19

Account Reviews

- Speedway
- Maverick
- Jacksons
 - Chevron
- Kum & Go
- Casey's
- Quick Trip

Buc-ee's

- **Cumberland Farms**
- Stewarts
- **Global Partners**





























Category Sets



ONFIDENTIAL - FT Docket No. 9 9

MAVERIK









Category Sets













































Category Sets

Outdoor Signage






















Exterior POS




























Category Sets


Interior Category Sets & Signage:

Account Information & Strategy

Confidential

Vape Category:

Currently QuikTrip is carrying Riptide Blue Rasp, Tropical, Berry Crunch, Mango, and Mint in both 2.4% & 5.0%. We are in the process of setting up Bright Leaf Tobacco as well.



Category Sets





Cumberland Farms, Signage

Cumberland









ONFIDENTIAL - FT Docket No. 3 3



Stewarts Shops – Sets










TPB-JLI-FT

FEDERAL TRADE COMMISSION | OFFICE OF THE SECRETARY | FILED 05/07/2021 | Document No. 601358 | PAGE PAGE PUBLIC*

TPB-JLI-FT

Back Up Data

TPB-JLI-FT



FIDENDIAL - FT Docket No. 9393

TPB-JLI-FT

PUBLIC EXHIBIT A-3 PX3135

In Camera Treatment Requested For Entirety Of Document

PUBLIC EXHIBIT A-4 PX3145

IVG Business Presentation - September 2019



















Public

Wholesale Transition to Vapor Beast

- Vapor Supply Website has been shutdown.
- Direct Vapor wholesale site will be turned off this week. IT double checking that drop shippers will not be affected.
- exception of international orders. Currently M2 is not set up All DV orders are being entered in Vapor Beast M2, with the with country codes and we will NAV until that set up is complete.
- have a solid understanding of the sales and customer touch Training in California was completed last week. We now point processes



Customer Service Update

- We saw a 3K increase in Contact Center cost to \$65,700. I audited the call and email costs and determined we had an increase in contacts due to inquiries into flavor bans. We had more agent entered sales as customers called in to order bulk E-Liquid. We currently trending at \$56K cost for the month of October.
- We have delayed the "No Back Order" test on Direct Vapor until the warehouse is transferred to KY.
- HDP/Subscriptions. We currently have 7950 subscriptions down from 10,400 in August. Most of the subscription loss is due to blocked states where we had cancel.




FIDEN**OIAL** - FT Docket No. 9393

Q4 Online Initiatives

- **Go-forward process**
- Wholesale Transition Supply → VB
- IVG MKTG team to handle all VB marketing
- Department Restructure
- DirectCBD
- **Enhancements**
- Pending IT delayed
 - Marketing
- Leafly email done 0
- Leafly article pending 0
- Fractl content pending 0
- Adding more affiliates WIP
- DV & VF
- IT Enhancements delayed
 - Display continues
- SBS product mix analysis
- BF/ CM preparations




Early Look at DirectCBD.com Sales (AUG 2019 Launch)



 ∞

TURNING POINT

Brick & Mortar - State of the Stores



Rip Stick & Pod Test

- 9 questions ranking product attributes 1-5
- 200 Giveaways complete received 15 responses
- Continuing to resend to obtain more responses

Q11 Please share any other comments you may have about your experience with the RipStick device below:

Skipped: 8 Answered: 7

RESPONSES

Improve air flow a little, and I would happily purchase more.

awful

You guys really have to make sure that when you bring out a new product, make sure that it works properly. I love the size of the ripstick. That's the only positive I have to say about the ripstick. It's a shame because I was so looking forward to using the ripstick but using 2 ripsticks and both of them failed, I will not be purchasing any more ripsticks.

I really want to like this Pod system but it needs some work on the juice end

I loved the device itself! Small and compact, good daw, long battery life. Il only wish you offered more menthol flavored pods. enjoy the fruit but like the cool feeling of the menthol Gotta be honest, the juice is trash. It's so harsh and tastes like it's pre burnt. I tried both flavors and gave up immediately after 2 pulls. It's that bad. Sorry,


Also like the low nicotine choice I have love 1.2 level can't find other pods with low nicotine.






Rip Stick Test Responses

Q1: How would you rate the e-liquid flavors of the Rip Stick device?



Q2: How would you rate the Rip Stick battery performance?

1 Strongly Dislike 2 3 4 5 Strongly Like



Q3: How would you rate the draw from the Rip Stick device?

1 Strongly Dislike 2 3 4 5 Strongly Like




FEDERAL TRADE COMMISSION | OFFICE OF THE SECRETARY | FILED 05/07/2021 | Document No. 601358 | PAGE Page 0125 *Public*

Rip Stick Test Responses


Q5: The flavor of the e-liquids when compared to other pod systems is:

Q7: The draw of the Rip Stick compared to other pod systems is:




Q8: Compared to other pod systems, my overall satisfaction with the Rip Stick is:

Q6: Comparing the Rip Stick to other pod system's battery life and performance, the Ripstick is:



Rip Stick Test Responses

Q9: Will you be purchasing more Rip Tide pods for use with your Rip Stick device?



Battery life and pods are used up quickly

Good for every once in a while, for convenience

The Draw is awful. I should not have to give myself a hernia just to get a hit.

The flavors taste like tobacco with a very small hint of the advertised flavor

gives u cancer right as u hit

The e-liquid tastes like smoke and not the flavor advertiser

Because I had 2 ripsticks and the batteries just died for no reason

Need more menthol fruit favors

flavors are good


I really liked it. It was new and interesting.

Just like the hit it gives & like the flavor @

Flavor was not good

TURNING POINT 12

CBD Trend Overview (All IVG Channels)



Sept. Recap: Total CBD Sales down -16% or -\$42.5k vs. Aug. Overall Q3-19 CBD Sales down -8% or -\$72.4k vs. Q2-19 Oct. trending \$167k / -23% or -\$50.4k vs Sept.


8/1/2019 ■ 9/1/2019 \$18K \$17K \$14K **Pre-Filled Pods** E-Liquid Category is most hard-hit by recent events: Disposable Q3 IVG CBD Sales by Category (Top 5 Categories) Edibles Sublingual E-Liquid \$80K \$60K \$40K \$20K \$0K \$120K \$100K \$140K \$180K \$160K


	ale 🗖 SBS US Store						9/1/2019
Q3 2019 CBD Sales by Channel	■ directvapor.com ■ B&M ■ Vaporfi.com □ DV Wholesale □ SBS US Store						8/1/2019
Q3 2019 CI	por.com ■ B&M ■Va						7/1/2019
	directva directva	\$100,000	\$80,000	\$60,000	\$40,000	\$20,000	\$0

Channel	Q2 2019	Q3 2019	Q2 2019 Q3 2019 % Change \$ Change	\$ Change
DirectVapor	\$317,490	\$317,490 \$299,451	%9-	-\$18,038
Brick&Mortar	\$253,494	\$204,378	-19%	-\$49,116
VaporFi.com	\$161,670	\$161,670 \$169,155	2%	\$7,485
DV Wholesale	\$114,171	\$92,220	-19%	-\$21,951
South Beach Smoke	\$9,261	\$18,504	100%	\$9,243
Total	\$826,085	\$856,085 \$783,707	%8-	-\$72,378



Nu-X CBD Overview





Nu-X CBD Recap:

- CBD Sales increased 39% or \$13.3k vs. August
- % of total CBD share increased 8.6% in Sept. driven by promotions



9/1/2019


Riptide Trend Overview (All IVG Channels)

■ directvapor.com ■ Vaporfi.com ■ B&M ■ Vaporfi.com.au ■ SBS US Store □ DV Wholesale

\$35,000

\$30,000

Q3 2019 - Total Riptide Sales by IVG Channel




\$20,000

\$25,000

\$15,000

\$10,000



\$5,000

\$2,101 \$ Change -\$2.607 \$13,15 \$38.21 36% -49% %69-3% -1% \$8,005 \$1,171 \$59,229 \$14,639 \$49,803 \$39,197 \$170,873 \$5,904 \$77,416 \$14,200 \$3,778 \$220,127 \$72,380 \$50,226 South Beach Smoke VaporFi.com.AU **DV Wholesale** Brick&Mortar VaporFi.com DirectVapor Total

\$438

Sept. Recap: Total Riptide Sales down -19% or -\$19k vs. Aug.

Overall Q3 Riptide Sales down -22% or -\$49.3k vs. Q2-19

Oct. trending \$38k / flat vs Sept.



PUBLIC EXHIBIT A-5 PX7030 RX0133

Larry Wexler Confidential January 29, 2021

UNITED STATES OF AMERICA

FEDERAL TRADE COMMISSION

OFFICE OF ADMINISTRATIVE LAW JUDGES

-----X

In the Matter of

ALTRIA GROUP, INC.,

a corporation,

-and-

Docket No. 9393

JUUL LABS, INC.,

a corporation,

Respondents.

----X

* * * CONFIDENTIAL * * *

(Via remote videoconference)

January 29, 2021 9:05 a.m. Eastern

Confidential Videoconference

Deposition of LARRY WEXLER, before

Kristi Cruz, a Notary Public of the State of

New York.

Larry Wexler Confidential January 29, 2021

```
Page 2
                                                                                                            Page 4
    APPEARANCES: (All appearing remotely)
                                                               -----T N D E X-----
                                                                                  EXAMINATION BY
                                                               LARRY WEXLER
    FEDERAL TRADE COMMISSION
                                                                                 MR. SOWLATI
                                                                                                       5. 185
    Attorneys for Complainant
                                                                                  MR. LEE
          600 Pennsylvania Avenue, NW
6
          Washington, D.C. 20580
         JOONSUK LEE, ESQ.
                                                              EXHIBITS PREVIOUSLY MARKED/REFERRED TO:
    BY:
8
9
          ERIK M. HERRON, ESQ.
                                                               Wexler 1 - page 13
          EDDIE WATKINS, ESQ.
                                                              Wexler 3 - page 52
10
                                                          10
11
          202.326.2289
                                                          11
                                                               Wexler 13 - page 73
12
          jlee4@ftc.gov
                                                           12
                                                               Wexler 4 - page 80
13
                                                          13
                                                               Wexler 5 - page 88
14
    WACHTELL LIPTON ROSEN & KATZ
                                                          14
                                                               Wexler 7 - page 114
15
                                                               Wexler 8 - page 123
    Attorneys for Respondent Altria Group, Inc.
                                                          15
16
          51 West 52nd Street
                                                               Wexler 9 - page 129
17
                                                          17
                                                               Wexler 10 - page 136
          New York, New York 10019
18
    BY: ADAM SOWLATI, ESQ.
                                                               Wexler 12 - page 141
                                                               Wexler 11 - page 143
19
          KEVIN S. SCHWARTZ, ESO.
                                                          19
          ADAM L. GOODMAN, ESQ.
                                                          20
20
21
          212.403.1062
                                                          21
          asowlati@wlrk.com
                                                           22
                                                          23
23
24
                                                           24
25
                                                           25
                                                 Page 3
                                                                                                            Page 5
1
                                                                            PROCEEDINGS - CONFIDENTIAL
    APPEARANCES: (Cont'd)
                                                           2
                                                                            THE COURT REPORTER: The attorneys
                                                           3
                                                                      participating in this deposition
    CLEARY GOTTLIEB STEEN & HAMILTON LLP
                                                           4
                                                                      acknowledge that I am not physically
    Attorneys for Respondent JUUL Labs, Inc.
                                                           5
                                                                      present in the deposition room and that I
          2112 Pennsylvania Avenue, NW
                                                           6
                                                                      will be reporting this deposition
          Washington, D.C. 20037
                                                           7
                                                                      remotely. They further acknowledge that,
8
    BY: LINDEN BERNHARDT, ESQ.
                                                           8
                                                                      in lieu of an oath administered in person,
          202.974.1500
                                                           9
                                                                      the witness will verbally declare his/her
10
          lbernhardt@cgsh.com
                                                          10
                                                                      testimony in this matter is under penalty
11
                                                          11
                                                                      of perjury.
12
    WILMER HALE
                                                          12
                                                                            The parties and their counsel
13
    Attorneys for the Witness
                                                          13
                                                                      consent to this arrangement and waive any
14
          60 State Street
                                                          14
                                                                      objections to this manner of reporting.
15
          Boston, Massachusetts 02109
                                                          15
                                                                      Please indicate your agreement by stating
16
    BY: MARK A. FORD, ESQ.
                                                           16
                                                                      your name and your agreement on the record.
          KATHERINE V. MACKEY, ESQ.
17
                                                          17
                                                                            (All parties consent to the
18
          617.526.6000
                                                          18
                                                                      stipulation.)
19
          mark.ford@wilmerhale.com
                                                                LARRY WEXLER,
                                                          19
20
                                                           20
                                                                      called as a witness, having been duly
21
    ALSO PRESENT:
                                                           21
                                                                      sworn by a Notary Public, was examined
22
          ZACH CZERENDA, Tech Support
                                                           22
                                                                      and testified as follows:
23
          CAITLIN MALOFF, Turning Point Brands, Inc.
                                                          23 EXAMINATION BY
24
                                                          24
                                                               MR. SOWLATI:
25
                                                           25
                                                                            Good morning, Mr. Wexler. Can you
                                                                      Ο.
```

Larry Wexler Confidential January 29, 2021

	Gandary		
1	Page 6		Page 8
1	L. WEXLER - CONFIDENTIAL	1	L. WEXLER - CONFIDENTIAL
2	please state and spell your full name for the	2	A. I was not aware.
3	record?	3	Q. Are you aware, Mr. Wexler, that
4	A. Including middle name?	4	after the FTC started this administrative
5	Q. Sure.	5	case, we, meaning Altria and JUUL's outside
6	A. Lawrence Stuart Wexler,	6	counsel, served a subpoena on Turning Point
7	L-A-W-R-E-N-C-E; middle name Stuart,	7	Brands asking for some documents?
8	S-T-U-A-R-T; last name Wexler, W-E-X-L-E-R.	8	A. Yes.
9	Q. Who is your employer?	9	Q. Are you aware that Turning Point has
10	A. Turning Point Brands.	10	produced documents, as a result of this
11	Q. And what is your current title?	11	process?
12	A. President and CEO.	12	A. Yes.
13	Q. Okay. Thank you for that	13	Q. Okay. Just a couple of questions
14	information. It's nice to meet you,	14	about your history giving testimony.
15	Mr. Wexler. My name is Adam Sowlati, I'm one	15	Have you ever testified in either a
16	of the counsel representing Altria in this	16	deposition or trial setting?
17	matter. Thank you so much for making yourself	17	A. Yes.
18	available today. I know you're very busy and	18	Q. Was that testimony given in
19	you and your company are third parties to this	19	connection with your work at Turning Point?
20	dispute, so we really appreciate you being	20	A. Yes.
21	here today. We're going to try and make this	21	Q. Okay. Can you briefly describe what
22	as efficient and quick and painless as	22	you gave testimony about?
23	possible.	23	A. I also gave testimony when I was at
24	A. Okay.	24	Philip Morris at Altria, sorry.
25	Q. So, just by way of background, do	25	Q. Okay. Well, if you could, just tell
	Page 7		Page 9
1	L. WEXLER - CONFIDENTIAL	1	L. WEXLER - CONFIDENTIAL
2	L. WEXLER - CONFIDENTIAL you understand you're here today to give	2	L. WEXLER - CONFIDENTIAL me about what you gave testimony at Philip
	L. WEXLER - CONFIDENTIAL		L. WEXLER - CONFIDENTIAL
2	L. WEXLER - CONFIDENTIAL you understand you're here today to give	2	L. WEXLER - CONFIDENTIAL me about what you gave testimony at Philip
2 3	L. WEXLER - CONFIDENTIAL you understand you're here today to give testimony in a legal case between the Federal	2	L. WEXLER - CONFIDENTIAL me about what you gave testimony at Philip Morris first.
2 3 4	L. WEXLER - CONFIDENTIAL you understand you're here today to give testimony in a legal case between the Federal Trade Commission and Altria and JUUL, right?	2 3 4	L. WEXLER - CONFIDENTIAL me about what you gave testimony at Philip Morris first. A. There was a dispute between Turning
2 3 4 5	L. WEXLER - CONFIDENTIAL you understand you're here today to give testimony in a legal case between the Federal Trade Commission and Altria and JUUL, right? A. Yes.	2 3 4 5	L. WEXLER - CONFIDENTIAL me about what you gave testimony at Philip Morris first. A. There was a dispute between Turning Point and one of its competitors, public
2 3 4 5 6	L. WEXLER - CONFIDENTIAL you understand you're here today to give testimony in a legal case between the Federal Trade Commission and Altria and JUUL, right? A. Yes. Q. And you understand that the FTC has	2 3 4 5 6	L. WEXLER - CONFIDENTIAL me about what you gave testimony at Philip Morris first. A. There was a dispute between Turning Point and one of its competitors, public tobacco.
2 3 4 5 6 7	L. WEXLER - CONFIDENTIAL you understand you're here today to give testimony in a legal case between the Federal Trade Commission and Altria and JUUL, right? A. Yes. Q. And you understand that the FTC has sued Altria and JUUL saying that a 35 percent	2 3 4 5 6 7	L. WEXLER - CONFIDENTIAL me about what you gave testimony at Philip Morris first. A. There was a dispute between Turning Point and one of its competitors, public tobacco. Q. Okay. Thanks for that information. Now, you're aware that this is a remote deposition. It's new for many of us,
2 3 4 5 6 7 8	L. WEXLER - CONFIDENTIAL you understand you're here today to give testimony in a legal case between the Federal Trade Commission and Altria and JUUL, right? A. Yes. Q. And you understand that the FTC has sued Altria and JUUL saying that a 35 percent investment that Altria made in JUUL was	2 3 4 5 6 7 8	L. WEXLER - CONFIDENTIAL me about what you gave testimony at Philip Morris first. A. There was a dispute between Turning Point and one of its competitors, public tobacco. Q. Okay. Thanks for that information. Now, you're aware that this is a
2 3 4 5 6 7 8 9	L. WEXLER - CONFIDENTIAL you understand you're here today to give testimony in a legal case between the Federal Trade Commission and Altria and JUUL, right? A. Yes. Q. And you understand that the FTC has sued Altria and JUUL saying that a 35 percent investment that Altria made in JUUL was anti-competitive; is that right?	2 3 4 5 6 7 8	L. WEXLER - CONFIDENTIAL me about what you gave testimony at Philip Morris first. A. There was a dispute between Turning Point and one of its competitors, public tobacco. Q. Okay. Thanks for that information. Now, you're aware that this is a remote deposition. It's new for many of us, so we'll just try and cooperate and get through some technical glitches that may occur
2 3 4 5 6 7 8 9	L. WEXLER - CONFIDENTIAL you understand you're here today to give testimony in a legal case between the Federal Trade Commission and Altria and JULL, right? A. Yes. Q. And you understand that the FTC has sued Altria and JULL saying that a 35 percent investment that Altria made in JULL was anti-competitive; is that right? A. I can't speak to the specific legal	2 3 4 5 6 7 8 9	L. WEXLER - CONFIDENTIAL me about what you gave testimony at Philip Morris first. A. There was a dispute between Turning Point and one of its competitors, public tobacco. Q. Okay. Thanks for that information. Now, you're aware that this is a remote deposition. It's new for many of us, so we'll just try and cooperate and get
2 3 4 5 6 7 8 9 10	L. WEXLER - CONFIDENTIAL you understand you're here today to give testimony in a legal case between the Federal Trade Commission and Altria and JUUL, right? A. Yes. Q. And you understand that the FTC has sued Altria and JUUL saying that a 35 percent investment that Altria made in JUUL was anti-competitive; is that right? A. I can't speak to the specific legal issues involved, but I understand that the FTC	2 3 4 5 6 7 8 9 10	L. WEXLER - CONFIDENTIAL me about what you gave testimony at Philip Morris first. A. There was a dispute between Turning Point and one of its competitors, public tobacco. Q. Okay. Thanks for that information. Now, you're aware that this is a remote deposition. It's new for many of us, so we'll just try and cooperate and get through some technical glitches that may occur
2 3 4 5 6 7 8 9 10 11 12	L. WEXLER - CONFIDENTIAL you understand you're here today to give testimony in a legal case between the Federal Trade Commission and Altria and JUUL, right? A. Yes. Q. And you understand that the FTC has sued Altria and JUUL saying that a 35 percent investment that Altria made in JUUL was anti-competitive; is that right? A. I can't speak to the specific legal issues involved, but I understand that the FTC is suing Philip Morris I'm sorry. I worked	2 3 4 5 6 7 8 9 10 11 12	L. WEXLER - CONFIDENTIAL me about what you gave testimony at Philip Morris first. A. There was a dispute between Turning Point and one of its competitors, public tobacco. Q. Okay. Thanks for that information. Now, you're aware that this is a remote deposition. It's new for many of us, so we'll just try and cooperate and get through some technical glitches that may occur and be as efficient as possible.
2 3 4 5 6 7 8 9 10 11 12 13	L. WEXLER - CONFIDENTIAL you understand you're here today to give testimony in a legal case between the Federal Trade Commission and Altria and JUUL, right? A. Yes. Q. And you understand that the FTC has sued Altria and JUUL saying that a 35 percent investment that Altria made in JUUL was anti-competitive; is that right? A. I can't speak to the specific legal issues involved, but I understand that the FTC is suing Philip Morris I'm sorry. I worked there 20 years, and I will slip and say Philip	2 3 4 5 6 7 8 9 10 11 12 13	L. WEXLER - CONFIDENTIAL me about what you gave testimony at Philip Morris first. A. There was a dispute between Turning Point and one of its competitors, public tobacco. Q. Okay. Thanks for that information. Now, you're aware that this is a remote deposition. It's new for many of us, so we'll just try and cooperate and get through some technical glitches that may occur and be as efficient as possible. Just so you understand what's going
2 3 4 5 6 7 8 9 10 11 12 13 14	L. WEXLER - CONFIDENTIAL you understand you're here today to give testimony in a legal case between the Federal Trade Commission and Altria and JUUL, right? A. Yes. Q. And you understand that the FTC has sued Altria and JUUL saying that a 35 percent investment that Altria made in JUUL was anti-competitive; is that right? A. I can't speak to the specific legal issues involved, but I understand that the FTC is suing Philip Morris I'm sorry. I worked there 20 years, and I will slip and say Philip Morris pretty often Altria acquisition of a	2 3 4 5 6 7 8 9 10 11 12 13 14	L. WEXLER - CONFIDENTIAL me about what you gave testimony at Philip Morris first. A. There was a dispute between Turning Point and one of its competitors, public tobacco. Q. Okay. Thanks for that information. Now, you're aware that this is a remote deposition. It's new for many of us, so we'll just try and cooperate and get through some technical glitches that may occur and be as efficient as possible. Just so you understand what's going to happen today, you've been in a deposition
2 3 4 5 6 7 8 9 10 11 12 13 14 15	L. WEXLER - CONFIDENTIAL you understand you're here today to give testimony in a legal case between the Federal Trade Commission and Altria and JUUL, right? A. Yes. Q. And you understand that the FTC has sued Altria and JUUL saying that a 35 percent investment that Altria made in JUUL was anti-competitive; is that right? A. I can't speak to the specific legal issues involved, but I understand that the FTC is suing Philip Morris I'm sorry. I worked there 20 years, and I will slip and say Philip Morris pretty often Altria acquisition of a portion of JUUL.	2 3 4 5 6 7 8 9 10 11 12 13 14 15	L. WEXLER - CONFIDENTIAL me about what you gave testimony at Philip Morris first. A. There was a dispute between Turning Point and one of its competitors, public tobacco. Q. Okay. Thanks for that information. Now, you're aware that this is a remote deposition. It's new for many of us, so we'll just try and cooperate and get through some technical glitches that may occur and be as efficient as possible. Just so you understand what's going to happen today, you've been in a deposition before. We're going to ask you a number of
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	L. WEXLER - CONFIDENTIAL you understand you're here today to give testimony in a legal case between the Federal Trade Commission and Altria and JUUL, right? A. Yes. Q. And you understand that the FTC has sued Altria and JUUL saying that a 35 percent investment that Altria made in JUUL was anti-competitive; is that right? A. I can't speak to the specific legal issues involved, but I understand that the FTC is suing Philip Morris I'm sorry. I worked there 20 years, and I will slip and say Philip Morris pretty often Altria acquisition of a portion of JUUL. Q. Are you aware that before FTC filed	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	L. WEXLER - CONFIDENTIAL me about what you gave testimony at Philip Morris first. A. There was a dispute between Turning Point and one of its competitors, public tobacco. Q. Okay. Thanks for that information. Now, you're aware that this is a remote deposition. It's new for many of us, so we'll just try and cooperate and get through some technical glitches that may occur and be as efficient as possible. Just so you understand what's going to happen today, you've been in a deposition before. We're going to ask you a number of questions. I'll go first, then an attorney,
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	L. WEXLER - CONFIDENTIAL you understand you're here today to give testimony in a legal case between the Federal Trade Commission and Altria and JUUL, right? A. Yes. Q. And you understand that the FTC has sued Altria and JUUL saying that a 35 percent investment that Altria made in JUUL was anti-competitive; is that right? A. I can't speak to the specific legal issues involved, but I understand that the FTC is suing Philip Morris I'm sorry. I worked there 20 years, and I will slip and say Philip Morris pretty often Altria acquisition of a portion of JUUL. Q. Are you aware that before FTC filed this case, they conducted an investigation?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	L. WEXLER - CONFIDENTIAL me about what you gave testimony at Philip Morris first. A. There was a dispute between Turning Point and one of its competitors, public tobacco. Q. Okay. Thanks for that information. Now, you're aware that this is a remote deposition. It's new for many of us, so we'll just try and cooperate and get through some technical glitches that may occur and be as efficient as possible. Just so you understand what's going to happen today, you've been in a deposition before. We're going to ask you a number of questions. I'll go first, then an attorney, Mr. Lee, an attorney representing the FTC,
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	L. WEXLER - CONFIDENTIAL you understand you're here today to give testimony in a legal case between the Federal Trade Commission and Altria and JUUL, right? A. Yes. Q. And you understand that the FTC has sued Altria and JUUL saying that a 35 percent investment that Altria made in JUUL was anti-competitive; is that right? A. I can't speak to the specific legal issues involved, but I understand that the FTC is suing Philip Morris I'm sorry. I worked there 20 years, and I will slip and say Philip Morris pretty often Altria acquisition of a portion of JUUL. Q. Are you aware that before FTC filed this case, they conducted an investigation? A. Yes.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	L. WEXLER - CONFIDENTIAL me about what you gave testimony at Philip Morris first. A. There was a dispute between Turning Point and one of its competitors, public tobacco. Q. Okay. Thanks for that information. Now, you're aware that this is a remote deposition. It's new for many of us, so we'll just try and cooperate and get through some technical glitches that may occur and be as efficient as possible. Just so you understand what's going to happen today, you've been in a deposition before. We're going to ask you a number of questions. I'll go first, then an attorney, Mr. Lee, an attorney representing the FTC, will have an opportunity to ask you questions.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	L. WEXLER - CONFIDENTIAL you understand you're here today to give testimony in a legal case between the Federal Trade Commission and Altria and JUUL, right? A. Yes. Q. And you understand that the FTC has sued Altria and JUUL saying that a 35 percent investment that Altria made in JUUL was anti-competitive; is that right? A. I can't speak to the specific legal issues involved, but I understand that the FTC is suing Philip Morris I'm sorry. I worked there 20 years, and I will slip and say Philip Morris pretty often Altria acquisition of a portion of JUUL. Q. Are you aware that before FTC filed this case, they conducted an investigation? A. Yes. Q. Are you also aware that you signed a	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	L. WEXLER - CONFIDENTIAL me about what you gave testimony at Philip Morris first. A. There was a dispute between Turning Point and one of its competitors, public tobacco. Q. Okay. Thanks for that information. Now, you're aware that this is a remote deposition. It's new for many of us, so we'll just try and cooperate and get through some technical glitches that may occur and be as efficient as possible. Just so you understand what's going to happen today, you've been in a deposition before. We're going to ask you a number of questions. I'll go first, then an attorney, Mr. Lee, an attorney representing the FTC, will have an opportunity to ask you questions. Do you understand that?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	L. WEXLER - CONFIDENTIAL you understand you're here today to give testimony in a legal case between the Federal Trade Commission and Altria and JUUL, right? A. Yes. Q. And you understand that the FTC has sued Altria and JUUL saying that a 35 percent investment that Altria made in JUUL was anti-competitive; is that right? A. I can't speak to the specific legal issues involved, but I understand that the FTC is suing Philip Morris I'm sorry. I worked there 20 years, and I will slip and say Philip Morris pretty often Altria acquisition of a portion of JUUL. Q. Are you aware that before FTC filed this case, they conducted an investigation? A. Yes. Q. Are you also aware that you signed a Declaration that Turning Point Brand and its	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	L. WEXLER - CONFIDENTIAL me about what you gave testimony at Philip Morris first. A. There was a dispute between Turning Point and one of its competitors, public tobacco. Q. Okay. Thanks for that information. Now, you're aware that this is a remote deposition. It's new for many of us, so we'll just try and cooperate and get through some technical glitches that may occur and be as efficient as possible. Just so you understand what's going to happen today, you've been in a deposition before. We're going to ask you a number of questions. I'll go first, then an attorney, Mr. Lee, an attorney representing the FTC, will have an opportunity to ask you questions. Do you understand that? A. Yes.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	L. WEXLER - CONFIDENTIAL you understand you're here today to give testimony in a legal case between the Federal Trade Commission and Altria and JUUL, right? A. Yes. Q. And you understand that the FTC has sued Altria and JUUL saying that a 35 percent investment that Altria made in JUUL was anti-competitive; is that right? A. I can't speak to the specific legal issues involved, but I understand that the FTC is suing Philip Morris I'm sorry. I worked there 20 years, and I will slip and say Philip Morris pretty often Altria acquisition of a portion of JUUL. Q. Are you aware that before FTC filed this case, they conducted an investigation? A. Yes. Q. Are you also aware that you signed a Declaration that Turning Point Brand and its counsel gave to the FTC?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	L. WEXLER - CONFIDENTIAL me about what you gave testimony at Philip Morris first. A. There was a dispute between Turning Point and one of its competitors, public tobacco. Q. Okay. Thanks for that information. Now, you're aware that this is a remote deposition. It's new for many of us, so we'll just try and cooperate and get through some technical glitches that may occur and be as efficient as possible. Just so you understand what's going to happen today, you've been in a deposition before. We're going to ask you a number of questions. I'll go first, then an attorney, Mr. Lee, an attorney representing the FTC, will have an opportunity to ask you questions. Do you understand that? A. Yes. Q. Okay. I'm just going to go through
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	L. WEXLER - CONFIDENTIAL you understand you're here today to give testimony in a legal case between the Federal Trade Commission and Altria and JUUL, right? A. Yes. Q. And you understand that the FTC has sued Altria and JUUL saying that a 35 percent investment that Altria made in JUUL was anti-competitive; is that right? A. I can't speak to the specific legal issues involved, but I understand that the FTC is suing Philip Morris I'm sorry. I worked there 20 years, and I will slip and say Philip Morris pretty often Altria acquisition of a portion of JUUL. Q. Are you aware that before FTC filed this case, they conducted an investigation? A. Yes. Q. Are you also aware that you signed a Declaration that Turning Point Brand and its counsel gave to the FTC? A. Yes.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	L. WEXLER - CONFIDENTIAL me about what you gave testimony at Philip Morris first. A. There was a dispute between Turning Point and one of its competitors, public tobacco. Q. Okay. Thanks for that information. Now, you're aware that this is a remote deposition. It's new for many of us, so we'll just try and cooperate and get through some technical glitches that may occur and be as efficient as possible. Just so you understand what's going to happen today, you've been in a deposition before. We're going to ask you a number of questions. I'll go first, then an attorney, Mr. Lee, an attorney representing the FTC, will have an opportunity to ask you questions. Do you understand that? A. Yes. Q. Okay. I'm just going to go through a few more ground rules, understanding that
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	L. WEXLER - CONFIDENTIAL you understand you're here today to give testimony in a legal case between the Federal Trade Commission and Altria and JUUL, right? A. Yes. Q. And you understand that the FTC has sued Altria and JUUL saying that a 35 percent investment that Altria made in JUUL was anti-competitive; is that right? A. I can't speak to the specific legal issues involved, but I understand that the FTC is suing Philip Morris I'm sorry. I worked there 20 years, and I will slip and say Philip Morris pretty often Altria acquisition of a portion of JUUL. Q. Are you aware that before FTC filed this case, they conducted an investigation? A. Yes. Q. Are you also aware that you signed a Declaration that Turning Point Brand and its counsel gave to the FTC? A. Yes. Q. Are you aware, Mr. Wexler, that your	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	L. WEXLER - CONFIDENTIAL me about what you gave testimony at Philip Morris first. A. There was a dispute between Turning Point and one of its competitors, public tobacco. Q. Okay. Thanks for that information. Now, you're aware that this is a remote deposition. It's new for many of us, so we'll just try and cooperate and get through some technical glitches that may occur and be as efficient as possible. Just so you understand what's going to happen today, you've been in a deposition before. We're going to ask you a number of questions. I'll go first, then an attorney, Mr. Lee, an attorney representing the FTC, will have an opportunity to ask you questions. Do you understand that? A. Yes. Q. Okay. I'm just going to go through a few more ground rules, understanding that you're experienced with depositions before.

Larry Wexler Confidential January 29, 2021

Page 10 Page 12 1 L. WEXLER - CONFIDENTIAL 1 L. WEXLER - CONFIDENTIAL 2 be testifying under oath in a court at trial? 2 Ο. Do you have any form of 3 Yes. 3 communication with your attorneys at disposal, 4 Q. Okay. We should try not to speak 4 such as a chat function or text messaging? 5 over each other today. Although at times it 5 No. My phone is off. 6 might look like we're having a conversation, 6 Mr. Wexler, as we've just discussed, 7 there's a court reporter here taking down you prepared a Declaration in connection with 7 everything we're saying. So to make her job 8 this matter. I plan to go through and ask you 8 questions about it. I'll show you some other 9 easier, I ask that you let me finish asking 9 questions before you answer, and I'll try and documents, but I'll keep referring to that 10 10 11 Declaration to organize our discussion today. return the favor by letting you finish your 11 12 answer before I ask another question. 12 So it would be great if you could keep it Α. That is fair. 13 handy. 13 14 Similarly, in order for the court 14 I don't have anything on my desk. I 15 reporter to take down your answers, I ask that 15 don't have it handy. Maybe they should send 16 you please answer verbally with a yes or no 16 it to the chat room so I can put it up on my 17 rather than nodding or making some other 17 screen. 18 gesture. Okay? 18 I am going to share that right now 19 Α. Understood. 19 with you via the Zoom chat. Hopefully this 20 20 works. If a question I ask is unclear, 21 please let me know. I'll try to restate it so 21 A. Okay. This will be a test. 22 it's clear. Okay. It says that it sent 22 0. 23 From time to time, your counsel may 23 successfully. 24 24 object to certain questions. Unless a Let's see if it made it. Sorry, I'm Α. 25 question is asking you for privileged playing with two screens. Page 11 Page 13 L. WEXLER - CONFIDENTIAL L. WEXLER - CONFIDENTIAL 1 1 2 information, your counsel is just making an 2 No problem. Once you have that 3 objection for the record, and you should still 3 open, I will suggest that you don't close it answer the question after he or she makes the because I will be constantly referring to it. 4 4 5 objection. Does that make sense? 5 That's why I thought it would be a good idea to keep it open on my desk. 6 Α. Understood. 6 7 We're going to take a look at some 7 Did that work? 0. 8 documents which will be marked as exhibits to 8 Α. Yeah, I have it open. 9 your deposition. I understand you may have 9 Ο. I'm going to go ahead and mark your 10 had an opportunity to practice the Zoom chat 10 Declaration as Wexler Exhibit 1. Is this a 11 function, which is what I'll use to share 11 Declaration that you signed on March 26, 2020? 12 documents. 12 I'll take a look at it. Α. 13 Today's deposition is not an 13 Yes, it does look like it. 14 endurance test. If there comes a time you 14 How did you come to prepare and sign 0. 15 need a break, just let me know. We'll take a 15 it? 16 quick break. But if there's a question 16 Α. I was interviewed by the FTC. They 17 pending, I ask that you please answer the 17 asked me to give some insights from my 18 question before we take the break. Does that 18 experience of being in the tobacco business work? and selling products in C-stores. And I 19 19 20 conducted an interview with them, and the Α. Understood. 20 21 With those ground rules out of the 21 document was prepared, and I made one small 22 way, Mr. Wexler, is there anything that may 22 edit and signed it. 23 affect your ability to give truthful and 23 Q. Okay. Did the FTC reach out to you 24 complete testimony today? 24 initially? 25 Not that I'm aware of. 25 Α. Α. I was approached by my general

Larry Wexler Confidential January 29, 2021

1 2			
	Page 14	_	Page 16
2	L. WEXLER - CONFIDENTIAL	1	L. WEXLER - CONFIDENTIAL
	counsel.	2	Q. Are there any employers or job
3	Q. Can you tell me whom you spoke with	3	opportunities you've had that are not
4	at the FTC?	4	mentioned in Paragraph 1?
5 6	A. I have an unbelievable facility for	5	A. Yeah, I had a lot of summer jobs
7	forgetting every name I've ever been told. No, I can't.	7	when I was in college. I started up a company
8		8	while I was in college that I didn't mention here, and it doesn't really specify each of my
9	Q. Can you tell me about the conversation? What did you discuss with them?	9	jobs at Philip Morris, nor does it specify the
10	A. It was a broad-ranging conversation,	10	companies I worked with as a consultant.
11	and we discussed a lot of elements about the	11	Q. Okay. Now, you left Philip Morris
12	vape business, he seemed to be interested in	12	in 1998, right?
13	learning about the vape business, and also how	13	A. Yes.
14	one markets in C-stores, and a little bit	14	Q. Why did you leave Philip Morris, in
15	about my experience at Philip Morris I	15	1998?
16	quess it was Philip Morris then, so I'll call	16	A. I was being considered for the job
17	it Philip Morris because it's easier for me.	17	of running Philip Morris USA. A guy named
18	Q. Recognizing that it's now	18	Mike Szymanczyk was given the job, and he
19	A. Altria.	19	decided that he did not want to work with me
20	Q Altria.	20	anymore. I was offered some opportunities in
21	How did you come to cover the	21	International, didn't want to move my family,
22	particular subjects in your Declaration?	22	and so I decided to leave.
23	A. I was asked questions.	23	Q. Okay. So, the option was either go
24	Q. Are there topics that the FTC asked	24	international or find another opportunity?
25	you to address that are not reflected in the	25	A. As I remember it, yes.
	Page 15		Page 17
1	L. WEXLER - CONFIDENTIAL	1	L. WEXLER - CONFIDENTIAL
2	Declaration?	2	Q. What did you do, as a consultant
3	A. I don't remember. I don't remember	3	
			from 1998 to 2003?
4	anything of significance that was done with	4	A. I worked with start-ups.
5	the Declaration.	5	A. I worked with start-ups. Q. What type of start-ups?
5	the Declaration. Q. And they prepared the first draft of	5 6	A. I worked with start-ups.Q. What type of start-ups?A. There were a number of them. I did
5 6 7	the Declaration. Q. And they prepared the first draft of the Declaration, you said?	5 6 7	A. I worked with start-ups. Q. What type of start-ups? A. There were a number of them. I did the obligatory internet start-up. I worked
5 6 7 8	the Declaration. Q. And they prepared the first draft of the Declaration, you said? A. My general counsel walked it into my	5 6 7 8	A. I worked with start-ups. Q. What type of start-ups? A. There were a number of them. I did the obligatory internet start-up. I worked with a cable company that was starting up an
5 6 7 8 9	the Declaration. Q. And they prepared the first draft of the Declaration, you said? A. My general counsel walked it into my office and said, "This is the Declaration,"	5 6 7 8 9	A. I worked with start-ups. Q. What type of start-ups? A. There were a number of them. I did the obligatory internet start-up. I worked with a cable company that was starting up an operation in Japan, interestingly selling a
5 6 7 8 9	the Declaration. Q. And they prepared the first draft of the Declaration, you said? A. My general counsel walked it into my office and said, "This is the Declaration," and that's as much as I know.	5 6 7 8 9	A. I worked with start-ups. Q. What type of start-ups? A. There were a number of them. I did the obligatory internet start-up. I worked with a cable company that was starting up an operation in Japan, interestingly selling a science fiction channel to Japan, which an
5 6 7 8 9 10	the Declaration. Q. And they prepared the first draft of the Declaration, you said? A. My general counsel walked it into my office and said, "This is the Declaration," and that's as much as I know. Q. Okay. And you said you made one	5 6 7 8 9 10	A. I worked with start-ups. Q. What type of start-ups? A. There were a number of them. I did the obligatory internet start-up. I worked with a cable company that was starting up an operation in Japan, interestingly selling a science fiction channel to Japan, which an emerging company selling a science fiction
5 6 7 8 9 10 11	the Declaration. Q. And they prepared the first draft of the Declaration, you said? A. My general counsel walked it into my office and said, "This is the Declaration," and that's as much as I know. Q. Okay. And you said you made one small change?	5 6 7 8 9 10 11 12	A. I worked with start-ups. Q. What type of start-ups? A. There were a number of them. I did the obligatory internet start-up. I worked with a cable company that was starting up an operation in Japan, interestingly selling a science fiction channel to Japan, which an emerging company selling a science fiction channel in Japan, which I find very amusing.
5 6 7 8 9 10 11 12 13	the Declaration. Q. And they prepared the first draft of the Declaration, you said? A. My general counsel walked it into my office and said, "This is the Declaration," and that's as much as I know. Q. Okay. And you said you made one small change? A. Yeah. I don't remember what it was.	5 6 7 8 9 10 11 12 13	A. I worked with start-ups. Q. What type of start-ups? A. There were a number of them. I did the obligatory internet start-up. I worked with a cable company that was starting up an operation in Japan, interestingly selling a science fiction channel to Japan, which an emerging company selling a science fiction channel in Japan, which I find very amusing. I also worked with a company that,
5 6 7 8 9 10 11 12 13 14	the Declaration. Q. And they prepared the first draft of the Declaration, you said? A. My general counsel walked it into my office and said, "This is the Declaration," and that's as much as I know. Q. Okay. And you said you made one small change? A. Yeah. I don't remember what it was. It was pretty minor. It was just something	5 6 7 8 9 10 11 12 13	A. I worked with start-ups. Q. What type of start-ups? A. There were a number of them. I did the obligatory internet start-up. I worked with a cable company that was starting up an operation in Japan, interestingly selling a science fiction channel to Japan, which an emerging company selling a science fiction channel in Japan, which I find very amusing. I also worked with a company that, when you get your credit card bills, you get
5 6 7 8 9 10 11 12 13 14 15	the Declaration. Q. And they prepared the first draft of the Declaration, you said? A. My general counsel walked it into my office and said, "This is the Declaration," and that's as much as I know. Q. Okay. And you said you made one small change? A. Yeah. I don't remember what it was. It was pretty minor. It was just something that wasn't clear, so I changed the language.	5 6 7 8 9 10 11 12 13 14	A. I worked with start-ups. Q. What type of start-ups? A. There were a number of them. I did the obligatory internet start-up. I worked with a cable company that was starting up an operation in Japan, interestingly selling a science fiction channel to Japan, which an emerging company selling a science fiction channel in Japan, which I find very amusing. I also worked with a company that, when you get your credit card bills, you get offers for free magazines, free magazine
5 6 7 8 9 10 11 12 13 14 15 16	the Declaration. Q. And they prepared the first draft of the Declaration, you said? A. My general counsel walked it into my office and said, "This is the Declaration," and that's as much as I know. Q. Okay. And you said you made one small change? A. Yeah. I don't remember what it was. It was pretty minor. It was just something that wasn't clear, so I changed the language. Q. Were there any discussions with the	5 6 7 8 9 10 11 12 13 14 15 16	A. I worked with start-ups. Q. What type of start-ups? A. There were a number of them. I did the obligatory internet start-up. I worked with a cable company that was starting up an operation in Japan, interestingly selling a science fiction channel to Japan, which an emerging company selling a science fiction channel in Japan, which I find very amusing. I also worked with a company that, when you get your credit card bills, you get offers for free magazines, free magazine subscriptions. Did you ever notice that? Now
5 6 7 8 9 10 11 12 13 14 15 16 17	the Declaration. Q. And they prepared the first draft of the Declaration, you said? A. My general counsel walked it into my office and said, "This is the Declaration," and that's as much as I know. Q. Okay. And you said you made one small change? A. Yeah. I don't remember what it was. It was pretty minor. It was just something that wasn't clear, so I changed the language. Q. Were there any discussions with the FTC, since you signed the Declaration?	5 6 7 8 9 10 11 12 13 14 15 16 17	A. I worked with start-ups. Q. What type of start-ups? A. There were a number of them. I did the obligatory internet start-up. I worked with a cable company that was starting up an operation in Japan, interestingly selling a science fiction channel to Japan, which an emerging company selling a science fiction channel in Japan, which I find very amusing. I also worked with a company that, when you get your credit card bills, you get offers for free magazines, free magazine subscriptions. Did you ever notice that? Now they're called Synapse. I worked with that
5 6 7 8 9 10 11 12 13 14 15 16 17 18	the Declaration. Q. And they prepared the first draft of the Declaration, you said? A. My general counsel walked it into my office and said, "This is the Declaration," and that's as much as I know. Q. Okay. And you said you made one small change? A. Yeah. I don't remember what it was. It was pretty minor. It was just something that wasn't clear, so I changed the language. Q. Were there any discussions with the FTC, since you signed the Declaration? A. No, I do not remember any.	5 6 7 8 9 10 11 12 13 14 15 16 17 18	A. I worked with start-ups. Q. What type of start-ups? A. There were a number of them. I did the obligatory internet start-up. I worked with a cable company that was starting up an operation in Japan, interestingly selling a science fiction channel to Japan, which an emerging company selling a science fiction channel in Japan, which I find very amusing. I also worked with a company that, when you get your credit card bills, you get offers for free magazines, free magazine subscriptions. Did you ever notice that? Now they're called Synapse. I worked with that company.
5 6 7 8 9 10 11 12 13 14 15 16 17 18	the Declaration. Q. And they prepared the first draft of the Declaration, you said? A. My general counsel walked it into my office and said, "This is the Declaration," and that's as much as I know. Q. Okay. And you said you made one small change? A. Yeah. I don't remember what it was. It was pretty minor. It was just something that wasn't clear, so I changed the language. Q. Were there any discussions with the FTC, since you signed the Declaration? A. No, I do not remember any. Q. Why don't we start at the top of	5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	A. I worked with start-ups. Q. What type of start-ups? A. There were a number of them. I did the obligatory internet start-up. I worked with a cable company that was starting up an operation in Japan, interestingly selling a science fiction channel to Japan, which an emerging company selling a science fiction channel in Japan, which I find very amusing. I also worked with a company that, when you get your credit card bills, you get offers for free magazines, free magazine subscriptions. Did you ever notice that? Now they're called Synapse. I worked with a commodity And I also worked with a commodity
5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	the Declaration. Q. And they prepared the first draft of the Declaration, you said? A. My general counsel walked it into my office and said, "This is the Declaration," and that's as much as I know. Q. Okay. And you said you made one small change? A. Yeah. I don't remember what it was. It was pretty minor. It was just something that wasn't clear, so I changed the language. Q. Were there any discussions with the FTC, since you signed the Declaration? A. No, I do not remember any. Q. Why don't we start at the top of your Declaration, Mr. Wexler, the first	5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	A. I worked with start-ups. Q. What type of start-ups? A. There were a number of them. I did the obligatory internet start-up. I worked with a cable company that was starting up an operation in Japan, interestingly selling a science fiction channel to Japan, which an emerging company selling a science fiction channel in Japan, which I find very amusing. I also worked with a company that, when you get your credit card bills, you get offers for free magazines, free magazine subscriptions. Did you ever notice that? Now they're called Synapse. I worked with that company. And I also worked with a commodity hedge fund.
5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	the Declaration. Q. And they prepared the first draft of the Declaration, you said? A. My general counsel walked it into my office and said, "This is the Declaration," and that's as much as I know. Q. Okay. And you said you made one small change? A. Yeah. I don't remember what it was. It was pretty minor. It was just something that wasn't clear, so I changed the language. Q. Were there any discussions with the FTC, since you signed the Declaration? A. No, I do not remember any. Q. Why don't we start at the top of your Declaration, Mr. Wexler, the first paragraph.	5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	A. I worked with start-ups. Q. What type of start-ups? A. There were a number of them. I did the obligatory internet start-up. I worked with a cable company that was starting up an operation in Japan, interestingly selling a science fiction channel to Japan, which an emerging company selling a science fiction channel in Japan, which I find very amusing. I also worked with a company that, when you get your credit card bills, you get offers for free magazines, free magazine subscriptions. Did you ever notice that? Now they're called Synapse. I worked with that company. And I also worked with a commodity hedge fund. Q. Okay. Mr. Wexler, why don't we turn
5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	the Declaration. Q. And they prepared the first draft of the Declaration, you said? A. My general counsel walked it into my office and said, "This is the Declaration," and that's as much as I know. Q. Okay. And you said you made one small change? A. Yeah. I don't remember what it was. It was pretty minor. It was just something that wasn't clear, so I changed the language. Q. Were there any discussions with the FTC, since you signed the Declaration? A. No, I do not remember any. Q. Why don't we start at the top of your Declaration, Mr. Wexler, the first paragraph. A. Okay.	5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	A. I worked with start-ups. Q. What type of start-ups? A. There were a number of them. I did the obligatory internet start-up. I worked with a cable company that was starting up an operation in Japan, interestingly selling a science fiction channel to Japan, which an emerging company selling a science fiction channel in Japan, which I find very amusing. I also worked with a company that, when you get your credit card bills, you get offers for free magazines, free magazine subscriptions. Did you ever notice that? Now they're called Synapse. I worked with that company. And I also worked with a commodity hedge fund. Q. Okay. Mr. Wexler, why don't we turn to Paragraph 2 of your Declaration.
5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	the Declaration. Q. And they prepared the first draft of the Declaration, you said? A. My general counsel walked it into my office and said, "This is the Declaration," and that's as much as I know. Q. Okay. And you said you made one small change? A. Yeah. I don't remember what it was. It was pretty minor. It was just something that wasn't clear, so I changed the language. Q. Were there any discussions with the FTC, since you signed the Declaration? A. No, I do not remember any. Q. Why don't we start at the top of your Declaration, Mr. Wexler, the first paragraph.	5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	A. I worked with start-ups. Q. What type of start-ups? A. There were a number of them. I did the obligatory internet start-up. I worked with a cable company that was starting up an operation in Japan, interestingly selling a science fiction channel to Japan, which an emerging company selling a science fiction channel in Japan, which I find very amusing. I also worked with a company that, when you get your credit card bills, you get offers for free magazines, free magazine subscriptions. Did you ever notice that? Now they're called Synapse. I worked with that company. And I also worked with a commodity hedge fund. Q. Okay. Mr. Wexler, why don't we turn
5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	the Declaration. Q. And they prepared the first draft of the Declaration, you said? A. My general counsel walked it into my office and said, "This is the Declaration," and that's as much as I know. Q. Okay. And you said you made one small change? A. Yeah. I don't remember what it was. It was pretty minor. It was just something that wasn't clear, so I changed the language. Q. Were there any discussions with the FTC, since you signed the Declaration? A. No, I do not remember any. Q. Why don't we start at the top of your Declaration, Mr. Wexler, the first paragraph. A. Okay. Q. Does Paragraph 1 correctly capture	5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	A. I worked with start-ups. Q. What type of start-ups? A. There were a number of them. I did the obligatory internet start-up. I worked with a cable company that was starting up an operation in Japan, interestingly selling a science fiction channel to Japan, which an emerging company selling a science fiction channel in Japan, which I find very amusing. I also worked with a company that, when you get your credit card bills, you get offers for free magazines, free magazine subscriptions. Did you ever notice that? Now they're called Synapse. I worked with that company. And I also worked with a commodity hedge fund. Q. Okay. Mr. Wexler, why don't we turn to Paragraph 2 of your Declaration. A. Okay.

Larry Wexler Confidential January 29, 2021

	January	49,	2021
	Page 18		Page 20
1	L. WEXLER - CONFIDENTIAL	1	L. WEXLER - CONFIDENTIAL
2	A. Yes.	2	A. Liquid was made to our
3	Q. You say that Turning Point operates	3	specifications.
4	in three segments; smokeless tobacco products,	4	Q. Now, RipTide is a pod system, right?
5	smoking products, and NewGen products.	5	A. Yes. It also has open liquids, tank
6	Does Turning Point manufacture its	6	liquids.
7	own products in all three segments?	7	Q. What is a pod system?
8	A. The bulk of the products we sell are	8	A. A pod system is a vapor device that
9	made by third parties.	9	has a battery, and it has pods that are sold
10	Q. Okay.	10	separately. And when connected, they make one
11	A. We do make our moist snuff.	11	unit, and the consumer can just simply vape on
12	Q. And you also make direct-type	12	it and get the vapor that they're looking for.
13	products, which we'll discuss later?	13	Q. And just to be clear, RipTide is the
14	A. It was produced by others for us.	14	only pod system that Turning Point currently
15	Q. Mr. Wexler, what are NewGen	15	manufactures, right?
16	products?	16	A. It is the only pod system that we
17	A. NewGen products NewGen is a	17	manufacture, yes.
18	division we started to put our products that	18	Q. Okay.
19	we call new generation. They're nontobacco	19	A. Well, we don't manufacture it.
20	products. They could contain nicotine, but	20	Q. Okay.
21	they're nontobacco products.	21	A. It's manufactured under the
22	Q. And NewGen products include closed	22	contract.
23	system e-vapor products, right?	23	Q. Besides RipTide, has Turning Point
24	A. Both closed and open, yes.	24	manufactured, either itself or through a
25	Q. What closed system products has	25	contractor, any other pod-based product in the
			- 01
1	Page 19 L. WEXLER - CONFIDENTIAL	1	Page 21 L. WEXLER - CONFIDENTIAL
2	NewGen either developed in-house or acquired	2	past?
3	or licensed?	3	A. Not that I can remember.
4	A. The principal one was RipTide.	4	Q. How about any other closed systems?
5	Q. And you said that RipTide was	5	A. Well, if you think about closed
6	licensed?	6	systems, we sell nutraceutical products that
7	A. No, I did not say that.	7	are closed systems. We also sold a product
8	Q. Oh, it wasn't. Okay.	8	called V2 from a company called VMR that we
9	But you have a contract manufacturer	9	did in partnership with VMR. We have been
10	that produces that for you?	10	involved with other closed systems. Also
11	A. Yes.	11	Q. Why don't we sorry. Why don't
12	Q. Who is that contract manufacturer?	12	we
13	A. I'm drawing a blank right now. It	13	MR. FORD: Larry, you should
14	is one of the major Chinese vape manufacturers.	14	complete your answer, if you had something
15	Q. Okay. Do you have an exclusive	15	else to add.
16	right sorry. Strike that.	16	THE WITNESS: Okay.
17	Did you develop the IP for RipTide,	17	A. So, I just want to be clear, we've
18	or that was developed by the Chinese	18	talked about we do sell third-party
19	manufacturer?	19	products that are closed systems. It's just,
20	A. When you're talking about "IP,"	20	those are the only two that we make to our
21	which component of the product IP are you	21	specifications and sell.
		22	Q. I see.
22	talking about?		
22 23	Q. Well, I guess there's the liquid,	23	What is the difference between a
			-
23	Q. Well, I guess there's the liquid,	23	What is the difference between a

Page 22 Page 24 1 L. WEXLER - CONFIDENTIAL L. WEXLER - CONFIDENTIAL 1 2 subset of closed systems. 2 shops. 3 Okay. I guess maybe we should take 3 What is an e-commerce sales engine? Q. 4 a step back. 4 Α. Essentially, the marketing is not 5 5 done face to face; it's done over the What are closed system e-vapor 6 products? 6 internet. We have a website. We also have a 7 The way I term "closed systems" is 7 group of salespeople who call vape shops to 8 that the closed system is a system in which 8 generate orders. 9 the liquid is embedded in the capsule, in the 9 Q. You note that Vapor Shark is a vapor 10 container, and it has the ability to either be 10 supply wholesaler and line of vape shops. 11 one single unit, which can be disposable; 11 How is Vapor Shark's wholesale 12 12 where you buy the whole unit, including the business different than Vapor Beast's 13 battery. We call those disposable. Or they 13 distribution business? 14 could be a cartridge system where you could 14 It's a lot less successful. 15 buy a cartridge that can be attached to a 15 Okay. But is there anything 16 battery. Or it can be a pod system, which 16 different between a distribution business and 17 17 a wholesale business, or are they the same tends to be larger, and also liquid is 18 contained in it, and you can put it into it 18 thing? 19 and attach it. 19 A. It is -- it's pretty much the same 20 20 Now, there are some pod systems on thing. I think the terminology difference is 21 21 the market that are also open systems. That that Vapor Shark had some proprietary 22 is, the pod can be opened and refilled by the products. 22 23 consumer. 23 Those proprietary products are open 24 Q. Now, you mentioned the V2 product. 24 system proprietary products or closed system? 25 What is the V2 product? I would classify that as open Page 23 Page 25 1 L. WEXLER - CONFIDENTIAL 1 L. WEXLER - CONFIDENTIAL 2 V2 product was one of the original Α. 2 system. 3 e-cigs, e-vapor products. It is a 3 Q. Can we turn to Paragraph 4 of your 4 4 classification that we call Cigalikes. It Declaration? 5 looks very much like a cigarette. It's 5 Α. Yes. 6 smaller than a pod system. It basically 6 You say that Turning Point operates 7 7 resembles a cigarette. 12 corporate stores and 40 franchise stores. 8 8 Do you still sell the V2? Do these stores sell closed system Ο. 9 Α. No, we do not. 9 e-vapor products? 10 Why did you stop selling the V2? 10 The JUUL company bought VMR. And 11 11 12 what they did is, we had a partnership with 12 13 VMR, and they basically terminated the 13 14 partnership. 14 15 15 We're going to talk a little bit 16 more about Cigalikes a bit later. But if we 16 17 17 could, turn to Paragraph 3 of your 18 Declaration. 18 19 Α. 19 Okay. Hold on. Okay. 20 You say the Vapor Beast is an 20 21 e-commerce sales engine and a vapor supply 21 22 22 wholesaler and line of vape shops. Do you see 23 that? 23 24 Α. Yeah. It's principally a 24 25 third-party distributor of products to vape 25

Page 26 Page 28 1 L. WEXLER - CONFIDENTIAL L. WEXLER - CONFIDENTIAL 2 2 Q. Did you sell any other pod-based 3 3 systems? 4 4 Α. I believe that in the stores, there 5 5 were some other pod-based systems. 6 6 Do you recall if you sold Vuse Alto? 7 7 It was never mentioned to me. We never discussed -- it was never discussed in 8 8 9 9 my presence that we sold Vuse Alto. I didn't 10 10 review all the SKUs. There are 4,000 SKUs in 11 11 this business, so it takes a lot of time to 12 12 keep up on it. 13 13 Q. NJOY ACE or myblu INTENSE? 14 14 I can't say with certainty that any 15 15 of them were sold. It wouldn't surprise me, 16 Understood. Did these stores sell 16 if they were. 17 17 closed system e-vapor products? Ο. Do you recall if your wholesale 18 Α. 18 business sells these products? 19 Do you recall which closed system 19 I think that one of our wholesale 20 20 businesses sold myblu, for a period of time. e-vapor products? It's the only thing I can remember of any 21 In fact, if you go back to Vapor 21 22 Shark, Vapor Shark was one of the earliest significance. As I said, we did sell JUUL, a 22 23 third parties to be able to sell JUUL. So, 23 lot of JUUL at one time. 24 Q. until JUUL shut off Vapor Shark, it actually 24 And when did you stop selling JUUL 25 was a significant part of Vapor Shark's again? I don't think I got that. Page 27 Page 29 1 L. WEXLER - CONFIDENTIAL 1 L. WEXLER - CONFIDENTIAL 2 business in the stores, as an example. 2 Just after they told us they 3 You mentioned that JUUL shut down 3 wouldn't give it to us anymore. I don't 4 Vapor Shark. 4 remember the date. 5 Why did it -- what do you mean by it 5 Do you know if it was in 2018 or Ο. 6 shut down Vapor Shark? 6 2019? 7 7 MR. FORD: I think he said, "shut Α. I can't speculate. 8 off." 8 Why don't we turn to Paragraph 5 of 9 MR. SOWLATI: Shut off. Sorry. your Declaration. You say that your wholesale 10 THE WITNESS: Thank you. 10 figures include both closed and open systems, MR. FORD: Go ahead. 11 11 although open systems account for a much 12 I don't know why they did it. Vapor 12 larger part. 13 Shark had an agreement to have access to JUUL. 13 When you say, "much larger part," 14 They're one of the first third-party people to 14 are you able to give me a ballpark on what 15 engage with JUUL. And when JUUL became 15 percent of your total sales are open systems popular, there was a rumor that they were 16 16 versus closed? 17 having some supply issues, there was a 17 Α. Significantly over 50 percent. 18 shortage in the market, and they stopped 18 Do you know if it's about 19 selling it to the Vapor Shark. 19 80 percent? 20 Ο. Did that materially affect your 20 That would be fair. It fluctuates, 21 sales? 21 from time to time. I never calculated the 22 At the time, I think it was close to 22 average over time. 23 17 percent of Vapor Shark's sales, if I 23 Q. Okav. remember correctly. That's pretty 24 24 Α. But it's very significant. 25 25 And is it generally accurate to say

significant, yes.

	January	- ,	
	Page 30		Page 32
1	L. WEXLER - CONFIDENTIAL	1	L. WEXLER - CONFIDENTIAL
2	that vape shops tend not to sell a large	2	reasons why people want to switch from
3	amount of closed systems while convenience	3	cigarettes. I can't speak to any one
4	stores tend to sell a significant amount of	4	individual's desire.
5	closed systems?	5	Q. So, you don't see how Cigalikes can
6	MR. LEE: Objection to form.	6	carry the stigma associated for some people of
7	MR. FORD: Objection. Vague.	7	cigarettes?
8	A. Can you repeat the question, please?	8	A. I imagine that there are some people
9	Q. Generally, closed systems are	9	who felt more comfortable with Cigalikes
10	primarily sold at convenience stores as	10	because they function like a cigarette; same
11	opposed to vape shops, right?	11	shame and form. In fact, we still have a
12	A. I think our wholesale business'	12	Cigalike business. We have a product called
13	sales reflect the mix of products that were	13	South Beach Smoke that still sells Cigalikes
14	sold in vape shops, yes.	14	to people.
15	Q. I'd like to turn to Paragraphs 6 and	15	I think people may be comfortable
16	7 of your Declaration. We briefly discussed	16	with them. Some people want to get as far
17	Cigalikes, just a second ago, and I have a few	17	away from cigarettes as possible, so they make
18	more questions about them.	18	choices. I think there's a lot of cigarette
19	To begin, Mr. Wexler, what is a	19	smokers and there's a lot of people who are
20	Cigalike?	20	associated with vape, and there's a lot of
21	A. Cigalike is terminology that we use	21	reasons for that.
22	to describe a product that looks very much	22	Q. Cigalikes have seen their share
23	like a cigarette. It is cylinder, it's	23	decrease pretty dramatically in recent years,
24	roughly about the same length of a cigarette,	24	right?
25	and it's decorated very similar to a	25	A. Yes. In recent years, I don't know.
	Page 31		Page 33
1	L. WEXLER - CONFIDENTIAL	1	L. WEXLER - CONFIDENTIAL
2	L. WEXLER - CONFIDENTIAL cigarette.	2	-
2 3	L. WEXLER - CONFIDENTIAL cigarette. Q. Cigalikes have a number of	2	L. WEXLER - CONFIDENTIAL It happened more in the 2014, 2015, to 2018 period.
2 3 4	L. WEXLER - CONFIDENTIAL cigarette. Q. Cigalikes have a number of drawbacks, right?	2 3 4	L. WEXLER - CONFIDENTIAL It happened more in the 2014, 2015, to 2018 period. Q. And why is that?
2 3 4 5	L. WEXLER - CONFIDENTIAL cigarette. Q. Cigalikes have a number of drawbacks, right? A. Yes.	2 3 4 5	L. WEXLER - CONFIDENTIAL It happened more in the 2014, 2015, to 2018 period. Q. And why is that? A. Cigalikes, as a product, had some
2 3 4 5 6	L. WEXLER - CONFIDENTIAL cigarette. Q. Cigalikes have a number of drawbacks, right? A. Yes. Q. And you just said Cigalikes resemble	2 3 4 5 6	L. WEXLER - CONFIDENTIAL It happened more in the 2014, 2015, to 2018 period. Q. And why is that? A. Cigalikes, as a product, had some drawbacks. The size of it didn't allow for
2 3 4 5 6 7	L. WEXLER - CONFIDENTIAL cigarette. Q. Cigalikes have a number of drawbacks, right? A. Yes. Q. And you just said Cigalikes resemble the size and shape of a cigarette, right?	2 3 4 5 6 7	L. WEXLER - CONFIDENTIAL It happened more in the 2014, 2015, to 2018 period. Q. And why is that? A. Cigalikes, as a product, had some drawbacks. The size of it didn't allow for large enough batteries, so it didn't deliver
2 3 4 5 6 7 8	L. WEXLER - CONFIDENTIAL cigarette. Q. Cigalikes have a number of drawbacks, right? A. Yes. Q. And you just said Cigalikes resemble the size and shape of a cigarette, right? A. Yes.	2 3 4 5 6 7 8	L. WEXLER - CONFIDENTIAL It happened more in the 2014, 2015, to 2018 period. Q. And why is that? A. Cigalikes, as a product, had some drawbacks. The size of it didn't allow for large enough batteries, so it didn't deliver enough vapor. I think the decline of
2 3 4 5 6 7 8	L. WEXLER - CONFIDENTIAL cigarette. Q. Cigalikes have a number of drawbacks, right? A. Yes. Q. And you just said Cigalikes resemble the size and shape of a cigarette, right? A. Yes. Q. As a result, they carry the stigma	2 3 4 5 6 7 8 9	L. WEXLER - CONFIDENTIAL It happened more in the 2014, 2015, to 2018 period. Q. And why is that? A. Cigalikes, as a product, had some drawbacks. The size of it didn't allow for large enough batteries, so it didn't deliver enough vapor. I think the decline of Cigalikes started when open systems appeared
2 3 4 5 6 7 8 9	L. WEXLER - CONFIDENTIAL cigarette. Q. Cigalikes have a number of drawbacks, right? A. Yes. Q. And you just said Cigalikes resemble the size and shape of a cigarette, right? A. Yes. Q. As a result, they carry the stigma of cigarettes, correct?	2 3 4 5 6 7 8 9	L. WEXLER - CONFIDENTIAL It happened more in the 2014, 2015, to 2018 period. Q. And why is that? A. Cigalikes, as a product, had some drawbacks. The size of it didn't allow for large enough batteries, so it didn't deliver enough vapor. I think the decline of Cigalikes started when open systems appeared on the market. Open systems had larger
2 3 4 5 6 7 8 9 10	L. WEXLER - CONFIDENTIAL cigarette. Q. Cigalikes have a number of drawbacks, right? A. Yes. Q. And you just said Cigalikes resemble the size and shape of a cigarette, right? A. Yes. Q. As a result, they carry the stigma of cigarettes, correct? A. I can't speak to that.	2 3 4 5 6 7 8 9 10	L. WEXLER - CONFIDENTIAL It happened more in the 2014, 2015, to 2018 period. Q. And why is that? A. Cigalikes, as a product, had some drawbacks. The size of it didn't allow for large enough batteries, so it didn't deliver enough vapor. I think the decline of Cigalikes started when open systems appeared on the market. Open systems had larger batteries, had a bigger range of flavors.
2 3 4 5 6 7 8 9 10 11 12	L. WEXLER - CONFIDENTIAL cigarette. Q. Cigalikes have a number of drawbacks, right? A. Yes. Q. And you just said Cigalikes resemble the size and shape of a cigarette, right? A. Yes. Q. As a result, they carry the stigma of cigarettes, correct? A. I can't speak to that. Q. Okay. Well, for smokers looking to	2 3 4 5 6 7 8 9 10 11	L. WEXLER - CONFIDENTIAL It happened more in the 2014, 2015, to 2018 period. Q. And why is that? A. Cigalikes, as a product, had some drawbacks. The size of it didn't allow for large enough batteries, so it didn't deliver enough vapor. I think the decline of Cigalikes started when open systems appeared on the market. Open systems had larger batteries, had a bigger range of flavors. They gave the individual a way of customizing
2 3 4 5 6 7 8 9 10 11 12 13	L. WEXLER - CONFIDENTIAL cigarette. Q. Cigalikes have a number of drawbacks, right? A. Yes. Q. And you just said Cigalikes resemble the size and shape of a cigarette, right? A. Yes. Q. As a result, they carry the stigma of cigarettes, correct? A. I can't speak to that. Q. Okay. Well, for smokers looking to switch from cigarettes, the shape of a	2 3 4 5 6 7 8 9 10 11 12 13	L. WEXLER - CONFIDENTIAL It happened more in the 2014, 2015, to 2018 period. Q. And why is that? A. Cigalikes, as a product, had some drawbacks. The size of it didn't allow for large enough batteries, so it didn't deliver enough vapor. I think the decline of Cigalikes started when open systems appeared on the market. Open systems had larger batteries, had a bigger range of flavors. They gave the individual a way of customizing their vaping experience. You could get
2 3 4 5 6 7 8 9 10 11 12 13 14	L. WEXLER - CONFIDENTIAL cigarette. Q. Cigalikes have a number of drawbacks, right? A. Yes. Q. And you just said Cigalikes resemble the size and shape of a cigarette, right? A. Yes. Q. As a result, they carry the stigma of cigarettes, correct? A. I can't speak to that. Q. Okay. Well, for smokers looking to switch from cigarettes, the shape of a cigarette would, you know, might strike	2 3 4 5 6 7 8 9 10 11 12 13 14	L. WEXLER - CONFIDENTIAL It happened more in the 2014, 2015, to 2018 period. Q. And why is that? A. Cigalikes, as a product, had some drawbacks. The size of it didn't allow for large enough batteries, so it didn't deliver enough vapor. I think the decline of Cigalikes started when open systems appeared on the market. Open systems had larger batteries, had a bigger range of flavors. They gave the individual a way of customizing their vaping experience. You could get different nicotine strengths, a much greater
2 3 4 5 6 7 8 9 10 11 12 13 14 15	L. WEXLER - CONFIDENTIAL cigarette. Q. Cigalikes have a number of drawbacks, right? A. Yes. Q. And you just said Cigalikes resemble the size and shape of a cigarette, right? A. Yes. Q. As a result, they carry the stigma of cigarettes, correct? A. I can't speak to that. Q. Okay. Well, for smokers looking to switch from cigarettes, the shape of a cigarette would, you know, might strike that.	2 3 4 5 6 7 8 9 10 11 12 13 14 15	L. WEXLER - CONFIDENTIAL It happened more in the 2014, 2015, to 2018 period. Q. And why is that? A. Cigalikes, as a product, had some drawbacks. The size of it didn't allow for large enough batteries, so it didn't deliver enough vapor. I think the decline of Cigalikes started when open systems appeared on the market. Open systems had larger batteries, had a bigger range of flavors. They gave the individual a way of customizing their vaping experience. You could get different nicotine strengths, a much greater variety of flavors, you could get devices that
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	L. WEXLER - CONFIDENTIAL cigarette. Q. Cigalikes have a number of drawbacks, right? A. Yes. Q. And you just said Cigalikes resemble the size and shape of a cigarette, right? A. Yes. Q. As a result, they carry the stigma of cigarettes, correct? A. I can't speak to that. Q. Okay. Well, for smokers looking to switch from cigarettes, the shape of a cigarette would, you know, might strike that. For many health-conscious people, a	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	L. WEXLER - CONFIDENTIAL It happened more in the 2014, 2015, to 2018 period. Q. And why is that? A. Cigalikes, as a product, had some drawbacks. The size of it didn't allow for large enough batteries, so it didn't deliver enough vapor. I think the decline of Cigalikes started when open systems appeared on the market. Open systems had larger batteries, had a bigger range of flavors. They gave the individual a way of customizing their vaping experience. You could get different nicotine strengths, a much greater variety of flavors, you could get devices that had more or less energy, create big plumes of
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	L. WEXLER - CONFIDENTIAL cigarette. Q. Cigalikes have a number of drawbacks, right? A. Yes. Q. And you just said Cigalikes resemble the size and shape of a cigarette, right? A. Yes. Q. As a result, they carry the stigma of cigarettes, correct? A. I can't speak to that. Q. Okay. Well, for smokers looking to switch from cigarettes, the shape of a cigarette would, you know, might strike that. For many health-conscious people, a cigarette has a negative connotation, right?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	L. WEXLER - CONFIDENTIAL It happened more in the 2014, 2015, to 2018 period. Q. And why is that? A. Cigalikes, as a product, had some drawbacks. The size of it didn't allow for large enough batteries, so it didn't deliver enough vapor. I think the decline of Cigalikes started when open systems appeared on the market. Open systems had larger batteries, had a bigger range of flavors. They gave the individual a way of customizing their vaping experience. You could get different nicotine strengths, a much greater variety of flavors, you could get devices that had more or less energy, create big plumes of smoke, small plumes of smoke. The open
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	L. WEXLER - CONFIDENTIAL cigarette. Q. Cigalikes have a number of drawbacks, right? A. Yes. Q. And you just said Cigalikes resemble the size and shape of a cigarette, right? A. Yes. Q. As a result, they carry the stigma of cigarettes, correct? A. I can't speak to that. Q. Okay. Well, for smokers looking to switch from cigarettes, the shape of a cigarette would, you know, might strike that. For many health-conscious people, a cigarette has a negative connotation, right? MR. FORD: Objection.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	L. WEXLER - CONFIDENTIAL It happened more in the 2014, 2015, to 2018 period. Q. And why is that? A. Cigalikes, as a product, had some drawbacks. The size of it didn't allow for large enough batteries, so it didn't deliver enough vapor. I think the decline of Cigalikes started when open systems appeared on the market. Open systems had larger batteries, had a bigger range of flavors. They gave the individual a way of customizing their vaping experience. You could get different nicotine strengths, a much greater variety of flavors, you could get devices that had more or less energy, create big plumes of smoke, small plumes of smoke. The open systems were the first thing that really
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	L. WEXLER - CONFIDENTIAL cigarette. Q. Cigalikes have a number of drawbacks, right? A. Yes. Q. And you just said Cigalikes resemble the size and shape of a cigarette, right? A. Yes. Q. As a result, they carry the stigma of cigarettes, correct? A. I can't speak to that. Q. Okay. Well, for smokers looking to switch from cigarettes, the shape of a cigarette would, you know, might strike that. For many health-conscious people, a cigarette has a negative connotation, right? MR. FORD: Objection. MR. LEE: Same objection.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	L. WEXLER - CONFIDENTIAL It happened more in the 2014, 2015, to 2018 period. Q. And why is that? A. Cigalikes, as a product, had some drawbacks. The size of it didn't allow for large enough batteries, so it didn't deliver enough vapor. I think the decline of Cigalikes started when open systems appeared on the market. Open systems had larger batteries, had a bigger range of flavors. They gave the individual a way of customizing their vaping experience. You could get different nicotine strengths, a much greater variety of flavors, you could get devices that had more or less energy, create big plumes of smoke, small plumes of smoke. The open systems were the first thing that really started hurting the sales of Cigalikes.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	L. WEXLER - CONFIDENTIAL cigarette. Q. Cigalikes have a number of drawbacks, right? A. Yes. Q. And you just said Cigalikes resemble the size and shape of a cigarette, right? A. Yes. Q. As a result, they carry the stigma of cigarettes, correct? A. I can't speak to that. Q. Okay. Well, for smokers looking to switch from cigarettes, the shape of a cigarette would, you know, might strike that. For many health-conscious people, a cigarette has a negative connotation, right? MR. FORD: Objection. MR. LEE: Same objection. A. Can be.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	L. WEXLER - CONFIDENTIAL It happened more in the 2014, 2015, to 2018 period. Q. And why is that? A. Cigalikes, as a product, had some drawbacks. The size of it didn't allow for large enough batteries, so it didn't deliver enough vapor. I think the decline of Cigalikes started when open systems appeared on the market. Open systems had larger batteries, had a bigger range of flavors. They gave the individual a way of customizing their vaping experience. You could get different nicotine strengths, a much greater variety of flavors, you could get devices that had more or less energy, create big plumes of smoke, small plumes of smoke. The open systems were the first thing that really started hurting the sales of Cigalikes. People started switching to open systems.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	L. WEXLER - CONFIDENTIAL cigarette. Q. Cigalikes have a number of drawbacks, right? A. Yes. Q. And you just said Cigalikes resemble the size and shape of a cigarette, right? A. Yes. Q. As a result, they carry the stigma of cigarettes, correct? A. I can't speak to that. Q. Okay. Well, for smokers looking to switch from cigarettes, the shape of a cigarette would, you know, might strike that. For many health-conscious people, a cigarette has a negative connotation, right? MR. FORD: Objection. MR. LEE: Same objection. A. Can be. Q. Many individuals looking to switch	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	L. WEXLER - CONFIDENTIAL It happened more in the 2014, 2015, to 2018 period. Q. And why is that? A. Cigalikes, as a product, had some drawbacks. The size of it didn't allow for large enough batteries, so it didn't deliver enough vapor. I think the decline of Cigalikes started when open systems appeared on the market. Open systems had larger batteries, had a bigger range of flavors. They gave the individual a way of customizing their vaping experience. You could get different nicotine strengths, a much greater variety of flavors, you could get devices that had more or less energy, create big plumes of smoke, small plumes of smoke. The open systems were the first thing that really started hurting the sales of Cigalikes. People started switching to open systems. Q. And pods have taken a significant
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	L. WEXLER - CONFIDENTIAL cigarette. Q. Cigalikes have a number of drawbacks, right? A. Yes. Q. And you just said Cigalikes resemble the size and shape of a cigarette, right? A. Yes. Q. As a result, they carry the stigma of cigarettes, correct? A. I can't speak to that. Q. Okay. Well, for smokers looking to switch from cigarettes, the shape of a cigarette would, you know, might strike that. For many health-conscious people, a cigarette has a negative connotation, right? MR. FORD: Objection. MR. LEE: Same objection. A. Can be. Q. Many individuals looking to switch from smoking are looking to switch to a	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	L. WEXLER - CONFIDENTIAL It happened more in the 2014, 2015, to 2018 period. Q. And why is that? A. Cigalikes, as a product, had some drawbacks. The size of it didn't allow for large enough batteries, so it didn't deliver enough vapor. I think the decline of Cigalikes started when open systems appeared on the market. Open systems had larger batteries, had a bigger range of flavors. They gave the individual a way of customizing their vaping experience. You could get different nicotine strengths, a much greater variety of flavors, you could get devices that had more or less energy, create big plumes of smoke, small plumes of smoke. The open systems were the first thing that really started hurting the sales of Cigalikes. People started switching to open systems. Q. And pods have taken a significant share away of Cigalikes, too, right?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	L. WEXLER - CONFIDENTIAL cigarette. Q. Cigalikes have a number of drawbacks, right? A. Yes. Q. And you just said Cigalikes resemble the size and shape of a cigarette, right? A. Yes. Q. As a result, they carry the stigma of cigarettes, correct? A. I can't speak to that. Q. Okay. Well, for smokers looking to switch from cigarettes, the shape of a cigarette would, you know, might strike that. For many health-conscious people, a cigarette has a negative connotation, right? MR. FORD: Objection. MR. LEE: Same objection. A. Can be. Q. Many individuals looking to switch from smoking are looking to switch to a healthier alternative, right?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	L. WEXLER - CONFIDENTIAL It happened more in the 2014, 2015, to 2018 period. Q. And why is that? A. Cigalikes, as a product, had some drawbacks. The size of it didn't allow for large enough batteries, so it didn't deliver enough vapor. I think the decline of Cigalikes started when open systems appeared on the market. Open systems had larger batteries, had a bigger range of flavors. They gave the individual a way of customizing their vaping experience. You could get different nicotine strengths, a much greater variety of flavors, you could get devices that had more or less energy, create big plumes of smoke, small plumes of smoke. The open systems were the first thing that really started hurting the sales of Cigalikes. People started switching to open systems. Q. And pods have taken a significant share away of Cigalikes, too, right? A. Excuse me?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	L. WEXLER - CONFIDENTIAL cigarette. Q. Cigalikes have a number of drawbacks, right? A. Yes. Q. And you just said Cigalikes resemble the size and shape of a cigarette, right? A. Yes. Q. As a result, they carry the stigma of cigarettes, correct? A. I can't speak to that. Q. Okay. Well, for smokers looking to switch from cigarettes, the shape of a cigarette would, you know, might strike that. For many health-conscious people, a cigarette has a negative connotation, right? MR. FORD: Objection. MR. LEE: Same objection. A. Can be. Q. Many individuals looking to switch from smoking are looking to switch to a	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	L. WEXLER - CONFIDENTIAL It happened more in the 2014, 2015, to 2018 period. Q. And why is that? A. Cigalikes, as a product, had some drawbacks. The size of it didn't allow for large enough batteries, so it didn't deliver enough vapor. I think the decline of Cigalikes started when open systems appeared on the market. Open systems had larger batteries, had a bigger range of flavors. They gave the individual a way of customizing their vaping experience. You could get different nicotine strengths, a much greater variety of flavors, you could get devices that had more or less energy, create big plumes of smoke, small plumes of smoke. The open systems were the first thing that really started hurting the sales of Cigalikes. People started switching to open systems. Q. And pods have taken a significant share away of Cigalikes, too, right?

	Page 34		Page 36
1	L. WEXLER - CONFIDENTIAL	1	L. WEXLER - CONFIDENTIAL
2	A. I believe that the sales of pods has	2	level of satisfaction than the options you get
3	grown much faster than Cigalikes, and Cigalike	3	from open systems and the options you get from
4	sales have actually declined. But I think	4	some pod systems and disposable systems.
5	that the first big hit to Cigalikes was the	5	Q. I don't want to jump around too
6	open systems, and then pods certainly replaced	6	much, but if we take a quick look at Paragraph
7	them, certainly in C-stores. Pods grew much	7	11, you note there that JUUL's products
8	larger than Cigalikes.	8	contain relatively high levels of nicotine, as
9	Q. And you'd agree that the form factor	9	high as 5 percent. Do you see that?
10	of pods contributed to their success, right?	10	A. Yes.
11	A. I think there's a whole range of	11	Q. Given the rise of products like JUUL
12	MR. FORD: Hold on.	12	with nicotine concentrations in the 5 percent
13	Objection. Vague.	13	range, a product with 1.8 percent to
14	A. What specifically are you asking?	14	2.4 percent nicotine would have difficulty
15	Q. You can answer.	15	seeing the success of products like JUUL,
16	I was asking: You'd agree that the	16	right?
17	form factor of pods contributed to their	17	MR. LEE: Objection to form.
18	success, right?	18	MR. FORD: Vague.
19	A. I think there are many issues that	19	A. There would be repeat the
20	contributed to the success of pods.	20	question, please.
21	Q. Including the form factor?	21	Q. Sure. So, given the rise of
22	A. I imagine there's some consumers who	22	products like JUUL with a nicotine
23	like the form factor. I can't speak to any	23	concentration in the 5 percent range, a
24	individual.	24	product with 1.8 percent to 2.4 percent
25	Q. Mr. Wexler, in Paragraph 7, you say	25	nicotine would have difficulty of seeing the
	Page 35		Page 37
1	L. WEXLER - CONFIDENTIAL	1	L. WEXLER - CONFIDENTIAL
2	that most Cigalikes were relatively low in	2	success of products like JUUL, right?
3	nicotine concentration. Do you see that?	3	MR. FORD: Objection.
4			Tatt Total objection.
	A. Yes.	4	MR. LEE: Same objection.
5	A. Yes. Q. When you say the nicotine	4 5	· ·
5 6			MR. LEE: Same objection.
	Q. When you say the nicotine	5	MR. LEE: Same objection. Q. You can answer.
6	Q. When you say the nicotine concentration was relatively low, you're	5 6	MR. LEE: Same objection. Q. You can answer. A. Okay. So, you're isolating on the
6 7	Q. When you say the nicotine concentration was relatively low, you're comparing Cigalikes, in part, to pods like	5 6 7	MR. LEE: Same objection. Q. You can answer. A. Okay. So, you're isolating on the percent of the nicotine, but you're not asking
6 7 8	Q. When you say the nicotine concentration was relatively low, you're comparing Cigalikes, in part, to pods like JUUL, right?	5 6 7 8	MR. LEE: Same objection. Q. You can answer. A. Okay. So, you're isolating on the percent of the nicotine, but you're not asking the right question. The right question is the
6 7 8 9	Q. When you say the nicotine concentration was relatively low, you're comparing Cigalikes, in part, to pods like JUUL, right? A. Yes, in part. But there's a range	5 6 7 8 9	MR. LEE: Same objection. Q. You can answer. A. Okay. So, you're isolating on the percent of the nicotine, but you're not asking the right question. The right question is the combination of the battery, combination of the
6 7 8 9 10	Q. When you say the nicotine concentration was relatively low, you're comparing Cigalikes, in part, to pods like JUUL, right? A. Yes, in part. But there's a range of options in the vape market. And I think	5 6 7 8 9	MR. LEE: Same objection. Q. You can answer. A. Okay. So, you're isolating on the percent of the nicotine, but you're not asking the right question. The right question is the combination of the battery, combination of the liquid, the combination of the amount of
6 7 8 9 10 11	Q. When you say the nicotine concentration was relatively low, you're comparing Cigalikes, in part, to pods like JUUL, right? A. Yes, in part. But there's a range of options in the vape market. And I think the real issue is that the ability of the	5 6 7 8 9 10	MR. LEE: Same objection. Q. You can answer. A. Okay. So, you're isolating on the percent of the nicotine, but you're not asking the right question. The right question is the combination of the battery, combination of the liquid, the combination of the amount of nicotine, the amount of vapor that's produced.
6 7 8 9 10 11 12	Q. When you say the nicotine concentration was relatively low, you're comparing Cigalikes, in part, to pods like JUUL, right? A. Yes, in part. But there's a range of options in the vape market. And I think the real issue is that the ability of the Cigalikes to deliver the nicotine to the	5 6 7 8 9 10 11 12	MR. LEE: Same objection. Q. You can answer. A. Okay. So, you're isolating on the percent of the nicotine, but you're not asking the right question. The right question is the combination of the battery, combination of the liquid, the combination of the amount of nicotine, the amount of vapor that's produced. There are open systems that have
6 7 8 9 10 11 12 13	Q. When you say the nicotine concentration was relatively low, you're comparing Cigalikes, in part, to pods like JUUL, right? A. Yes, in part. But there's a range of options in the vape market. And I think the real issue is that the ability of the Cigalikes to deliver the nicotine to the consumer, it didn't have as much impact.	5 6 7 8 9 10 11 12 13	MR. LEE: Same objection. Q. You can answer. A. Okay. So, you're isolating on the percent of the nicotine, but you're not asking the right question. The right question is the combination of the battery, combination of the liquid, the combination of the amount of nicotine, the amount of vapor that's produced. There are open systems that have lower levels of nicotine that are very
6 7 8 9 10 11 12 13 14	Q. When you say the nicotine concentration was relatively low, you're comparing Cigalikes, in part, to pods like JUUL, right? A. Yes, in part. But there's a range of options in the vape market. And I think the real issue is that the ability of the Cigalikes to deliver the nicotine to the consumer, it didn't have as much impact. Q. Can you explain that further?	5 6 7 8 9 10 11 12 13	MR. LEE: Same objection. Q. You can answer. A. Okay. So, you're isolating on the percent of the nicotine, but you're not asking the right question. The right question is the combination of the battery, combination of the liquid, the combination of the amount of nicotine, the amount of vapor that's produced. There are open systems that have lower levels of nicotine that are very successful; that use liquids with lower levels
6 7 8 9 10 11 12 13 14 15	Q. When you say the nicotine concentration was relatively low, you're comparing Cigalikes, in part, to pods like JUUL, right? A. Yes, in part. But there's a range of options in the vape market. And I think the real issue is that the ability of the Cigalikes to deliver the nicotine to the consumer, it didn't have as much impact. Q. Can you explain that further? A. Well, the small battery created less	5 6 7 8 9 10 11 12 13 14	MR. LEE: Same objection. Q. You can answer. A. Okay. So, you're isolating on the percent of the nicotine, but you're not asking the right question. The right question is the combination of the battery, combination of the liquid, the combination of the amount of nicotine, the amount of vapor that's produced. There are open systems that have lower levels of nicotine that are very successful; that use liquids with lower levels of nicotine that are very successful because
6 7 8 9 10 11 12 13 14 15 16	Q. When you say the nicotine concentration was relatively low, you're comparing Cigalikes, in part, to pods like JUUL, right? A. Yes, in part. But there's a range of options in the vape market. And I think the real issue is that the ability of the Cigalikes to deliver the nicotine to the consumer, it didn't have as much impact. Q. Can you explain that further? A. Well, the small battery created less vape; less vape carries less nicotine. So,	5 6 7 8 9 10 11 12 13 14 15 16	MR. LEE: Same objection. Q. You can answer. A. Okay. So, you're isolating on the percent of the nicotine, but you're not asking the right question. The right question is the combination of the battery, combination of the liquid, the combination of the amount of nicotine, the amount of vapor that's produced. There are open systems that have lower levels of nicotine that are very successful; that use liquids with lower levels of nicotine that are very successful because the amount of vapor is larger. And some
6 7 8 9 10 11 12 13 14 15 16 17	Q. When you say the nicotine concentration was relatively low, you're comparing Cigalikes, in part, to pods like JUUL, right? A. Yes, in part. But there's a range of options in the vape market. And I think the real issue is that the ability of the Cigalikes to deliver the nicotine to the consumer, it didn't have as much impact. Q. Can you explain that further? A. Well, the small battery created less vape; less vape carries less nicotine. So, therefore, the consumer would get less	5 6 7 8 9 10 11 12 13 14 15 16 17	MR. LEE: Same objection. Q. You can answer. A. Okay. So, you're isolating on the percent of the nicotine, but you're not asking the right question. The right question is the combination of the battery, combination of the liquid, the combination of the amount of nicotine, the amount of vapor that's produced. There are open systems that have lower levels of nicotine that are very successful; that use liquids with lower levels of nicotine that are very successful because the amount of vapor is larger. And some consumers are looking for more vapor, but not
6 7 8 9 10 11 12 13 14 15 16 17 18	Q. When you say the nicotine concentration was relatively low, you're comparing Cigalikes, in part, to pods like JUUL, right? A. Yes, in part. But there's a range of options in the vape market. And I think the real issue is that the ability of the Cigalikes to deliver the nicotine to the consumer, it didn't have as much impact. Q. Can you explain that further? A. Well, the small battery created less vape; less vape carries less nicotine. So, therefore, the consumer would get less satisfaction.	5 6 7 8 9 10 11 12 13 14 15 16 17 18	MR. LEE: Same objection. Q. You can answer. A. Okay. So, you're isolating on the percent of the nicotine, but you're not asking the right question. The right question is the combination of the battery, combination of the liquid, the combination of the amount of nicotine, the amount of vapor that's produced. There are open systems that have lower levels of nicotine that are very successful; that use liquids with lower levels of nicotine that are very successful because the amount of vapor is larger. And some consumers are looking for more vapor, but not necessarily for higher levels of nicotine.
6 7 8 9 10 11 12 13 14 15 16 17 18 19	Q. When you say the nicotine concentration was relatively low, you're comparing Cigalikes, in part, to pods like JUUL, right? A. Yes, in part. But there's a range of options in the vape market. And I think the real issue is that the ability of the Cigalikes to deliver the nicotine to the consumer, it didn't have as much impact. Q. Can you explain that further? A. Well, the small battery created less vape; less vape carries less nicotine. So, therefore, the consumer would get less satisfaction. Q. You would consider 1.8 percent to	5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	MR. LEE: Same objection. Q. You can answer. A. Okay. So, you're isolating on the percent of the nicotine, but you're not asking the right question. The right question is the combination of the battery, combination of the liquid, the combination of the amount of nicotine, the amount of vapor that's produced. There are open systems that have lower levels of nicotine that are very successful; that use liquids with lower levels of nicotine that are very successful because the amount of vapor is larger. And some consumers are looking for more vapor, but not necessarily for higher levels of nicotine. There's a range of consumers and
6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	Q. When you say the nicotine concentration was relatively low, you're comparing Cigalikes, in part, to pods like JUUL, right? A. Yes, in part. But there's a range of options in the vape market. And I think the real issue is that the ability of the Cigalikes to deliver the nicotine to the consumer, it didn't have as much impact. Q. Can you explain that further? A. Well, the small battery created less vape; less vape carries less nicotine. So, therefore, the consumer would get less satisfaction. Q. You would consider 1.8 percent to 2.4 percent nicotine concentration to be at	5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	MR. LEE: Same objection. Q. You can answer. A. Okay. So, you're isolating on the percent of the nicotine, but you're not asking the right question. The right question is the combination of the battery, combination of the liquid, the combination of the amount of nicotine, the amount of vapor that's produced. There are open systems that have lower levels of nicotine that are very successful; that use liquids with lower levels of nicotine that are very successful because the amount of vapor is larger. And some consumers are looking for more vapor, but not necessarily for higher levels of nicotine. There's a range of consumers and nicotine, and there are all kinds of
6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	Q. When you say the nicotine concentration was relatively low, you're comparing Cigalikes, in part, to pods like JUUL, right? A. Yes, in part. But there's a range of options in the vape market. And I think the real issue is that the ability of the Cigalikes to deliver the nicotine to the consumer, it didn't have as much impact. Q. Can you explain that further? A. Well, the small battery created less vape; less vape carries less nicotine. So, therefore, the consumer would get less satisfaction. Q. You would consider 1.8 percent to 2.4 percent nicotine concentration to be at the low level that would contribute to low	5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	MR. LEE: Same objection. Q. You can answer. A. Okay. So, you're isolating on the percent of the nicotine, but you're not asking the right question. The right question is the combination of the battery, combination of the liquid, the combination of the amount of nicotine, the amount of vapor that's produced. There are open systems that have lower levels of nicotine that are very successful; that use liquids with lower levels of nicotine that are very successful because the amount of vapor is larger. And some consumers are looking for more vapor, but not necessarily for higher levels of nicotine. There's a range of consumers and nicotine, and there are all kinds of subsegments. You can't make it as a universal
6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	Q. When you say the nicotine concentration was relatively low, you're comparing Cigalikes, in part, to pods like JUUL, right? A. Yes, in part. But there's a range of options in the vape market. And I think the real issue is that the ability of the Cigalikes to deliver the nicotine to the consumer, it didn't have as much impact. Q. Can you explain that further? A. Well, the small battery created less vape; less vape carries less nicotine. So, therefore, the consumer would get less satisfaction. Q. You would consider 1.8 percent to 2.4 percent nicotine concentration to be at the low level that would contribute to low overall consumer satisfaction, right? A. I would consider the 1.8 to 2.4 combined with the battery and the amount of	5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	MR. LEE: Same objection. Q. You can answer. A. Okay. So, you're isolating on the percent of the nicotine, but you're not asking the right question. The right question is the combination of the battery, combination of the liquid, the combination of the amount of nicotine, the amount of vapor that's produced. There are open systems that have lower levels of nicotine that are very successful; that use liquids with lower levels of nicotine that are very successful because the amount of vapor is larger. And some consumers are looking for more vapor, but not necessarily for higher levels of nicotine. There's a range of consumers and nicotine, and there are all kinds of subsegments. You can't make it as a universal statement. Q. Right. But all else equal, a product with a 1.8 percent to 2.4 percent
6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	Q. When you say the nicotine concentration was relatively low, you're comparing Cigalikes, in part, to pods like JUUL, right? A. Yes, in part. But there's a range of options in the vape market. And I think the real issue is that the ability of the Cigalikes to deliver the nicotine to the consumer, it didn't have as much impact. Q. Can you explain that further? A. Well, the small battery created less vape; less vape carries less nicotine. So, therefore, the consumer would get less satisfaction. Q. You would consider 1.8 percent to 2.4 percent nicotine concentration to be at the low level that would contribute to low overall consumer satisfaction, right? A. I would consider the 1.8 to 2.4	5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	MR. LEE: Same objection. Q. You can answer. A. Okay. So, you're isolating on the percent of the nicotine, but you're not asking the right question. The right question is the combination of the battery, combination of the liquid, the combination of the amount of nicotine, the amount of vapor that's produced. There are open systems that have lower levels of nicotine that are very successful; that use liquids with lower levels of nicotine that are very successful because the amount of vapor is larger. And some consumers are looking for more vapor, but not necessarily for higher levels of nicotine. There's a range of consumers and nicotine, and there are all kinds of subsegments. You can't make it as a universal statement. Q. Right. But all else equal, a

	- January	1	
	Page 38		Page 40
1	L. WEXLER - CONFIDENTIAL	1	L. WEXLER - CONFIDENTIAL
2	success as a product in the 5 percent range,	2	Q. The nicotine hit provided by an
3	right?	3	e-vapor product is important in determining
4	MR. FORD: Objection. Asked and	4	whether it will see commercial success, right?
5	answered.	5	MR. LEE: Objection to form.
6	MR. LEE: Objection.	6	A. You keep on isolating on the
7 8	A. I don't know that I could add	7	nicotine, the nicotine hit. Nicotine is,
9	anything more than I already said.	9	obviously, a very important component of why people buy vapor products, but there's also
10	Q. Okay. Why don't we turn to	10	factors such as the amount of vapor, the
11	Paragraph 8 of your Declaration. A. Which one?	11	flavors, the range of flavors, the taste.
12	Q. Paragraph 8 of your Declaration.	12	It's, basically, the whole experience. It's
13	A. Okay. Hold on.	13	not just one thing. It's an important it
14	Yes.	14	is an element, but it is part of a larger
15	Q. Okay. In the second to last	15	package of elements. In other words, coming
16	sentence, you say, "Open systems provide a	16	out with the highest nicotine product would
17	larger nicotine hit than Cigalikes."	17	not necessarily make you the biggest success.
18	What is a nicotine hit?	18	Q. I want to go back to Paragraph 7,
19	A. It is an expression that some vapers	19	Mr. Wexler. You talk about the drawbacks
20	have used with me, and it is the way they feel	20	there of Cigalikes, and you mention a few
21	the nicotine when it goes into their body.	21	things; you mention battery puffs, you mention
22	Q. Why is a nicotine hit important to	22	flavors, and the mention the nicotine
23	smokers?	23	strength.
24	A. Apparently, in the way I'm	24	So, clearly the nicotine strength
25	talking about vapers, not smokers.	25	was one of the three factors you thought was
	-		
	Page 39		Page 41
1	L. WEXLER - CONFIDENTIAL	1	L. WEXLER - CONFIDENTIAL
2	L. WEXLER - CONFIDENTIAL Q. To a vaper.	2	L. WEXLER - CONFIDENTIAL important and contributed to low, overall,
2 3	L. WEXLER - CONFIDENTIAL Q. To a vaper. A. According to the consumers that I	2	L. WEXLER - CONFIDENTIAL important and contributed to low, overall, consumer satisfaction, right?
2 3 4	L. WEXLER - CONFIDENTIAL Q. To a vaper. A. According to the consumers that I talk to, that is one of the things they look	2 3 4	L. WEXLER - CONFIDENTIAL important and contributed to low, overall, consumer satisfaction, right? A. The amount of nicotine in the
2 3 4 5	L. WEXLER - CONFIDENTIAL Q. To a vaper. A. According to the consumers that I talk to, that is one of the things they look for; they look for the way the product makes	2 3 4 5	L. WEXLER - CONFIDENTIAL important and contributed to low, overall, consumer satisfaction, right? A. The amount of nicotine in the product combined with the battery and the
2 3 4 5 6	L. WEXLER - CONFIDENTIAL Q. To a vaper. A. According to the consumers that I talk to, that is one of the things they look for; they look for the way the product makes them feel. That's why they're using the	2 3 4 5 6	L. WEXLER - CONFIDENTIAL important and contributed to low, overall, consumer satisfaction, right? A. The amount of nicotine in the product combined with the battery and the amount of vapor produced delivered less
2 3 4 5 6 7	L. WEXLER - CONFIDENTIAL Q. To a vaper. A. According to the consumers that I talk to, that is one of the things they look for; they look for the way the product makes them feel. That's why they're using the product.	2 3 4 5 6 7	L. WEXLER - CONFIDENTIAL important and contributed to low, overall, consumer satisfaction, right? A. The amount of nicotine in the product combined with the battery and the amount of vapor produced delivered less satisfaction to consumers. These consumers,
2 3 4 5 6 7 8	L. WEXLER - CONFIDENTIAL Q. To a vaper. A. According to the consumers that I talk to, that is one of the things they look for; they look for the way the product makes them feel. That's why they're using the product. Q. And most of the vapers you speak to	2 3 4 5 6 7 8	L. WEXLER - CONFIDENTIAL important and contributed to low, overall, consumer satisfaction, right? A. The amount of nicotine in the product combined with the battery and the amount of vapor produced delivered less satisfaction to consumers. These consumers, when they had alternatives, chose other
2 3 4 5 6 7 8 9	L. WEXLER - CONFIDENTIAL Q. To a vaper. A. According to the consumers that I talk to, that is one of the things they look for; they look for the way the product makes them feel. That's why they're using the product. Q. And most of the vapers you speak to are vapers that frequent vape shops, right?	2 3 4 5 6 7 8 9	L. WEXLER - CONFIDENTIAL important and contributed to low, overall, consumer satisfaction, right? A. The amount of nicotine in the product combined with the battery and the amount of vapor produced delivered less satisfaction to consumers. These consumers, when they had alternatives, chose other products, and I believe that was one of the
2 3 4 5 6 7 8 9	L. WEXLER - CONFIDENTIAL Q. To a vaper. A. According to the consumers that I talk to, that is one of the things they look for; they look for the way the product makes them feel. That's why they're using the product. Q. And most of the vapers you speak to are vapers that frequent vape shops, right? A. I'm a very curious guy, and I will	2 3 4 5 6 7 8 9	L. WEXLER - CONFIDENTIAL important and contributed to low, overall, consumer satisfaction, right? A. The amount of nicotine in the product combined with the battery and the amount of vapor produced delivered less satisfaction to consumers. These consumers, when they had alternatives, chose other products, and I believe that was one of the factors, yes.
2 3 4 5 6 7 8 9 10	L. WEXLER - CONFIDENTIAL Q. To a vaper. A. According to the consumers that I talk to, that is one of the things they look for; they look for the way the product makes them feel. That's why they're using the product. Q. And most of the vapers you speak to are vapers that frequent vape shops, right? A. I'm a very curious guy, and I will ask whenever I see a vaper, I'll ask him,	2 3 4 5 6 7 8 9 10	L. WEXLER - CONFIDENTIAL important and contributed to low, overall, consumer satisfaction, right? A. The amount of nicotine in the product combined with the battery and the amount of vapor produced delivered less satisfaction to consumers. These consumers, when they had alternatives, chose other products, and I believe that was one of the factors, yes. Q. Mr. Wexler, can we turn to
2 3 4 5 6 7 8 9 10 11 12	L. WEXLER - CONFIDENTIAL Q. To a vaper. A. According to the consumers that I talk to, that is one of the things they look for; they look for the way the product makes them feel. That's why they're using the product. Q. And most of the vapers you speak to are vapers that frequent vape shops, right? A. I'm a very curious guy, and I will ask whenever I see a vaper, I'll ask him, whether he's on the street, in a vape shop, in	2 3 4 5 6 7 8 9 10 11 12	L. WEXLER - CONFIDENTIAL important and contributed to low, overall, consumer satisfaction, right? A. The amount of nicotine in the product combined with the battery and the amount of vapor produced delivered less satisfaction to consumers. These consumers, when they had alternatives, chose other products, and I believe that was one of the factors, yes. Q. Mr. Wexler, can we turn to Paragraph 10 of your Declaration? You mention
2 3 4 5 6 7 8 9 10 11 12 13	L. WEXLER - CONFIDENTIAL Q. To a vaper. A. According to the consumers that I talk to, that is one of the things they look for; they look for the way the product makes them feel. That's why they're using the product. Q. And most of the vapers you speak to are vapers that frequent vape shops, right? A. I'm a very curious guy, and I will ask whenever I see a vaper, I'll ask him, whether he's on the street, in a vape shop, in a C-store, at a party. It doesn't matter.	2 3 4 5 6 7 8 9 10 11 12 13	L. WEXLER - CONFIDENTIAL important and contributed to low, overall, consumer satisfaction, right? A. The amount of nicotine in the product combined with the battery and the amount of vapor produced delivered less satisfaction to consumers. These consumers, when they had alternatives, chose other products, and I believe that was one of the factors, yes. Q. Mr. Wexler, can we turn to Paragraph 10 of your Declaration? You mention that because of their small size, closed
2 3 4 5 6 7 8 9 10 11 12 13 14	L. WEXLER - CONFIDENTIAL Q. To a vaper. A. According to the consumers that I talk to, that is one of the things they look for; they look for the way the product makes them feel. That's why they're using the product. Q. And most of the vapers you speak to are vapers that frequent vape shops, right? A. I'm a very curious guy, and I will ask whenever I see a vaper, I'll ask him, whether he's on the street, in a vape shop, in a C-store, at a party. It doesn't matter. I'll talk to anybody.	2 3 4 5 6 7 8 9 10 11 12 13 14	L. WEXLER - CONFIDENTIAL important and contributed to low, overall, consumer satisfaction, right? A. The amount of nicotine in the product combined with the battery and the amount of vapor produced delivered less satisfaction to consumers. These consumers, when they had alternatives, chose other products, and I believe that was one of the factors, yes. Q. Mr. Wexler, can we turn to Paragraph 10 of your Declaration? You mention that because of their small size, closed systems are more discreet than open systems.
2 3 4 5 6 7 8 9 10 11 12 13 14 15	L. WEXLER - CONFIDENTIAL Q. To a vaper. A. According to the consumers that I talk to, that is one of the things they look for; they look for the way the product makes them feel. That's why they're using the product. Q. And most of the vapers you speak to are vapers that frequent vape shops, right? A. I'm a very curious guy, and I will ask whenever I see a vaper, I'll ask him, whether he's on the street, in a vape shop, in a C-store, at a party. It doesn't matter. I'll talk to anybody. Q. Right. But most of your direct	2 3 4 5 6 7 8 9 10 11 12 13 14 15	L. WEXLER - CONFIDENTIAL important and contributed to low, overall, consumer satisfaction, right? A. The amount of nicotine in the product combined with the battery and the amount of vapor produced delivered less satisfaction to consumers. These consumers, when they had alternatives, chose other products, and I believe that was one of the factors, yes. Q. Mr. Wexler, can we turn to Paragraph 10 of your Declaration? You mention that because of their small size, closed systems are more discreet than open systems. What is the importance for consumers
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	L. WEXLER - CONFIDENTIAL Q. To a vaper. A. According to the consumers that I talk to, that is one of the things they look for; they look for the way the product makes them feel. That's why they're using the product. Q. And most of the vapers you speak to are vapers that frequent vape shops, right? A. I'm a very curious guy, and I will ask whenever I see a vaper, I'll ask him, whether he's on the street, in a vape shop, in a C-store, at a party. It doesn't matter. I'll talk to anybody. Q. Right. But most of your direct knowledge through your business is through	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	L. WEXLER - CONFIDENTIAL important and contributed to low, overall, consumer satisfaction, right? A. The amount of nicotine in the product combined with the battery and the amount of vapor produced delivered less satisfaction to consumers. These consumers, when they had alternatives, chose other products, and I believe that was one of the factors, yes. Q. Mr. Wexler, can we turn to Paragraph 10 of your Declaration? You mention that because of their small size, closed systems are more discreet than open systems. What is the importance for consumers of a product being discreet?
2 3 4 5 6 7 8 9 10 11 12 13 14 15	L. WEXLER - CONFIDENTIAL Q. To a vaper. A. According to the consumers that I talk to, that is one of the things they look for; they look for the way the product makes them feel. That's why they're using the product. Q. And most of the vapers you speak to are vapers that frequent vape shops, right? A. I'm a very curious guy, and I will ask whenever I see a vaper, I'll ask him, whether he's on the street, in a vape shop, in a C-store, at a party. It doesn't matter. I'll talk to anybody. Q. Right. But most of your direct	2 3 4 5 6 7 8 9 10 11 12 13 14 15	L. WEXLER - CONFIDENTIAL important and contributed to low, overall, consumer satisfaction, right? A. The amount of nicotine in the product combined with the battery and the amount of vapor produced delivered less satisfaction to consumers. These consumers, when they had alternatives, chose other products, and I believe that was one of the factors, yes. Q. Mr. Wexler, can we turn to Paragraph 10 of your Declaration? You mention that because of their small size, closed systems are more discreet than open systems. What is the importance for consumers of a product being discreet?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	L. WEXLER - CONFIDENTIAL Q. To a vaper. A. According to the consumers that I talk to, that is one of the things they look for; they look for the way the product makes them feel. That's why they're using the product. Q. And most of the vapers you speak to are vapers that frequent vape shops, right? A. I'm a very curious guy, and I will ask whenever I see a vaper, I'll ask him, whether he's on the street, in a vape shop, in a C-store, at a party. It doesn't matter. I'll talk to anybody. Q. Right. But most of your direct knowledge through your business is through vape shops, right? MR. FORD: Objection. Vague.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	L. WEXLER - CONFIDENTIAL important and contributed to low, overall, consumer satisfaction, right? A. The amount of nicotine in the product combined with the battery and the amount of vapor produced delivered less satisfaction to consumers. These consumers, when they had alternatives, chose other products, and I believe that was one of the factors, yes. Q. Mr. Wexler, can we turn to Paragraph 10 of your Declaration? You mention that because of their small size, closed systems are more discreet than open systems. What is the importance for consumers of a product being discreet? A. I think there's two reasons for
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	L. WEXLER - CONFIDENTIAL Q. To a vaper. A. According to the consumers that I talk to, that is one of the things they look for; they look for the way the product makes them feel. That's why they're using the product. Q. And most of the vapers you speak to are vapers that frequent vape shops, right? A. I'm a very curious guy, and I will ask whenever I see a vaper, I'll ask him, whether he's on the street, in a vape shop, in a C-store, at a party. It doesn't matter. I'll talk to anybody. Q. Right. But most of your direct knowledge through your business is through vape shops, right? MR. FORD: Objection. Vague.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	L. WEXLER - CONFIDENTIAL important and contributed to low, overall, consumer satisfaction, right? A. The amount of nicotine in the product combined with the battery and the amount of vapor produced delivered less satisfaction to consumers. These consumers, when they had alternatives, chose other products, and I believe that was one of the factors, yes. Q. Mr. Wexler, can we turn to Paragraph 10 of your Declaration? You mention that because of their small size, closed systems are more discreet than open systems. What is the importance for consumers of a product being discreet? A. I think there's two reasons for consumers seeking out discreetness. One,
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	L. WEXLER - CONFIDENTIAL Q. To a vaper. A. According to the consumers that I talk to, that is one of the things they look for; they look for the way the product makes them feel. That's why they're using the product. Q. And most of the vapers you speak to are vapers that frequent vape shops, right? A. I'm a very curious guy, and I will ask whenever I see a vaper, I'll ask him, whether he's on the street, in a vape shop, in a C-store, at a party. It doesn't matter. I'll talk to anybody. Q. Right. But most of your direct knowledge through your business is through vape shops, right? MR. FORD: Objection. Vague. A. I have a very broad background in	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	L. WEXLER - CONFIDENTIAL important and contributed to low, overall, consumer satisfaction, right? A. The amount of nicotine in the product combined with the battery and the amount of vapor produced delivered less satisfaction to consumers. These consumers, when they had alternatives, chose other products, and I believe that was one of the factors, yes. Q. Mr. Wexler, can we turn to Paragraph 10 of your Declaration? You mention that because of their small size, closed systems are more discreet than open systems. What is the importance for consumers of a product being discreet? A. I think there's two reasons for consumers seeking out discreetness. One, generally, if they're smaller and more
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	L. WEXLER - CONFIDENTIAL Q. To a vaper. A. According to the consumers that I talk to, that is one of the things they look for; they look for the way the product makes them feel. That's why they're using the product. Q. And most of the vapers you speak to are vapers that frequent vape shops, right? A. I'm a very curious guy, and I will ask whenever I see a vaper, I'll ask him, whether he's on the street, in a vape shop, in a C-store, at a party. It doesn't matter. I'll talk to anybody. Q. Right. But most of your direct knowledge through your business is through vape shops, right? MR. FORD: Objection. Vague. A. I have a very broad background in tobacco and nicotine and vaping, so I can't say that the majority of my knowledge comes	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	L. WEXLER - CONFIDENTIAL important and contributed to low, overall, consumer satisfaction, right? A. The amount of nicotine in the product combined with the battery and the amount of vapor produced delivered less satisfaction to consumers. These consumers, when they had alternatives, chose other products, and I believe that was one of the factors, yes. Q. Mr. Wexler, can we turn to Paragraph 10 of your Declaration? You mention that because of their small size, closed systems are more discreet than open systems. What is the importance for consumers of a product being discreet? A. I think there's two reasons for consumers seeking out discreetness. One, generally, if they're smaller and more discreet, they're more portable. You can slip
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	L. WEXLER - CONFIDENTIAL Q. To a vaper. A. According to the consumers that I talk to, that is one of the things they look for; they look for the way the product makes them feel. That's why they're using the product. Q. And most of the vapers you speak to are vapers that frequent vape shops, right? A. I'm a very curious guy, and I will ask whenever I see a vaper, I'll ask him, whether he's on the street, in a vape shop, in a C-store, at a party. It doesn't matter. I'll talk to anybody. Q. Right. But most of your direct knowledge through your business is through vape shops, right? MR. FORD: Objection. Vague. A. I have a very broad background in tobacco and nicotine and vaping, so I can't	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	L. WEXLER - CONFIDENTIAL important and contributed to low, overall, consumer satisfaction, right? A. The amount of nicotine in the product combined with the battery and the amount of vapor produced delivered less satisfaction to consumers. These consumers, when they had alternatives, chose other products, and I believe that was one of the factors, yes. Q. Mr. Wexler, can we turn to Paragraph 10 of your Declaration? You mention that because of their small size, closed systems are more discreet than open systems. What is the importance for consumers of a product being discreet? A. I think there's two reasons for consumers seeking out discreetness. One, generally, if they're smaller and more discreet, they're more portable. You can slip them in your pocket. They're just more
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	L. WEXLER - CONFIDENTIAL Q. To a vaper. A. According to the consumers that I talk to, that is one of the things they look for; they look for the way the product makes them feel. That's why they're using the product. Q. And most of the vapers you speak to are vapers that frequent vape shops, right? A. I'm a very curious guy, and I will ask whenever I see a vaper, I'll ask him, whether he's on the street, in a vape shop, in a C-store, at a party. It doesn't matter. I'll talk to anybody. Q. Right. But most of your direct knowledge through your business is through vape shops, right? MR. FORD: Objection. Vague. A. I have a very broad background in tobacco and nicotine and vaping, so I can't say that the majority of my knowledge comes from vape shops. I spent 20 years at Philip	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	L. WEXLER - CONFIDENTIAL important and contributed to low, overall, consumer satisfaction, right? A. The amount of nicotine in the product combined with the battery and the amount of vapor produced delivered less satisfaction to consumers. These consumers, when they had alternatives, chose other products, and I believe that was one of the factors, yes. Q. Mr. Wexler, can we turn to Paragraph 10 of your Declaration? You mention that because of their small size, closed systems are more discreet than open systems. What is the importance for consumers of a product being discreet? A. I think there's two reasons for consumers seeking out discreetness. One, generally, if they're smaller and more discreet, they're more portable. You can slip them in your pocket. They're just more accessible.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	L. WEXLER - CONFIDENTIAL Q. To a vaper. A. According to the consumers that I talk to, that is one of the things they look for; they look for the way the product makes them feel. That's why they're using the product. Q. And most of the vapers you speak to are vapers that frequent vape shops, right? A. I'm a very curious guy, and I will ask whenever I see a vaper, I'll ask him, whether he's on the street, in a vape shop, in a C-store, at a party. It doesn't matter. I'll talk to anybody. Q. Right. But most of your direct knowledge through your business is through vape shops, right? MR. FORD: Objection. Vague. A. I have a very broad background in tobacco and nicotine and vaping, so I can't say that the majority of my knowledge comes from vape shops. I spent 20 years at Philip Morris.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	L. WEXLER - CONFIDENTIAL important and contributed to low, overall, consumer satisfaction, right? A. The amount of nicotine in the product combined with the battery and the amount of vapor produced delivered less satisfaction to consumers. These consumers, when they had alternatives, chose other products, and I believe that was one of the factors, yes. Q. Mr. Wexler, can we turn to Paragraph 10 of your Declaration? You mention that because of their small size, closed systems are more discreet than open systems. What is the importance for consumers of a product being discreet? A. I think there's two reasons for consumers seeking out discreetness. One, generally, if they're smaller and more discreet, they're more portable. You can slip them in your pocket. They're just more accessible. The other thing is that, some people

Page 42 Page 44 1 L. WEXLER - CONFIDENTIAL 1 L. WEXLER - CONFIDENTIAL 2 embarrassed about being a vaper, being a 2 uptake is even more rapid than JUUL's. 3 smoker, and they don't want to create big 3 Right. And you're referring to a PK 4 plumes of smoke and call attention to 4 curve; is that right? 5 themselves when they're vaping. 5 Α. That's the nomenclature, yes. 6 And let's turn to Paragraph 11 of 6 And so, in your view, it's important 7 7 your Declaration. for a product to seek commercial success for 8 it to have satisfaction closer to that of a Α. 8 9 You mentioned earlier that there 9 cigarette? ٥. were a number of reasons for the rise of pods MR. FORD: Objection. 10 10 11 11 and the increase in their popularity. Yeah. I think, as I said, the Α. 12 Can you expound on that? 12 studies I read were from JUUL. And I know Yeah. Pod systems had a number of that they've attributed a lot of their 13 13 Α. 14 advantages, compared to open systems. They're success with their ability to imitate a 14 15 smaller, more compact, easier to transport. 15 cigarette. I have no reason to disbelieve 16 Re-supplying a pod system is a little easier 16 that. 17 than re-supplying an open system. And 17 And you actually note, in Paragraph 0. 18 compared to Cigalikes, they had larger 18 11 of your Declaration, that this was a, 19 batteries, more effective batteries, they are 19 quote, "innovation," right? 20 more effective at taking the liquid and 20 Α. Yeah. They were the first on the 21 turning it into vapor and giving consumers an 21 market to get as close to a cigarette as they 22 experience that they desire. 22 did. The first in the market that I know of, 23 Okay. One of the other factors you 23 anyway. 24 mention in your Declaration is that "JUUL's 24 0. Mr. Wexler, you mention benzoic products contain relatively high levels of 25 acid. What is benzoic acid? Page 43 Page 45 1 L. WEXLER - CONFIDENTIAL 1 L. WEXLER - CONFIDENTIAL 2 nicotine, as high as 5 percent, and use 2 Benzoic acid is an additive that 3 benzoic acid to increase the body's nicotine 3 JUUL spoke a lot about. I'm not a scientist, absorption rate, creating satisfaction closer 4 4 so I can't speak to the exact mechanism and 5 to that of a cigarette." the way it works, but in talks to my scientists, what they tell me is that the 6 Why was it important for JUUL's rise 6 7 that it create a satisfaction closer to a 7 addition of benzoic acid allowed the consumer 8 cigarette? 8 to get more nicotine into their system faster. 9 Α. Well, a lot of that information came 9 But I'm not a scientist, so I don't know if I 10 from JUUL. They published these studies that 10 got that exactly right. 11 showed the nicotine-uptake curve for JUUL 11 So, that would help create 12 versus other vapor products. When you smoke a 12 satisfaction closer to that of a cigarette, 13 cigarette, what happens is that the 13 right? 14 bloodstream gets a fairly sharp rise in 14 A. To get the PK curve closer to a 15 nicotine and then starts retreating over time. 15 cigarette, yes. 16 And the curve on JUUL more closely resembled 16 Ο. And that's something that a lot 17 the curve of a cigarette, whereas open system 17 of -- that many cigarette smokers looking to 18 products and some other vapor products don't 18 switch from cigarettes are looking for, right? really have as high a spike in the beginning. MR. LEE: Objection to form. 19 19 20 And essentially, it builds over time more than I can't speak to what -- smokers in 20 Α. having a spike. 21 21 general, there are a couple people I talked to 22 They all wind up pretty much at the 22 who vape JUUL and said, "This is the closest 23 same place because consumers tend to seek out 23 thing that I've gotten to a cigarette, I found 24 a certain level of nicotine over time. But 24 to a cigarette." But that's a sample of a 25 JUUL's uptake was much more rapid. Cigarette handful. It's not a scientific sample.

		2,	
	Page 46		Page 48
1	L. WEXLER - CONFIDENTIAL	1	L. WEXLER - CONFIDENTIAL
2	Q. Okay. Do you think that the	2	vaper, and I couldn't speak from my own
3	discreet format, the pod shape, was also	3	experience.
4	necessary for JUUL to see the success it's	4	Q. Mr. Wexler, for the pod-based
5	seen?	5	products that Turning Point has sold, how did
6	A. I can't say whether it was necessary	6	it set the price of those products?
7	or not.	7	MR. FORD: Objection. I just want
8	Q. Do you think it helped?	8	it clear for the record, when you say
9	A. Consumers talked about it a lot, so	9	"pod-based products that Turning Point has
10	it must have had some appeal.	10	sold," do you mean Turning Point branded
11	Q. Mr. Wexler, you say in Paragraph 11	11	products versus third-party products that
12	that pods have seen rapid growth in the last	12	may be sold through distribution channels?
13	two years. Do you see that?	13	Just to clarify the record.
14	A. Yes.	14	MR. SOWLATI: Right. I'm referring
15	Q. When you're referring to the last	15	to third-party products, generally.
16	two years, you're referring to 2018 until when	16	MR. FORD: Okay.
17	you signed the Declaration in March 2020,	17	A. And you're talking about third-party
18	right?	18	products?
19	A. I believe that's what I was thinking	19	Q. Yes. Third-party pod-based
20	there, yes.	20	products.
21	Q. What do you mean by, "rapid growth"?	21	MR. FORD: I object to the question
22	A. Their share in the measured market,	22	on vagueness grounds.
23	which is C-stores, the share of pod systems	23	But go ahead and answer to the
24	went up significantly, and the volume went up	24	extent you can, Mr. Wexler.
25	significantly.	25	A. Okay. So, you're asking for us
1	Page 47	1	Page 49
1 2	L. WEXLER - CONFIDENTIAL	1 2	L. WEXLER - CONFIDENTIAL
2	L. WEXLER - CONFIDENTIAL Q. Okay. And they've also taken share	2	L. WEXLER - CONFIDENTIAL for how we establish markups, our markups on
2 3	L. WEXLER - CONFIDENTIAL Q. Okay. And they've also taken share away of other closed system and Cigalikes,	2	L. WEXLER - CONFIDENTIAL for how we establish markups, our markups on third-party products that we sold?
2 3 4	L. WEXLER - CONFIDENTIAL Q. Okay. And they've also taken share away of other closed system and Cigalikes, right?	2 3 4	L. WEXLER - CONFIDENTIAL for how we establish markups, our markups on third-party products that we sold? Q. Well, let me be a little more clear.
2 3 4 5	L. WEXLER - CONFIDENTIAL Q. Okay. And they've also taken share away of other closed system and Cigalikes, right? A. Yes. If they're growing share	2 3 4 5	L. WEXLER - CONFIDENTIAL for how we establish markups, our markups on third-party products that we sold? Q. Well, let me be a little more clear. When you set the prices for
2 3 4 5 6	L. WEXLER - CONFIDENTIAL Q. Okay. And they've also taken share away of other closed system and Cigalikes, right? A. Yes. If they're growing share open systems are not really sold in C-stores,	2 3 4 5 6	L. WEXLER - CONFIDENTIAL for how we establish markups, our markups on third-party products that we sold? Q. Well, let me be a little more clear. When you set the prices for third-party pod systems, did you take into
2 3 4 5 6 7	L. WEXLER - CONFIDENTIAL Q. Okay. And they've also taken share away of other closed system and Cigalikes, right? A. Yes. If they're growing share open systems are not really sold in C-stores, for the most part. But if they're taking	2 3 4 5 6 7	L. WEXLER - CONFIDENTIAL for how we establish markups, our markups on third-party products that we sold? Q. Well, let me be a little more clear. When you set the prices for third-party pod systems, did you take into account the price of other pod-based systems?
2 3 4 5 6	L. WEXLER - CONFIDENTIAL Q. Okay. And they've also taken share away of other closed system and Cigalikes, right? A. Yes. If they're growing share open systems are not really sold in C-stores,	2 3 4 5 6	L. WEXLER - CONFIDENTIAL for how we establish markups, our markups on third-party products that we sold? Q. Well, let me be a little more clear. When you set the prices for third-party pod systems, did you take into
2 3 4 5 6 7 8	L. WEXLER - CONFIDENTIAL Q. Okay. And they've also taken share away of other closed system and Cigalikes, right? A. Yes. If they're growing share open systems are not really sold in C-stores, for the most part. But if they're taking share in C-stores, it had to come from the Cigalikes.	2 3 4 5 6 7 8	L. WEXLER - CONFIDENTIAL for how we establish markups, our markups on third-party products that we sold? Q. Well, let me be a little more clear. When you set the prices for third-party pod systems, did you take into account the price of other pod-based systems? MR. FORD: Objection. A. Look, there's a whole mechanism for
2 3 4 5 6 7 8	L. WEXLER - CONFIDENTIAL Q. Okay. And they've also taken share away of other closed system and Cigalikes, right? A. Yes. If they're growing share open systems are not really sold in C-stores, for the most part. But if they're taking share in C-stores, it had to come from the Cigalikes. Q. Mr. Wexler, are you familiar with	2 3 4 5 6 7 8	L. WEXLER - CONFIDENTIAL for how we establish markups, our markups on third-party products that we sold? Q. Well, let me be a little more clear. When you set the prices for third-party pod systems, did you take into account the price of other pod-based systems? MR. FORD: Objection.
2 3 4 5 6 7 8 9	L. WEXLER - CONFIDENTIAL Q. Okay. And they've also taken share away of other closed system and Cigalikes, right? A. Yes. If they're growing share open systems are not really sold in C-stores, for the most part. But if they're taking share in C-stores, it had to come from the Cigalikes.	2 3 4 5 6 7 8 9	L. WEXLER - CONFIDENTIAL for how we establish markups, our markups on third-party products that we sold? Q. Well, let me be a little more clear. When you set the prices for third-party pod systems, did you take into account the price of other pod-based systems? MR. FORD: Objection. A. Look, there's a whole mechanism for setting prices, and in general, the market
2 3 4 5 6 7 8 9 10 11 12	L. WEXLER - CONFIDENTIAL Q. Okay. And they've also taken share away of other closed system and Cigalikes, right? A. Yes. If they're growing share open systems are not really sold in C-stores, for the most part. But if they're taking share in C-stores, it had to come from the Cigalikes. Q. Mr. Wexler, are you familiar with other pod-based products that utilize either benzoic acid or nicotine salts, like Vuse	2 3 4 5 6 7 8 9 10 11 12	L. WEXLER - CONFIDENTIAL for how we establish markups, our markups on third-party products that we sold? Q. Well, let me be a little more clear. When you set the prices for third-party pod systems, did you take into account the price of other pod-based systems? MR. FORD: Objection. A. Look, there's a whole mechanism for setting prices, and in general, the market would determine that. For instance, if there was a shortage of JUUL in the marketplace and
2 3 4 5 6 7 8 9 10 11 12 13	L. WEXLER - CONFIDENTIAL Q. Okay. And they've also taken share away of other closed system and Cigalikes, right? A. Yes. If they're growing share open systems are not really sold in C-stores, for the most part. But if they're taking share in C-stores, it had to come from the Cigalikes. Q. Mr. Wexler, are you familiar with other pod-based products that utilize either	2 3 4 5 6 7 8 9 10 11 12 13	L. WEXLER - CONFIDENTIAL for how we establish markups, our markups on third-party products that we sold? Q. Well, let me be a little more clear. When you set the prices for third-party pod systems, did you take into account the price of other pod-based systems? MR. FORD: Objection. A. Look, there's a whole mechanism for setting prices, and in general, the market would determine that. For instance, if there was a shortage of JUUL in the marketplace and we had an inventory of JUUL, we might raise
2 3 4 5 6 7 8 9 10 11 12 13 14	L. WEXLER - CONFIDENTIAL Q. Okay. And they've also taken share away of other closed system and Cigalikes, right? A. Yes. If they're growing share open systems are not really sold in C-stores, for the most part. But if they're taking share in C-stores, it had to come from the Cigalikes. Q. Mr. Wexler, are you familiar with other pod-based products that utilize either benzoic acid or nicotine salts, like Vuse Alto, NJOY ACE, or myblu? A. I don't believe NJOY uses benzoic	2 3 4 5 6 7 8 9 10 11 12 13 14	L. WEXLER - CONFIDENTIAL for how we establish markups, our markups on third-party products that we sold? Q. Well, let me be a little more clear. When you set the prices for third-party pod systems, did you take into account the price of other pod-based systems? MR. FORD: Objection. A. Look, there's a whole mechanism for setting prices, and in general, the market would determine that. For instance, if there was a shortage of JUUL in the marketplace and we had an inventory of JUUL, we might raise the price of JUUL relative to other products.
2 3 4 5 6 7 8 9 10 11 12 13 14 15	L. WEXLER - CONFIDENTIAL Q. Okay. And they've also taken share away of other closed system and Cigalikes, right? A. Yes. If they're growing share open systems are not really sold in C-stores, for the most part. But if they're taking share in C-stores, it had to come from the Cigalikes. Q. Mr. Wexler, are you familiar with other pod-based products that utilize either benzoic acid or nicotine salts, like Vuse Alto, NJOY ACE, or myblu?	2 3 4 5 6 7 8 9 10 11 12 13 14 15	L. WEXLER - CONFIDENTIAL for how we establish markups, our markups on third-party products that we sold? Q. Well, let me be a little more clear. When you set the prices for third-party pod systems, did you take into account the price of other pod-based systems? MR. FORD: Objection. A. Look, there's a whole mechanism for setting prices, and in general, the market would determine that. For instance, if there was a shortage of JUUL in the marketplace and we had an inventory of JUUL, we might raise the price of JUUL relative to other products. It's basically, you know, supply and demand
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	L. WEXLER - CONFIDENTIAL Q. Okay. And they've also taken share away of other closed system and Cigalikes, right? A. Yes. If they're growing share open systems are not really sold in C-stores, for the most part. But if they're taking share in C-stores, it had to come from the Cigalikes. Q. Mr. Wexler, are you familiar with other pod-based products that utilize either benzoic acid or nicotine salts, like Vuse Alto, NJOY ACE, or myblu? A. I don't believe NJOY uses benzoic acid, but I think they use something that has some of the same functions as benzoic acid.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	L. WEXLER - CONFIDENTIAL for how we establish markups, our markups on third-party products that we sold? Q. Well, let me be a little more clear. When you set the prices for third-party pod systems, did you take into account the price of other pod-based systems? MR. FORD: Objection. A. Look, there's a whole mechanism for setting prices, and in general, the market would determine that. For instance, if there was a shortage of JUUL in the marketplace and we had an inventory of JUUL, we might raise the price of JUUL relative to other products. It's basically, you know, supply and demand actually works. So, pricing is dictated in a
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	L. WEXLER - CONFIDENTIAL Q. Okay. And they've also taken share away of other closed system and Cigalikes, right? A. Yes. If they're growing share open systems are not really sold in C-stores, for the most part. But if they're taking share in C-stores, it had to come from the Cigalikes. Q. Mr. Wexler, are you familiar with other pod-based products that utilize either benzoic acid or nicotine salts, like Vuse Alto, NJOY ACE, or myblu? A. I don't believe NJOY uses benzoic acid, but I think they use something that has	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	L. WEXLER - CONFIDENTIAL for how we establish markups, our markups on third-party products that we sold? Q. Well, let me be a little more clear. When you set the prices for third-party pod systems, did you take into account the price of other pod-based systems? MR. FORD: Objection. A. Look, there's a whole mechanism for setting prices, and in general, the market would determine that. For instance, if there was a shortage of JUUL in the marketplace and we had an inventory of JUUL, we might raise the price of JUUL relative to other products. It's basically, you know, supply and demand actually works. So, pricing is dictated in a lot of cases. If there is fair competition
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	L. WEXLER - CONFIDENTIAL Q. Okay. And they've also taken share away of other closed system and Cigalikes, right? A. Yes. If they're growing share open systems are not really sold in C-stores, for the most part. But if they're taking share in C-stores, it had to come from the Cigalikes. Q. Mr. Wexler, are you familiar with other pod-based products that utilize either benzoic acid or nicotine salts, like Vuse Alto, NJOY ACE, or myblu? A. I don't believe NJOY uses benzoic acid, but I think they use something that has some of the same functions as benzoic acid. Q. Can you explain to me what you mean by that there are other strike that.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	L. WEXLER - CONFIDENTIAL for how we establish markups, our markups on third-party products that we sold? Q. Well, let me be a little more clear. When you set the prices for third-party pod systems, did you take into account the price of other pod-based systems? MR. FORD: Objection. A. Look, there's a whole mechanism for setting prices, and in general, the market would determine that. For instance, if there was a shortage of JUUL in the marketplace and we had an inventory of JUUL, we might raise the price of JUUL relative to other products. It's basically, you know, supply and demand actually works. So, pricing is dictated in a lot of cases. If there is fair competition and if there is free competition, then you
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	L. WEXLER - CONFIDENTIAL Q. Okay. And they've also taken share away of other closed system and Cigalikes, right? A. Yes. If they're growing share open systems are not really sold in C-stores, for the most part. But if they're taking share in C-stores, it had to come from the Cigalikes. Q. Mr. Wexler, are you familiar with other pod-based products that utilize either benzoic acid or nicotine salts, like Vuse Alto, NJOY ACE, or myblu? A. I don't believe NJOY uses benzoic acid, but I think they use something that has some of the same functions as benzoic acid. Q. Can you explain to me what you mean by that there are other strike that. So, there are other substances that	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	L. WEXLER - CONFIDENTIAL for how we establish markups, our markups on third-party products that we sold? Q. Well, let me be a little more clear. When you set the prices for third-party pod systems, did you take into account the price of other pod-based systems? MR. FORD: Objection. A. Look, there's a whole mechanism for setting prices, and in general, the market would determine that. For instance, if there was a shortage of JUUL in the marketplace and we had an inventory of JUUL, we might raise the price of JUUL relative to other products. It's basically, you know, supply and demand actually works. So, pricing is dictated in a lot of cases. If there is fair competition
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	L. WEXLER - CONFIDENTIAL Q. Okay. And they've also taken share away of other closed system and Cigalikes, right? A. Yes. If they're growing share open systems are not really sold in C-stores, for the most part. But if they're taking share in C-stores, it had to come from the Cigalikes. Q. Mr. Wexler, are you familiar with other pod-based products that utilize either benzoic acid or nicotine salts, like Vuse Alto, NJOY ACE, or myblu? A. I don't believe NJOY uses benzoic acid, but I think they use something that has some of the same functions as benzoic acid. Q. Can you explain to me what you mean by that there are other strike that. So, there are other substances that provide an experience similar to benzoic acid,	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	L. WEXLER - CONFIDENTIAL for how we establish markups, our markups on third-party products that we sold? Q. Well, let me be a little more clear. When you set the prices for third-party pod systems, did you take into account the price of other pod-based systems? MR. FORD: Objection. A. Look, there's a whole mechanism for setting prices, and in general, the market would determine that. For instance, if there was a shortage of JUUL in the marketplace and we had an inventory of JUUL, we might raise the price of JUUL relative to other products. It's basically, you know, supply and demand actually works. So, pricing is dictated in a lot of cases. If there is fair competition and if there is free competition, then you will get pricing that is set by supply and demand.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	L. WEXLER - CONFIDENTIAL Q. Okay. And they've also taken share away of other closed system and Cigalikes, right? A. Yes. If they're growing share open systems are not really sold in C-stores, for the most part. But if they're taking share in C-stores, it had to come from the Cigalikes. Q. Mr. Wexler, are you familiar with other pod-based products that utilize either benzoic acid or nicotine salts, like Vuse Alto, NJOY ACE, or myblu? A. I don't believe NJOY uses benzoic acid, but I think they use something that has some of the same functions as benzoic acid. Q. Can you explain to me what you mean by that there are other strike that. So, there are other substances that provide an experience similar to benzoic acid, is what you're saying?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	L. WEXLER - CONFIDENTIAL for how we establish markups, our markups on third-party products that we sold? Q. Well, let me be a little more clear. When you set the prices for third-party pod systems, did you take into account the price of other pod-based systems? MR. FORD: Objection. A. Look, there's a whole mechanism for setting prices, and in general, the market would determine that. For instance, if there was a shortage of JUUL in the marketplace and we had an inventory of JUUL, we might raise the price of JUUL relative to other products. It's basically, you know, supply and demand actually works. So, pricing is dictated in a lot of cases. If there is fair competition and if there is free competition, then you will get pricing that is set by supply and demand. Q. Okay. So, when you're setting the
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	L. WEXLER - CONFIDENTIAL Q. Okay. And they've also taken share away of other closed system and Cigalikes, right? A. Yes. If they're growing share open systems are not really sold in C-stores, for the most part. But if they're taking share in C-stores, it had to come from the Cigalikes. Q. Mr. Wexler, are you familiar with other pod-based products that utilize either benzoic acid or nicotine salts, like Vuse Alto, NJOY ACE, or myblu? A. I don't believe NJOY uses benzoic acid, but I think they use something that has some of the same functions as benzoic acid. Q. Can you explain to me what you mean by that there are other strike that. So, there are other substances that provide an experience similar to benzoic acid, is what you're saying? A. I can only say what the	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	L. WEXLER - CONFIDENTIAL for how we establish markups, our markups on third-party products that we sold? Q. Well, let me be a little more clear. When you set the prices for third-party pod systems, did you take into account the price of other pod-based systems? MR. FORD: Objection. A. Look, there's a whole mechanism for setting prices, and in general, the market would determine that. For instance, if there was a shortage of JUUL in the marketplace and we had an inventory of JUUL, we might raise the price of JUUL relative to other products. It's basically, you know, supply and demand actually works. So, pricing is dictated in a lot of cases. If there is fair competition and if there is free competition, then you will get pricing that is set by supply and demand. Q. Okay. So, when you're setting the price of JUUL, would you take a look at the
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	L. WEXLER - CONFIDENTIAL Q. Okay. And they've also taken share away of other closed system and Cigalikes, right? A. Yes. If they're growing share open systems are not really sold in C-stores, for the most part. But if they're taking share in C-stores, it had to come from the Cigalikes. Q. Mr. Wexler, are you familiar with other pod-based products that utilize either benzoic acid or nicotine salts, like Vuse Alto, NJOY ACE, or myblu? A. I don't believe NJOY uses benzoic acid, but I think they use something that has some of the same functions as benzoic acid. Q. Can you explain to me what you mean by that there are other strike that. So, there are other substances that provide an experience similar to benzoic acid, is what you're saying? A. I can only say what the manufacturers say. I'm not a vaper. I do	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	L. WEXLER - CONFIDENTIAL for how we establish markups, our markups on third-party products that we sold? Q. Well, let me be a little more clear. When you set the prices for third-party pod systems, did you take into account the price of other pod-based systems? MR. FORD: Objection. A. Look, there's a whole mechanism for setting prices, and in general, the market would determine that. For instance, if there was a shortage of JUUL in the marketplace and we had an inventory of JUUL, we might raise the price of JUUL relative to other products. It's basically, you know, supply and demand actually works. So, pricing is dictated in a lot of cases. If there is fair competition and if there is free competition, then you will get pricing that is set by supply and demand. Q. Okay. So, when you're setting the price of JUUL, would you take a look at the price of another pod-based product?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	L. WEXLER - CONFIDENTIAL Q. Okay. And they've also taken share away of other closed system and Cigalikes, right? A. Yes. If they're growing share open systems are not really sold in C-stores, for the most part. But if they're taking share in C-stores, it had to come from the Cigalikes. Q. Mr. Wexler, are you familiar with other pod-based products that utilize either benzoic acid or nicotine salts, like Vuse Alto, NJOY ACE, or myblu? A. I don't believe NJOY uses benzoic acid, but I think they use something that has some of the same functions as benzoic acid. Q. Can you explain to me what you mean by that there are other strike that. So, there are other substances that provide an experience similar to benzoic acid, is what you're saying? A. I can only say what the	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	L. WEXLER - CONFIDENTIAL for how we establish markups, our markups on third-party products that we sold? Q. Well, let me be a little more clear. When you set the prices for third-party pod systems, did you take into account the price of other pod-based systems? MR. FORD: Objection. A. Look, there's a whole mechanism for setting prices, and in general, the market would determine that. For instance, if there was a shortage of JUUL in the marketplace and we had an inventory of JUUL, we might raise the price of JUUL relative to other products. It's basically, you know, supply and demand actually works. So, pricing is dictated in a lot of cases. If there is fair competition and if there is free competition, then you will get pricing that is set by supply and demand. Q. Okay. So, when you're setting the price of JUUL, would you take a look at the

Page 50 1 L. WEXLER - CONFIDENTIAL 2 it's an open market and it's a fair-priced 3 market, we get a sense of what our customers 4 are willing to pay, and we try to extract as 5 much economic rent as we can with our pricing 6 without while still maintaining our 7 long-term relationships. In other words, we 8 don't try to I know this is on the record, 1 L. WEXLER - CONFIDENTIAL 2 MR. FORD: Sounds good. 3 THE WITNESS: Fine by me. 4 MR. SOWLATI: Maybe we can so the record. 6 (Recess was taken.) 7 BY MR. SOWLATI: 8 Q. Mr. Wexler, I am going to so	Page 52
2 it's an open market and it's a fair-priced 3 market, we get a sense of what our customers 4 are willing to pay, and we try to extract as 5 much economic rent as we can with our pricing 6 without while still maintaining our 7 long-term relationships. In other words, we 2 MR. FORD: Sounds good. 3 THE WITNESS: Fine by me. 4 MR. SOWLATI: Maybe we can sense of what our pricing to pay, and we try to extract as 5 much economic rent as we can with our pricing to lost our pricing to lo	return at
market, we get a sense of what our customers are willing to pay, and we try to extract as much economic rent as we can with our pricing muth economic rent as we can with our pricing without while still maintaining our long-term relationships. In other words, we 3 THE WITNESS: Fine by me. 4 MR. SOWLATI: Maybe we can sense of what our customers 5 10:10. Off the record. 6 (Recess was taken.) 7 BY MR. SOWLATI:	return at
4 are willing to pay, and we try to extract as 5 much economic rent as we can with our pricing 6 without while still maintaining our 7 long-term relationships. In other words, we 7 BY MR. SOWLATI: Maybe we can see that the second of the	return at
5 much economic rent as we can with our pricing 5 10:10. Off the record. 6 without while still maintaining our 6 (Recess was taken.) 7 long-term relationships. In other words, we 7 BY MR. SOWLATI:	return at
6 without while still maintaining our 6 (Recess was taken.) 7 long-term relationships. In other words, we 7 BY MR. SOWLATI:	
7 long-term relationships. In other words, we 7 BY MR. SOWLATI:	
, ,	
8 don't try to I know this is on the record, 8 Q. Mr. Wexler, I am going to s	
	end you a
9 so the word I was going to use is probably not 9 document right now through Zoom chat.	
appropriate. We don't try to take advantage 10 A. And you're going to ask me	to
of our customers, but we do try to extract as 11 perform my technological	
12 much economic rent. 12 Q. Right. Can you please let	me know
And so, the market, there's all 13 when you've received the document?	
14 kinds of prices for all kinds of pod products, 14 A. I have received the documen	t. I'm
but they all have different levels of supply 15 assuming you want me to open it, righ	t?
16 and demand. And it also is a function of how 16 Q. Yes. Mr. Wexler, this docu	ment is
17 much the pod system is charging us. If 17 Turning Point's Q1 2019 Earnings Call	dated
18 someone's charging us more and we have to get 18 May 1, 2019. The document is stamped	Wexler
19 a certain amount of margin in order to pay for 19 EX 3. I can give you a minute to rev	iew the
20 our overhead and shipping, fulfillment and 20 document.	
21 selling costs and all that to make a profit, 21 A. Okay. Hold on.	
22 then that price would tend to be higher. But 22 You said this is a transcrip	pt?
23 it's, basically, the market dictates the 23 Q. Right. This is your Q1 201	
	9 I
24 price. 24 should say, Turning Point's Q1 2019 E	
24 price. 24 should say, Turning Point's Q1 2019 E 25 Q. In setting the pod price of 25 Call dated May 1, 2019.	
25 Q. In setting the pod price of 25 Call dated May 1, 2019. Page 51	
25 Q. In setting the pod price of 25 Call dated May 1, 2019. 1 L. WEXLER - CONFIDENTIAL Page 51 1 L. WEXLER - CONFIDENTIAL	Page 53
25 Q. In setting the pod price of 25 Call dated May 1, 2019. Page 51 L. WEXLER - CONFIDENTIAL pod-based systems, you don't take into account 2 Mr. Wexler, have you had a	Page 53
25 Q. In setting the pod price of 25 Call dated May 1, 2019. Page 51 L. WEXLER - CONFIDENTIAL pod-based systems, you don't take into account the price of Cigalikes, do you? 25 Call dated May 1, 2019. L. WEXLER - CONFIDENTIAL Mr. Wexler, have you had a review the document?	Page 53
Q. In setting the pod price of Page 51 L. WEXLER - CONFIDENTIAL pod-based systems, you don't take into account the price of Cigalikes, do you? A. It would never occur to me to look 25 Call dated May 1, 2019. L. WEXLER - CONFIDENTIAL Mr. WexLer, have you had a review the document? A. It would never occur to me to look 4 A. Yes.	Page 53
25 Q. In setting the pod price of Page 51 L. WEXLER - CONFIDENTIAL pod-based systems, you don't take into account the price of Cigalikes, do you? A. It would never occur to me to look at the price of Cigalikes. 25 Call dated May 1, 2019. L. WEXLER - CONFIDENTIAL Mr. Wexler, have you had a review the document? A. Yes. Q. Okay, great.	Page 53
25 Q. In setting the pod price of Page 51 L. WEXLER - CONFIDENTIAL pod-based systems, you don't take into account the price of Cigalikes, do you? A. It would never occur to me to look at the price of Cigalikes. Q. Okay. Would you say, generally, Call dated May 1, 2019. L. WEXLER - CONFIDENTIAL Mr. Wexler, have you had a review the document? A. Yes. Q. Okay, great. Mr. Wexler, do you recognize	Page 53 chance to
Q. In setting the pod price of Page 51 L. WEXLER - CONFIDENTIAL pod-based systems, you don't take into account the price of Cigalikes, do you? A. It would never occur to me to look the price of Cigalikes. Q. Okay. Would you say, generally, that Cigalike users are different than pod Call dated May 1, 2019. L. WEXLER - CONFIDENTIAL Mr. Wexler, have you had a review the document? A. Yes. Q. Okay, great. Mr. Wexler, do you recognized that Cigalike users are different than pod To document to be Turning Point's Q1 201	Page 53 chance to
Q. In setting the pod price of Page 51 L. WEXLER - CONFIDENTIAL pod-based systems, you don't take into account the price of Cigalikes, do you? A. It would never occur to me to look at the price of Cigalikes. Q. Okay. Would you say, generally, that Cigalike users are different than pod users? Call dated May 1, 2019. L. WEXLER - CONFIDENTIAL Mr. Wexler, have you had a review the document? A. Yes. Q. Okay, great. Mr. Wexler, do you recognized that Cigalike users are different than pod Accument to be Turning Point's Q1 201 Earnings Call transcript?	Page 53 chance to se this
Q. In setting the pod price of Page 51 L. WEXLER - CONFIDENTIAL pod-based systems, you don't take into account the price of Cigalikes, do you? A. It would never occur to me to look at the price of Cigalikes. Q. Okay. Would you say, generally, that Cigalike users are different than pod users? A. I think if you look at the Call dated May 1, 2019. L. WEXLER - CONFIDENTIAL Are weller, have you had a review the document? A. Yes. Q. Okay, great. Mr. Wexler, do you recogniz document to be Turning Point's Q1 201 Earnings Call transcript? A. I think if you look at the	Page 53 chance to se this 9
Q. In setting the pod price of Page 51 L. WEXLER - CONFIDENTIAL pod-based systems, you don't take into account the price of Cigalikes, do you? A. It would never occur to me to look at the price of Cigalikes. Q. Okay, Would you say, generally, that Cigalike users are different than pod users? A. I think if you look at the demographics of Cigalike users today, the 25 Call dated May 1, 2019. L. WEXLER - CONFIDENTIAL A. Wexler, have you had a review the document? A. Yes. Q. Okay, great. Mr. Wexler, do you recogniz document to be Turning Point's Q1 201 Earnings Call transcript? A. I think if you look at the demographics of Cigalike users today, the 10 before, but it does appear to be a transcript to the price of the pri	Page 53 chance to se this 9
25 Q. In setting the pod price of Page 51 L. WEXLER - CONFIDENTIAL pod-based systems, you don't take into account the price of Cigalikes, do you? A. It would never occur to me to look at the price of Cigalikes. Q. Okay. Would you say, generally, that Cigalike users are different than pod users? A. I think if you look at the demographics of Cigalike users today, the demographics of Cigalike user, at least in Call dated May 1, 2019. L. WEXLER - CONFIDENTIAL A. Wexler, have you had a review the document? A. Yes. Q. Okay, great. Mr. Wexler, do you recognized to be Turning Point's Q1 201 Earnings Call transcript? A. I think if you look at the demographics of Cigalike users today, the 10 before, but it does appear to be a transcript average age of a Cigalike user, at least in 11 of a first quarter call.	Page 53 chance to se this 9 ent
25 Q. In setting the pod price of Page 51 L. WEXLER - CONFIDENTIAL pod-based systems, you don't take into account the price of Cigalikes, do you? A. It would never occur to me to look the price of Cigalikes. Q. Okay. Would you say, generally, that Cigalike users are different than pod users? A. I think if you look at the demographics of Cigalike users today, the average age of a Cigalike user, at least in our B2C environment, is probably over the age 25 Call dated May 1, 2019. L. WEXLER - CONFIDENTIAL L. WEXLER - CONFIDENTIAL A. Wexler, have you had a review the document? A. Yes. Q. Okay, great. Mr. Wexler, do you recognize document to be Turning Point's Q1 201 B. L. WEXLER - CONFIDENTIAL A. Yes. Q. Okay, great. Mr. Wexler, do you recognize document to be Turning Point's Q1 201 before, but it does appear to be a transported to the second of turning Point's Q2. Okay. As CEO of Turning Point's Q2. Okay. As CEO of Turning Point's Q2.	Page 53 chance to se this 9 ent canscript
Page 51 1 L. WEXLER - CONFIDENTIAL 2 pod-based systems, you don't take into account 3 the price of Cigalikes, do you? 4 A. It would never occur to me to look 5 at the price of Cigalikes. 6 Q. Okay. Would you say, generally, 7 that Cigalike users are different than pod 8 users? 9 A. I think if you look at the 10 demographics of Cigalike users today, the 11 average age of a Cigalike user, at least in 12 our B2C environment, is probably over the age 13 of 50. I think the average age is about 55. Page 51 1 L. WEXLER - CONFIDENTIAL 1 L. WEXLER - CONFIDENTIAL 1 L. WEXLER - CONFIDENTIAL 2 Mr. Wexler, have you had a review the document? 4 A. Yes. 5 Q. Okay, great. 6 Mr. Wexler, do you recognize document to be Turning Point's Q1 201 8 Earnings Call transcript? 9 A. I 've never seen this document of a first quarter call. 10 Defore, but it does appear to be a transcript of a first quarter call. 11 Q. Okay. As CEO of Turning Point of 50. I think the average age is about 55. 12 Death of a first quarter call. 13 Q. Okay. As CEO of Turning Point of 50. I think the average age is about 55.	Page 53 chance to se this 9 ent canscript
Page 51 L. WEXLER - CONFIDENTIAL pod-based systems, you don't take into account the price of Cigalikes, do you? A. It would never occur to me to look the price of Cigalikes. Q. Okay. Would you say, generally, that Cigalike users are different than pod users? A. I think if you look at the demographics of Cigalike users today, the average age of a Cigalike user, at least in our B2C environment, is probably over the age That number has been about six months old. Page 51 L. WEXLER - CONFIDENTIAL L. WEXLER - CONFIDENTIAL A. Wexler, have you had a greview the document? A. Yes. Q. Okay, great. Q. Okay, great. A. Wexler, do you recognize document to be Turning Point's Q1 201 Bearnings Call transcript? A. I think if you look at the pefore, but it does appear to be a transcript of a first quarter call. Q. Okay. As CEO of Turning Point of a first quarterly earning call investors, right?	Page 53 chance to se this 9 ent canscript
Page 51 1 L. WEXLER - CONFIDENTIAL 2 pod-based systems, you don't take into account 3 the price of Cigalikes, do you? 4 A. It would never occur to me to look 5 at the price of Cigalikes. 6 Q. Okay. Would you say, generally, 7 that Cigalike users are different than pod 8 users? 9 A. I think if you look at the 10 demographics of Cigalike users today, the 11 average age of a Cigalike user, at least in 12 our B2C environment, is probably over the age 13 That number has been about six months old. 15 Pod systems are significantly younger in our 16 Call dated May 1, 2019. 25 Call dated May 1, 2019. 26 Call dated May 1, 2019. 27 L. WEXLER - CONFIDENTIAL 1 L. WEXLER - CONFIDENTIAL 1 L. WEXLER - CONFIDENTIAL 1 A. Yes.	Page 53 chance to se this 9 ent enscript oint, you s with
Page 51 L. WEXLER - CONFIDENTIAL pod-based systems, you don't take into account the price of Cigalikes, do you? A. It would never occur to me to look that Cigalike users are different than pod users? A. I think if you look at the demographics of Cigalike users today, the demographics of Cigalike users, at least in average age of a Cigalike user, at least in our B2C environment, is probably over the age for that number has been about six months old. Page 51 L. WEXLER - CONFIDENTIAL L. WEXLER - CONFIDENTIAL L. WEXLER - CONFIDENTIAL A. Yes. One Way, great. A. Yes. One Okay, great. Mr. Wexler, do you recognize document to be Turning Point's Q1 201 Bearnings Call transcript? A. I 've never seen this document of a first quarter call. Our B2C environment, is probably over the age 10 of 50. I think the average age is about 55. That number has been about six months old. That number has been about six months old. That number has been about six months old. Page 51 L. WEXLER - CONFIDENTIAL L. WEXLE	Page 53 chance to se this 9 ent canscript sint, you s with
Page 51 1 L. WEXLER - CONFIDENTIAL 2 pod-based systems, you don't take into account 3 the price of Cigalikes, do you? 4 A. It would never occur to me to look 5 at the price of Cigalikes. 6 Q. Okay. Would you say, generally, 7 that Cigalike users are different than pod 8 users? 9 A. I think if you look at the 10 demographics of Cigalike users today, the 11 average age of a Cigalike user, at least in 12 our B2C environment, is probably over the age 13 of 50. I think the average age is about 55. 14 That number has been about six months old. 15 Pod systems are significantly younger in our 16 particular database. They'd be 30 and 17 under somewhere is around the average. Page 51 1 L. WEXLER - CONFIDENTIAL 1 Mr. Wexler, have you had a review the document? 4 A. Yes. 9 Q. Okay, great. 9 A. I've never seen this document to be Turning Point's Q1 201 8 Earnings Call transcript? 9 A. I've never seen this document to be fore, but it docs appear to be a transcript? 9 A. I've never seen this document to be fore, but it docs appear to be a transcript? 10 document to be Turning Point's Q1 201 10	Page 53 chance to se this 9 ent canscript sint, you s with
Page 51 1 L. WEXLER - CONFIDENTIAL 2 pod-based systems, you don't take into account 3 the price of Cigalikes, do you? 4 A. It would never occur to me to look 5 at the price of Cigalikes. 6 Q. Okay. Would you say, generally, 7 that Cigalike users are different than pod 8 users? 9 A. I think if you look at the 10 demographics of Cigalike users today, the 11 average age of a Cigalike user, at least in 12 our B2C environment, is probably over the age 13 of 50. I think the average age is about 55. 14 That number has been about six months old. 15 Pod systems are significantly younger in our 16 Q. So, it sounds like they're pretty 18 L. WEXLER - CONFIDENTIAL 1 Mr. Wexler, have you had a review the document? 1 Mr. Wexler, have you had a review the document? 1 A. Yes. Q. Okay, great. Mr. Wexler, have you had a review the document? 1 A. Yes. 1 Earnings Call transcript? A. I've never seen this document to be fore, but it does appear to be a transcript of a first quarter call. 1 Q. Okay. As CEO of Turning Po participate in quarterly earning call investors, right? 1 A. Yes. 1 A. Yes. 1 A. Yes. 2 Okay. As CEO of Turning Po participate in quarterly earning call investors, right? 1 A. Yes. 2 Okay. As CEO of Turning Po participate in quarterly earning call investors, right? 3 Okay. As CEO of Turning Po participate in quarterly earning call investors, right? 3 Okay. The following the following transcript. 4 A. Yes. 5 Q. Okay. As CEO of Turning Po participate in quarterly earning call investors, right? 4 A. Yes. 6 D. Very. The following transcript. 7 A.	Page 53 chance to se this 9 ent canscript sint, you s with
Page 51 1 L. WEXLER - CONFIDENTIAL 2 pod-based systems, you don't take into account 3 the price of Cigalikes, do you? 4 A. It would never occur to me to look 5 at the price of Cigalikes. 6 Q. Okay. Would you say, generally, 7 that Cigalike users are different than pod 8 users? 9 A. I think if you look at the 10 demographics of Cigalike users today, the 11 average age of a Cigalike user, at least in 12 our B2C environment, is probably over the age 13 of 50. I think the average age is about 55. 14 That number has been about six months old. 15 Pod systems are significantly younger in our 16 Q. So, it sounds like they're pretty 17 different demographics, then? 18 Q. So, it sounds like they're pretty 19 different demographics, then? 2 Call dated May 1, 2019. L. WEXLER - CONFIDENTIAL Mr. Wexler, have you had a service the document? A. Yes. 9 A. I' the document? 4 A. Yes. 9 A. I've never seen this document of a first quarter call. 10 before, but it does appear to be a transcript? 9 Q. Okay. As CEO of Turning Portation participate in quarterly earning call. 11 investors, right? 12 A. Yes. 13 participate in quarterly earning call. 14 investors, right? 15 A. Yes. 16 Q. I'd like to turn to the page of the page of the stamps on the bortation of the page of the stamps on the bortation of the page of the stamps on the bortation of the page of the stamps on the bortation of the page of the stamps on the bortation of the page of the stamps on the bortation of the page of the stamps on the bortation of the page of the stamps on the bortation of the page of the stamps on the bortation of the page of the page of the stamps on the bortation of the page of the stamps on the bortation of the page of the stamps on the bortation of the page	Page 53 chance to ee this 9 ent canscript cint, you s with de stamped
Page 51 1 L. WEXLER - CONFIDENTIAL 2 pod-based systems, you don't take into account 3 the price of Cigalikes, do you? 4 A. It would never occur to me to look 5 at the price of Cigalikes. 6 Q. Okay. Would you say, generally, 7 that Cigalike users are different than pod 8 users? 9 A. I think if you look at the 10 demographics of Cigalike users today, the 11 average age of a Cigalike user, at least in 12 our BZC environment, is probably over the age 13 of 50. I think the average age is about 55. 14 That number has been about six months old. 15 Pod systems are significantly younger in our 16 particular database. They'd be 30 and 17 under somewhere is around the average. 20 A. I believe that they're very 20 Q. In the paragraph that's this	Page 53 chance to e this e this anscript oint, you s with e stamped oottom
Page 51 1 L. WEXLER - CONFIDENTIAL 2 pod-based systems, you don't take into account 3 the price of Cigalikes, do you? 4 A. It would never occur to me to look 5 at the price of Cigalikes. 6 Q. Okay. Would you say, generally, 7 that Cigalike users are different than pod 8 users? 9 A. I think if you look at the 10 demographics of Cigalike users today, the 11 average age of a Cigalike user, at least in 12 our B2C environment, is probably over the age 13 of 50. I think the average age is about 55. 14 That number has been about six months old. 15 Pod systems are significantly younger in our 16 particular database. They'd be 30 and 17 under somewhere is around the average. 18 Q. So, it sounds like they're pretty 19 different demographics. 25 Call dated May 1, 2019. 1 L. WEXLER - CONFIDENTIAL 2 Mr. Wexler, have you had a service with edocument? 4 A. Yes. 5 Q. Okay, great. 6 Q. Okay, great. 6 Mr. Wexler, do you recogniz document to be Turning Point's Q1 201 8 Earnings Call transcript? 9 A. I 've never seen this document of a first quarter call. 10 before, but it does appear to be a transcript of a first quarter call. 11 of a first quarter call. 12 Q. Okay. As CEO of Turning Point of a first quarter call. 13 participate in quarterly earning call. 14 investors, right? 15 A. Yes. 16 Q. I'd like to turn to the page of a contraction of a first quarter to page of a contraction of a first quarter call. 14 investors, right? 15 A. Yes. 16 Q. I'd like to turn to the page of a contraction of a first quarter of a first quarter call. 16 Q. I'd like to turn to the page of a contraction of a first quarter call. 17 A. Yes. 18 Q. So, it sounds like they're pretty 19 different demographics, then? 19 A. Okay. I'm on that page. 20 Q. In the paragraph that's third different demographics.	Page 53 chance to e this e this anscript oint, you s with e stamped oottom
Page 51 1	Page 53 chance to e this e this anscript canscript cansc
Page 51 1 L. WEXLER - CONFIDENTIAL 2 pod-based systems, you don't take into account 3 the price of Cigalikes, do you? 4 A. It would never occur to me to look 5 at the price of Cigalikes. 6 Q. Okay. Would you say, generally, 7 that Cigalike users are different than pod 8 users? 9 A. I think if you look at the 10 demographics of Cigalike user, at least in 11 average age of a Cigalike user, at least in 11 cour B2C environment, is probably over the age 12 Q. Okay. As CBO of Turning Po 13 of 50. I think the average age is about 55. 14 That number has been about six months old. 15 Pod systems are significantly younger in our 16 particular database. They'd be 30 and 17 under somewhere is around the average. 18 Q. So, it sounds like they're pretty 19 different demographics, then? 20 A. I believe that they're very 21 different demographics. 22 Q. Okay. 23 MR. SOWLATI: So, we've been going 25 Call dated May 1, 2019. L. WEXLER - CONFIDENTIAL 1 Mr. Wexler, have you had a review the document? 4 A. Yes. 9 A. I'we never seen this document to be Turning Point's Q1 201 8 Earnings Call transcript? 9 A. I've never seen this document to fa first quarter call. 10 of a first quarter call. 11	Page 53 chance to se this 9 ent enscript sint, you s with se stamped oottom and from all but
Page 51 1	Page 53 chance to se this 9 ent canscript sint, you s with se stamped oottom and from all but

	January	- ,	
	Page 54		Page 56
1	L. WEXLER - CONFIDENTIAL	1	L. WEXLER - CONFIDENTIAL
2	"When looking at the company as a whole."	2	this sales force has helped you in your
3	A. Yes, sorry. You started with a	3	ability to offer RipTide in 4,000 to 6,000
4	different sentence, so you confused me.	4	stores, as you note in your Declaration?
5	Q. I'm focused on the second sentence	5	A. It is the mechanism we use to get
6	where you say, "While still small but getting	6	into stores.
7	bigger, our traditional retail sales force is	7	Q. Would you say the sales force has
8	exceptionally effective. We expect the sales	8	been instrumental?
9	force to provide a meaningful differentiation	9	A. Yeah. If we didn't have a sales
10	as compared to our competitors in the place of	10	force, we probably would not have gotten into
11	not only RipTide, but also mainstream CBD	11	nearly as many stores.
12	distribution."	12	Q. Can you turn to the page stamped
13	Do you see that?	13	3006 of your remarks. That's the next page.
14	A. Yes.	14	A. I'm on 6.
15	Q. Okay. Mr. Wexler, it's your	15	Q. I'm looking at the third paragraph
16	practice to be truthful and accurate when you	16	from the top.
17	speak to your investors, whether in an	17	A. Can you just give me what the first
18	earnings transcript or a press release or any	18	couple of words are, so I know I'm on the
19	other public filing, right?	19	right part?
20	A. I try to be truthful in my entire	20	Q. "Most recently, consumers are
21	life.	21	fiercely adopting vapor products."
22	Q. And especially when speaking to your	22	A. Yes.
23	investors, right?	23	Q. You say in that paragraph that
24	A. Yes.	24	"Closed system or e-cigarette market is
25	Q. Okay. What did you mean, when you	25	already a \$6 billion segment at retail.
	Page 55		Page 57
1	Page 55 L. WEXLER - CONFIDENTIAL	1	Page 57 L. WEXLER - CONFIDENTIAL
1 2		1 2	
	L. WEXLER - CONFIDENTIAL		L. WEXLER - CONFIDENTIAL
2 3 4	L. WEXLER - CONFIDENTIAL said, your retail sales force is exceptionally effective? A. I use the phrase when I talk	2 3 4	L. WEXLER - CONFIDENTIAL However, the technology is changing and consumers are actively searching out new alternatives in the vapor space. A select
2 3 4 5	L. WEXLER - CONFIDENTIAL said, your retail sales force is exceptionally effective? A. I use the phrase when I talk about I'm very proud of my sales force, and	2 3 4 5	L. WEXLER - CONFIDENTIAL However, the technology is changing and consumers are actively searching out new alternatives in the vapor space. A select number of brands have realized good commercial
2 3 4 5 6	L. WEXLER - CONFIDENTIAL said, your retail sales force is exceptionally effective? A. I use the phrase when I talk about I'm very proud of my sales force, and I often use the phrase that it punches well	2 3 4 5 6	L. WEXLER - CONFIDENTIAL However, the technology is changing and consumers are actively searching out new alternatives in the vapor space. A select number of brands have realized good commercial success in this environment." Do you see
2 3 4 5 6 7	L. WEXLER - CONFIDENTIAL said, your retail sales force is exceptionally effective? A. I use the phrase when I talk about I'm very proud of my sales force, and I often use the phrase that it punches well above its weight. We have a relatively small	2 3 4 5 6 7	L. WEXLER - CONFIDENTIAL However, the technology is changing and consumers are actively searching out new alternatives in the vapor space. A select number of brands have realized good commercial success in this environment." Do you see that?
2 3 4 5 6 7 8	L. WEXLER - CONFIDENTIAL said, your retail sales force is exceptionally effective? A. I use the phrase when I talk about I'm very proud of my sales force, and I often use the phrase that it punches well above its weight. We have a relatively small sales force. It's getting bigger, but it's	2 3 4 5 6 7 8	L. WEXLER - CONFIDENTIAL However, the technology is changing and consumers are actively searching out new alternatives in the vapor space. A select number of brands have realized good commercial success in this environment." Do you see that? A. Yes.
2 3 4 5 6 7 8	L. WEXLER - CONFIDENTIAL said, your retail sales force is exceptionally effective? A. I use the phrase when I talk about I'm very proud of my sales force, and I often use the phrase that it punches well above its weight. We have a relatively small sales force. It's getting bigger, but it's significantly smaller than most of our	2 3 4 5 6 7 8 9	L. WEXLER - CONFIDENTIAL However, the technology is changing and consumers are actively searching out new alternatives in the vapor space. A select number of brands have realized good commercial success in this environment." Do you see that? A. Yes. Q. Mr. Wexler, the new alternatives you
2 3 4 5 6 7 8 9	L. WEXLER - CONFIDENTIAL said, your retail sales force is exceptionally effective? A. I use the phrase when I talk about I'm very proud of my sales force, and I often use the phrase that it punches well above its weight. We have a relatively small sales force. It's getting bigger, but it's significantly smaller than most of our competitors, but it certainly differentiates	2 3 4 5 6 7 8 9	L. WEXLER - CONFIDENTIAL However, the technology is changing and consumers are actively searching out new alternatives in the vapor space. A select number of brands have realized good commercial success in this environment." Do you see that? A. Yes. Q. Mr. Wexler, the new alternatives you were referring to were pod systems like JUUL,
2 3 4 5 6 7 8 9 10	L. WEXLER - CONFIDENTIAL said, your retail sales force is exceptionally effective? A. I use the phrase when I talk about I'm very proud of my sales force, and I often use the phrase that it punches well above its weight. We have a relatively small sales force. It's getting bigger, but it's significantly smaller than most of our competitors, but it certainly differentiates us against the smaller companies that we	2 3 4 5 6 7 8 9 10	L. WEXLER - CONFIDENTIAL However, the technology is changing and consumers are actively searching out new alternatives in the vapor space. A select number of brands have realized good commercial success in this environment." Do you see that? A. Yes. Q. Mr. Wexler, the new alternatives you were referring to were pod systems like JUUL, right?
2 3 4 5 6 7 8 9 10 11 12	L. WEXLER - CONFIDENTIAL said, your retail sales force is exceptionally effective? A. I use the phrase when I talk about I'm very proud of my sales force, and I often use the phrase that it punches well above its weight. We have a relatively small sales force. It's getting bigger, but it's significantly smaller than most of our competitors, but it certainly differentiates us against the smaller companies that we [inaudible].	2 3 4 5 6 7 8 9 10 11	L. WEXLER - CONFIDENTIAL However, the technology is changing and consumers are actively searching out new alternatives in the vapor space. A select number of brands have realized good commercial success in this environment." Do you see that? A. Yes. Q. Mr. Wexler, the new alternatives you were referring to were pod systems like JUUL, right? A. I can't say today what I was
2 3 4 5 6 7 8 9 10 11 12 13	L. WEXLER - CONFIDENTIAL said, your retail sales force is exceptionally effective? A. I use the phrase when I talk about I'm very proud of my sales force, and I often use the phrase that it punches well above its weight. We have a relatively small sales force. It's getting bigger, but it's significantly smaller than most of our competitors, but it certainly differentiates us against the smaller companies that we [inaudible]. Q. Okay. Now, in your Declaration, in	2 3 4 5 6 7 8 9 10 11 12 13	L. WEXLER - CONFIDENTIAL However, the technology is changing and consumers are actively searching out new alternatives in the vapor space. A select number of brands have realized good commercial success in this environment." Do you see that? A. Yes. Q. Mr. Wexler, the new alternatives you were referring to were pod systems like JUUL, right? A. I can't say today what I was thinking back then.
2 3 4 5 6 7 8 9 10 11 12 13 14	L. WEXLER - CONFIDENTIAL said, your retail sales force is exceptionally effective? A. I use the phrase when I talk about I'm very proud of my sales force, and I often use the phrase that it punches well above its weight. We have a relatively small sales force. It's getting bigger, but it's significantly smaller than most of our competitors, but it certainly differentiates us against the smaller companies that we [inaudible]. Q. Okay. Now, in your Declaration, in Paragraph 11, you say that you've been able to	2 3 4 5 6 7 8 9 10 11 12 13 14	L. WEXLER - CONFIDENTIAL However, the technology is changing and consumers are actively searching out new alternatives in the vapor space. A select number of brands have realized good commercial success in this environment." Do you see that? A. Yes. Q. Mr. Wexler, the new alternatives you were referring to were pod systems like JUUL, right? A. I can't say today what I was thinking back then. Q. Okay. But do you agree that there
2 3 4 5 6 7 8 9 10 11 12 13 14 15	L. WEXLER - CONFIDENTIAL said, your retail sales force is exceptionally effective? A. I use the phrase when I talk about I'm very proud of my sales force, and I often use the phrase that it punches well above its weight. We have a relatively small sales force. It's getting bigger, but it's significantly smaller than most of our competitors, but it certainly differentiates us against the smaller companies that we [inaudible]. Q. Okay. Now, in your Declaration, in Paragraph 11, you say that you've been able to offer RipTide in 4,000 or it's currently	2 3 4 5 6 7 8 9 10 11 12 13 14 15	L. WEXLER - CONFIDENTIAL However, the technology is changing and consumers are actively searching out new alternatives in the vapor space. A select number of brands have realized good commercial success in this environment." Do you see that? A. Yes. Q. Mr. Wexler, the new alternatives you were referring to were pod systems like JUUL, right? A. I can't say today what I was thinking back then. Q. Okay. But do you agree that there were a number of new alternatives at the time?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	L. WEXLER - CONFIDENTIAL said, your retail sales force is exceptionally effective? A. I use the phrase when I talk about I'm very proud of my sales force, and I often use the phrase that it punches well above its weight. We have a relatively small sales force. It's getting bigger, but it's significantly smaller than most of our competitors, but it certainly differentiates us against the smaller companies that we [inaudible]. Q. Okay. Now, in your Declaration, in Paragraph 11, you say that you've been able to offer RipTide in 4,000 or it's currently offered in 4,000 to 6,000 convenience stores.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	L. WEXLER - CONFIDENTIAL However, the technology is changing and consumers are actively searching out new alternatives in the vapor space. A select number of brands have realized good commercial success in this environment." Do you see that? A. Yes. Q. Mr. Wexler, the new alternatives you were referring to were pod systems like JUUL, right? A. I can't say today what I was thinking back then. Q. Okay. But do you agree that there were a number of new alternatives at the time? A. In this space, there's new
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	L. WEXLER - CONFIDENTIAL said, your retail sales force is exceptionally effective? A. I use the phrase when I talk about I'm very proud of my sales force, and I often use the phrase that it punches well above its weight. We have a relatively small sales force. It's getting bigger, but it's significantly smaller than most of our competitors, but it certainly differentiates us against the smaller companies that we [inaudible]. Q. Okay. Now, in your Declaration, in Paragraph 11, you say that you've been able to offer RipTide in 4,000 or it's currently offered in 4,000 to 6,000 convenience stores. Has this sales force helped you	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	L. WEXLER - CONFIDENTIAL However, the technology is changing and consumers are actively searching out new alternatives in the vapor space. A select number of brands have realized good commercial success in this environment." Do you see that? A. Yes. Q. Mr. Wexler, the new alternatives you were referring to were pod systems like JUUL, right? A. I can't say today what I was thinking back then. Q. Okay. But do you agree that there were a number of new alternatives at the time? A. In this space, there's new alternatives every month across open systems
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	L. WEXLER - CONFIDENTIAL said, your retail sales force is exceptionally effective? A. I use the phrase when I talk about I'm very proud of my sales force, and I often use the phrase that it punches well above its weight. We have a relatively small sales force. It's getting bigger, but it's significantly smaller than most of our competitors, but it certainly differentiates us against the smaller companies that we [inaudible]. Q. Okay. Now, in your Declaration, in Paragraph 11, you say that you've been able to offer RipTide in 4,000 or it's currently offered in 4,000 to 6,000 convenience stores. Has this sales force helped you achieve that sort of distribution?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	L. WEXLER - CONFIDENTIAL However, the technology is changing and consumers are actively searching out new alternatives in the vapor space. A select number of brands have realized good commercial success in this environment." Do you see that? A. Yes. Q. Mr. Wexler, the new alternatives you were referring to were pod systems like JUUL, right? A. I can't say today what I was thinking back then. Q. Okay. But do you agree that there were a number of new alternatives at the time? A. In this space, there's new alternatives every month across open systems and closed systems and Cigalikes.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	L. WEXLER - CONFIDENTIAL said, your retail sales force is exceptionally effective? A. I use the phrase when I talk about I'm very proud of my sales force, and I often use the phrase that it punches well above its weight. We have a relatively small sales force. It's getting bigger, but it's significantly smaller than most of our competitors, but it certainly differentiates us against the smaller companies that we [inaudible]. Q. Okay. Now, in your Declaration, in Paragraph 11, you say that you've been able to offer RipTide in 4,000 or it's currently offered in 4,000 to 6,000 convenience stores. Has this sales force helped you achieve that sort of distribution? MR. LEE: Well, objection as to	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	L. WEXLER - CONFIDENTIAL However, the technology is changing and consumers are actively searching out new alternatives in the vapor space. A select number of brands have realized good commercial success in this environment." Do you see that? A. Yes. Q. Mr. Wexler, the new alternatives you were referring to were pod systems like JUUL, right? A. I can't say today what I was thinking back then. Q. Okay. But do you agree that there were a number of new alternatives at the time? A. In this space, there's new alternatives every month across open systems and closed systems and Cigalikes. Q. Right. So, it seems like a fairly
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	L. WEXLER - CONFIDENTIAL said, your retail sales force is exceptionally effective? A. I use the phrase when I talk about I'm very proud of my sales force, and I often use the phrase that it punches well above its weight. We have a relatively small sales force. It's getting bigger, but it's significantly smaller than most of our competitors, but it certainly differentiates us against the smaller companies that we [inaudible]. Q. Okay. Now, in your Declaration, in Paragraph 11, you say that you've been able to offer RipTide in 4,000 or it's currently offered in 4,000 to 6,000 convenience stores. Has this sales force helped you achieve that sort of distribution? MR. LEE: Well, objection as to form.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	L. WEXLER - CONFIDENTIAL However, the technology is changing and consumers are actively searching out new alternatives in the vapor space. A select number of brands have realized good commercial success in this environment." Do you see that? A. Yes. Q. Mr. Wexler, the new alternatives you were referring to were pod systems like JUUL, right? A. I can't say today what I was thinking back then. Q. Okay. But do you agree that there were a number of new alternatives at the time? A. In this space, there's new alternatives every month across open systems and closed systems and Cigalikes. Q. Right. So, it seems like a fairly competitive market, then, right?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	L. WEXLER - CONFIDENTIAL said, your retail sales force is exceptionally effective? A. I use the phrase when I talk about I'm very proud of my sales force, and I often use the phrase that it punches well above its weight. We have a relatively small sales force. It's getting bigger, but it's significantly smaller than most of our competitors, but it certainly differentiates us against the smaller companies that we [inaudible]. Q. Okay. Now, in your Declaration, in Paragraph 11, you say that you've been able to offer RipTide in 4,000 or it's currently offered in 4,000 to 6,000 convenience stores. Has this sales force helped you achieve that sort of distribution? MR. LEE: Well, objection as to form. And, also, I don't think that that's	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	L. WEXLER - CONFIDENTIAL However, the technology is changing and consumers are actively searching out new alternatives in the vapor space. A select number of brands have realized good commercial success in this environment." Do you see that? A. Yes. Q. Mr. Wexler, the new alternatives you were referring to were pod systems like JUUL, right? A. I can't say today what I was thinking back then. Q. Okay. But do you agree that there were a number of new alternatives at the time? A. In this space, there's new alternatives every month across open systems and closed systems and Cigalikes. Q. Right. So, it seems like a fairly competitive market, then, right? MR. FORD: Objection.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	L. WEXLER - CONFIDENTIAL said, your retail sales force is exceptionally effective? A. I use the phrase when I talk about I'm very proud of my sales force, and I often use the phrase that it punches well above its weight. We have a relatively small sales force. It's getting bigger, but it's significantly smaller than most of our competitors, but it certainly differentiates us against the smaller companies that we [inaudible]. Q. Okay. Now, in your Declaration, in Paragraph 11, you say that you've been able to offer RipTide in 4,000 or it's currently offered in 4,000 to 6,000 convenience stores. Has this sales force helped you achieve that sort of distribution? MR. LEE: Well, objection as to form. And, also, I don't think that that's in Paragraph 11.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	L. WEXLER - CONFIDENTIAL However, the technology is changing and consumers are actively searching out new alternatives in the vapor space. A select number of brands have realized good commercial success in this environment." Do you see that? A. Yes. Q. Mr. Wexler, the new alternatives you were referring to were pod systems like JUUL, right? A. I can't say today what I was thinking back then. Q. Okay. But do you agree that there were a number of new alternatives at the time? A. In this space, there's new alternatives every month across open systems and closed systems and Cigalikes. Q. Right. So, it seems like a fairly competitive market, then, right? MR. FORD: Objection. MR. LEE: Objection. Vague.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	L. WEXLER - CONFIDENTIAL said, your retail sales force is exceptionally effective? A. I use the phrase when I talk about I'm very proud of my sales force, and I often use the phrase that it punches well above its weight. We have a relatively small sales force. It's getting bigger, but it's significantly smaller than most of our competitors, but it certainly differentiates us against the smaller companies that we [inaudible]. Q. Okay. Now, in your Declaration, in Paragraph 11, you say that you've been able to offer RipTide in 4,000 or it's currently offered in 4,000 to 6,000 convenience stores. Has this sales force helped you achieve that sort of distribution? MR. LEE: Well, objection as to form. And, also, I don't think that that's	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	L. WEXLER - CONFIDENTIAL However, the technology is changing and consumers are actively searching out new alternatives in the vapor space. A select number of brands have realized good commercial success in this environment." Do you see that? A. Yes. Q. Mr. Wexler, the new alternatives you were referring to were pod systems like JUUL, right? A. I can't say today what I was thinking back then. Q. Okay. But do you agree that there were a number of new alternatives at the time? A. In this space, there's new alternatives every month across open systems and closed systems and Cigalikes. Q. Right. So, it seems like a fairly competitive market, then, right? MR. FORD: Objection.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	L. WEXLER - CONFIDENTIAL said, your retail sales force is exceptionally effective? A. I use the phrase when I talk about I'm very proud of my sales force, and I often use the phrase that it punches well above its weight. We have a relatively small sales force. It's getting bigger, but it's significantly smaller than most of our competitors, but it certainly differentiates us against the smaller companies that we [inaudible]. Q. Okay. Now, in your Declaration, in Paragraph 11, you say that you've been able to offer RipTide in 4,000 or it's currently offered in 4,000 to 6,000 convenience stores. Has this sales force helped you achieve that sort of distribution? MR. LEE: Well, objection as to form. And, also, I don't think that that's in Paragraph 11. MR. FORD: I think it's Paragraph	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	L. WEXLER - CONFIDENTIAL However, the technology is changing and consumers are actively searching out new alternatives in the vapor space. A select number of brands have realized good commercial success in this environment." Do you see that? A. Yes. Q. Mr. Wexler, the new alternatives you were referring to were pod systems like JUUL, right? A. I can't say today what I was thinking back then. Q. Okay. But do you agree that there were a number of new alternatives at the time? A. In this space, there's new alternatives every month across open systems and closed systems and Cigalikes. Q. Right. So, it seems like a fairly competitive market, then, right? MR. FORD: Objection. MR. LEE: Objection. Vague. Q. You can answer.

Page 58 Page 60 1 L. WEXLER - CONFIDENTIAL 1 L. WEXLER - CONFIDENTIAL 2 Ο. All right. Well, you said, "In this 2 and didn't have all the contracts that you 3 space, there's new players every day"; is that 3 have with cigarettes and moist snuff. And you 4 right? 4 were still able to get in independent displays 5 Yeah, it would particularly be true 5 and you can get promotions and you get signage 6 before the PMTA rules were put in place. 6 up, because there was no offsetting signage 7 7 There was a lot of people coming out with required by the majors because you didn't have 8 innovations. I'm talking about the whole 8 contracts in this area. And it was a market 9 space, not just pods, but across open systems 9 where you could compete. It was a much fairer 10 10 and e-vapor, in general. open market. 11 11 Can you tell me which products Then what happened in the second 12 you're referring to when you say, "A select 12 phase of the evolution of the vape market, and number of brands have realized good commercial I mentioned this before, open systems came 13 13 14 success in this environment"? 14 along. Now, there were some inherent 15 As I said, I can't remember what I 15 limitations to Cigalikes; the battery, the 16 was thinking at that time. It's back in 2019. 16 amount of vapor it produced, the way the vapor 17 A lot has happened since then. 17 got into your system, the amount of 18 You stated that you believe that 18 satisfaction that you got. When open systems 19 there's room for other brands and better 19 came along, all of a sudden, you got this 20 products like RipTide from Nu-X. 20 plethora; this whole range of products. A lot 21 You said there's room for other 21 of innovation. There were products that were 22 brands and better products because there's 22 geared towards delivering concentrated streams 23 rooms for other brands to enter the market, 23 of vapor that delivered more nicotine; there 24 correct? 24 were others that were there to deliver big 25 Yes. Okay. So, let's go back to Α. 25 plumes of smoke and you got your nicotine just Page 59 Page 61 L. WEXLER - CONFIDENTIAL L. WEXLER - CONFIDENTIAL 1 1 2 what I remember about 2019. This is -- the 2 by quantity. There actually became, like, 3 e-vapor market has been in continuous 3 clubs and competitions where they were called evolution since it appeared in the market, and smoke chases where they'd sit there and blow 4 4 5 we had different phases. We had the Cigalike vape at each other. It was kind of hilarious, 5 phase, which was the first entry into the 6 6 when you think about it. 7 market. And there were a number of products 7 Then it started going into when the 8 that came out by different competitors, and 8 pod systems started coming out, and since 9 some products grew and got bigger and other 9 then, there's been disposables and other 10 products did not. 10 things. This is a segment that, again, up 11 As an example, when we introduced 11 until the PMTA, which slowly has put a 12 dramatic halt to some of the innovation, this V2, there were 180 products, branded products 12 13 that preceded us in the market. Within 18 13 is a category that changed fairly rapidly. 14 months, we were the number five player, and we 14 When you think about it, it first showed up in 15 were number five behind Altria. I'm trying 15 2008 and 2009. And the number of SKUs that 16 really hard to say Altria and not Philip 16 have been introduced from 2009, we carry 17 17 something like 4,000 SKUs for the vape shops. Morris. Altria, a Reynolds product, a product 18 called Logic that was eventually bought by 18 That gives you an idea of the amount of 19 Japan Tobacco and a product being put out by innovation and introductions and how dynamic 19 20 Imperial. And we were number five in the 20 the market was at the time. It was a fairly 21 market. 21 open market. 22 At that time, it was somewhat, I'll 22 Ο. So, just to be clear, in May 2019, 23 call it, less organized than some of the other 23 you still believed the market was dynamic,

right?

MR. FORD: Objection. Vague.

24

25

24

25

tobacco categories. So, you didn't really

have the established merchandising fixtures

Page 62 Page 64 1 L. WEXLER - CONFIDENTIAL 1 L. WEXLER - CONFIDENTIAL 2 Α. Yeah. When you say open market, I 2 Α. The range of products that were 3 think in May of 2019, it was starting to close 3 available at that time. I don't think I was 4 off; the majors were starting to get more and 4 specifying any particular company in that 5 more of the market share. I don't believe 5 statement. there -- I don't remember there being any 6 6 Q. Were you referring to JUUL? 7 contracts at that point, but it was starting JUUL would be one of the companies I 7 Α. 8 to get much tougher to get into the C-stores. 8 would have been referring to. 9 Compare our experience with V2, when 9 Q. And what did you mean by "impact"? The way the consumer responds to the 10 within 18 months we were the number five 10 Α. product. 11 player. And then, our experience with 11 12 RipTide, distribution was -- you know, was 12 It sounds like you all were pretty Ο. excited about RipTide. Can you tell me why? 13 decent, but it was extremely expensive, and it 13 14 really limited our ability to do much else 14 Yeah. We had done -- you know, we 15 with the product because the cost of getting 15 don't have the resources to do really 16 distribution was so high. 16 extensive, high priced, quantitative studies, 17 But just to be clear, you told your 17 but we had spent a lot of time on -- let me 18 investors that you believe there's room for 18 draw a parallel. 19 other brands and better products like RipTide, 19 So, in moist snuff, when we decided 20 in May 2019, right? to enter the moist snuff market, we sat down, 20 21 I'm a believer that there's always 21 and we have a group of people who truly love 22 the products. In fact, I have some moist room for better products. 22 23 Mr. Wexler, earlier you testified 23 snuff in here. I should have asked you if it 24 that Turning Point provided the specifications was okay. I didn't want to -- some people 24 for the e-liquid to the Chinese manufacturer don't particularly like watching other people 25 Page 63 Page 65 L. WEXLER - CONFIDENTIAL 1 L. WEXLER - CONFIDENTIAL 1 2 for RipTide, right? 2 consume moist snuff, so I'll ask that now. 3 Α. 3 But we spent months and months going through getting samples, trials, tinkering, 4 Ο. Is sounds like RipTide has a lot of 4 features that vapers are looking for. We'll going back and forth to get a product that we 5 5 talk about that more in a minute. thought was differentiated, and we actually 6 6 7 And it sounds like you must have a 7 invented a different way -- not really 8 very capable in-house innovation team, 8 invented. We used a totally different 9 wouldn't you say? 9 methodology to prepare the tobacco and moist 10 Α. I'd like it to be better. It is 10 snuff for consumption, and we got a product 11 pretty good. 11 that is very differentiated. It's softer, it Now, you said that RipTide flavor 12 12 feels better in the mouth, it delivers Ο. 13 delivery and impact is superior to competitive 13 nicotine over a longer period of time, at 14 entries, and consumers are ready to adapt. 14 least for me. Consumers saw it as being 15 Which competitive entries are you 15 something different, and the way we found that 16 referring to? 16 out is, giving it out to consumers and getting 17 17 them to respond and giving us feedback. Α. I'm sorry. Repeat the question? I 18 thought you were going someplace else with it, 18 Again, we don't have the resources so I -to do the -- if I was at Philip Morris -- when 19 19 20 No problem. In the fourth paragraph 20 I was at Philip Morris, we had focus groups; 21 from the top in your earnings transcript, you 21 we'd do some quant studies; we'd have -- we 22 said that RipTide flavor delivery and impact would have spent millions of dollars on market 23 is superior to competitive entries, and I'm 23 research just to understand how consumers 24 asking which competitive entries you are 24 relate to the product. I'm telling this story

25

25

referring to.

because I relate it to RipTide. And we came

Page 66 Page 68 L. WEXLER - CONFIDENTIAL L. WEXLER - CONFIDENTIAL 1 1 2 up with a product that was unique, and it's 2 there, and what I was trying to communicate --3 been growing fairly consistently since we 3 the reason I chose those words, I was trying 4 entered the market. 4 to communicate that we were fairly 5 5 enthusiastic about the product and that we had We use the same sort of process with 6 RipTide. We had a lot of in-house people use 6 gotten some pretty good feedback from the 7 7 it, give their reactions. We adjusted it and people that we gave it to when they tried it. 8 changed it. We went outside and gave it to 8 So, it sounds like you were saying Ο. 9 consumers; not quant studies that we could say 9 that RipStick provided a better nicotine that we gave it to 5,000 consumers and it got experience than other products like JUUL, 10 10 11 11 right? preference on X percent and all that. 12 And what we found, there was a 12 MR. FORD: Objection. Vague. subsegment of vaper that is we gave did to 13 I wasn't -- I don't think I was 13 Α. 14 that said, "Yeah, I really like this. This is 14 specifying any particular product or any other 15 better than the other products I've tried in 15 company, when I was saying that. I think I 16 the market." We wouldn't have lunched it 16 was just speaking to the reaction that 17 unless we had that kind of response. So, 17 consumers had to our products. 18 yeah, we had some confidence that there was a 18 Well, you did say it provides an 19 subset of consumers that liked the product 19 incomparable nicotine experience. 20 better. 20 Yes, I think that it was -- as I 21 I don't think we were in a position 21 said, I may have had my marketing hat on 22 to say -- and if my words implied that, then I 22 there, yes. 23 probably should have clarified them -- that it 23 Q. The incomparable nicotine experience 24 was better than any other product on the 24 comes, in part, from the use of NicTech, 25 market, or 100 percent of consumers thought right? Page 67 Page 69 L. WEXLER - CONFIDENTIAL L. WEXLER - CONFIDENTIAL 1 1 2 this was a better product. I don't think you 2 Α. Yes, we believe that the technology 3 ever find a product like that where 3 helped people enjoy the product. 100 percent of the consumers will give you 4 How does NicTech help RipTide 4 Ο. preference on it. That just doesn't happen. provide an incomparable nicotine experience? 5 5 It would be nice. I'd like to develop one. I don't know. That's proprietary 6 6 7 That would be wonderful, but I think it's 7 knowledge, and I'd rather do it -- can I just 8 somewhat unrealistic. 8 talk in broad terms? 9 You mention that -- first of all, 9 We have a protective order here, so 10 what is RipStick, and how is that different 10 I'd like to know how it provides an 11 than RipTide? Just so I'm clear. 11 incomparable nicotine experience. 12 That may have been a -- we may have 12 MR. FORD: We've designated the 13 created some confusion. We tried to 13 transcript confidential. Why don't you 14 differentiate the technology of the device 14 give your high-level answer and see if he 15 itself from the pod. So, RipTide was the pod, 15 wants to get more technical? He may not 16 and RipStick was the actual device. I think 16 want to get more technical. 17 that was -- looking back, I think that may 17 And I'm not a chemist. I probably Ο. 18 have been a source of confusion. 18 won't, but I'd love to hear. You said that they delivered a 19 19 I was going to say, you'll have to 20 smoother draw for an incomparable nicotine get my chemist. So, I think we'll probably be 20 21 experience. 21 talking on the same level. 22 Can you tell me why it was important 22 Okay. So, essentially what NicTech 23 to tell investors that it provided an 23 is, is a nicotine technology. By 24 incomparable nicotine experience? 24 "technology," it's a combination of nicotine 25 25 I think I had my marketing hat on with other ingredients that makes it more Α.

Page 70 Page 72 L. WEXLER - CONFIDENTIAL 1 L. WEXLER - CONFIDENTIAL 1 2 efficient, in terms of how people respond to 2 helps the entire experience. The experience 3 each level of nicotine, so that by combining 3 is not just a single point. It's not just, 4 nicotine with other, I guess, chemicals, for 4 you know, if you're at 4.8, you know, that's lack of a better word -- it sounds very harsh. 5 5 the magic number, and 3.6 or 5.5 you can't -different consumers have different tastes and 6 And as a consumer I'd rather not hear that, 6 but by combining nicotine with other elements, 7 different ways of relating to the product, so 7 the consumer can experience a different level it's -- and we believe that the combination of 8 8 9 of satisfaction that lasts a different length 9 NicTech, which covers a number of different elements, was an experience that we found that 10 10 11 I see. So, in that way, it acts 11 consumers -- a portion of consumers enjoy and Ο. 12 similarly to a benzoic acid or a nicotine 12 said they liked it. salt? 13 RipTide's incomparable nicotine 13 Ο. 14 I can't speak to the exact chemistry 14 experience also comes from the fact that it 15 of benzoic acid versus this. I don't know. 15 has an offering at 5 percent nicotine 16 There's a series of things that I've heard 16 strength, right? 17 about benzoic acid that I can't speak to, as 17 MR. FORD: Objection. 18 an expert, and I don't know if it's worth 18 Α. I think -- I'll go back to my former 19 repeating. But what it does, it works with 19 answers. It is an element of the experience. 20 the body chemistry -- the NicTech works with 20 I don't know that there's magic in 5 versus 21 the body chemistry to give the consumers more 21 4.8 versus 4.6 versus 5.2. But the 22 enjoyment. 22 combination of all the elements, put together, 23 Okay. So, would you agree that, all 23 impacts different consumers differently. And 24 24 some like that combination of elements, and else equal, the nicotine that's at, let's say, some like other combination of elements. 25 5 percent concentration with NicTech, the 25 Page 71 Page 73 L. WEXLER - CONFIDENTIAL L. WEXLER - CONFIDENTIAL 1 1 2 other product doesn't have NicTech, NicTech is 2 I think Stoker's has an incomparable 3 going to give a better experience? 3 taste -- for me, has an incomparable taste of MR. FORD: Objection to form. 4 moist snuff, but there's plenty of people who 4 5 MR. LEE: Objection to form. 5 use Copenhagen. Better for who? You have to ask the 6 6 MR. SOWLATI: I just sent a 7 consumer which one was better. Again, 7 document. Hopefully it doesn't take too 8 particularly in vape, there's just a range of 8 long. This is Wexler EX 13. 9 experiences that people are looking at. And 9 This is a RipTide e-liquid 10 as I said before in my answers to a previous 10 advertisement that we found in your 11 question, you know we went out there. We did 11 production. If you could turn to the page 12 not get 100 percent of the people that said 12 stamped 13009. 13 this is better than anything else -- I wish 13 MR. FORD: Larry, you should feel 14 they did, but that this is better than every 14 free to look through the whole thing. 15 other product in the market. 15 THE WITNESS: Just so I can maybe 16 We did get a subsegment of consumers 16 frame it how we might have used it. that said, "This is a better experience." And 17 MR. FORD: Yes. 17 18 a lot of the people in-house said, "This is 18 Is this a finished document? I see Α. what I would use." things crossed out and... 19 19 20 And you said that that's in part Q. 20 Q. It was in your files like that. 21 because of nicotine -- strike that. 21 Α. Okay. So, do we know if this was a 22 You would say that that's, in part, 22 draft or a final product? 23 because of NicTech, right? 23 Ο. It doesn't have a draft stamp on it. 24 We believe that the combination of 24 What's that? 25 25 all the elements combined with the battery MR. FORD: He can make any

1 2				
2		Page 74		Page 76
		L. WEXLER - CONFIDENTIAL	1	L. WEXLER - CONFIDENTIAL
	_	sentation, one way or the other. You	2	good; the way it fits in your hand, the way
3		nly testify about what you know,	3	you could use it, keep it pretty discreet. It
4	Larry		4	had a different sort of feel and texture. We
5	7	THE WITNESS: Okay.	5 6	tried to give it a different sort of feel and texture on the outside. That's what I
7	Α.	And you want me on Page 13?	7	
8	Q.	13-009	8	remember.
	Dwoolstha	Do you see that? It says,	9	Q. I'm going to stick with Page 6, but I want to turn to the remarks of Graham A.
10	A.	ough Nicotine Technology." Yeah, I'm just looking at the rest	10	Purdy, which starts at the bottom of the page.
	of the do		11	Mr. Wexler, who is Mr. Purdy?
12	i the do	Okay. 009?	12	A. Mr. Purdy is someone who works for
13	Q.	Yes.	13	me. He is currently the COO of Turning Point
14	Δ.	Okay. It has bottles on it? Just	14	Brands.
		I'm on the right page.	15	
16	Q.	Yes. And it says, "Breakthrough	16	Q. Mr. Purdy is someone you trust and you know to give truthful and accurate
		Technology" on the top of the page.	17	information in these calls just like you do,
18	A.	Yes.	18	right?
19	Q.	You're referring to NicTech here,	19	A. Yes.
	ight?	Tou Te Teleffing to Nicredi here,	20	Q. In the first paragraph of
21	A.	That's what it says.	21	Mr. Purdy's remarks, at the very bottom he
22	Q.	Okay. It says, "higher in nicotine	22	says, "RipTide RipStick device and pod system
		ion." Do you see that?	23	is like no other entry into the marketplace
24	A.	Yes.	24	before it."
25	Q.	And that comes from the NicTech,	25	RipTide, at this time, was like no
	χ.			
		Page 75		Page 77
1		Page 75	1	Page 77 L. WEXLER - CONFIDENTIAL
	ight?		1 2	
	ight? A.			L. WEXLER - CONFIDENTIAL
2 r: 3 4 ha	A. was ye	L. WEXLER - CONFIDENTIAL NicTech is part of the reason why it s.	2 3 4	L. WEXLER - CONFIDENTIAL other entry into the market before it, in part, because of NicTech, right? MR. FORD: Objection.
2 r: 3 4 ha	A. as ye Q.	L. WEXLER - CONFIDENTIAL NicTech is part of the reason why it s. Okay. Why don't we turn back to the	2 3 4 5	L. WEXLER - CONFIDENTIAL other entry into the market before it, in part, because of NicTech, right? MR. FORD: Objection. A. Okay. So, exactly how are you
2 r: 3 4 ha 5 6 la	A. as ye Q. ast docu	L. WEXLER - CONFIDENTIAL NicTech is part of the reason why it s. Okay. Why don't we turn back to the ment that we were on. This is,	2 3 4 5 6	L. WEXLER - CONFIDENTIAL other entry into the market before it, in part, because of NicTech, right? MR. FORD: Objection. A. Okay. So, exactly how are you framing, like no entry before it? If you're
2 r: 3 4 ha 5 6 1a 7 as	A. as ye Q. ast docu	L. WEXLER - CONFIDENTIAL NicTech is part of the reason why it s. Okay. Why don't we turn back to the ment that we were on. This is, xler EX 3. This is your Q1 2019	2 3 4 5 6 7	L. WEXLER - CONFIDENTIAL other entry into the market before it, in part, because of NicTech, right? MR. FORD: Objection. A. Okay. So, exactly how are you framing, like no entry before it? If you're saying it's a pod system, there were other pod
2 r. 3 4 h. 5 6 1. 7 a. 8 Th	A. as ye Q. ast docu gain, We urning P	I. WEXLER - CONFIDENTIAL NicTech is part of the reason why it s. Okay. Why don't we turn back to the ment that we were on. This is, xler EX 3. This is your Q1 2019 oint Earnings Call dated May 1st,	2 3 4 5 6 7 8	L. WEXLER - CONFIDENTIAL other entry into the market before it, in part, because of NicTech, right? MR. FORD: Objection. A. Okay. So, exactly how are you framing, like no entry before it? If you're saying it's a pod system, there were other pod systems. But what we're saying is that, the
2 r: 3 4 h: 5 6 1: 7 a; 8 T: 9 2:	A. as ye Q. ast docu gain, We urning P	L. WEXLER - CONFIDENTIAL NicTech is part of the reason why it s. Okay. Why don't we turn back to the ment that we were on. This is, xler EX 3. This is your Q1 2019 oint Earnings Call dated May 1st, 11 give you a second to get back to	2 3 4 5 6 7 8	L. WEXLER - CONFIDENTIAL other entry into the market before it, in part, because of NicTech, right? MR. FORD: Objection. A. Okay. So, exactly how are you framing, like no entry before it? If you're saying it's a pod system, there were other pod systems. But what we're saying is that, the combination of features was unique. There's
2 r: 3 4 h: 5 6 1: 7 a: 8 T: 9 2: 10 t: 1	A. A. A. Q. ast docu gain, We urning P 1019. I' hat docu	L. WEXLER - CONFIDENTIAL NicTech is part of the reason why it s. Okay. Why don't we turn back to the ment that we were on. This is, xler EX 3. This is your Q1 2019 oint Earnings Call dated May 1st, 11 give you a second to get back to ment.	2 3 4 5 6 7 8 9	L. WEXLER - CONFIDENTIAL other entry into the market before it, in part, because of NicTech, right? MR. FORD: Objection. A. Okay. So, exactly how are you framing, like no entry before it? If you're saying it's a pod system, there were other pod systems. But what we're saying is that, the combination of features was unique. There's no other product that had the combination of
2 r: 3 4 h: 5 6 1: 7 as: 8 T: 9 2: 10 t: 11	A. As ye Q. Ast docu legain, We Curning P 1019. I' hat docu A.	L. WEXLER - CONFIDENTIAL NicTech is part of the reason why it s. Okay. Why don't we turn back to the ment that we were on. This is, xler EX 3. This is your Q1 2019 oint Earnings Call dated May 1st, ll give you a second to get back to ment. I'm on that document.	2 3 4 5 6 7 8 9 10	L. WEXLER - CONFIDENTIAL other entry into the market before it, in part, because of NicTech, right? MR. FORD: Objection. A. Okay. So, exactly how are you framing, like no entry before it? If you're saying it's a pod system, there were other pod systems. But what we're saying is that, the combination of features was unique. There's no other product that had the combination of features that RipTide had.
2 r: 3 4 h: 5 6 1: 7 as 7 9 2: 10 t: 11 12	A. as ye Q. ast docu gain, We turning P 1019. I' hat docu A. Q.	L. WEXLER - CONFIDENTIAL NicTech is part of the reason why it s. Okay. Why don't we turn back to the ment that we were on. This is, xler EX 3. This is your Q1 2019 oint Earnings Call dated May 1st, ll give you a second to get back to ment. I'm on that document. Again, on the page stamped 3006,	2 3 4 5 6 7 8 9 10 11 12	L. WEXLER - CONFIDENTIAL other entry into the market before it, in part, because of NicTech, right? MR. FORD: Objection. A. Okay. So, exactly how are you framing, like no entry before it? If you're saying it's a pod system, there were other pod systems. But what we're saying is that, the combination of features was unique. There's no other product that had the combination of features that RipTide had. Q. Okay. If we look at the next page
2 r: 3 4 h: 5 6 1: 7 as 8 T: 9 2: 10 t: 11 1: 2 13 f: 6	A. as ye Q. ast docu gain, We curning P 1019. I' hat docu A. Q. fourth fr	L. WEXLER - CONFIDENTIAL NicTech is part of the reason why it s. Okay. Why don't we turn back to the ment that we were on. This is, xler EX 3. This is your Q1 2019 oint Earnings Call dated May 1st, 11 give you a second to get back to ment. I'm on that document. Again, on the page stamped 3006, om the top, you said that RipStick	2 3 4 5 6 7 8 9 10 11 12 13	L. WEXLER - CONFIDENTIAL other entry into the market before it, in part, because of NicTech, right? MR. FORD: Objection. A. Okay. So, exactly how are you framing, like no entry before it? If you're saying it's a pod system, there were other pod systems. But what we're saying is that, the combination of features was unique. There's no other product that had the combination of features that RipTide had. Q. Okay. If we look at the next page on the top, we're on 3007, so the next page of
2 r: 3 4 h: 5 6 1: 7 as 8 T: 9 2: 10 t: 11 1: 12 13 f: d: 14 d: 14	A. as ye Q. ast docu gain, We Gurning P G019. I' hat docu A. Q. Gourth fr levice is	L. WEXLER - CONFIDENTIAL NicTech is part of the reason why it s. Okay. Why don't we turn back to the ment that we were on. This is, xler EX 3. This is your Q1 2019 oint Earnings Call dated May 1st, 11 give you a second to get back to ment. I'm on that document. Again, on the page stamped 3006, om the top, you said that RipStick a superior small form factor	2 3 4 5 6 7 8 9 10 11 12 13 14	L. WEXLER - CONFIDENTIAL other entry into the market before it, in part, because of NicTech, right? MR. FORD: Objection. A. Okay. So, exactly how are you framing, like no entry before it? If you're saying it's a pod system, there were other pod systems. But what we're saying is that, the combination of features was unique. There's no other product that had the combination of features that RipTide had. Q. Okay. If we look at the next page on the top, we're on 3007, so the next page of Mr. Purdy's remarks.
2 r: 3 4 h: 5 6 1: 7 a: 8 T: 9 2: 10 t: 11 12 13 f: 14 d: 15	A. As ye Q. Ast docu gain, We Curning P Co19. I' hat docu A. Q. Courth fr levice is A.	L. WEXLER - CONFIDENTIAL NicTech is part of the reason why it s. Okay. Why don't we turn back to the ment that we were on. This is, xler EX 3. This is your Q1 2019 oint Earnings Call dated May 1st, 11 give you a second to get back to ment. I'm on that document. Again, on the page stamped 3006, om the top, you said that RipStick a superior small form factor Okay. Can you just tell me the	2 3 4 5 6 7 8 9 10 11 12 13 14 15	L. WEXLER - CONFIDENTIAL other entry into the market before it, in part, because of NicTech, right? MR. FORD: Objection. A. Okay. So, exactly how are you framing, like no entry before it? If you're saying it's a pod system, there were other pod systems. But what we're saying is that, the combination of features was unique. There's no other product that had the combination of features that RipTide had. Q. Okay. If we look at the next page on the top, we're on 3007, so the next page of Mr. Purdy's remarks. A. Okay. Hold on.
2 r: 3 4 h: 5 6 l: 7 a: 8 T: 10 t: 11 12 13 f: 14 d: 15 16 f:	A. as ye Q. ast docu gain, We Turning P 1019. I' hat docu A. Q. fourth fr levice is A. irst wor	NicTech is part of the reason why it s. Okay. Why don't we turn back to the ment that we were on. This is, xler EX 3. This is your Q1 2019 oint Earnings Call dated May 1st, 11 give you a second to get back to ment. I'm on that document. Again, on the page stamped 3006, om the top, you said that RipStick a superior small form factor Okay. Can you just tell me the ds of the paragraph?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	L. WEXLER - CONFIDENTIAL other entry into the market before it, in part, because of NicTech, right? MR. FORD: Objection. A. Okay. So, exactly how are you framing, like no entry before it? If you're saying it's a pod system, there were other pod systems. But what we're saying is that, the combination of features was unique. There's no other product that had the combination of features that RipTide had. Q. Okay. If we look at the next page on the top, we're on 3007, so the next page of Mr. Purdy's remarks. A. Okay. Hold on. And where are you?
2 r: 3 4 h: 5 6 1: 7 a: 8 T: 9 2: 10 t: 11 1: 12 13 f: 6: 15 16 f: 17	A. as ye Q. ast docu gain, We Turning P 1019. I' hat docu A. Q. Tourth fr levice is A. Tirst wor Q.	NicTech is part of the reason why it s. Okay. Why don't we turn back to the ment that we were on. This is, xler EX 3. This is your Q1 2019 oint Earnings Call dated May 1st, 11 give you a second to get back to ment. I'm on that document. Again, on the page stamped 3006, om the top, you said that RipStick a superior small form factor — Okay. Can you just tell me the ds of the paragraph? "RipTide is a proprietary pod-based"	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	L. WEXLER - CONFIDENTIAL other entry into the market before it, in part, because of NicTech, right? MR. FORD: Objection. A. Okay. So, exactly how are you framing, like no entry before it? If you're saying it's a pod system, there were other pod systems. But what we're saying is that, the combination of features was unique. There's no other product that had the combination of features that RipTide had. Q. Okay. If we look at the next page on the top, we're on 3007, so the next page of Mr. Purdy's remarks. A. Okay. Hold on. And where are you? Q. At the very top.
2 r: 3 4 h: 5 6 1: 7 as: 8 T: 9 2: 10 t: 11 12 13 f: 14 d: 15 16 f: 17 18 v: 8	A. as ye Q. ast docu gain, We furning P 1019. I' hat docu A. Q. fourth fr levice is A. first wor Q. rapor sys	L. WEXLER - CONFIDENTIAL NicTech is part of the reason why it s. Okay. Why don't we turn back to the ment that we were on. This is, xler EX 3. This is your Q1 2019 oint Earnings Call dated May 1st, ll give you a second to get back to ment. I'm on that document. Again, on the page stamped 3006, om the top, you said that RipStick a superior small form factor Okay. Can you just tell me the ds of the paragraph? "RipTide is a proprietary pod-based tem."	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	L. WEXLER - CONFIDENTIAL other entry into the market before it, in part, because of NicTech, right? MR. FORD: Objection. A. Okay. So, exactly how are you framing, like no entry before it? If you're saying it's a pod system, there were other pod systems. But what we're saying is that, the combination of features was unique. There's no other product that had the combination of features that RipTide had. Q. Okay. If we look at the next page on the top, we're on 3007, so the next page of Mr. Purdy's remarks. A. Okay. Hold on. And where are you? Q. At the very top. A. It starts, "1.4 milliliters"? Am I
2 r: 3 4 h: 5 6 1: 7 as 7 1: 12 13 f: 14 d: 15 16 f: 17 18 v: 19	A. as ye Q. ast docu gain, We curning P 1019. I' hat docu A. Q. courth fr levice is A. first wor Q. rapor sys A.	L. WEXLER - CONFIDENTIAL NicTech is part of the reason why it s. Okay. Why don't we turn back to the ment that we were on. This is, xler EX 3. This is your Q1 2019 oint Earnings Call dated May 1st, ll give you a second to get back to ment. I'm on that document. Again, on the page stamped 3006, om the top, you said that RipStick a superior small form factor Okay. Can you just tell me the ds of the paragraph? "RipTide is a proprietary pod-based tem." Okay.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	L. WEXLER - CONFIDENTIAL other entry into the market before it, in part, because of NicTech, right? MR. FORD: Objection. A. Okay. So, exactly how are you framing, like no entry before it? If you're saying it's a pod system, there were other pod systems. But what we're saying is that, the combination of features was unique. There's no other product that had the combination of features that RipTide had. Q. Okay. If we look at the next page on the top, we're on 3007, so the next page of Mr. Purdy's remarks. A. Okay. Hold on. And where are you? Q. At the very top. A. It starts, "1.4 milliliters"? Am I on the right page?
2 r: 3 4 h: 5 6 l: 7 as 8 T: 9 2: 10 t: 11 12 13 f: 14 d: 15 16 f: 17 18 v: 19 20	A. as ye Q. ast docu gain, We curning P col9. I' chat docu A. Q. courth fr levice is A. cirst wor Q. capor sys A. Q.	NicTech is part of the reason why it s. Okay. Why don't we turn back to the ment that we were on. This is, xler EX 3. This is your Q1 2019 oint Earnings Call dated May 1st, 11 give you a second to get back to ment. I'm on that document. Again, on the page stamped 3006, om the top, you said that RipStick a superior small form factor Okay. Can you just tell me the ds of the paragraph? "RipTide is a proprietary pod-based tem." Okay. And I'm looking at the last	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	L. WEXLER - CONFIDENTIAL other entry into the market before it, in part, because of NicTech, right? MR. FORD: Objection. A. Okay. So, exactly how are you framing, like no entry before it? If you're saying it's a pod system, there were other pod systems. But what we're saying is that, the combination of features was unique. There's no other product that had the combination of features that RipTide had. Q. Okay. If we look at the next page on the top, we're on 3007, so the next page of Mr. Purdy's remarks. A. Okay. Hold on. And where are you? Q. At the very top. A. It starts, "1.4 milliliters"? Am I on the right page? Q. Yes, it starts at 1.4 milliliters.
2 r: 3	A. as ye Q. ast docu gain, We Curning P 1019. I' hat docu A. Q. Courth fr device is A. Cirst wor Q. Tapor sys A. Q. Gentence.	NicTech is part of the reason why it s. Okay. Why don't we turn back to the ment that we were on. This is, xler EX 3. This is your Q1 2019 oint Earnings Call dated May 1st, 11 give you a second to get back to ment. I'm on that document. Again, on the page stamped 3006, om the top, you said that RipStick a superior small form factor Okay. Can you just tell me the ds of the paragraph? "RipTide is a proprietary pod-based tem." Okay. And I'm looking at the last You said, "The RipStick device is a	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	L. WEXLER - CONFIDENTIAL other entry into the market before it, in part, because of NicTech, right? MR. FORD: Objection. A. Okay. So, exactly how are you framing, like no entry before it? If you're saying it's a pod system, there were other pod systems. But what we're saying is that, the combination of features was unique. There's no other product that had the combination of features that RipTide had. Q. Okay. If we look at the next page on the top, we're on 3007, so the next page of Mr. Purdy's remarks. A. Okay. Hold on. And where are you? Q. At the very top. A. It starts, "1.4 milliliters"? Am I on the right page? Q. Yes, it starts at 1.4 milliliters. A. Okay.
2 r: 3	A. as ye Q. ast docu gain, We Curning P 1019. I' hat docu A. Q. Courth fr device is A. Cirst wor Q. capor sys A. Q. capor sys	NicTech is part of the reason why it s. Okay. Why don't we turn back to the ment that we were on. This is, xler EX 3. This is your Q1 2019 oint Earnings Call dated May 1st, ll give you a second to get back to ment. I'm on that document. Again, on the page stamped 3006, om the top, you said that RipStick a superior small form factor Okay. Can you just tell me the ds of the paragraph? "RipTide is a proprietary pod-based tem." Okay. And I'm looking at the last You said, "The RipStick device is a small form factor."	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	L. WEXLER - CONFIDENTIAL other entry into the market before it, in part, because of NicTech, right? MR. FORD: Objection. A. Okay. So, exactly how are you framing, like no entry before it? If you're saying it's a pod system, there were other pod systems. But what we're saying is that, the combination of features was unique. There's no other product that had the combination of features that RipTide had. Q. Okay. If we look at the next page on the top, we're on 3007, so the next page of Mr. Purdy's remarks. A. Okay. Hold on. And where are you? Q. At the very top. A. It starts, "1.4 milliliters"? Am I on the right page? Q. Yes, it starts at 1.4 milliliters. A. Okay. Q. Mr. Purdy says that RipTide was an
2 r: 3 4 h: 5 6 l: 7 aa 8 T: 9 2: 10 t: 11 12 13 fc 14 dc 15 16 f: 17 18 v: 19 20 21 sc 22 s:	A. as ye Q. ast docu gain, We Turning P 1019. I' hat docu A. Q. fourth fr levice is A. first wor Q. apor sys A. Q. centence.	NicTech is part of the reason why it s. Okay. Why don't we turn back to the ment that we were on. This is, xler EX 3. This is your Q1 2019 oint Earnings Call dated May 1st, 11 give you a second to get back to ment. I'm on that document. Again, on the page stamped 3006, om the top, you said that RipStick a superior small form factor Okay. Can you just tell me the ds of the paragraph? "RipTide is a proprietary pod-based tem." Okay. And I'm looking at the last You said, "The RipStick device is a small form factor." What about RipStick gives it a	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	L. WEXLER - CONFIDENTIAL other entry into the market before it, in part, because of NicTech, right? MR. FORD: Objection. A. Okay. So, exactly how are you framing, like no entry before it? If you're saying it's a pod system, there were other pod systems. But what we're saying is that, the combination of features was unique. There's no other product that had the combination of features that RipTide had. Q. Okay. If we look at the next page on the top, we're on 3007, so the next page of Mr. Purdy's remarks. A. Okay. Hold on. And where are you? Q. At the very top. A. It starts, "1.4 milliliters"? Am I on the right page? Q. Yes, it starts at 1.4 milliliters. A. Okay. Q. Mr. Purdy says that RipTide was an exceptional adult consumer value proposition.
2 r: 3 4 h: 5 6 l: 7 a: 8 T: 9 2: 10 t: 11 12 13 f: 14 d: 15 16 f: 17 18 v: 19 20 21 s: 22 s:	A. as ye Q. ast docu gain, We Turning P 1019. I' hat docu A. Q. fourth fr levice is A. first wor Q. apor sys A. Q. centence.	NicTech is part of the reason why it s. Okay. Why don't we turn back to the ment that we were on. This is, xler EX 3. This is your Q1 2019 oint Earnings Call dated May 1st, ll give you a second to get back to ment. I'm on that document. Again, on the page stamped 3006, om the top, you said that RipStick a superior small form factor Okay. Can you just tell me the ds of the paragraph? "RipTide is a proprietary pod-based tem." Okay. And I'm looking at the last You said, "The RipStick device is a small form factor."	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	L. WEXLER - CONFIDENTIAL other entry into the market before it, in part, because of NicTech, right? MR. FORD: Objection. A. Okay. So, exactly how are you framing, like no entry before it? If you're saying it's a pod system, there were other pod systems. But what we're saying is that, the combination of features was unique. There's no other product that had the combination of features that RipTide had. Q. Okay. If we look at the next page on the top, we're on 3007, so the next page of Mr. Purdy's remarks. A. Okay. Hold on. And where are you? Q. At the very top. A. It starts, "1.4 milliliters"? Am I on the right page? Q. Yes, it starts at 1.4 milliliters. A. Okay. Q. Mr. Purdy says that RipTide was an

	- January		
	Page 78		Page 80
1	L. WEXLER - CONFIDENTIAL	1	L. WEXLER - CONFIDENTIAL
2	A. Well, what we were trying to do was	2	paragraph that starts, "Our long-term guidance
3	give greater value to the consumer, and value	3	on the NewGen margin has been 25 to 30 percent.
4	comes in many different forms. So, we made	4	Will stay as the RipTide products, the CBDs
5	our pods, the size of our pods larger. It was	5	flow through, those margins are going to
6	1.4 milliliters rather than if I remember	6	hold." Do you see that?
7	correctly, JUUL was somewhere around	7	A. I do.
8	1 milliliter, at the time. It also had this	8	Q. Mr. Wexler, the profitability of
9	technology that we had with it.	9	your products is important, right?
10	And so, we felt as though we were	10	A. That's why we exist.
11	putting together a great set of value. Value	11	Q. Fair enough. And you were telling
12	comes in many different forms; it comes in	12	your investors that RipTide was going to
13	price, it comes in product quality, it comes	13	maintain positive profitability targets,
14	in flavors, it comes in quantities, it comes	14	right?
15	in convenience. There's all sorts of elements	15	MR. FORD: Objection.
16	of value.	16	MR. LEE: Objection. Vague.
17	Q. And also the price?	17	A. Yeah, I think you've got to put it
18	A. Price is one element of value,	18	within the context of as it flows through,
19	certainly, yeah.	19	meaning over time, that this is where we
20	Q. Mr. Purdy notes that the soft launch	20	expect RipTide targets to be.
21	for RipTide was especially compelling.	21	Q. Mr. Wexler, we can put that document
22	In what way was it compelling?	22	to the side. I am going to be loading a new
23	A. Can I read the context in which he	23	document.
24	said it?	24	A. Is this Exhibit 4?
25	Q. Yes, of course. He says, "The	25	Q. Yes. It's stamped Wexler EX 4, and
	-		
1	Page 79	1	Page 81
1	L. WEXLER - CONFIDENTIAL	1	L. WEXLER - CONFIDENTIAL
2	exceptional adult consumer value proposition	2	it's your Q2 2019 earnings transcript
3	coupled with what I believe to be superior	3	A. Let me get it downloaded first so I
4	satisfaction have proven to be especially	4	can be with you.
5	compelling during our soft launch in the first	5	MR. SOWLATI: Just for the record,
6	quarter."	6	I'm going to state what document is. This
7	A. Okay. What is your question?	7	is Wexler EX 4, and it's Turning Point's
8	Q. My question is: In what way was it	8	Q2 2019 Earnings Transcript dated July 31,
9	an especially compelling soft launch?	9	2019.
10	A. You'd have to ask him for the	10	MR. FORD: As with the other
11	context in which he made that remark. These	11	documents, feel free to skim through just
12	are not my words; these are his.	12	to get context.
13	Q. Okay. Let's stick with this	13	THE WITNESS: Yeah, I just want to
14	document, and let's turn to the page stamped	14	get some context.
15	3010.	15	MR. SOWLATI: No problem. Please
16	A. And we're still in the earnings	16	let me know when you're done.
17	call?	17	THE WITNESS: Okay.
18	Q. Yes.	18	Q. Mr. Wexler, do you recognize this to
19	A. 3010?	19	be your Q2 2019 earnings transcript?
20	Q. Yes.	20	A. As I've said before, I've never seen
21	A. Okay. Hold on.	21	it in this format, but it does appear to be my
22	The Q and A?	22	second quarter transcript.
23	Q. Yes.	23	Q. Can we turn to the page stamped
	A Olfarr Tim thoma	24	4005? I'm looking at the paragraph that's
24	A. Okay. I'm there.		
24 25	Q. In the middle of the page, there's a	25	fourth from the bottom. It starts, "Let's

Page 82 Page 84 L. WEXLER - CONFIDENTIAL 1 L. WEXLER - CONFIDENTIAL 1 2 start with a fresh look at Nu-X portfolio of 2 Ο. "Including a product that," and I'm 3 products." 3 quoting you, "that provided uncompromised 4 Do you see that? 4 satisfaction"? 5 T do. 5 MR. FORD: Objection. Α. Right after that, there is a 6 6 A. I don't even know how to address 7 7 sentence where you note that "RipTide was that question. We believe we put together a positioned to meet former smoker preferences 8 package consumers told us -- a package of 8 9 at a value price point." 9 attributes that would be good for consumers. Why was it important for RipTide to We had a subsegment of consumers who told us 10 10 11 be positioned to meet former smoker 11 they really liked it and this was something 12 preferences? 12 that they would use. So yeah, we wouldn't We believe that the vast, vast introduce a product if we didn't think that 13 Α. 13 14 majority of vapers are former smokers. We 14 consumers would like that. 15 don't really market to get for initiation. We 15 And one of the things you thought 16 really target against people who are 16 consumers would like was the uncompromised 17 experienced with smoke and they want to go to 17 satisfaction? 18 vapor. That's where our corporate efforts are 18 MR. FORD: Objection. Vague. 19 focused. 19 If you're asking me what I think Α. 20 consumers like, I think consumers like the Q. Got it. And you said, "RipTide was 20 21 at a value price point." 21 whole range of attributes that basically --22 Is that because it was priced 22 that that particular combination creates 23 competitively with JUUL and other pod-based 23 satisfaction with the consumer. That's why 24 products? they buy the product. Consumers don't 24 MR. FORD: Objection. Vague. 25 25 generally buy products they don't -- they're Page 83 Page 85 L. WEXLER - CONFIDENTIAL 1 L. WEXLER - CONFIDENTIAL 1 2 Α. I don't remember what the market 2 not satisfied with. 3 situation was there. But when we say it's a 3 And that's -- but it's a whole range value price, it may have been an exact same of things. It could be the packaging; it 4 4 price, but it had more liquid in the pods. I could be the brand positioning; it could be 5 just don't remember the specifics of value, in the taste; it could be the flavor; it could be 6 6 7 this context. 7 the size; it could be the feel; it could be 8 You also say in this paragraph that, 8 how it performs. You know, brands are complex 9 "The leading brand was doing 60 million pods 9 things; products are complex things. 10 per month." 10 Right. And you specifically told 11 You're referring to JUUL, right? 11 shareholders that NicTech yields uncompromised 12 Α. I would presume that I was, yes. 12 satisfaction, and you thought it was important 13 Now, despite JUUL's performance, in 13 to tell shareholders that, right? 14 the middle of 2019, you believed there was a 14 MR. LEE: Objection to form. 15 meaningful opportunity in the market, right? 15 Α. I obviously used those words, so I 16 Α. This was a segment that was growing 16 used those words. 17 rapidly, and we felt that consumers would want 17 0. Okay. Let's turn to the next page, 18 to have additional competitors in there 18 where you'll see Mr. Purdy's remarks start at because, as I've said many times during this the bottom. I'm actually, sorry, not going to 19 19 20 deposition, there's a whole range of consumer focus on this page. I just wanted to identify 21 desires. People get satisfied differently 21 that now Mr. Purdy, the President of Nu-X 22 with different combination and package of 22 Ventures, would be speaking. 23 attributes. And so, we felt given people 23 I want to turn to the following 24 we've talked to, that there was room for a 24 page, which is the page stamped 4007. In the 25 product like RipTide among those consumers. 25 first full paragraph which starts, "But rest

	January	ZJ,	2021
	Page 86		Page 88
1	L. WEXLER - CONFIDENTIAL	1	L. WEXLER - CONFIDENTIAL
2	assured there are a myriad of other	2	shipments into stores.
3	opportunities in the product development	3	Q. I see.
4	pipeline," I wanted to focus you on	4	A. You put an initial distribution in,
5	Mr. Purdy's remarks where he says, "RipTide	5	then the store would order product and it
6	and our NicTech technology delivered	6	would be shipped in, and we monitor that.
7	compelling results in the quarter."	7	That's how I would use that term, in
8	In what way did they provide	8	particular.
9	compelling results?	9	Q. Mr. Wexler, you can put this
10	A. We're starting to turn to our sales	10	earnings transcript to the side. Just give me
11	forces, and we were making some headway in	11	one second while I get the next document
12	getting distribution, and we spent a large	12	ready. This is a large document,
13	bushel full of money in order to get	13	15 megabytes, so it's going to take a second
14	distribution in Speedway. I believe that I	14	to load.
15	can't speak for exactly what he was talking	15	Have you been able to load that
16	about, but for us, having a new product and	16	document?
17	getting into a major chain that early was	17	A. I'm about to open it.
18	something different; something that we hadn't	18	MR. SOWLATI: Just for the record,
19	really done in the past. But it cost us a ton	19	this document is stamped Wexler EX 5, and
20	of money.	20	it's a RipTide product launch sales
21	More importantly, the way we got	21	training deck that was in your files.
22	into Speedway was, they had a problem. They	22	THE WITNESS: Okay.
23	had bought a product called Mystic, which was	23	Q. I'm just going to focus on a few
24	made by an independent manufacturer, and they	24	slides, but I'm going to give you a second
25	had a lot of inventory with it, and they	25	A. Yeah, can I just
	Page 87		Page 89
1	L. WEXLER - CONFIDENTIAL	1	L. WEXLER - CONFIDENTIAL
2	couldn't get it out of their system. They	2	Q. No problem.
3	basically came to us and said, "Can you fix	3	MR. FORD: You should skim through
4	this problem for us?" And since we had more	4	it. It's a large deck. You don't have to
5	experience handling vape products which had	5	read every slide, but you can skim through
6	restricted disposal requirements and things of	6	it.
7	that nature, we stepped in and helped them	7	It's still loading for me, so before
8	we solved their problem and gave them a bunch	8	you ask any questions, let me make sure I
9	of money, and they helped solve our problem by	9	can open it.
10	giving us distribution on RipTide.	10	A. When I look at these slides, it
11	Q. Mr. Purdy says that "Reorder rates	11	reminds me to remind my employees to make the
12	are proving encouraging."	12	typeface larger so I can read it.
13	Reorder rates refers to purchases of	13	MR. FORD: I'm ready when you are,
14	cartridges or pods, right?	14	Larry, but skim through it.
15	A. Reorder rates, when he talks about	15	THE WITNESS: This is a large file.
16	reorder rates again, he's saying this, I'm	16	A. Okay.
17	speculating, I guess, which maybe I shouldn't	17	Q. Mr. Wexler, do you recognize this
18	do	18	deck?
19	MR. FORD: You should not speculate.	19	A. It appears to be a sales training
20	A. I can't speak to what he meant by	20	document.
21	that.	21	Q. Have you seen this deck before?
22	Q. What do you understand reorder rates	22	A. Excuse me?
		1	
23	to be?	23	Q. Have you seen this deck before?
23 24	to be? A. Okay. If I were to use reorder	23	Q. Have you seen this deck before? A. I probably did. I see a lot of
			_

			1	
1		Page 90 L. WEXLER - CONFIDENTIAL	1	Page 92 L. WEXLER - CONFIDENTIAL
2	Q.	Can we turn to Wexler EX 5-005.	2	them, and price is one of the elements of
3	Ω.	Okay.	3	competition.
4	Q.	Now, this page discusses NicTech.	4	Q. Now, the presentation shows that the
5	Q.	It was important to highlight	5	RipStick device was being priced at 99 cents,
6	NigTech v	ery early on in this deck, right?	6	the intro price. Do you see that?
7	NICIECII V	MR. FORD: Objection. Vague. Lacks	7	A. Yes.
8	found	ation.	8	Q. So, there's really no comparison.
9	Tourio	MR. LEE: Same objection.	9	RipTide was being priced much lower
10	0.	You can answer.	10	than JUUL, right?
11	Α.	I'm not sure what you mean by	11	MR. FORD: Objection. Vaque.
12	"importan		12	A. In this particular comparison,
13	Q.	Well, the discussion of NicTech is	13	that's what it shows.
14		rly on in this sales training deck,	14	Q. And if we look at NJOY ACE, for
15	wouldn't		15	example, its device kit intro was also 99
16	WOULDIT C	It's on Page 5.	16	cents, right?
17	Q.	And the slide says, "NicTech	17	A. Yes.
18		heightened nicotine satisfaction."	18	Q. That's a pretty compelling price for
19	Is that r	•	19	consumers, wouldn't you say?
20	A.	That's what the slide says, yes.	20	MR. LEE: Objection to form.
21	Q.	And do you agree with that?	21	MR. FORD: Objection. Vague.
22	Α.	Yeah, compared to a lot of other	22	A. I can't speak to what consumers I
23		NicTech provides heightened nicotine	23	can only speak to what we do.
24	satisfact		24	Q. But it's significantly lower than
25	Q.	Can we turn to the page stamped	25	JUUL, right?
	~ -			
		Page 91		Page 93
1				
		L. WEXLER - CONFIDENTIAL	1	L. WEXLER - CONFIDENTIAL
2	5-0021.		2	A. It is obvious that it's lower than
3	A.	5-002?	2 3	A. It is obvious that it's lower than JUUL, yes.
3 4	A. Q.	5-002? 5-021. I'm sorry, I misspoke.	2 3 4	A. It is obvious that it's lower than JUUL, yes. Q. In fact, just looking at this chart,
3 4 5	A. Q. A.	5-002? 5-021. I'm sorry, I misspoke. 5-021. Okay.	2 3 4 5	A. It is obvious that it's lower than JUUL, yes. Q. In fact, just looking at this chart, it looks like all of these products are
3 4 5 6	A. Q. A. Q.	5-002? 5-021. I'm sorry, I misspoke. 5-021. Okay. There's "Pod system typical consumer	2 3 4 5 6	A. It is obvious that it's lower than JUUL, yes. Q. In fact, just looking at this chart, it looks like all of these products are undercutting JUUL on price; isn't that right?
3 4 5 6 7	A. Q. A. Q. retail pr	5-002? 5-021. I'm sorry, I misspoke. 5-021. Okay. There's "Pod system typical consumer icing." It's at the top.	2 3 4 5 6 7	A. It is obvious that it's lower than JUUL, yes. Q. In fact, just looking at this chart, it looks like all of these products are undercutting JUUL on price; isn't that right? MR. FORD: Objection. Vague.
3 4 5 6 7 8	A. Q. A. Q. retail pr	5-002? 5-021. I'm sorry, I misspoke. 5-021. Okay. There's "Pod system typical consumer icing." It's at the top. Yes.	2 3 4 5 6 7 8	A. It is obvious that it's lower than JUUL, yes. Q. In fact, just looking at this chart, it looks like all of these products are undercutting JUUL on price; isn't that right? MR. FORD: Objection. Vague. A. Well, I think what you've got to
3 4 5 6 7 8	A. Q. A. Q. retail pr A. Q.	5-002? 5-021. I'm sorry, I misspoke. 5-021. Okay. There's "Pod system typical consumer icing." It's at the top. Yes. Well, this shows a number of	2 3 4 5 6 7 8	A. It is obvious that it's lower than JUUL, yes. Q. In fact, just looking at this chart, it looks like all of these products are undercutting JUUL on price; isn't that right? MR. FORD: Objection. Vague. A. Well, I think what you've got to look at the context of what this pricing is.
3 4 5 6 7 8 9	A. Q. A. Q. retail pr A. Q. different	5-002? 5-021. I'm sorry, I misspoke. 5-021. Okay. There's "Pod system typical consumer icing." It's at the top. Yes. Well, this shows a number of products; RipTide, JUUL, Vuse Alto,	2 3 4 5 6 7 8 9	A. It is obvious that it's lower than JUUL, yes. Q. In fact, just looking at this chart, it looks like all of these products are undercutting JUUL on price; isn't that right? MR. FORD: Objection. Vague. A. Well, I think what you've got to look at the context of what this pricing is. You're focusing on the pricing of the device.
3 4 5 6 7 8 9 10	A. Q. A. Q. retail pr A. Q.	5-002? 5-021. I'm sorry, I misspoke. 5-021. Okay. There's "Pod system typical consumer icing." It's at the top. Yes. Well, this shows a number of products; RipTide, JUUL, Vuse Alto, d Leap.	2 3 4 5 6 7 8 9 10	A. It is obvious that it's lower than JUUL, yes. Q. In fact, just looking at this chart, it looks like all of these products are undercutting JUUL on price; isn't that right? MR. FORD: Objection. Vague. A. Well, I think what you've got to look at the context of what this pricing is. You're focusing on the pricing of the device. In a pod system, you've really got a two-step
3 4 5 6 7 8 9 10 11 12	A. Q. A. Q. retail pr A. Q. different myblu, an	5-002? 5-021. I'm sorry, I misspoke. 5-021. Okay. There's "Pod system typical consumer icing." It's at the top. Yes. Well, this shows a number of products; RipTide, JUUL, Vuse Alto, d Leap. These products are each other's	2 3 4 5 6 7 8 9 10 11 12	A. It is obvious that it's lower than JUUL, yes. Q. In fact, just looking at this chart, it looks like all of these products are undercutting JUUL on price; isn't that right? MR. FORD: Objection. Vague. A. Well, I think what you've got to look at the context of what this pricing is. You're focusing on the pricing of the device. In a pod system, you've really got a two-step selling process. First you've got to get the
3 4 5 6 7 8 9 10 11 12 13	A. Q. A. Q. retail pr A. Q. different myblu, an	5-002? 5-021. I'm sorry, I misspoke. 5-021. Okay. There's "Pod system typical consumer icing." It's at the top. Yes. Well, this shows a number of products; RipTide, JUUL, Vuse Alto, d Leap. These products are each other's rs, right?	2 3 4 5 6 7 8 9 10 11 12 13	A. It is obvious that it's lower than JUUL, yes. Q. In fact, just looking at this chart, it looks like all of these products are undercutting JUUL on price; isn't that right? MR. FORD: Objection. Vague. A. Well, I think what you've got to look at the context of what this pricing is. You're focusing on the pricing of the device. In a pod system, you've really got a two-step selling process. First you've got to get the consumer to buy the device. Then they can buy
3 4 5 6 7 8 9 10 11 12 13 14	A. Q. A. Q. retail pr A. Q. different myblu, an	5-002? 5-021. I'm sorry, I misspoke. 5-021. Okay. There's "Pod system typical consumer icing." It's at the top. Yes. Well, this shows a number of products; RipTide, JUUL, Vuse Alto, d Leap. These products are each other's rs, right? Yeah, they're you know, these	2 3 4 5 6 7 8 9 10 11 12 13 14	A. It is obvious that it's lower than JUUL, yes. Q. In fact, just looking at this chart, it looks like all of these products are undercutting JUUL on price; isn't that right? MR. FORD: Objection. Vague. A. Well, I think what you've got to look at the context of what this pricing is. You're focusing on the pricing of the device. In a pod system, you've really got a two-step selling process. First you've got to get the consumer to buy the device. Then they can buy pods. These pods are not interchangeable.
3 4 5 6 7 8 9 10 11 12 13 14 15	A. Q. A. Q. retail pr A. Q. different myblu, an competito A. types of	5-002? 5-021. I'm sorry, I misspoke. 5-021. Okay. There's "Pod system typical consumer icing." It's at the top. Yes. Well, this shows a number of products; RipTide, JUUL, Vuse Alto, d Leap. These products are each other's rs, right? Yeah, they're you know, these products also compete with they're	2 3 4 5 6 7 8 9 10 11 12 13 14 15	A. It is obvious that it's lower than JUUL, yes. Q. In fact, just looking at this chart, it looks like all of these products are undercutting JUUL on price; isn't that right? MR. FORD: Objection. Vague. A. Well, I think what you've got to look at the context of what this pricing is. You're focusing on the pricing of the device. In a pod system, you've really got a two-step selling process. First you've got to get the consumer to buy the device. Then they can buy pods. These pods are not interchangeable. You can't use a JUUL pod on a RipTide device
3 4 5 6 7 8 9 10 11 12 13 14 15 16	A. Q. A. Q. retail pr A. Q. different myblu, an competito A. types of competing	5-002? 5-021. I'm sorry, I misspoke. 5-021. Okay. There's "Pod system typical consumer icing." It's at the top. Yes. Well, this shows a number of products; RipTide, JUUL, Vuse Alto, d Leap. These products are each other's rs, right? Yeah, they're you know, these products also compete with they're for consumers. But yeah, these are	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	A. It is obvious that it's lower than JUUL, yes. Q. In fact, just looking at this chart, it looks like all of these products are undercutting JUUL on price; isn't that right? MR. FORD: Objection. Vague. A. Well, I think what you've got to look at the context of what this pricing is. You're focusing on the pricing of the device. In a pod system, you've really got a two-step selling process. First you've got to get the consumer to buy the device. Then they can buy pods. These pods are not interchangeable. You can't use a JUUL pod on a RipTide device or an NJOY pod on a myblu device.
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	A. Q. A. Q. retail pr A. Q. different myblu, an competito A. types of competing the large	5-002? 5-021. I'm sorry, I misspoke. 5-021. Okay. There's "Pod system typical consumer icing." It's at the top. Yes. Well, this shows a number of products; RipTide, JUUL, Vuse Alto, d Leap. These products are each other's rs, right? Yeah, they're you know, these products also compete with they're for consumers. But yeah, these are st nationally distributed pod	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	A. It is obvious that it's lower than JUUL, yes. Q. In fact, just looking at this chart, it looks like all of these products are undercutting JUUL on price; isn't that right? MR. FORD: Objection. Vague. A. Well, I think what you've got to look at the context of what this pricing is. You're focusing on the pricing of the device. In a pod system, you've really got a two-step selling process. First you've got to get the consumer to buy the device. Then they can buy pods. These pods are not interchangeable. You can't use a JUUL pod on a RipTide device or an NJOY pod on a myblu device. And so, since the so,
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	A. Q. A. Q. retail pr A. Q. different myblu, an competito A. types of competing the large systems -	5-002? 5-021. I'm sorry, I misspoke. 5-021. Okay. There's "Pod system typical consumer icing." It's at the top. Yes. Well, this shows a number of products; RipTide, JUUL, Vuse Alto, d Leap. These products are each other's rs, right? Yeah, they're you know, these products also compete with they're for consumers. But yeah, these are st nationally distributed pod	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	A. It is obvious that it's lower than JUUL, yes. Q. In fact, just looking at this chart, it looks like all of these products are undercutting JUUL on price; isn't that right? MR. FORD: Objection. Vague. A. Well, I think what you've got to look at the context of what this pricing is. You're focusing on the pricing of the device. In a pod system, you've really got a two-step selling process. First you've got to get the consumer to buy the device. Then they can buy pods. These pods are not interchangeable. You can't use a JUUL pod on a RipTide device or an NJOY pod on a myblu device. And so, since the so, essentially, what these were priced at was
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	A. Q. A. Q. retail pr A. Q. different myblu, an competito A. types of competing the large systems - Q.	5-002? 5-021. I'm sorry, I misspoke. 5-021. Okay. There's "Pod system typical consumer icing." It's at the top. Yes. Well, this shows a number of products; RipTide, JUUL, Vuse Alto, d Leap. These products are each other's rs, right? Yeah, they're you know, these products also compete with they're for consumers. But yeah, these are st nationally distributed pod Now, RipTide was I'm sorry, you	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	A. It is obvious that it's lower than JUUL, yes. Q. In fact, just looking at this chart, it looks like all of these products are undercutting JUUL on price; isn't that right? MR. FORD: Objection. Vague. A. Well, I think what you've got to look at the context of what this pricing is. You're focusing on the pricing of the device. In a pod system, you've really got a two-step selling process. First you've got to get the consumer to buy the device. Then they can buy pods. These pods are not interchangeable. You can't use a JUUL pod on a RipTide device or an NJOY pod on a myblu device. And so, since the so, essentially, what these were priced at was because people didn't have our devices, so
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	A. Q. A. Q. retail pr A. Q. different myblu, an competito A. types of competing the large systems - Q. can speak	5-002? 5-021. I'm sorry, I misspoke. 5-021. Okay. There's "Pod system typical consumer icing." It's at the top. Yes. Well, this shows a number of products; RipTide, JUUL, Vuse Alto, d Leap. These products are each other's rs, right? Yeah, they're you know, these products also compete with they're for consumers. But yeah, these are st nationally distributed pod Now, RipTide was I'm sorry, you	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	A. It is obvious that it's lower than JUUL, yes. Q. In fact, just looking at this chart, it looks like all of these products are undercutting JUUL on price; isn't that right? MR. FORD: Objection. Vague. A. Well, I think what you've got to look at the context of what this pricing is. You're focusing on the pricing of the device. In a pod system, you've really got a two-step selling process. First you've got to get the consumer to buy the device. Then they can buy pods. These pods are not interchangeable. You can't use a JUUL pod on a RipTide device or an NJOY pod on a myblu device. And so, since the so, essentially, what these were priced at was because people didn't have our devices, so they couldn't buy our pods. Our pods is where
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	A. Q. A. Q. retail pr A. Q. different myblu, an competito A. types of competing the large systems - Q. can speak A.	5-002? 5-021. I'm sorry, I misspoke. 5-021. Okay. There's "Pod system typical consumer icing." It's at the top. Yes. Well, this shows a number of products; RipTide, JUUL, Vuse Alto, d Leap. These products are each other's rs, right? Yeah, they're you know, these products also compete with they're for consumers. But yeah, these are st nationally distributed pod Now, RipTide was I'm sorry, you at the time. Sorry.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	A. It is obvious that it's lower than JUUL, yes. Q. In fact, just looking at this chart, it looks like all of these products are undercutting JUUL on price; isn't that right? MR. FORD: Objection. Vague. A. Well, I think what you've got to look at the context of what this pricing is. You're focusing on the pricing of the device. In a pod system, you've really got a two-step selling process. First you've got to get the consumer to buy the device. Then they can buy pods. These pods are not interchangeable. You can't use a JUUL pod on a RipTide device or an NJOY pod on a myblu device. And so, since the so, essentially, what these were priced at was because people didn't have our devices, so they couldn't buy our pods. Our pods is where the product is delivered. So we're tying to
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	A. Q. A. Q. retail pr A. Q. different myblu, an competito A. types of competing the large systems - Q. can speak A. Q.	5-002? 5-021. I'm sorry, I misspoke. 5-021. Okay. There's "Pod system typical consumer icing." It's at the top. Yes. Well, this shows a number of products; RipTide, JUUL, Vuse Alto, d Leap. These products are each other's rs, right? Yeah, they're you know, these products also compete with they're for consumers. But yeah, these are st nationally distributed pod Now, RipTide was I'm sorry, you at the time. Sorry. RipTide was being priced to compete	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	A. It is obvious that it's lower than JUUL, yes. Q. In fact, just looking at this chart, it looks like all of these products are undercutting JUUL on price; isn't that right? MR. FORD: Objection. Vague. A. Well, I think what you've got to look at the context of what this pricing is. You're focusing on the pricing of the device. In a pod system, you've really got a two-step selling process. First you've got to get the consumer to buy the device. Then they can buy pods. These pods are not interchangeable. You can't use a JUUL pod on a RipTide device or an NJOY pod on a myblu device. And so, since the so, essentially, what these were priced at was because people didn't have our devices, so they couldn't buy our pods. Our pods is where the product is delivered. So we're tying to get as many devices into people's hands as
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	A. Q. A. Q. retail pr A. Q. different myblu, an competito A. types of competing the large systems - Q. can speak A. Q. with thes	5-002? 5-021. I'm sorry, I misspoke. 5-021. Okay. There's "Pod system typical consumer icing." It's at the top. Yes. Well, this shows a number of products; RipTide, JUUL, Vuse Alto, d Leap. These products are each other's rs, right? Yeah, they're you know, these products also compete with they're for consumers. But yeah, these are st nationally distributed pod Now, RipTide was I'm sorry, you at the time. Sorry. RipTide was being priced to compete e pod-based products, including JUUL,	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	A. It is obvious that it's lower than JUUL, yes. Q. In fact, just looking at this chart, it looks like all of these products are undercutting JUUL on price; isn't that right? MR. FORD: Objection. Vague. A. Well, I think what you've got to look at the context of what this pricing is. You're focusing on the pricing of the device. In a pod system, you've really got a two-step selling process. First you've got to get the consumer to buy the device. Then they can buy pods. These pods are not interchangeable. You can't use a JUUL pod on a RipTide device or an NJOY pod on a myblu device. And so, since the so, essentially, what these were priced at was because people didn't have our devices, so they couldn't buy our pods. Our pods is where the product is delivered. So we're tying to get as many devices into people's hands as possible so they can try our pods.
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	A. Q. A. Q. retail pr A. Q. different myblu, an competito A. types of competing the large systems - Q. can speak A. Q. with thes	5-002? 5-021. I'm sorry, I misspoke. 5-021. Okay. There's "Pod system typical consumer icing." It's at the top. Yes. Well, this shows a number of products; RipTide, JUUL, Vuse Alto, d Leap. These products are each other's rs, right? Yeah, they're you know, these products also compete with they're for consumers. But yeah, these are st nationally distributed pod Now, RipTide was I'm sorry, you at the time. Sorry. RipTide was being priced to compete	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	A. It is obvious that it's lower than JUUL, yes. Q. In fact, just looking at this chart, it looks like all of these products are undercutting JUUL on price; isn't that right? MR. FORD: Objection. Vague. A. Well, I think what you've got to look at the context of what this pricing is. You're focusing on the pricing of the device. In a pod system, you've really got a two-step selling process. First you've got to get the consumer to buy the device. Then they can buy pods. These pods are not interchangeable. You can't use a JUUL pod on a RipTide device or an NJOY pod on a myblu device. And so, since the so, essentially, what these were priced at was because people didn't have our devices, so they couldn't buy our pods. Our pods is where the product is delivered. So we're tying to get as many devices into people's hands as

	Page 94		Page 96
1	L. WEXLER - CONFIDENTIAL	1	L. WEXLER - CONFIDENTIAL
2	But all of the devices are priced	2	A. Yes.
3	significantly lower all of the devices of	3	Q. Okay.
4	the products on this page are priced	4	A. There's nothing unusual about a new
5	significantly lower than JUUL, right?	5	product coming out and some promotional prices
6	MR. LEE: Objection.	6	in order to attract new consumers. That's a
7	MR. FORD: Objection. Vague.	7	classic marketing approach. There's nothing
8	Q. Sorry. Did you answer?	8	surprising about that.
9	A. Okay. If the question you're	9	I mean, you're trying to get people
10	asking, in looking at this page and looking at	10	away from their brand preference and bring
11	the line on each box where it says, "device	11	them to a new experience, and you've got to
12	price," then it appears that each of the	12	give them some inducement to do that.
13	prices are lower than the price of JUUL.	13	MR. SOWLATI: I think we've been
14	Q. And you just mentioned pods and the	14	going for about an hour. Should we take a
15	importance of pods. RipTide's price was	15	ten-minute break?
16	lower RipTide's pod price was priced lower	16	MR. FORD: Yes. Sounds good.
17	than JUUL's pod price, right?	17	MR. SOWLATI: Should we reconvene at
18	A. Yeah, I don't know they're	18	11:20?
19	one-and-one comparable. I don't know that it	19	MR. FORD: Yes.
20	because they're different quantities of	20	MR. LEE: Sure.
21	nicotine, JUUL sold in multipacks, we sold	21	MR. SOWLATI: Great. We can go off
22	singles. Looking at the prices and comparing	22	the record.
23	them, it takes much more thought and analysis	23	(Recess was taken.)
24	before you can say anything about the relative	24	BY MR. SOWLATI:
25	pricing.	25	Q. Mr. Wexler, you can put the press
1	Page 95 L. WEXLER - CONFIDENTIAL	1	Page 97 L. WEXLER - CONFIDENTIAL
1 2	L. WEXLER - CONFIDENTIAL	1 2	L. WEXLER - CONFIDENTIAL
	L. WEXLER - CONFIDENTIAL Q. Well, to be clear, RipTide, each pod		
2	L. WEXLER - CONFIDENTIAL Q. Well, to be clear, RipTide, each pod has more liquid than JUUL, right?	2	L. WEXLER - CONFIDENTIAL release aside. I just have a quick question about
2 3	L. WEXLER - CONFIDENTIAL Q. Well, to be clear, RipTide, each pod has more liquid than JUUL, right? A. Yes, I believe that's true, yes.	2	L. WEXLER - CONFIDENTIAL release aside. I just have a quick question about A. Wait, wait, wait. We were on a
2 3 4 5	L. WEXLER - CONFIDENTIAL Q. Well, to be clear, RipTide, each pod has more liquid than JUUL, right? A. Yes, I believe that's true, yes. Q. So, when you compare the pricing of	2 3 4 5	L. WEXLER - CONFIDENTIAL release aside. I just have a quick question about A. Wait, wait, wait. We were on a sales training document.
2 3 4	L. WEXLER - CONFIDENTIAL Q. Well, to be clear, RipTide, each pod has more liquid than JUUL, right? A. Yes, I believe that's true, yes. Q. So, when you compare the pricing of the two, it looks like RipTide's pod price is	2 3 4	L. WEXLER - CONFIDENTIAL release aside. I just have a quick question about A. Wait, wait, wait. We were on a sales training document. Q. Oh, I'm sorry. Yes, we were on a
2 3 4 5 6 7	L. WEXLER - CONFIDENTIAL Q. Well, to be clear, RipTide, each pod has more liquid than JUUL, right? A. Yes, I believe that's true, yes. Q. So, when you compare the pricing of the two, it looks like RipTide's pod price is lower, right?	2 3 4 5	L. WEXLER - CONFIDENTIAL release aside. I just have a quick question about A. Wait, wait, wait. We were on a sales training document. Q. Oh, I'm sorry. Yes, we were on a training transcript. You can put that aside.
2 3 4 5 6	L. WEXLER - CONFIDENTIAL Q. Well, to be clear, RipTide, each pod has more liquid than JUUL, right? A. Yes, I believe that's true, yes. Q. So, when you compare the pricing of the two, it looks like RipTide's pod price is lower, right? A. No, you cannot say that. And as I	2 3 4 5 6 7	L. WEXLER - CONFIDENTIAL release aside. I just have a quick question about A. Wait, wait, wait. We were on a sales training document. Q. Oh, I'm sorry. Yes, we were on a
2 3 4 5 6 7 8	L. WEXLER - CONFIDENTIAL Q. Well, to be clear, RipTide, each pod has more liquid than JUUL, right? A. Yes, I believe that's true, yes. Q. So, when you compare the pricing of the two, it looks like RipTide's pod price is lower, right? A. No, you cannot say that. And as I just said, JUUL sold their pods in multipacks.	2 3 4 5 6 7 8	L. WEXLER - CONFIDENTIAL release aside. I just have a quick question about A. Wait, wait, wait. We were on a sales training document. Q. Oh, I'm sorry. Yes, we were on a training transcript. You can put that aside. I'm going to be turning now to your Declaration.
2 3 4 5 6 7 8 9	L. WEXLER - CONFIDENTIAL Q. Well, to be clear, RipTide, each pod has more liquid than JUUL, right? A. Yes, I believe that's true, yes. Q. So, when you compare the pricing of the two, it looks like RipTide's pod price is lower, right? A. No, you cannot say that. And as I just said, JUUL sold their pods in multipacks. So, you have to add up all the quantity of the	2 3 4 5 6 7 8	L. WEXLER - CONFIDENTIAL release aside. I just have a quick question about A. Wait, wait, wait. We were on a sales training document. Q. Oh, I'm sorry. Yes, we were on a training transcript. You can put that aside. I'm going to be turning now to your Declaration. A. Okay. Let me go back to it.
2 3 4 5 6 7 8 9	L. WEXLER - CONFIDENTIAL Q. Well, to be clear, RipTide, each pod has more liquid than JUUL, right? A. Yes, I believe that's true, yes. Q. So, when you compare the pricing of the two, it looks like RipTide's pod price is lower, right? A. No, you cannot say that. And as I just said, JUUL sold their pods in multipacks.	2 3 4 5 6 7 8 9	L. WEXLER - CONFIDENTIAL release aside. I just have a quick question about A. Wait, wait, wait. We were on a sales training document. Q. Oh, I'm sorry. Yes, we were on a training transcript. You can put that aside. I'm going to be turning now to your Declaration. A. Okay. Let me go back to it. Okay.
2 3 4 5 6 7 8 9 10	L. WEXLER - CONFIDENTIAL Q. Well, to be clear, RipTide, each pod has more liquid than JUUL, right? A. Yes, I believe that's true, yes. Q. So, when you compare the pricing of the two, it looks like RipTide's pod price is lower, right? A. No, you cannot say that. And as I just said, JUUL sold their pods in multipacks. So, you have to add up all the quantity of the nicotine and then divide by the price. Even	2 3 4 5 6 7 8 9 10	L. WEXLER - CONFIDENTIAL release aside. I just have a quick question about A. Wait, wait, wait. We were on a sales training document. Q. Oh, I'm sorry. Yes, we were on a training transcript. You can put that aside. I'm going to be turning now to your Declaration. A. Okay. Let me go back to it. Okay. Q. If I could focus you for a minute on
2 3 4 5 6 7 8 9 10 11 12	L. WEXLER - CONFIDENTIAL Q. Well, to be clear, RipTide, each pod has more liquid than JUUL, right? A. Yes, I believe that's true, yes. Q. So, when you compare the pricing of the two, it looks like RipTide's pod price is lower, right? A. No, you cannot say that. And as I just said, JUUL sold their pods in multipacks. So, you have to add up all the quantity of the nicotine and then divide by the price. Even that doesn't tell you what the relative value	2 3 4 5 6 7 8 9 10 11	L. WEXLER - CONFIDENTIAL release aside. I just have a quick question about A. Wait, wait, wait. We were on a sales training document. Q. Oh, I'm sorry. Yes, we were on a training transcript. You can put that aside. I'm going to be turning now to your Declaration. A. Okay. Let me go back to it. Okay.
2 3 4 5 6 7 8 9 10 11 12 13	L. WEXLER - CONFIDENTIAL Q. Well, to be clear, RipTide, each pod has more liquid than JUUL, right? A. Yes, I believe that's true, yes. Q. So, when you compare the pricing of the two, it looks like RipTide's pod price is lower, right? A. No, you cannot say that. And as I just said, JUUL sold their pods in multipacks. So, you have to add up all the quantity of the nicotine and then divide by the price. Even that doesn't tell you what the relative value is because these devices could potentially use	2 3 4 5 6 7 8 9 10 11 12 13	L. WEXLER - CONFIDENTIAL release aside. I just have a quick question about A. Wait, wait, wait. We were on a sales training document. Q. Oh, I'm sorry. Yes, we were on a training transcript. You can put that aside. I'm going to be turning now to your Declaration. A. Okay. Let me go back to it. Okay. Q. If I could focus you for a minute on Paragraph 22.
2 3 4 5 6 7 8 9 10 11 12 13 14	L. WEXLER - CONFIDENTIAL Q. Well, to be clear, RipTide, each pod has more liquid than JUUL, right? A. Yes, I believe that's true, yes. Q. So, when you compare the pricing of the two, it looks like RipTide's pod price is lower, right? A. No, you cannot say that. And as I just said, JUUL sold their pods in multipacks. So, you have to add up all the quantity of the nicotine and then divide by the price. Even that doesn't tell you what the relative value is because these devices could potentially use different quantities of the liquid on each	2 3 4 5 6 7 8 9 10 11 12 13 14	L. WEXLER - CONFIDENTIAL release aside. I just have a quick question about A. Wait, wait, wait. We were on a sales training document. Q. Oh, I'm sorry. Yes, we were on a training transcript. You can put that aside. I'm going to be turning now to your Declaration. A. Okay. Let me go back to it. Okay. Q. If I could focus you for a minute on Paragraph 22. A. I'm sorry. Did you say Paragraph
2 3 4 5 6 7 8 9 10 11 12 13 14 15	L. WEXLER - CONFIDENTIAL Q. Well, to be clear, RipTide, each pod has more liquid than JUUL, right? A. Yes, I believe that's true, yes. Q. So, when you compare the pricing of the two, it looks like RipTide's pod price is lower, right? A. No, you cannot say that. And as I just said, JUUL sold their pods in multipacks. So, you have to add up all the quantity of the nicotine and then divide by the price. Even that doesn't tell you what the relative value is because these devices could potentially use different quantities of the liquid on each product. I mean, they probably do depending	2 3 4 5 6 7 8 9 10 11 12 13 14 15	L. WEXLER - CONFIDENTIAL release aside. I just have a quick question about A. Wait, wait, wait. We were on a sales training document. Q. Oh, I'm sorry. Yes, we were on a training transcript. You can put that aside. I'm going to be turning now to your Declaration. A. Okay. Let me go back to it. Okay. Q. If I could focus you for a minute on Paragraph 22. A. I'm sorry. Did you say Paragraph 22?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	L. WEXLER - CONFIDENTIAL Q. Well, to be clear, RipTide, each pod has more liquid than JUUL, right? A. Yes, I believe that's true, yes. Q. So, when you compare the pricing of the two, it looks like RipTide's pod price is lower, right? A. No, you cannot say that. And as I just said, JUUL sold their pods in multipacks. So, you have to add up all the quantity of the nicotine and then divide by the price. Even that doesn't tell you what the relative value is because these devices could potentially use different quantities of the liquid on each product. I mean, they probably do depending on the pod anyway. So, the price was the	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	L. WEXLER - CONFIDENTIAL release aside. I just have a quick question about A. Wait, wait, wait. We were on a sales training document. Q. Oh, I'm sorry. Yes, we were on a training transcript. You can put that aside. I'm going to be turning now to your Declaration. A. Okay. Let me go back to it. Okay. Q. If I could focus you for a minute on Paragraph 22. A. I'm sorry. Did you say Paragraph 22? Q. Yes. Are you there?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	L. WEXLER - CONFIDENTIAL Q. Well, to be clear, RipTide, each pod has more liquid than JUUL, right? A. Yes, I believe that's true, yes. Q. So, when you compare the pricing of the two, it looks like RipTide's pod price is lower, right? A. No, you cannot say that. And as I just said, JUUL sold their pods in multipacks. So, you have to add up all the quantity of the nicotine and then divide by the price. Even that doesn't tell you what the relative value is because these devices could potentially use different quantities of the liquid on each product. I mean, they probably do depending on the pod anyway. So, the price was the price, and the list price is lower, but it's	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	L. WEXLER - CONFIDENTIAL release aside. I just have a quick question about A. Wait, wait, wait. We were on a sales training document. Q. Oh, I'm sorry. Yes, we were on a training transcript. You can put that aside. I'm going to be turning now to your Declaration. A. Okay. Let me go back to it. Okay. Q. If I could focus you for a minute on Paragraph 22. A. I'm sorry. Did you say Paragraph 22? Q. Yes. Are you there? A. I'm getting there.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	L. WEXLER - CONFIDENTIAL Q. Well, to be clear, RipTide, each pod has more liquid than JUUL, right? A. Yes, I believe that's true, yes. Q. So, when you compare the pricing of the two, it looks like RipTide's pod price is lower, right? A. No, you cannot say that. And as I just said, JUUL sold their pods in multipacks. So, you have to add up all the quantity of the nicotine and then divide by the price. Even that doesn't tell you what the relative value is because these devices could potentially use different quantities of the liquid on each product. I mean, they probably do depending on the pod anyway. So, the price was the price, and the list price is lower, but it's comparing apples and oranges.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	L. WEXLER - CONFIDENTIAL release aside. I just have a quick question about A. Wait, wait, wait. We were on a sales training document. Q. Oh, I'm sorry. Yes, we were on a training transcript. You can put that aside. I'm going to be turning now to your Declaration. A. Okay. Let me go back to it. Okay. Q. If I could focus you for a minute on Paragraph 22. A. I'm sorry. Did you say Paragraph 22? Q. Yes. Are you there? A. I'm getting there. Okay.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	L. WEXLER - CONFIDENTIAL Q. Well, to be clear, RipTide, each pod has more liquid than JUUL, right? A. Yes, I believe that's true, yes. Q. So, when you compare the pricing of the two, it looks like RipTide's pod price is lower, right? A. No, you cannot say that. And as I just said, JUUL sold their pods in multipacks. So, you have to add up all the quantity of the nicotine and then divide by the price. Even that doesn't tell you what the relative value is because these devices could potentially use different quantities of the liquid on each product. I mean, they probably do depending on the pod anyway. So, the price was the price, and the list price is lower, but it's comparing apples and oranges. Q. Okay, right. So I'm looking at this	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	L. WEXLER - CONFIDENTIAL release aside. I just have a quick question about A. Wait, wait, wait. We were on a sales training document. Q. Oh, I'm sorry. Yes, we were on a training transcript. You can put that aside. I'm going to be turning now to your Declaration. A. Okay. Let me go back to it. Okay. Q. If I could focus you for a minute on Paragraph 22. A. I'm sorry. Did you say Paragraph 22? Q. Yes. Are you there? A. I'm getting there. Okay. Q. You referred to a significant number
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	L. WEXLER - CONFIDENTIAL Q. Well, to be clear, RipTide, each pod has more liquid than JUUL, right? A. Yes, I believe that's true, yes. Q. So, when you compare the pricing of the two, it looks like RipTide's pod price is lower, right? A. No, you cannot say that. And as I just said, JUUL sold their pods in multipacks. So, you have to add up all the quantity of the nicotine and then divide by the price. Even that doesn't tell you what the relative value is because these devices could potentially use different quantities of the liquid on each product. I mean, they probably do depending on the pod anyway. So, the price was the price, and the list price is lower, but it's comparing apples and oranges. Q. Okay, right. So I'm looking at this JUUL two pack .7-milliliter pod, 9.99. If	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	L. WEXLER - CONFIDENTIAL release aside. I just have a quick question about A. Wait, wait, wait. We were on a sales training document. Q. Oh, I'm sorry. Yes, we were on a training transcript. You can put that aside. I'm going to be turning now to your Declaration. A. Okay. Let me go back to it. Okay. Q. If I could focus you for a minute on Paragraph 22. A. I'm sorry. Did you say Paragraph 22? Q. Yes. Are you there? A. I'm getting there. Okay. Q. You referred to a significant number of customers who would not expect to switch to
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	L. WEXLER - CONFIDENTIAL Q. Well, to be clear, RipTide, each pod has more liquid than JUUL, right? A. Yes, I believe that's true, yes. Q. So, when you compare the pricing of the two, it looks like RipTide's pod price is lower, right? A. No, you cannot say that. And as I just said, JUUL sold their pods in multipacks. So, you have to add up all the quantity of the nicotine and then divide by the price. Even that doesn't tell you what the relative value is because these devices could potentially use different quantities of the liquid on each product. I mean, they probably do depending on the pod anyway. So, the price was the price, and the list price is lower, but it's comparing apples and oranges. Q. Okay, right. So I'm looking at this JUUL two pack .7-milliliter pod, 9.99. If we're going to compare apples to apples, we'll	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	L. WEXLER - CONFIDENTIAL release aside. I just have a quick question about A. Wait, wait, wait. We were on a sales training document. Q. Oh, I'm sorry. Yes, we were on a training transcript. You can put that aside. I'm going to be turning now to your Declaration. A. Okay. Let me go back to it. Okay. Q. If I could focus you for a minute on Paragraph 22. A. I'm sorry. Did you say Paragraph 22? Q. Yes. Are you there? A. I'm getting there. Okay. Q. You referred to a significant number of customers who would not expect to switch to open tank systems if there were a 5 percent
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	L. WEXLER - CONFIDENTIAL Q. Well, to be clear, RipTide, each pod has more liquid than JUUL, right? A. Yes, I believe that's true, yes. Q. So, when you compare the pricing of the two, it looks like RipTide's pod price is lower, right? A. No, you cannot say that. And as I just said, JUUL sold their pods in multipacks. So, you have to add up all the quantity of the nicotine and then divide by the price. Even that doesn't tell you what the relative value is because these devices could potentially use different quantities of the liquid on each product. I mean, they probably do depending on the pod anyway. So, the price was the price, and the list price is lower, but it's comparing apples and oranges. Q. Okay, right. So I'm looking at this JUUL two pack .7-milliliter pod, 9.99. If we're going to compare apples to apples, we'll say, okay, in total, you get 1.4 milliliters	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	L. WEXLER - CONFIDENTIAL release aside. I just have a quick question about A. Wait, wait, wait. We were on a sales training document. Q. Oh, I'm sorry. Yes, we were on a training transcript. You can put that aside. I'm going to be turning now to your Declaration. A. Okay. Let me go back to it. Okay. Q. If I could focus you for a minute on Paragraph 22. A. I'm sorry. Did you say Paragraph 22? Q. Yes. Are you there? A. I'm getting there. Okay. Q. You referred to a significant number of customers who would not expect to switch to open tank systems if there were a 5 percent increase in the price of pods.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	L. WEXLER - CONFIDENTIAL Q. Well, to be clear, RipTide, each pod has more liquid than JUUL, right? A. Yes, I believe that's true, yes. Q. So, when you compare the pricing of the two, it looks like RipTide's pod price is lower, right? A. No, you cannot say that. And as I just said, JUUL sold their pods in multipacks. So, you have to add up all the quantity of the nicotine and then divide by the price. Even that doesn't tell you what the relative value is because these devices could potentially use different quantities of the liquid on each product. I mean, they probably do depending on the pod anyway. So, the price was the price, and the list price is lower, but it's comparing apples and oranges. Q. Okay, right. So I'm looking at this JUUL two pack .7-milliliter pod, 9.99. If we're going to compare apples to apples, we'll say, okay, in total, you get 1.4 milliliters in total with the JUUL pack for 9.99.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	L. WEXLER - CONFIDENTIAL release aside. I just have a quick question about A. Wait, wait, wait. We were on a sales training document. Q. Oh, I'm sorry. Yes, we were on a training transcript. You can put that aside. I'm going to be turning now to your Declaration. A. Okay. Let me go back to it. Okay. Q. If I could focus you for a minute on Paragraph 22. A. I'm sorry. Did you say Paragraph 22? Q. Yes. Are you there? A. I'm getting there. Okay. Q. You referred to a significant number of customers who would not expect to switch to open tank systems if there were a 5 percent increase in the price of pods. What is the significance of the 5

Page 98 Page 100 L. WEXLER - CONFIDENTIAL L. WEXLER - CONFIDENTIAL 1 1 2 5 percent is anything other than that's what I 2 Open systems is a totally different 3 was asked. 3 brand, totally different process. With open 4 Q. What do you consider significant or 4 systems, there's vast combinations of 5 not significant? 5 different things. You have batteries; you 6 Α. Different markets have --6 have coils; you have tanks; you have liquids; 7 7 MR. FORD: Objection. Vague. you have liquids of different strengths. A 8 Different markets have different 8 Α. lot of the open systems, you can actually 9 thresholds. 9 adjust the amount of air you can get from the outside and the temperatures. And there's 10 Okay. What I'm referring to is what 10 11 you said in your Declaration. You said, "I 11 almost infinite variety in open systems. So, 12 would not expect such an increase to drive a 12 it's a very different experience. significant number of customers to switch to 13 13 And somebody who is going to switch, 14 open tank systems." 14 who is a closed system consumer who is going 15 Α. Oh, I'm sorry, I thought you were 15 to switch to an open system, it's a totally 16 still talking about the 5 percent. So you're 16 different process. They've got to buy it at a 17 talking about the significance -- okay. So 17 different place. You generally can't find 18 let me -- maybe it would be best if I just 18 open systems in C-stores. It's a process 19 explained what I'm trying to say here and you 19 where we have to take a ton of decisions. 20 can ask questions on that. It's not just buying a device and then picking 20 21 Q. Well, can I just restate the 21 a flavor; you've got to decide what kind of 22 question for the record. 22 battery you want, what kind of size battery 23 Α. 23 you want, how much power you want, how much 24 flexibility you want over different features Okay. I'm asking you: What do you 24 0. consider significant or not significant, in on the battery system. 25 Page 99 Page 101 L. WEXLER - CONFIDENTIAL L. WEXLER - CONFIDENTIAL 1 1 2 terms of switching behavior to open tank 2 Then you go to tanks. There's all 3 systems? 3 kinds of different tanks. Then you go to 4 MR. FORD: Larry, if you do have to coils. There's different types of coils. And 4 5 explain the context in order to answer that's even before you get to the liquids, 5 that question, you should feel free to do because on the liquids, you have even more 6 6 7 7 variety. You have a much broader range of so. THE WITNESS: Thank you. 8 8 flavors, because closed systems go through 9 Α. Okay. So when I look at the open 9 distribution lanes where they can only have a limited number of SKUs. But in a vape shop 10 and closed systems, I see them as very 10 11 different margins. It's a very different user 11 where the vape shop is dedicated to it, they 12 experience. We talked a little bit about this 12 can have hundreds of SKUs, and maybe even some 13 during this deposition, but let me try to 13 of the large ones, maybe even more. 14 bring it all together. 14 So, it was my understanding that 15 So, the closed systems, particularly 15 with a small price adjustment, which is 16 the closed systems we've been talking about, 16 actually -- in some markets would be 17 you know, the JUULs, the NJOYs, and RipTides, 17 significant price change of 5 percent. That 18 it's a smaller product. It's discreet. They 18 would be not enough to motivate a large number generally have -- at the high end of nicotine of people to switch from a closed system to an 19 19 20 deliveries, it's battery based. It's very 20 open system because of all the other hurdles 21 convenient. You walk into a C-store, and if 21 that are involved, including most of the 22 you have a device, you can buy a device, you closed system devices are a lot bigger; you 23 can put it right in, you click it, you walk 23 lose your discreetness, you have to carry 24 out the C-store, and one step outside the 24 around the bottle with you, if you want to 25 C-store, you know, you're vaping away. Okay? 25 refill your -- it's hard to carry around some

Page 102 Page 104 L. WEXLER - CONFIDENTIAL L. WEXLER - CONFIDENTIAL 1 1 2 of these bottles in your pocket like you can 2 And has Turning Point conducted any 3 carry an extra pod in your pocket. There's a 3 studies to determine whether or not certain 4 lot of hurdles percentage of customers of pod products would 5 5 switch to open tank systems if there were a And then, you know, on top of it, 6 it's just a different experience. You know, 6 5 percent increase in pod prices? 7 7 you have to decide to get an open system that We have not done an econometric Α. 8 8 study on that. provides a lot of vapor. You tend to use 9 less -- lower nicotine on that. Or you can 9 Q. Okay. Mr. Wexler, a question for get some other ones where you can have a 10 you: You would agree that word of mouth 10 11 11 higher nicotine in it. matters for a product's success, right? 12 And quite frankly, I've watched a 12 Yes. It's one of the many factors 13 13 large number of consumers walk into vape that have to do with brand success. 14 stores to start the experience of using open 14 JUUL had a lot of word of mouth when 15 systems, and they spend a lot of time. It can 15 it was first introduced, right? 16 be a-half-an-hour, 45 minutes with the sales 16 MR. LEE: Objection. Foundation. 17 clerk. That's another hurdle for a closed 17 You can answer. 0. 18 system person to switch over. 18 Α. I mean, I heard about it. 19 Now, having said all that, there are 19 Q. You would also agree that the 20 some people who use both open systems and 20 quality of a product matters for its 21 closed systems. And what they do is, they 21 commercial success, too, right? 22 enjoy the open system experience. They 22 Α. It's one of the many factors. 23 generally do it at home. Where when they're 23 Q. Okay. And it's an important factor, 24 24 right? walking around, they may carry around a closed 25 system because they like to have the nicotine MR. LEE: Objection. Page 103 Page 105 L. WEXLER - CONFIDENTIAL 1 1 L. WEXLER - CONFIDENTIAL 2 more ready for them. 2 Α. Okay. So, I can only speak for 3 Now, well on the margin, some of 3 myself, as a consumer, that if a product had them shift some of their preference and use shoddy quality, I probably would tend not to 4 4 5 the open system more because of relative use it. 5 prices? Maybe. But in reality, the cost of a 6 6 Q. Would you agree that a product that 7 draw, call it, the per-draw cost in open 7 consumers don't like won't be successful, even 8 systems is so much lower already than the 8 if it has access to shelf space? 9 per-draw cost of a pod system, that I don't 9 MR. LEE: Objection to form. 10 see 5 percent being material given the hurdles 10 That's a -- you might want to unpack Α. 11 that you have to do to get over to the open 11 that question. Repeat the question again, systems. 12 12 because it seemed like a very odd question. 13 Now, they're both vape users. They 13 I just asked, would you agree that a 14 are both using vape, but consumers tend to 14 product that consumers don't like won't be 15 congregate and to go where they're 15 successful, even if it has access to shelf 16 comfortable. And I don't know that they go 16 space? 17 switching back and forth, again, on marginal 17 MR. LEE: Objection to form. 18 changes in price. 18 Okay. So, if you're asking me do Α. products that people don't like, are they 19 Mr. Wexler, I was just asking what 19 20 you meant by "significant," the word 20 successful or not successful? I think that in 21 21 "significant" in your Declaration. itself says everything you need to know about 22 Do you have a number you can give that question. The second clause has no 23 23 bearing on it. If people don't like the me? 24 24 product, they're not going to buy the product. Α. 25 Is it 20 percent? No? Okay. 25 That's kind of an absurd question. Q.

Page 106 Page 108 L. WEXLER - CONFIDENTIAL 1 L. WEXLER - CONFIDENTIAL 1 2 Ο. Fair enough. 2 do. So, it was the intention of Philip Morris 3 Mr. Wexler, I'm going turn to 3 to go as far as possible to put their products 4 Paragraphs 25 and 26 of your Declaration. in a superior position relative to other 5 Mr. Wexler, in these paragraphs, you speak 5 products and to inhibit other companies from being able to introduce products into the 6 quite a bit about what Philip Morris did and 6 7 how it contracts work, including what those C-store space, particularly low priced 7 contracts required with respect to shelf 8 8 products. 9 9 And to do that, essentially what space. 10 they did is, they created this club. The 10 But to be clear, you last worked at 11 Philip Morris 22 years ago, right? 11 original concept of these contracts, I think 12 Well, to be clear, I did leave 12 they were called masters. I seem to remember Philip Morris in 1998, and I guess, depending they're called masters, the masters contracts. 13 13 14 on your calculations, it's either 22 or 23 14 So, essentially, they formed this club where 15 years. 15 retailers have the option of joining or not 16 I think I can speak to this because 16 joining. 17 you cannot compete in tobacco without trying 17 So, there was no tie to saying, you 18 to understand Philip Morris' contracts. And 18 can't sell Marlboro unless you join this club. 19 by the way, Reynolds' contracts, as well, 19 But then they set up a pricing regimen and a 20 because combined, they carve up so much of the promotion regimen where it became very 20 21 shelf space that you cannot sell products, you 21 difficult for retailers to market Marlboro 22 22 unless they were a member in the club at some cannot operate in C-stores unless you 23 understand that. 23 24 And also, I think I have some 24 So as an example, before these 25 masters programs were put together, most particular expertise here because I was at 25 Page 107 Page 109 L. WEXLER - CONFIDENTIAL L. WEXLER - CONFIDENTIAL 1 1 2 Altria, Philip Morris, when these were 2 merchandising in the C-store space was basic-3 created, and I participated in thinking 3 -- think of it as a leasing program. So, a through some of the principles. I can, company would come in with a display. And I 4 4 5 honestly, say I wasn't overly involved in the seem to remember these numbers, and I could be 5 wrong on these numbers, and we would have what 6 exact details of writing the contracts. And 6 7 those contracts have changed over time, so I we call our B rack, which is a wire display 7 8 can't speak to each element of the contract, 8 which displayed packs. At that time you can 9 but I can speak to the principles behind 9 keep packs on the counter. So, it was 10 the -- and let me be of some help here because 10 incredibly important to lease counter space. 11 I think it's kind of helpful to understand the 11 And we would pay the retailers \$35 a month 12 principles behind the contracts. 12 whether they sold three packs or whether they 13 There's a lot of discussion and 13 sold 300 packs. They would get the same \$35 a 14 there were a lot of talks with lawyers, and I 14 month. And other competitors would do the 15 won't speak to that because I've been advised 15 same thing, and you'd have this whole wall of 16 that those discussions are privileged, but I 16 racks on the C-store counters. 17 will talk about some of the discussions that I 17 Philip Morris' innovation, Philip 18 had, that we had away from the lawyers, in 18 Morris' change was, they essentially went much digesting what the lawyers told us. So this further to align the retailers' interest with 19 19 20 their interest. They started compensating the is not communications directly from the 20 21 lawyers; this is conversations among people. 21 retailer not for leasing space, but for the 22 So, we had a lot of these 22 amount of product that they sold. And what 23 conversations with the lawyers that set out 23 they did there is, they had these tiers of

product -- of programs so that as you get

deeper into those tiers, the economic rewards

24

24

25

guidelines about what you can't do, what you

can do, bright lines of what you're willing to

Page 110 Page 112 L. WEXLER - CONFIDENTIAL 1 L. WEXLER - CONFIDENTIAL 1 2 are greater. You get more per pack sold or 2 contract, it had different elements to it. It 3 you can get a higher level of promotional 3 wasn't exactly the same. It had somewhat 4 dollars. 4 different elements. 5 5 So, if retail had both those Now, what became important is, 6 because Philip Morris was basically 6 contracts and almost every retailer had to 7 7 subsidizing the profitability on the sale of have them if they wanted to be in the business 8 each pack and because promotional dollars were of selling packs of cigarettes, if a 8 9 allocated to people who were inside the club 9 competitor came in and got a sign to announce and not outside the club, that if you were a new product, they had to give Philip Morris 10 10 11 outside the club, it was very, very difficult 11 another sign and Reynolds another sign, so it 12 to have any level of profitability and be 12 would cost them space for three signs for the one sign. 13 marketing and selling Marlboro products. So, 13 14 if you want to be in the retail sale --14 Mr. Wexler, thank you very much. I 15 Mr. Wexler, I'm sorry to stop you, 15 think you've answered my question quite a 16 but the pending question is: You last worked 16 while ago about when you last worked at Philip 17 at Philip Morris 22 years ago, right? And 17 Morris. I can ask you another question. 18 that's all I'm asking. 18 When you worked at Philip Morris, 19 MR. FORD: You can complete what you 19 e-vapor products did not exist, right? 20 20 were going to say, Larry. Α. No. 21 Because you were saying that I 21 Okay. And you were last involved in 22 haven't been there in 22 years, so I don't 22 drafting a Philip Morris retail contract 22 23 know anything about this, and I'm telling you 23 years ago, right? that I do. To be specific, I never drafted a 24 24 Α. 25 Ο. I just asked you if you worked there Philip Morris contract. I was just involved Page 111 Page 113 L. WEXLER - CONFIDENTIAL L. WEXLER - CONFIDENTIAL 1 1 2 22 years ago. 2 in creating the principles for those 3 MR. FORD: Let me just interject 3 contracts. 4 4 here. You can complete your thought, Ο. Okay. Have you reviewed contract 5 between an Altria subsidiary and a retailer, Larry. 5 6 6 in 22 years? If you want to move to strike, 7 Counsel, you can, and then we'll proceed. 7 Α. 8 THE WITNESS: Okay. 8 Ο. Which contract? 9 So getting back to where I was, so a 9 Α. I can't say exactly. I wouldn't 10 retailer would have a very difficult time 10 even know how to name them. I couldn't 11 being in the business of selling packs of 11 describe it. I have seen cigarette contracts; 12 cigarettes unless they were inside the club. 12 I've seen moist snuff contracts. 13 And part of the requirement was, Philip Morris 13 Q. When did you last review such a 14 asked for their share of the space for selling 14 contract? 15 packs of cigarettes that were equal to the 15 Α. I cannot remember the date. 16 market share. 16 Mr. Wexler, was it more than a year 17 17 Now, what became interesting -- and since you last reviewed an Altria contract 18 they also said that they would have to get a 18 with a retailer? certain number of signs. And the most curious 19 19 A. It was probably more than a year 20 thing about it was that, if any other company 20 ago. 21 21 came in with a sign, other than those allowed Q. Was it more than two years? 22 to, R. J. Reynolds, they would have to get 22 You're getting to the point where I 23 another sign. So, in other words, if a 23 have to figure out the date and look at the 24 retailer signed contracts with Philip Morris 24 calendar. 25 and then Reynolds came out with a very similar 25 Ο. Okay. Mr. Wexler, I'm going to turn

Page 114 Page 116 L. WEXLER - CONFIDENTIAL 1 L. WEXLER - CONFIDENTIAL 1 2 to Paragraph 28. You say that convenience 2 extraordinary step of taking a product off 3 stores are reluctant to give space to other 3 their hand that they couldn't dispose of at 4 companies such as Turning Point. great cost, and also offer them extremely high 5 It is my belief that C-stores are in 5 levels of promotional dollars and rebates that 6 a position where they can't give enough space 6 basically made the -- took away any to Turning Point because the contracts do not 7 profitability we possibly could get from 7 have enough space left over for all the 8 RipTide in order to do that. 8 9 competitors in the industry. 9 And I'd also add that we have a I am going to load a document, or 10 tried and true experience with our sales 10 11 send a document via Zoom chat. 11 force. As I think I said earlier, sales force 12 Is it Number 7? 12 punches above its weight. We generally get Α. Yes. For the record, this is your 13 13 about a 40 percent hit rate on new products, Ο. 14 Q32019 earnings call transcript. It's dated 14 and RipTide was slower than that in getting 15 November 1, 2019, and it's stamped Wexler EX 7. 15 into C-stores. But we were able, through 16 Mr. Wexler, do you recognize this to 16 spending a lot of money at fairly unprofitable 17 be Turning Point's 03 2019 Earnings Call 17 levels, get into Speedway, and we also got 18 Transcript? 18 into another major chain. 19 As I've said before, on these 19 Mr. Purdy didn't tell shareholders 20 transcripts, I've never seen this form before, 20 about these concerns about getting the product 21 but let me scroll through. If I read some of 21 into Speedway or the fact that it was fairly 22 my comments, I'll remember it. 22 unprofitable, did he? 23 Okav. 23 MR. FORD: Objection. Lacks 24 24 Mr. Wexler, we can turn to the page foundation. Ο. stamped 7-006. Mr. Purdy, the Chief Operating 25 You can answer, Larry. Page 115 Page 117 L. WEXLER - CONFIDENTIAL 1 1 L. WEXLER - CONFIDENTIAL 2 Officer of Turning Point, says, in the 2 Α. There are no words here to that 3 paragraph in the middle of the point that 3 effect. starts, "Moving to RipTide." 4 In fact, he says -- if we look at 4 0. 5 the third paragraph from the bottom, he says, Do you see that? 5 Yes. This was the third quarter "All of us at TPB are especially excited with 6 6 7 call November '19? 7 not only our Nu-X products to date, but more 8 Yes. And in the middle of the page, 8 so with building momentum and enthusiasm of 9 there's a paragraph where Mr. Purdy says, 9 our trade partners. Results to date are 10 "Moving to RipTide." Do you see that? 10 encouraging, but only a shadow of what's to 11 Α. Yes. 11 come." 12 12 Mr. Purdy says that "U.S. retail's That sounds pretty positive, right? Ο. 13 footprint of RipTide has expanded by 13 MR. FORD: Objection. Vague. 14 approximately 7,000 stores, including two 14 MR. LEE: Objection to form. 15 large leading convenience store chains in just 15 Q. You can answer. I can repeat the 16 the quarter." Do you see that? 16 question. 17 17 Α. Yes. Mr. Purdy sounds positive, right? 18 Q. So, Mr. Wexler, Turning Point, 18 He's a fairly positive guy. Α. MR. FORD: Objection. 19 despite your concern that you express in your 19 20 Declaration about access to space, Turning 20 Q. Well, he was telling your 21 21 shareholders that the results to date are Point was able to get RipTide into 7,000 22 additional stores in just a quarter, right? 22 encouraging. Is that not right? 23 Right, and about half of those 23 Yeah, I don't know whether he's 24 stores came from our introducing into 24 talking about the CBD line or -- I can't speak 25 Speedway, in which we had to take the 25 to what he's actually talking about in that

	Page 118		Page 120
1	L. WEXLER - CONFIDENTIAL	1	L. WEXLER - CONFIDENTIAL
2	paragraph.	2	continuing
3	Q. Okay. And he says that the trade	3	MR. FORD: Counsel, Counsel,
4	partners are also excited.	4	Counsel, Counsel, no one is entitled to
5	Who are the trade partners?	5	cut off my witness under any rule under
6	A. Wholesalers and retailers.	6	any law. I'm never going to allow it.
7	Q. Including convenience stores?	7	MR. SCHWARTZ: No one's trying to
8	A. They're one of our trade classes we	8	cut off your witness, but he's entitled to
9	sell in.	9	ask the question and to pursue getting an
10	Q. I want to go back to the paragraph	10	answer to his question. No one's trying
11	we started in, the paragraph starting "Moving	11	to stop him from answering.
12	to RipTide." Mr. Purdy is talking about	12	You also shouldn't be speaking more
13	RipTide there, and he says, "Early traction	13	than objection to form. No other coaching
14	has been good."	14	or otherwise is appropriate from any
15	That's also a positive statement,	15	counselors in any deposition. We all know
16	right?	16	that. Thank you.
17	MR. LEE: Objection to form.	17	I'll turn it back to Mr. Sowlati.
18	A. I don't know exactly what he's	18	MR. FORD: Go ahead with your
19	talking about in terms of, I don't know if	19	answer, Larry.
20	that was in distribution, consumer comments.	20	Q. Why don't I repeat the question
21	I don't know exactly where he stood there.	21	because there was quite a bit of colloquy.
22	Q. He didn't mention anything about	22	My question was: Mr. Purdy did not
23	troubles getting access to space at retailers,	23	mention to shareholders any concerns about
24	did he?	24	getting access to space, did he?
25	MR. FORD: Objection. Vague.	25	MR. FORD: Objection.
23	Tit. 10tb objection. Vague.	23	rat. Total objection.
	Page 119		Page 121
1	Page 119	1	Page 121 L. WEXLER - CONFIDENTIAL
1 2		1 2	
	L. WEXLER - CONFIDENTIAL		L. WEXLER - CONFIDENTIAL
2	L. WEXLER - CONFIDENTIAL A. Okay. So, let's back up.	2	L. WEXLER - CONFIDENTIAL MR. LEE: Objection to form.
2 3	L. WEXLER - CONFIDENTIAL A. Okay. So, let's back up. Q. I can repeat the question because I	2	L. WEXLER - CONFIDENTIAL MR. LEE: Objection to form. A. So again, let me try to give a
2 3 4	L. WEXLER - CONFIDENTIAL A. Okay. So, let's back up. Q. I can repeat the question because I know there was an objection.	2 3 4	L. WEXLER - CONFIDENTIAL MR. LEE: Objection to form. A. So again, let me try to give a context. We it is not unusual in fact,
2 3 4 5	L. WEXLER - CONFIDENTIAL A. Okay. So, let's back up. Q. I can repeat the question because I know there was an objection. He didn't mention anything about	2 3 4 5	L. WEXLER - CONFIDENTIAL MR. LEE: Objection to form. A. So again, let me try to give a context. We it is not unusual in fact, it is normal for us to have troubles getting
2 3 4 5 6	L. WEXLER - CONFIDENTIAL A. Okay. So, let's back up. Q. I can repeat the question because I know there was an objection. He didn't mention anything about difficulty getting access to shelf space, did	2 3 4 5 6	L. WEXLER - CONFIDENTIAL MR. LEE: Objection to form. A. So again, let me try to give a context. We it is not unusual in fact, it is normal for us to have troubles getting shelf space in C-stores. In fact, we have a
2 3 4 5 6 7	L. WEXLER - CONFIDENTIAL A. Okay. So, let's back up. Q. I can repeat the question because I know there was an objection. He didn't mention anything about difficulty getting access to shelf space, did he?	2 3 4 5 6 7	L. WEXLER - CONFIDENTIAL MR. LEE: Objection to form. A. So again, let me try to give a context. We it is not unusual in fact, it is normal for us to have troubles getting shelf space in C-stores. In fact, we have a product, our Stoker's chew our Stoker's
2 3 4 5 6 7 8	L. WEXLER - CONFIDENTIAL A. Okay. So, let's back up. Q. I can repeat the question because I know there was an objection. He didn't mention anything about difficulty getting access to shelf space, did he? MR. FORD: Objection.	2 3 4 5 6 7 8	L. WEXLER - CONFIDENTIAL MR. LEE: Objection to form. A. So again, let me try to give a context. We it is not unusual in fact, it is normal for us to have troubles getting shelf space in C-stores. In fact, we have a product, our Stoker's chew our Stoker's moist, that is the fastest growing product in
2 3 4 5 6 7 8 9	L. WEXLER - CONFIDENTIAL A. Okay. So, let's back up. Q. I can repeat the question because I know there was an objection. He didn't mention anything about difficulty getting access to shelf space, did he? MR. FORD: Objection. A. But let's go back and derive the	2 3 4 5 6 7 8	L. WEXLER - CONFIDENTIAL MR. LEE: Objection to form. A. So again, let me try to give a context. We it is not unusual in fact, it is normal for us to have troubles getting shelf space in C-stores. In fact, we have a product, our Stoker's chew our Stoker's moist, that is the fastest growing product in moist snuff. It has growing continuously for
2 3 4 5 6 7 8 9	L. WEXLER - CONFIDENTIAL A. Okay. So, let's back up. Q. I can repeat the question because I know there was an objection. He didn't mention anything about difficulty getting access to shelf space, did he? MR. FORD: Objection. A. But let's go back and derive the context	2 3 4 5 6 7 8 9	L. WEXLER - CONFIDENTIAL MR. LEE: Objection to form. A. So again, let me try to give a context. We it is not unusual in fact, it is normal for us to have troubles getting shelf space in C-stores. In fact, we have a product, our Stoker's chew our Stoker's moist, that is the fastest growing product in moist snuff. It has growing continuously for the 10, 12 years that it has been in
2 3 4 5 6 7 8 9 10	L. WEXLER - CONFIDENTIAL A. Okay. So, let's back up. Q. I can repeat the question because I know there was an objection. He didn't mention anything about difficulty getting access to shelf space, did he? MR. FORD: Objection. A. But let's go back and derive the context Q. Mr	2 3 4 5 6 7 8 9 10	L. WEXLER - CONFIDENTIAL MR. LEE: Objection to form. A. So again, let me try to give a context. We it is not unusual in fact, it is normal for us to have troubles getting shelf space in C-stores. In fact, we have a product, our Stoker's chew our Stoker's moist, that is the fastest growing product in moist snuff. It has growing continuously for the 10, 12 years that it has been in existence. And despite that
2 3 4 5 6 7 8 9 10 11 12	L. WEXLER - CONFIDENTIAL A. Okay. So, let's back up. Q. I can repeat the question because I know there was an objection. He didn't mention anything about difficulty getting access to shelf space, did he? MR. FORD: Objection. A. But let's go back and derive the context Q. Mr MR. FORD: Hold on. Don't interrupt	2 3 4 5 6 7 8 9 10 11	L. WEXLER - CONFIDENTIAL MR. LEE: Objection to form. A. So again, let me try to give a context. We it is not unusual in fact, it is normal for us to have troubles getting shelf space in C-stores. In fact, we have a product, our Stoker's chew our Stoker's moist, that is the fastest growing product in moist snuff. It has growing continuously for the 10, 12 years that it has been in existence. And despite that and despite that we keep on gaining share, we have trouble
2 3 4 5 6 7 8 9 10 11 12 13	L. WEXLER - CONFIDENTIAL A. Okay. So, let's back up. Q. I can repeat the question because I know there was an objection. He didn't mention anything about difficulty getting access to shelf space, did he? MR. FORD: Objection. A. But let's go back and derive the context Q. Mr MR. FORD: Hold on. Don't interrupt him. He heard your question, and he's	2 3 4 5 6 7 8 9 10 11 12 13	L. WEXLER - CONFIDENTIAL MR. LEE: Objection to form. A. So again, let me try to give a context. We it is not unusual in fact, it is normal for us to have troubles getting shelf space in C-stores. In fact, we have a product, our Stoker's chew our Stoker's moist, that is the fastest growing product in moist snuff. It has growing continuously for the 10, 12 years that it has been in existence. And despite that and despite that we keep on gaining share, we have trouble getting shelf space.
2 3 4 5 6 7 8 9 10 11 12 13 14	L. WEXLER - CONFIDENTIAL A. Okay. So, let's back up. Q. I can repeat the question because I know there was an objection. He didn't mention anything about difficulty getting access to shelf space, did he? MR. FORD: Objection. A. But let's go back and derive the context Q. Mr MR. FORD: Hold on. Don't interrupt him. He heard your question, and he's going to answer, and he's always entitled	2 3 4 5 6 7 8 9 10 11 12 13 14	L. WEXLER - CONFIDENTIAL MR. LEE: Objection to form. A. So again, let me try to give a context. We it is not unusual in fact, it is normal for us to have troubles getting shelf space in C-stores. In fact, we have a product, our Stoker's chew our Stoker's moist, that is the fastest growing product in moist snuff. It has growing continuously for the 10, 12 years that it has been in existence. And despite that and despite that we keep on gaining share, we have trouble getting shelf space. So, the fact that he didn't mention
2 3 4 5 6 7 8 9 10 11 12 13 14 15	L. WEXLER - CONFIDENTIAL A. Okay. So, let's back up. Q. I can repeat the question because I know there was an objection. He didn't mention anything about difficulty getting access to shelf space, did he? MR. FORD: Objection. A. But let's go back and derive the context Q. Mr MR. FORD: Hold on. Don't interrupt him. He heard your question, and he's going to answer, and he's always entitled to provide context.	2 3 4 5 6 7 8 9 10 11 12 13 14 15	L. WEXLER - CONFIDENTIAL MR. LEE: Objection to form. A. So again, let me try to give a context. We it is not unusual in fact, it is normal for us to have troubles getting shelf space in C-stores. In fact, we have a product, our Stoker's chew our Stoker's moist, that is the fastest growing product in moist snuff. It has growing continuously for the 10, 12 years that it has been in existence. And despite that and despite that we keep on gaining share, we have trouble getting shelf space. So, the fact that he didn't mention it is because that is our reality. That is
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	L. WEXLER - CONFIDENTIAL A. Okay. So, let's back up. Q. I can repeat the question because I know there was an objection. He didn't mention anything about difficulty getting access to shelf space, did he? MR. FORD: Objection. A. But let's go back and derive the context Q. Mr MR. FORD: Hold on. Don't interrupt him. He heard your question, and he's going to answer, and he's always entitled to provide context. Go ahead, Mr. Wexler.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	L. WEXLER - CONFIDENTIAL MR. LEE: Objection to form. A. So again, let me try to give a context. We it is not unusual in fact, it is normal for us to have troubles getting shelf space in C-stores. In fact, we have a product, our Stoker's chew our Stoker's moist, that is the fastest growing product in moist snuff. It has growing continuously for the 10, 12 years that it has been in existence. And despite that and despite that we keep on gaining share, we have trouble getting shelf space. So, the fact that he didn't mention it is because that is our reality. That is what we live with every day. We have trouble
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	L. WEXLER - CONFIDENTIAL A. Okay. So, let's back up. Q. I can repeat the question because I know there was an objection. He didn't mention anything about difficulty getting access to shelf space, did he? MR. FORD: Objection. A. But let's go back and derive the context Q. Mr MR. FORD: Hold on. Don't interrupt him. He heard your question, and he's going to answer, and he's always entitled to provide context. Go ahead, Mr. Wexler. MR. SCHWARTZ: Just to be clear, we	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	L. WEXLER - CONFIDENTIAL MR. LEE: Objection to form. A. So again, let me try to give a context. We it is not unusual in fact, it is normal for us to have troubles getting shelf space in C-stores. In fact, we have a product, our Stoker's chew our Stoker's moist, that is the fastest growing product in moist snuff. It has growing continuously for the 10, 12 years that it has been in existence. And despite that and despite that we keep on gaining share, we have trouble getting shelf space. So, the fact that he didn't mention it is because that is our reality. That is what we live with every day. We have trouble breaking into the racks, we have trouble
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	L. WEXLER - CONFIDENTIAL A. Okay. So, let's back up. Q. I can repeat the question because I know there was an objection. He didn't mention anything about difficulty getting access to shelf space, did he? MR. FORD: Objection. A. But let's go back and derive the context Q. Mr MR. FORD: Hold on. Don't interrupt him. He heard your question, and he's going to answer, and he's always entitled to provide context. Go ahead, Mr. Wexler. MR. SCHWARTZ: Just to be clear, we really have to stop the speaking	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	L. WEXLER - CONFIDENTIAL MR. LEE: Objection to form. A. So again, let me try to give a context. We it is not unusual in fact, it is normal for us to have troubles getting shelf space in C-stores. In fact, we have a product, our Stoker's chew our Stoker's moist, that is the fastest growing product in moist snuff. It has growing continuously for the 10, 12 years that it has been in existence. And despite that and despite that we keep on gaining share, we have trouble getting shelf space. So, the fact that he didn't mention it is because that is our reality. That is what we live with every day. We have trouble breaking into the stores because most of the
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	L. WEXLER - CONFIDENTIAL A. Okay. So, let's back up. Q. I can repeat the question because I know there was an objection. He didn't mention anything about difficulty getting access to shelf space, did he? MR. FORD: Objection. A. But let's go back and derive the context Q. Mr MR. FORD: Hold on. Don't interrupt him. He heard your question, and he's going to answer, and he's always entitled to provide context. Go ahead, Mr. Wexler. MR. SCHWARTZ: Just to be clear, we really have to stop the speaking objections. That's not appropriate; you know that. The person taking the	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	L. WEXLER - CONFIDENTIAL MR. LEE: Objection to form. A. So again, let me try to give a context. We it is not unusual in fact, it is normal for us to have troubles getting shelf space in C-stores. In fact, we have a product, our Stoker's chew our Stoker's moist, that is the fastest growing product in moist snuff. It has growing continuously for the 10, 12 years that it has been in existence. And despite that and despite that we keep on gaining share, we have trouble getting shelf space. So, the fact that he didn't mention it is because that is our reality. That is what we live with every day. We have trouble breaking into the racks, we have trouble breaking into the stores because most of the space is contracted out, and we're fighting
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	L. WEXLER - CONFIDENTIAL A. Okay. So, let's back up. Q. I can repeat the question because I know there was an objection. He didn't mention anything about difficulty getting access to shelf space, did he? MR. FORD: Objection. A. But let's go back and derive the context Q. Mr MR. FORD: Hold on. Don't interrupt him. He heard your question, and he's going to answer, and he's always entitled to provide context. Go ahead, Mr. Wexler. MR. SCHWARTZ: Just to be clear, we really have to stop the speaking objections. That's not appropriate; you know that. The person taking the deposition is entitled to ask the	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	L. WEXLER - CONFIDENTIAL MR. LEE: Objection to form. A. So again, let me try to give a context. We it is not unusual in fact, it is normal for us to have troubles getting shelf space in C-stores. In fact, we have a product, our Stoker's chew our Stoker's moist, that is the fastest growing product in moist snuff. It has growing continuously for the 10, 12 years that it has been in existence. And despite that and despite that we keep on gaining share, we have trouble getting shelf space. So, the fact that he didn't mention it is because that is our reality. That is what we live with every day. We have trouble breaking into the racks, we have trouble breaking into the stores because most of the space is contracted out, and we're fighting over the crumbs with the other competitors. So he didn't mention it, but I
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	L. WEXLER - CONFIDENTIAL A. Okay. So, let's back up. Q. I can repeat the question because I know there was an objection. He didn't mention anything about difficulty getting access to shelf space, did he? MR. FORD: Objection. A. But let's go back and derive the context Q. Mr MR. FORD: Hold on. Don't interrupt him. He heard your question, and he's going to answer, and he's always entitled to provide context. Go ahead, Mr. Wexler. MR. SCHWARTZ: Just to be clear, we really have to stop the speaking objections. That's not appropriate; you know that. The person taking the deposition is entitled to ask the questions and direct the witness to answer	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	L. WEXLER - CONFIDENTIAL MR. LEE: Objection to form. A. So again, let me try to give a context. We it is not unusual in fact, it is normal for us to have troubles getting shelf space in C-stores. In fact, we have a product, our Stoker's chew our Stoker's moist, that is the fastest growing product in moist snuff. It has growing continuously for the 10, 12 years that it has been in existence. And despite that and despite that we keep on gaining share, we have trouble getting shelf space. So, the fact that he didn't mention it is because that is our reality. That is what we live with every day. We have trouble breaking into the racks, we have trouble breaking into the stores because most of the space is contracted out, and we're fighting over the crumbs with the other competitors. So he didn't mention it, but I imagine it's certainly within the context of
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	L. WEXLER - CONFIDENTIAL A. Okay. So, let's back up. Q. I can repeat the question because I know there was an objection. He didn't mention anything about difficulty getting access to shelf space, did he? MR. FORD: Objection. A. But let's go back and derive the context Q. Mr MR. FORD: Hold on. Don't interrupt him. He heard your question, and he's going to answer, and he's always entitled to provide context. Go ahead, Mr. Wexler. MR. SCHWARTZ: Just to be clear, we really have to stop the speaking objections. That's not appropriate; you know that. The person taking the deposition is entitled to ask the questions and direct the witness to answer them. You can object to form. He can ask	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	L. WEXLER - CONFIDENTIAL MR. LEE: Objection to form. A. So again, let me try to give a context. We it is not unusual in fact, it is normal for us to have troubles getting shelf space in C-stores. In fact, we have a product, our Stoker's chew our Stoker's moist, that is the fastest growing product in moist snuff. It has growing continuously for the 10, 12 years that it has been in existence. And despite that and despite that we keep on gaining share, we have trouble getting shelf space. So, the fact that he didn't mention it is because that is our reality. That is what we live with every day. We have trouble breaking into the racks, we have trouble breaking into the stores because most of the space is contracted out, and we're fighting over the crumbs with the other competitors. So he didn't mention it, but I imagine it's certainly within the context of what he thought. But he wouldn't mention it
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	L. WEXLER - CONFIDENTIAL A. Okay. So, let's back up. Q. I can repeat the question because I know there was an objection. He didn't mention anything about difficulty getting access to shelf space, did he? MR. FORD: Objection. A. But let's go back and derive the context Q. Mr MR. FORD: Hold on. Don't interrupt him. He heard your question, and he's going to answer, and he's always entitled to provide context. Go ahead, Mr. Wexler. MR. SCHWARTZ: Just to be clear, we really have to stop the speaking objections. That's not appropriate; you know that. The person taking the deposition is entitled to ask the questions and direct the witness to answer	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	L. WEXLER - CONFIDENTIAL MR. LEE: Objection to form. A. So again, let me try to give a context. We it is not unusual in fact, it is normal for us to have troubles getting shelf space in C-stores. In fact, we have a product, our Stoker's chew our Stoker's moist, that is the fastest growing product in moist snuff. It has growing continuously for the 10, 12 years that it has been in existence. And despite that and despite that we keep on gaining share, we have trouble getting shelf space. So, the fact that he didn't mention it is because that is our reality. That is what we live with every day. We have trouble breaking into the racks, we have trouble breaking into the stores because most of the space is contracted out, and we're fighting over the crumbs with the other competitors. So he didn't mention it, but I imagine it's certainly within the context of

	Page 122		Page 124
1	L. WEXLER - CONFIDENTIAL	1	L. WEXLER - CONFIDENTIAL
2	transcript right in front of you, you can't	2	2019." So just to confirm
3	point to a single statement by Mr. Wexler	3	A. Where are you in the chart?
4	concerning shelf space, can you?	4	Q. I am not in the chart. I am in the
5	MR. LEE: Objection to form.	5	middle of the page. It says, "Programs
6	MR. FORD: Objection.	6	Currently Running," and the second to the top
7	MR. SOWLATI: I didn't even hear the	7	says, "RipTide promo through 2019."
8	witness speak.	8	Do you see that?
9	A. I don't think I said this.	9	A. Yes.
10	Q. Did Mr. Purdy say anything about	10	Q. Okay. So, just to confirm, at this
11	shelf space, in the transcript right in front	11	time, RipTide was at Speedway?
12	of you?	12	A. I'm sorry. You broke up.
13	MR. FORD: Objection.	13	Q. Just to confirm that in October
14	A. I can read it. Hold on. I'll have	14	2019, RipTide was being sold at Speedway?
15	to go back to the beginning of this to make	15	A. Yes.
16	sure he didn't cover it earlier.	16	Q. And Speedway is sorry.
17	It appears he didn't mention	17	A. Apparently, that's the case.
18	anything about shelf space.	18	Q. And Speedway is a leading
19	Q. In fact, he said, "Early traction	19	convenience store chain, right?
20	has been good."	20	A. Yes.
21	That's what he says, right?	21	Q. Can we turn to the page stamped
22	A. Those are the words he used. I	22	8-024.
23	don't know the context in which he used them.	23	A. Yes. Yes.
24	He can speak to that.	24	Q. Mr. Wexler, RipTide is a leading
25	Q. Let's go to another document. I'm	25	convenience store chain, right sorry.
	Page 123		Page 125
1	Page 123 L. WEXLER - CONFIDENTIAL	1	Page 125 L. WEXLER - CONFIDENTIAL
1 2		1 2	
	L. WEXLER - CONFIDENTIAL		L. WEXLER - CONFIDENTIAL
2	L. WEXLER - CONFIDENTIAL going to load that up. It's also a large	2	L. WEXLER - CONFIDENTIAL A. RipTide?
2 3	L. WEXLER - CONFIDENTIAL going to load that up. It's also a large document, 17 megabytes, so it's going to take	2	L. WEXLER - CONFIDENTIAL A. RipTide? Q. Strike that. RipTide may be in the
2 3 4	L. WEXLER - CONFIDENTIAL going to load that up. It's also a large document, 17 megabytes, so it's going to take a minute.	2 3 4	L. WEXLER - CONFIDENTIAL A. RipTide? Q. Strike that. RipTide may be in the future. Strike that.
2 3 4 5	L. WEXLER - CONFIDENTIAL going to load that up. It's also a large document, 17 megabytes, so it's going to take a minute. While that loads up for you, I'm	2 3 4 5	L. WEXLER - CONFIDENTIAL A. RipTide? Q. Strike that. RipTide may be in the future. Strike that. My question is: QuikTrip is a
2 3 4 5 6	L. WEXLER - CONFIDENTIAL going to load that up. It's also a large document, 17 megabytes, so it's going to take a minute. While that loads up for you, I'm going to state for the record, this is the	2 3 4 5 6	L. WEXLER - CONFIDENTIAL A. RipTide? Q. Strike that. RipTide may be in the future. Strike that. My question is: QuikTrip is a leading convenience store chain, right?
2 3 4 5 6 7 8 9	L. WEXLER - CONFIDENTIAL going to load that up. It's also a large document, 17 megabytes, so it's going to take a minute. While that loads up for you, I'm going to state for the record, this is the National Account Review dated October 23, 2019. It's stamped Wexler EX 8. Again, I'm only going to be going	2 3 4 5 6 7	L. WEXLER - CONFIDENTIAL A. RipTide? Q. Strike that. RipTide may be in the future. Strike that. My question is: QuikTrip is a leading convenience store chain, right? A. Yes.
2 3 4 5 6 7 8	L. WEXLER - CONFIDENTIAL going to load that up. It's also a large document, 17 megabytes, so it's going to take a minute. While that loads up for you, I'm going to state for the record, this is the National Account Review dated October 23, 2019. It's stamped Wexler EX 8. Again, I'm only going to be going through a few slides, but you can definitely	2 3 4 5 6 7 8	L. WEXLER - CONFIDENTIAL A. RipTide? Q. Strike that. RipTide may be in the future. Strike that. My question is: QuikTrip is a leading convenience store chain, right? A. Yes. Q. Can we turn to the next page? That's the page stamped 8-025. A. Yes.
2 3 4 5 6 7 8 9 10	L. WEXLER - CONFIDENTIAL going to load that up. It's also a large document, 17 megabytes, so it's going to take a minute. While that loads up for you, I'm going to state for the record, this is the National Account Review dated October 23, 2019. It's stamped Wexler EX 8. Again, I'm only going to be going through a few slides, but you can definitely scan through it. If you can, please let us	2 3 4 5 6 7 8 9 10	L. WEXLER - CONFIDENTIAL A. RipTide? Q. Strike that. RipTide may be in the future. Strike that. My question is: QuikTrip is a leading convenience store chain, right? A. Yes. Q. Can we turn to the next page? That's the page stamped 8-025. A. Yes. Q. Now, in the right, I think what
2 3 4 5 6 7 8 9 10 11 12	L. WEXLER - CONFIDENTIAL going to load that up. It's also a large document, 17 megabytes, so it's going to take a minute. While that loads up for you, I'm going to state for the record, this is the National Account Review dated October 23, 2019. It's stamped Wexler EX 8. Again, I'm only going to be going through a few slides, but you can definitely scan through it. If you can, please let us know when you're done.	2 3 4 5 6 7 8 9 10 11 12	L. WEXLER - CONFIDENTIAL A. RipTide? Q. Strike that. RipTide may be in the future. Strike that. My question is: QuikTrip is a leading convenience store chain, right? A. Yes. Q. Can we turn to the next page? That's the page stamped 8-025. A. Yes. Q. Now, in the right, I think what you're doing here is or the people that put
2 3 4 5 6 7 8 9 10 11 12 13	L. WEXLER - CONFIDENTIAL going to load that up. It's also a large document, 17 megabytes, so it's going to take a minute. While that loads up for you, I'm going to state for the record, this is the National Account Review dated October 23, 2019. It's stamped Wexler EX 8. Again, I'm only going to be going through a few slides, but you can definitely scan through it. If you can, please let us know when you're done. A. I just got it downloaded. Let me	2 3 4 5 6 7 8 9 10 11 12 13	L. WEXLER - CONFIDENTIAL A. RipTide? Q. Strike that. RipTide may be in the future. Strike that. My question is: QuikTrip is a leading convenience store chain, right? A. Yes. Q. Can we turn to the next page? That's the page stamped 8-025. A. Yes. Q. Now, in the right, I think what you're doing here is or the people that put this together is, they're circling in yellow
2 3 4 5 6 7 8 9 10 11 12 13 14	L. WEXLER - CONFIDENTIAL going to load that up. It's also a large document, 17 megabytes, so it's going to take a minute. While that loads up for you, I'm going to state for the record, this is the National Account Review dated October 23, 2019. It's stamped Wexler EX 8. Again, I'm only going to be going through a few slides, but you can definitely scan through it. If you can, please let us know when you're done. A. I just got it downloaded. Let me just take a look at it.	2 3 4 5 6 7 8 9 10 11 12 13 14	L. WEXLER - CONFIDENTIAL A. RipTide? Q. Strike that. RipTide may be in the future. Strike that. My question is: QuikTrip is a leading convenience store chain, right? A. Yes. Q. Can we turn to the next page? That's the page stamped 8-025. A. Yes. Q. Now, in the right, I think what you're doing here is or the people that put this together is, they're circling in yellow Turning Point's products. And on the one on
2 3 4 5 6 7 8 9 10 11 12 13 14 15	L. WEXLER - CONFIDENTIAL going to load that up. It's also a large document, 17 megabytes, so it's going to take a minute. While that loads up for you, I'm going to state for the record, this is the National Account Review dated October 23, 2019. It's stamped Wexler EX 8. Again, I'm only going to be going through a few slides, but you can definitely scan through it. If you can, please let us know when you're done. A. I just got it downloaded. Let me just take a look at it. Okay.	2 3 4 5 6 7 8 9 10 11 12 13 14 15	L. WEXLER - CONFIDENTIAL A. RipTide? Q. Strike that. RipTide may be in the future. Strike that. My question is: QuikTrip is a leading convenience store chain, right? A. Yes. Q. Can we turn to the next page? That's the page stamped 8-025. A. Yes. Q. Now, in the right, I think what you're doing here is or the people that put this together is, they're circling in yellow Turning Point's products. And on the one on the right, it's in small letters, but it says,
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	L. WEXLER - CONFIDENTIAL going to load that up. It's also a large document, 17 megabytes, so it's going to take a minute. While that loads up for you, I'm going to state for the record, this is the National Account Review dated October 23, 2019. It's stamped Wexler EX 8. Again, I'm only going to be going through a few slides, but you can definitely scan through it. If you can, please let us know when you're done. A. I just got it downloaded. Let me just take a look at it. Okay. Q. Mr. Wexler, are you familiar with	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	L. WEXLER - CONFIDENTIAL A. RipTide? Q. Strike that. RipTide may be in the future. Strike that. My question is: QuikTrip is a leading convenience store chain, right? A. Yes. Q. Can we turn to the next page? That's the page stamped 8-025. A. Yes. Q. Now, in the right, I think what you're doing here is or the people that put this together is, they're circling in yellow Turning Point's products. And on the one on the right, it's in small letters, but it says, "RipTide 99 cents."
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	L. WEXLER - CONFIDENTIAL going to load that up. It's also a large document, 17 megabytes, so it's going to take a minute. While that loads up for you, I'm going to state for the record, this is the National Account Review dated October 23, 2019. It's stamped Wexler EX 8. Again, I'm only going to be going through a few slides, but you can definitely scan through it. If you can, please let us know when you're done. A. I just got it downloaded. Let me just take a look at it. Okay. Q. Mr. Wexler, are you familiar with this document?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	L. WEXLER - CONFIDENTIAL A. RipTide? Q. Strike that. RipTide may be in the future. Strike that. My question is: QuikTrip is a leading convenience store chain, right? A. Yes. Q. Can we turn to the next page? That's the page stamped 8-025. A. Yes. Q. Now, in the right, I think what you're doing here is or the people that put this together is, they're circling in yellow Turning Point's products. And on the one on the right, it's in small letters, but it says, "RipTide 99 cents." Do you see that?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	L. WEXLER - CONFIDENTIAL going to load that up. It's also a large document, 17 megabytes, so it's going to take a minute. While that loads up for you, I'm going to state for the record, this is the National Account Review dated October 23, 2019. It's stamped Wexler EX 8. Again, I'm only going to be going through a few slides, but you can definitely scan through it. If you can, please let us know when you're done. A. I just got it downloaded. Let me just take a look at it. Okay. Q. Mr. Wexler, are you familiar with this document? A. It looks like what the National	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	L. WEXLER - CONFIDENTIAL A. RipTide? Q. Strike that. RipTide may be in the future. Strike that. My question is: QuikTrip is a leading convenience store chain, right? A. Yes. Q. Can we turn to the next page? That's the page stamped 8-025. A. Yes. Q. Now, in the right, I think what you're doing here is or the people that put this together is, they're circling in yellow Turning Point's products. And on the one on the right, it's in small letters, but it says, "RipTide 99 cents." Do you see that? A. To be honest, I think I need a new
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	L. WEXLER - CONFIDENTIAL going to load that up. It's also a large document, 17 megabytes, so it's going to take a minute. While that loads up for you, I'm going to state for the record, this is the National Account Review dated October 23, 2019. It's stamped Wexler EX 8. Again, I'm only going to be going through a few slides, but you can definitely scan through it. If you can, please let us know when you're done. A. I just got it downloaded. Let me just take a look at it. Okay. Q. Mr. Wexler, are you familiar with this document? A. It looks like what the National Account guys do from time to time;	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	L. WEXLER - CONFIDENTIAL A. RipTide? Q. Strike that. RipTide may be in the future. Strike that. My question is: QuikTrip is a leading convenience store chain, right? A. Yes. Q. Can we turn to the next page? That's the page stamped 8-025. A. Yes. Q. Now, in the right, I think what you're doing here is or the people that put this together is, they're circling in yellow Turning Point's products. And on the one on the right, it's in small letters, but it says, "RipTide 99 cents." Do you see that? A. To be honest, I think I need a new prescription for my glasses, and my sales guys
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	L. WEXLER - CONFIDENTIAL going to load that up. It's also a large document, 17 megabytes, so it's going to take a minute. While that loads up for you, I'm going to state for the record, this is the National Account Review dated October 23, 2019. It's stamped Wexler EX 8. Again, I'm only going to be going through a few slides, but you can definitely scan through it. If you can, please let us know when you're done. A. I just got it downloaded. Let me just take a look at it. Okay. Q. Mr. Wexler, are you familiar with this document? A. It looks like what the National Account guys do from time to time. I	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	L. WEXLER - CONFIDENTIAL A. RipTide? Q. Strike that. RipTide may be in the future. Strike that. My question is: QuikTrip is a leading convenience store chain, right? A. Yes. Q. Can we turn to the next page? That's the page stamped 8-025. A. Yes. Q. Now, in the right, I think what you're doing here is or the people that put this together is, they're circling in yellow Turning Point's products. And on the one on the right, it's in small letters, but it says, "RipTide 99 cents." Do you see that? A. To be honest, I think I need a new prescription for my glasses, and my sales guys tend to use pictures that are far too small
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	L. WEXLER - CONFIDENTIAL going to load that up. It's also a large document, 17 megabytes, so it's going to take a minute. While that loads up for you, I'm going to state for the record, this is the National Account Review dated October 23, 2019. It's stamped Wexler EX 8. Again, I'm only going to be going through a few slides, but you can definitely scan through it. If you can, please let us know when you're done. A. I just got it downloaded. Let me just take a look at it. Okay. Q. Mr. Wexler, are you familiar with this document? A. It looks like what the National Account guys do from time to time; presentations they do from time to time. I don't remember this specific document.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	L. WEXLER - CONFIDENTIAL A. RipTide? Q. Strike that. RipTide may be in the future. Strike that. My question is: QuikTrip is a leading convenience store chain, right? A. Yes. Q. Can we turn to the next page? That's the page stamped 8-025. A. Yes. Q. Now, in the right, I think what you're doing here is or the people that put this together is, they're circling in yellow Turning Point's products. And on the one on the right, it's in small letters, but it says, "RipTide 99 cents." Do you see that? A. To be honest, I think I need a new prescription for my glasses, and my sales guys tend to use pictures that are far too small for people with my eyesight. I cannot read
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	L. WEXLER - CONFIDENTIAL going to load that up. It's also a large document, 17 megabytes, so it's going to take a minute. While that loads up for you, I'm going to state for the record, this is the National Account Review dated October 23, 2019. It's stamped Wexler EX 8. Again, I'm only going to be going through a few slides, but you can definitely scan through it. If you can, please let us know when you're done. A. I just got it downloaded. Let me just take a look at it. Okay. Q. Mr. Wexler, are you familiar with this document? A. It looks like what the National Account guys do from time to time; presentations they do from time to time. I don't remember this specific document. Q. Okay. Can we turn to the page	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	L. WEXLER - CONFIDENTIAL A. RipTide? Q. Strike that. RipTide may be in the future. Strike that. My question is: QuikTrip is a leading convenience store chain, right? A. Yes. Q. Can we turn to the next page? That's the page stamped 8-025. A. Yes. Q. Now, in the right, I think what you're doing here is or the people that put this together is, they're circling in yellow Turning Point's products. And on the one on the right, it's in small letters, but it says, "RipTide 99 cents." Do you see that? A. To be honest, I think I need a new prescription for my glasses, and my sales guys tend to use pictures that are far too small for people with my eyesight. I cannot read that at all.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	L. WEXLER - CONFIDENTIAL going to load that up. It's also a large document, 17 megabytes, so it's going to take a minute. While that loads up for you, I'm going to state for the record, this is the National Account Review dated October 23, 2019. It's stamped Wexler EX 8. Again, I'm only going to be going through a few slides, but you can definitely scan through it. If you can, please let us know when you're done. A. I just got it downloaded. Let me just take a look at it. Okay. Q. Mr. Wexler, are you familiar with this document? A. It looks like what the National Account guys do from time to time; presentations they do from time to time. I don't remember this specific document. Q. Okay. Can we turn to the page stamped 8-003.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	L. WEXLER - CONFIDENTIAL A. RipTide? Q. Strike that. RipTide may be in the future. Strike that. My question is: QuikTrip is a leading convenience store chain, right? A. Yes. Q. Can we turn to the next page? That's the page stamped 8-025. A. Yes. Q. Now, in the right, I think what you're doing here is or the people that put this together is, they're circling in yellow Turning Point's products. And on the one on the right, it's in small letters, but it says, "RipTide 99 cents." Do you see that? A. To be honest, I think I need a new prescription for my glasses, and my sales guys tend to use pictures that are far too small for people with my eyesight. I cannot read that at all. Q. Okay. Let's go to the far left.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	L. WEXLER - CONFIDENTIAL going to load that up. It's also a large document, 17 megabytes, so it's going to take a minute. While that loads up for you, I'm going to state for the record, this is the National Account Review dated October 23, 2019. It's stamped Wexler EX 8. Again, I'm only going to be going through a few slides, but you can definitely scan through it. If you can, please let us know when you're done. A. I just got it downloaded. Let me just take a look at it. Okay. Q. Mr. Wexler, are you familiar with this document? A. It looks like what the National Account guys do from time to time; presentations they do from time to time. I don't remember this specific document. Q. Okay. Can we turn to the page	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	L. WEXLER - CONFIDENTIAL A. RipTide? Q. Strike that. RipTide may be in the future. Strike that. My question is: QuikTrip is a leading convenience store chain, right? A. Yes. Q. Can we turn to the next page? That's the page stamped 8-025. A. Yes. Q. Now, in the right, I think what you're doing here is or the people that put this together is, they're circling in yellow Turning Point's products. And on the one on the right, it's in small letters, but it says, "RipTide 99 cents." Do you see that? A. To be honest, I think I need a new prescription for my glasses, and my sales guys tend to use pictures that are far too small for people with my eyesight. I cannot read that at all.

	Page 126		Page 128
1	L. WEXLER - CONFIDENTIAL	1	L. WEXLER - CONFIDENTIAL
2	A. Yeah, I do.	2	it moves a little east from there, as well.
3	Q. And do you see there, it says,	3	Q. You were selling RipTide at Buc-ee's
4	"RipTide" in the middle of the page, and on	4	at this time, right?
5	the door there's an advertisement for that,	5	A. Yes.
6	"99 cents"?	6	Q. Okay. Actually, if we look at it,
7	A. Yes.	7	you can see on the right, there's a photo that
8	Q. So, at this time in October 2019,	8	shows you, RipTide, and on the left of it, on
9	RipTide was being sold at QuikTrip; is that	9	the very exact same level of shelf space, we
10	right?	10	see that Reynolds Ciro product is on there.
11	A. Apparently, yes.	11	Do you see that?
12	Q. Okay.	12	A. Which picture are you looking at?
13	A. Do we have a date when this was	13	Q. I'm looking at the picture on the
14	created?	14	right. You can see the RipTide product on the
15	Q. This is October 2019.	15	left, and then on the shelf over on the same
16	A. Okay.	16	level, you see Ciro. Do you see that?
17	Q. Actually, I could have made this	17	A. You may be able to see it; I can't.
18	easier for you if we go to the next page, the	18	Q. I'll represent to you that that's
19	page stamped 8-026. It says, "Currently	19	Ciro, which is a Vuse product.
20	QuikTrip is carrying RipTide Blue Razz,	20	Let's turn to 8-031.
21	Tropical, Berry Crunch, Mango, and Mint, in	21	A. Okay.
22	both 2.4 percent and 5 percent."	22	Q. The note on Buc-ee's says, "Our year
23	Do you see that?	23	commitment with them will be up in April and
24	A. Yes.	24	we will need to show a strong enough share to
25	Q. So, let's go to the next page. It's	25	continue to have the products in the account."
	Page 127		Page 129
1	Page 127 L. WEXLER - CONFIDENTIAL	1	Page 129 L. WEXLER - CONFIDENTIAL
1 2		1 2	
2 3	L. WEXLER - CONFIDENTIAL the page stamped 8-027. A. Okay.	2	L. WEXLER - CONFIDENTIAL Do you see that? A. Yes.
2 3 4	L. WEXLER - CONFIDENTIAL the page stamped 8-027. A. Okay. Q. The slide says that you currently	2 3 4	L. WEXLER - CONFIDENTIAL Do you see that? A. Yes. Q. Mr. Wexler, you can put that
2 3 4 5	L. WEXLER - CONFIDENTIAL the page stamped 8-027. A. Okay. Q. The slide says that you currently have a commitment from QuikTrip for RipTide	2 3 4 5	L. WEXLER - CONFIDENTIAL Do you see that? A. Yes. Q. Mr. Wexler, you can put that document to the side.
2 3 4 5 6	L. WEXLER - CONFIDENTIAL the page stamped 8-027. A. Okay. Q. The slide says that you currently have a commitment from QuikTrip for RipTide and Stoker's to be in the stores until August	2 3 4 5 6	L. WEXLER - CONFIDENTIAL Do you see that? A. Yes. Q. Mr. Wexler, you can put that document to the side. A. Okay.
2 3 4 5 6 7	L. WEXLER - CONFIDENTIAL the page stamped 8-027. A. Okay. Q. The slide says that you currently have a commitment from QuikTrip for RipTide and Stoker's to be in the stores until August 2020. Do you see that?	2 3 4 5 6 7	L. WEXLER - CONFIDENTIAL Do you see that? A. Yes. Q. Mr. Wexler, you can put that document to the side. A. Okay. Q. I'd like to send you another
2 3 4 5 6 7 8	L. WEXLER - CONFIDENTIAL the page stamped 8-027. A. Okay. Q. The slide says that you currently have a commitment from QuikTrip for RipTide and Stoker's to be in the stores until August 2020. Do you see that? A. Yes.	2 3 4 5 6 7 8	L. WEXLER - CONFIDENTIAL Do you see that? A. Yes. Q. Mr. Wexler, you can put that document to the side. A. Okay. Q. I'd like to send you another document. It should be available to you now.
2 3 4 5 6 7 8 9	L. WEXLER - CONFIDENTIAL the page stamped 8-027. A. Okay. Q. The slide says that you currently have a commitment from QuikTrip for RipTide and Stoker's to be in the stores until August 2020. Do you see that? A. Yes. Q. After that, the slide says, "Your	2 3 4 5 6 7 8 9	L. WEXLER - CONFIDENTIAL Do you see that? A. Yes. Q. Mr. Wexler, you can put that document to the side. A. Okay. Q. I'd like to send you another document. It should be available to you now. A. It just came in. Hold on.
2 3 4 5 6 7 8 9	L. WEXLER - CONFIDENTIAL the page stamped 8-027. A. Okay. Q. The slide says that you currently have a commitment from QuikTrip for RipTide and Stoker's to be in the stores until August 2020. Do you see that? A. Yes. Q. After that, the slide says, "Your arrangement for the following would be highly	2 3 4 5 6 7 8 9	L. WEXLER - CONFIDENTIAL Do you see that? A. Yes. Q. Mr. Wexler, you can put that document to the side. A. Okay. Q. I'd like to send you another document. It should be available to you now. A. It just came in. Hold on. Q. Just for the record, this document
2 3 4 5 6 7 8 9 10	L. WEXLER - CONFIDENTIAL the page stamped 8-027. A. Okay. Q. The slide says that you currently have a commitment from QuikTrip for RipTide and Stoker's to be in the stores until August 2020. Do you see that? A. Yes. Q. After that, the slide says, "Your arrangement for the following would be highly driven by the performance of both products."	2 3 4 5 6 7 8 9 10	L. WEXLER - CONFIDENTIAL Do you see that? A. Yes. Q. Mr. Wexler, you can put that document to the side. A. Okay. Q. I'd like to send you another document. It should be available to you now. A. It just came in. Hold on. Q. Just for the record, this document is stamped Wexler Exhibit 9. This is actually
2 3 4 5 6 7 8 9 10 11 12	L. WEXLER - CONFIDENTIAL the page stamped 8-027. A. Okay. Q. The slide says that you currently have a commitment from QuikTrip for RipTide and Stoker's to be in the stores until August 2020. Do you see that? A. Yes. Q. After that, the slide says, "Your arrangement for the following would be highly driven by the performance of both products." Do you see that, as well?	2 3 4 5 6 7 8 9 10 11	L. WEXLER - CONFIDENTIAL Do you see that? A. Yes. Q. Mr. Wexler, you can put that document to the side. A. Okay. Q. I'd like to send you another document. It should be available to you now. A. It just came in. Hold on. Q. Just for the record, this document is stamped Wexler Exhibit 9. This is actually RipTide's website, which I'll represent to you
2 3 4 5 6 7 8 9 10 11 12 13	L. WEXLER - CONFIDENTIAL the page stamped 8-027. A. Okay. Q. The slide says that you currently have a commitment from QuikTrip for RipTide and Stoker's to be in the stores until August 2020. Do you see that? A. Yes. Q. After that, the slide says, "Your arrangement for the following would be highly driven by the performance of both products." Do you see that, as well? A. Yes.	2 3 4 5 6 7 8 9 10 11 12 13	L. WEXLER - CONFIDENTIAL Do you see that? A. Yes. Q. Mr. Wexler, you can put that document to the side. A. Okay. Q. I'd like to send you another document. It should be available to you now. A. It just came in. Hold on. Q. Just for the record, this document is stamped Wexler Exhibit 9. This is actually RipTide's website, which I'll represent to you I accessed last week and took a screenshot of
2 3 4 5 6 7 8 9 10 11 12 13 14	L. WEXLER - CONFIDENTIAL the page stamped 8-027. A. Okay. Q. The slide says that you currently have a commitment from QuikTrip for RipTide and Stoker's to be in the stores until August 2020. Do you see that? A. Yes. Q. After that, the slide says, "Your arrangement for the following would be highly driven by the performance of both products." Do you see that, as well? A. Yes. Q. Mr. Wexler, for a retailer like	2 3 4 5 6 7 8 9 10 11 12 13 14	L. WEXLER - CONFIDENTIAL Do you see that? A. Yes. Q. Mr. Wexler, you can put that document to the side. A. Okay. Q. I'd like to send you another document. It should be available to you now. A. It just came in. Hold on. Q. Just for the record, this document is stamped Wexler Exhibit 9. This is actually RipTide's website, which I'll represent to you I accessed last week and took a screenshot of my computer.
2 3 4 5 6 7 8 9 10 11 12 13 14	L. WEXLER - CONFIDENTIAL the page stamped 8-027. A. Okay. Q. The slide says that you currently have a commitment from QuikTrip for RipTide and Stoker's to be in the stores until August 2020. Do you see that? A. Yes. Q. After that, the slide says, "Your arrangement for the following would be highly driven by the performance of both products." Do you see that, as well? A. Yes. Q. Mr. Wexler, for a retailer like QuikTrip that's deciding whether to stock an	2 3 4 5 6 7 8 9 10 11 12 13 14 15	L. WEXLER - CONFIDENTIAL Do you see that? A. Yes. Q. Mr. Wexler, you can put that document to the side. A. Okay. Q. I'd like to send you another document. It should be available to you now. A. It just came in. Hold on. Q. Just for the record, this document is stamped Wexler Exhibit 9. This is actually RipTide's website, which I'll represent to you I accessed last week and took a screenshot of my computer. A. It didn't open, so let me just go
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	L. WEXLER - CONFIDENTIAL the page stamped 8-027. A. Okay. Q. The slide says that you currently have a commitment from QuikTrip for RipTide and Stoker's to be in the stores until August 2020. Do you see that? A. Yes. Q. After that, the slide says, "Your arrangement for the following would be highly driven by the performance of both products." Do you see that, as well? A. Yes. Q. Mr. Wexler, for a retailer like QuikTrip that's deciding whether to stock an e-vapor product and renew a contract, the	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	L. WEXLER - CONFIDENTIAL Do you see that? A. Yes. Q. Mr. Wexler, you can put that document to the side. A. Okay. Q. I'd like to send you another document. It should be available to you now. A. It just came in. Hold on. Q. Just for the record, this document is stamped Wexler Exhibit 9. This is actually RipTide's website, which I'll represent to you I accessed last week and took a screenshot of my computer. A. It didn't open, so let me just go back and see if I can get it open.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	L. WEXLER - CONFIDENTIAL the page stamped 8-027. A. Okay. Q. The slide says that you currently have a commitment from QuikTrip for RipTide and Stoker's to be in the stores until August 2020. Do you see that? A. Yes. Q. After that, the slide says, "Your arrangement for the following would be highly driven by the performance of both products." Do you see that, as well? A. Yes. Q. Mr. Wexler, for a retailer like QuikTrip that's deciding whether to stock an e-vapor product and renew a contract, the product's performance matters, right?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	L. WEXLER - CONFIDENTIAL Do you see that? A. Yes. Q. Mr. Wexler, you can put that document to the side. A. Okay. Q. I'd like to send you another document. It should be available to you now. A. It just came in. Hold on. Q. Just for the record, this document is stamped Wexler Exhibit 9. This is actually RipTide's website, which I'll represent to you I accessed last week and took a screenshot of my computer. A. It didn't open, so let me just go back and see if I can get it open. Okay.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	L. WEXLER - CONFIDENTIAL the page stamped 8-027. A. Okay. Q. The slide says that you currently have a commitment from QuikTrip for RipTide and Stoker's to be in the stores until August 2020. Do you see that? A. Yes. Q. After that, the slide says, "Your arrangement for the following would be highly driven by the performance of both products." Do you see that, as well? A. Yes. Q. Mr. Wexler, for a retailer like QuikTrip that's deciding whether to stock an e-vapor product and renew a contract, the product's performance matters, right? A. Yes.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	L. WEXLER - CONFIDENTIAL Do you see that? A. Yes. Q. Mr. Wexler, you can put that document to the side. A. Okay. Q. I'd like to send you another document. It should be available to you now. A. It just came in. Hold on. Q. Just for the record, this document is stamped Wexler Exhibit 9. This is actually RipTide's website, which I'll represent to you I accessed last week and took a screenshot of my computer. A. It didn't open, so let me just go back and see if I can get it open. Okay. Q. Just to repeat, this is actually
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	L. WEXLER - CONFIDENTIAL the page stamped 8-027. A. Okay. Q. The slide says that you currently have a commitment from QuikTrip for RipTide and Stoker's to be in the stores until August 2020. Do you see that? A. Yes. Q. After that, the slide says, "Your arrangement for the following would be highly driven by the performance of both products." Do you see that, as well? A. Yes. Q. Mr. Wexler, for a retailer like QuikTrip that's deciding whether to stock an e-vapor product and renew a contract, the product's performance matters, right? A. Yes. Q. Okay. Can we turn to the page	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	L. WEXLER - CONFIDENTIAL Do you see that? A. Yes. Q. Mr. Wexler, you can put that document to the side. A. Okay. Q. I'd like to send you another document. It should be available to you now. A. It just came in. Hold on. Q. Just for the record, this document is stamped Wexler Exhibit 9. This is actually RipTide's website, which I'll represent to you I accessed last week and took a screenshot of my computer. A. It didn't open, so let me just go back and see if I can get it open. Okay. Q. Just to repeat, this is actually RipTide's website, which I'll represent that I
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	L. WEXLER - CONFIDENTIAL the page stamped 8-027. A. Okay. Q. The slide says that you currently have a commitment from QuikTrip for RipTide and Stoker's to be in the stores until August 2020. Do you see that? A. Yes. Q. After that, the slide says, "Your arrangement for the following would be highly driven by the performance of both products." Do you see that, as well? A. Yes. Q. Mr. Wexler, for a retailer like QuikTrip that's deciding whether to stock an e-vapor product and renew a contract, the product's performance matters, right? A. Yes. Q. Okay. Can we turn to the page stamped 8-029.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	L. WEXLER - CONFIDENTIAL Do you see that? A. Yes. Q. Mr. Wexler, you can put that document to the side. A. Okay. Q. I'd like to send you another document. It should be available to you now. A. It just came in. Hold on. Q. Just for the record, this document is stamped Wexler Exhibit 9. This is actually RipTide's website, which I'll represent to you I accessed last week and took a screenshot of my computer. A. It didn't open, so let me just go back and see if I can get it open. Okay. Q. Just to repeat, this is actually RipTide's website, which I'll represent that I accessed last week and took a screenshot of.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	L. WEXLER - CONFIDENTIAL the page stamped 8-027. A. Okay. Q. The slide says that you currently have a commitment from QuikTrip for RipTide and Stoker's to be in the stores until August 2020. Do you see that? A. Yes. Q. After that, the slide says, "Your arrangement for the following would be highly driven by the performance of both products." Do you see that, as well? A. Yes. Q. Mr. Wexler, for a retailer like QuikTrip that's deciding whether to stock an e-vapor product and renew a contract, the product's performance matters, right? A. Yes. Q. Okay. Can we turn to the page stamped 8-029. What is Buc-ee's?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	L. WEXLER - CONFIDENTIAL Do you see that? A. Yes. Q. Mr. Wexler, you can put that document to the side. A. Okay. Q. I'd like to send you another document. It should be available to you now. A. It just came in. Hold on. Q. Just for the record, this document is stamped Wexler Exhibit 9. This is actually RipTide's website, which I'll represent to you I accessed last week and took a screenshot of my computer. A. It didn't open, so let me just go back and see if I can get it open. Okay. Q. Just to repeat, this is actually RipTide's website, which I'll represent that I accessed last week and took a screenshot of. You guys have a handy-store locator, and I
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	L. WEXLER - CONFIDENTIAL the page stamped 8-027. A. Okay. Q. The slide says that you currently have a commitment from QuikTrip for RipTide and Stoker's to be in the stores until August 2020. Do you see that? A. Yes. Q. After that, the slide says, "Your arrangement for the following would be highly driven by the performance of both products." Do you see that, as well? A. Yes. Q. Mr. Wexler, for a retailer like QuikTrip that's deciding whether to stock an e-vapor product and renew a contract, the product's performance matters, right? A. Yes. Q. Okay. Can we turn to the page stamped 8-029. What is Buc-ee's? A. What is Buc-ee's?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	L. WEXLER - CONFIDENTIAL Do you see that? A. Yes. Q. Mr. Wexler, you can put that document to the side. A. Okay. Q. I'd like to send you another document. It should be available to you now. A. It just came in. Hold on. Q. Just for the record, this document is stamped Wexler Exhibit 9. This is actually RipTide's website, which I'll represent to you I accessed last week and took a screenshot of my computer. A. It didn't open, so let me just go back and see if I can get it open. Okay. Q. Just to repeat, this is actually RipTide's website, which I'll represent that I accessed last week and took a screenshot of. You guys have a handy-store locator, and I decided to put my New York zip code in there,
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	L. WEXLER - CONFIDENTIAL the page stamped 8-027. A. Okay. Q. The slide says that you currently have a commitment from QuikTrip for RipTide and Stoker's to be in the stores until August 2020. Do you see that? A. Yes. Q. After that, the slide says, "Your arrangement for the following would be highly driven by the performance of both products." Do you see that, as well? A. Yes. Q. Mr. Wexler, for a retailer like QuikTrip that's deciding whether to stock an e-vapor product and renew a contract, the product's performance matters, right? A. Yes. Q. Okay. Can we turn to the page stamped 8-029. What is Buc-ee's? A. What is Buc-ee's? Q. Yes.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	L. WEXLER - CONFIDENTIAL Do you see that? A. Yes. Q. Mr. Wexler, you can put that document to the side. A. Okay. Q. I'd like to send you another document. It should be available to you now. A. It just came in. Hold on. Q. Just for the record, this document is stamped Wexler Exhibit 9. This is actually RipTide's website, which I'll represent to you I accessed last week and took a screenshot of my computer. A. It didn't open, so let me just go back and see if I can get it open. Okay. Q. Just to repeat, this is actually RipTide's website, which I'll represent that I accessed last week and took a screenshot of. You guys have a handy-store locator, and I decided to put my New York zip code in there, which is 10128, which is the Upper East Side
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	L. WEXLER - CONFIDENTIAL the page stamped 8-027. A. Okay. Q. The slide says that you currently have a commitment from QuikTrip for RipTide and Stoker's to be in the stores until August 2020. Do you see that? A. Yes. Q. After that, the slide says, "Your arrangement for the following would be highly driven by the performance of both products." Do you see that, as well? A. Yes. Q. Mr. Wexler, for a retailer like QuikTrip that's deciding whether to stock an e-vapor product and renew a contract, the product's performance matters, right? A. Yes. Q. Okay. Can we turn to the page stamped 8-029. What is Buc-ee's? A. What is Buc-ee's?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	L. WEXLER - CONFIDENTIAL Do you see that? A. Yes. Q. Mr. Wexler, you can put that document to the side. A. Okay. Q. I'd like to send you another document. It should be available to you now. A. It just came in. Hold on. Q. Just for the record, this document is stamped Wexler Exhibit 9. This is actually RipTide's website, which I'll represent to you I accessed last week and took a screenshot of my computer. A. It didn't open, so let me just go back and see if I can get it open. Okay. Q. Just to repeat, this is actually RipTide's website, which I'll represent that I accessed last week and took a screenshot of. You guys have a handy-store locator, and I decided to put my New York zip code in there,

	Page 130		Page 132
1	L. WEXLER - CONFIDENTIAL	1	L. WEXLER - CONFIDENTIAL
2	secure space at 7-Eleven and Duane Reade,	2	that.
3	right?	3	Q. Mr. Wexler, I thought you are I
4	A. That's what it says.	4	mean, you testified earlier that you have
5	Q. I'm going to load one more	5	experience with convenience stores. Is that
6	document	6	not right?
7	A. This was just recently?	7	MR. FORD: Objection.
8	Q. I accessed this last week.	8	Argumentative.
9	A. Okay.	9	A. I'm sorry. I'm trying to be helpful
10	Q. Mr. Wexler, you can put that	10	here, but you're confusing me because you
11	document to the side.	11	asked me if JUUL had early success in vape
12	Mr. Wexler, JUUL was able to break	12	shops, and then you just said that I know a
13	through, in part, due to its innovative	13	lot about C-stores.
14	products, right?	14	Q. I'll repeat my question. You're
15	A. JUUL was out in front of the market.	15	aware that JUUL saw significant success in
16	Q. Right. And so my question was:	16	vape stores before it saw significant success
17	JUUL was able to break through, in part, due	17	in convenience stores, right?
18	to its innovative products, right?	18	MR. FORD: Objection.
19	A. Well, it was innovative in the	19	MR. LEE: Objection.
20	context that JUUL is one of the first pod	20	A. And I'm saying that I don't have
21	systems to get widespread distribution. So	21	data that tells me that JUUL was very
22	yeah, I would call that, in that context,	22	successful in the broad class of vape shops
23	innovative.	23	before it was successful in the broad class of
24	Q. It had a better product for a lot of	24	C-stores. The only thing I can speak to is
25	consumers than what was out in the market at	25	that I know that Vapor Shark was one of the
	-		
1	Page 131	1	Page 133
1 2	L. WEXLER - CONFIDENTIAL	1	L. WEXLER - CONFIDENTIAL
2	L. WEXLER - CONFIDENTIAL that time, right?	2	L. WEXLER - CONFIDENTIAL companies that had an agreement with the
2 3	L. WEXLER - CONFIDENTIAL that time, right? MR. FORD: Objection.	2	L. WEXLER - CONFIDENTIAL companies that had an agreement with the they had it before we bought them. They had
2 3 4	L. WEXLER - CONFIDENTIAL that time, right? MR. FORD: Objection. MR. LEE: Objection to form.	2 3 4	L. WEXLER - CONFIDENTIAL companies that had an agreement with the they had it before we bought them. They had an agreement with JUUL. They were selling
2 3 4 5	L. WEXLER - CONFIDENTIAL that time, right? MR. FORD: Objection. MR. LEE: Objection to form. A. I can't answer for every consumer.	2 3 4 5	L. WEXLER - CONFIDENTIAL companies that had an agreement with the they had it before we bought them. They had an agreement with JUUL. They were selling JUUL inside their stores, and at one point
2 3 4 5 6	L. WEXLER - CONFIDENTIAL that time, right? MR. FORD: Objection. MR. LEE: Objection to form. A. I can't answer for every consumer. I can say there were a lot of consumers buying	2 3 4 5 6	L. WEXLER - CONFIDENTIAL companies that had an agreement with the they had it before we bought them. They had an agreement with JUUL. They were selling JUUL inside their stores, and at one point JUUL represented about 17 percent of their
2 3 4 5 6 7	L. WEXLER - CONFIDENTIAL that time, right? MR. FORD: Objection. MR. LEE: Objection to form. A. I can't answer for every consumer. I can say there were a lot of consumers buying the product.	2 3 4 5 6 7	L. WEXLER - CONFIDENTIAL companies that had an agreement with the they had it before we bought them. They had an agreement with JUUL. They were selling JUUL inside their stores, and at one point JUUL represented about 17 percent of their sales. That's the only data that I have that
2 3 4 5 6	L. WEXLER - CONFIDENTIAL that time, right? MR. FORD: Objection. MR. LEE: Objection to form. A. I can't answer for every consumer. I can say there were a lot of consumers buying the product. Q. I'm sure you're aware of this, but	2 3 4 5 6	L. WEXLER - CONFIDENTIAL companies that had an agreement with the they had it before we bought them. They had an agreement with JUUL. They were selling JUUL inside their stores, and at one point JUUL represented about 17 percent of their sales. That's the only data that I have that I can speak to.
2 3 4 5 6 7 8	L. WEXLER - CONFIDENTIAL that time, right? MR. FORD: Objection. MR. LEE: Objection to form. A. I can't answer for every consumer. I can say there were a lot of consumers buying the product. Q. I'm sure you're aware of this, but JUUL was first introduced in vape stores,	2 3 4 5 6 7 8	L. WEXLER - CONFIDENTIAL companies that had an agreement with the they had it before we bought them. They had an agreement with JUUL. They were selling JUUL inside their stores, and at one point JUUL represented about 17 percent of their sales. That's the only data that I have that I can speak to. Q. Mr. Wexler, scrutiny around
2 3 4 5 6 7 8 9	L. WEXLER - CONFIDENTIAL that time, right? MR. FORD: Objection. MR. LEE: Objection to form. A. I can't answer for every consumer. I can say there were a lot of consumers buying the product. Q. I'm sure you're aware of this, but JUUL was first introduced in vape stores, right?	2 3 4 5 6 7 8 9	L. WEXLER - CONFIDENTIAL companies that had an agreement with the they had it before we bought them. They had an agreement with JUUL. They were selling JUUL inside their stores, and at one point JUUL represented about 17 percent of their sales. That's the only data that I have that I can speak to. Q. Mr. Wexler, scrutiny around e-vaping, regulatory scrutiny around e-vaping
2 3 4 5 6 7 8 9 10	L. WEXLER - CONFIDENTIAL that time, right? MR. FORD: Objection. MR. LEE: Objection to form. A. I can't answer for every consumer. I can say there were a lot of consumers buying the product. Q. I'm sure you're aware of this, but JUUL was first introduced in vape stores, right? A. I cannot speak to whether it was	2 3 4 5 6 7 8 9 10	L. WEXLER - CONFIDENTIAL companies that had an agreement with the they had it before we bought them. They had an agreement with JUUL. They were selling JUUL inside their stores, and at one point JUUL represented about 17 percent of their sales. That's the only data that I have that I can speak to. Q. Mr. Wexler, scrutiny around e-vaping, regulatory scrutiny around e-vaping really started to grow in late 2018, right?
2 3 4 5 6 7 8 9 10 11 12	L. WEXLER - CONFIDENTIAL that time, right? MR. FORD: Objection. MR. LEE: Objection to form. A. I can't answer for every consumer. I can say there were a lot of consumers buying the product. Q. I'm sure you're aware of this, but JUUL was first introduced in vape stores, right? A. I cannot speak to whether it was first introduced in vape stores. I do know	2 3 4 5 6 7 8 9 10 11	L. WEXLER - CONFIDENTIAL companies that had an agreement with the they had it before we bought them. They had an agreement with JUUL. They were selling JUUL inside their stores, and at one point JUUL represented about 17 percent of their sales. That's the only data that I have that I can speak to. Q. Mr. Wexler, scrutiny around e-vaping, regulatory scrutiny around e-vaping really started to grow in late 2018, right? A. I don't know at what point it I
2 3 4 5 6 7 8 9 10 11 12 13	L. WEXLER - CONFIDENTIAL that time, right? MR. FORD: Objection. MR. LEE: Objection to form. A. I can't answer for every consumer. I can say there were a lot of consumers buying the product. Q. I'm sure you're aware of this, but JUUL was first introduced in vape stores, right? A. I cannot speak to whether it was first introduced in vape stores. I do know that Vapor Shark was pretty early in JUUL's	2 3 4 5 6 7 8 9 10 11 12 13	L. WEXLER - CONFIDENTIAL companies that had an agreement with the they had it before we bought them. They had an agreement with JUUL. They were selling JUUL inside their stores, and at one point JUUL represented about 17 percent of their sales. That's the only data that I have that I can speak to. Q. Mr. Wexler, scrutiny around e-vaping, regulatory scrutiny around e-vaping really started to grow in late 2018, right? A. I don't know at what point it I don't know how to measure scrutiny and whether
2 3 4 5 6 7 8 9 10 11 12 13 14	L. WEXLER - CONFIDENTIAL that time, right? MR. FORD: Objection. MR. LEE: Objection to form. A. I can't answer for every consumer. I can say there were a lot of consumers buying the product. Q. I'm sure you're aware of this, but JUUL was first introduced in vape stores, right? A. I cannot speak to whether it was first introduced in vape stores. I do know that Vapor Shark was pretty early in JUUL's evolution, in terms of getting the product,	2 3 4 5 6 7 8 9 10 11 12 13 14	L. WEXLER - CONFIDENTIAL companies that had an agreement with the they had it before we bought them. They had an agreement with JUUL. They were selling JUUL inside their stores, and at one point JUUL represented about 17 percent of their sales. That's the only data that I have that I can speak to. Q. Mr. Wexler, scrutiny around e-vaping, regulatory scrutiny around e-vaping really started to grow in late 2018, right? A. I don't know at what point it I don't know how to measure scrutiny and whether it grew or didn't grow. I've been in the
2 3 4 5 6 7 8 9 10 11 12 13 14	L. WEXLER - CONFIDENTIAL that time, right? MR. FORD: Objection. MR. LEE: Objection to form. A. I can't answer for every consumer. I can say there were a lot of consumers buying the product. Q. I'm sure you're aware of this, but JUUL was first introduced in vape stores, right? A. I cannot speak to whether it was first introduced in vape stores. I do know that Vapor Shark was pretty early in JUUL's	2 3 4 5 6 7 8 9 10 11 12 13	L. WEXLER - CONFIDENTIAL companies that had an agreement with the they had it before we bought them. They had an agreement with JUUL. They were selling JUUL inside their stores, and at one point JUUL represented about 17 percent of their sales. That's the only data that I have that I can speak to. Q. Mr. Wexler, scrutiny around e-vaping, regulatory scrutiny around e-vaping really started to grow in late 2018, right? A. I don't know at what point it I don't know how to measure scrutiny and whether it grew or didn't grow. I've been in the tobacco business, and there's been scrutiny in
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	L. WEXLER - CONFIDENTIAL that time, right? MR. FORD: Objection. MR. LEE: Objection to form. A. I can't answer for every consumer. I can say there were a lot of consumers buying the product. Q. I'm sure you're aware of this, but JUUL was first introduced in vape stores, right? A. I cannot speak to whether it was first introduced in vape stores. I do know that Vapor Shark was pretty early in JUUL's evolution, in terms of getting the product, and they had vape shops. Q. You're aware that JUUL saw	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	L. WEXLER - CONFIDENTIAL companies that had an agreement with the they had it before we bought them. They had an agreement with JUUL. They were selling JUUL inside their stores, and at one point JUUL represented about 17 percent of their sales. That's the only data that I have that I can speak to. Q. Mr. Wexler, scrutiny around e-vaping, regulatory scrutiny around e-vaping really started to grow in late 2018, right? A. I don't know at what point it I don't know how to measure scrutiny and whether it grew or didn't grow. I've been in the tobacco business, and there's been scrutiny in the tobacco business ever since I've been in
2 3 4 5 6 7 8 9 10 11 12 13 14	L. WEXLER - CONFIDENTIAL that time, right? MR. FORD: Objection. MR. LEE: Objection to form. A. I can't answer for every consumer. I can say there were a lot of consumers buying the product. Q. I'm sure you're aware of this, but JUUL was first introduced in vape stores, right? A. I cannot speak to whether it was first introduced in vape stores. I do know that Vapor Shark was pretty early in JUUL's evolution, in terms of getting the product, and they had vape shops.	2 3 4 5 6 7 8 9 10 11 12 13 14 15	L. WEXLER - CONFIDENTIAL companies that had an agreement with the they had it before we bought them. They had an agreement with JUUL. They were selling JUUL inside their stores, and at one point JUUL represented about 17 percent of their sales. That's the only data that I have that I can speak to. Q. Mr. Wexler, scrutiny around e-vaping, regulatory scrutiny around e-vaping really started to grow in late 2018, right? A. I don't know at what point it I don't know how to measure scrutiny and whether it grew or didn't grow. I've been in the tobacco business, and there's been scrutiny in
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	L. WEXLER - CONFIDENTIAL that time, right? MR. FORD: Objection. MR. LEE: Objection to form. A. I can't answer for every consumer. I can say there were a lot of consumers buying the product. Q. I'm sure you're aware of this, but JUUL was first introduced in vape stores, right? A. I cannot speak to whether it was first introduced in vape stores. I do know that Vapor Shark was pretty early in JUUL's evolution, in terms of getting the product, and they had vape shops. Q. You're aware that JUUL saw significant success in vape shops before it	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	L. WEXLER - CONFIDENTIAL companies that had an agreement with the they had it before we bought them. They had an agreement with JUUL. They were selling JUUL inside their stores, and at one point JUUL represented about 17 percent of their sales. That's the only data that I have that I can speak to. Q. Mr. Wexler, scrutiny around e-vaping, regulatory scrutiny around e-vaping really started to grow in late 2018, right? A. I don't know at what point it I don't know how to measure scrutiny and whether it grew or didn't grow. I've been in the tobacco business, and there's been scrutiny in the tobacco business ever since I've been in it. And yes, there was scrutiny in vape. I
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	L. WEXLER - CONFIDENTIAL that time, right? MR. FORD: Objection. MR. LEE: Objection to form. A. I can't answer for every consumer. I can say there were a lot of consumers buying the product. Q. I'm sure you're aware of this, but JUUL was first introduced in vape stores, right? A. I cannot speak to whether it was first introduced in vape stores. I do know that Vapor Shark was pretty early in JUUL's evolution, in terms of getting the product, and they had vape shops. Q. You're aware that JUUL saw significant success in vape shops before it saw significant success in convenience stores, right?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	L. WEXLER - CONFIDENTIAL companies that had an agreement with the they had it before we bought them. They had an agreement with JUUL. They were selling JUUL inside their stores, and at one point JUUL represented about 17 percent of their sales. That's the only data that I have that I can speak to. Q. Mr. Wexler, scrutiny around e-vaping, regulatory scrutiny around e-vaping really started to grow in late 2018, right? A. I don't know at what point it I don't know how to measure scrutiny and whether it grew or didn't grow. I've been in the tobacco business, and there's been scrutiny in the tobacco business ever since I've been in it. And yes, there was scrutiny in vape. I don't know when it started growing. I don't
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	L. WEXLER - CONFIDENTIAL that time, right? MR. FORD: Objection. MR. LEE: Objection to form. A. I can't answer for every consumer. I can say there were a lot of consumers buying the product. Q. I'm sure you're aware of this, but JUUL was first introduced in vape stores, right? A. I cannot speak to whether it was first introduced in vape stores. I do know that Vapor Shark was pretty early in JUUL's evolution, in terms of getting the product, and they had vape shops. Q. You're aware that JUUL saw significant success in vape shops before it saw significant success in convenience stores, right? MR. LEE: Objection to form.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	L. WEXLER - CONFIDENTIAL companies that had an agreement with the they had it before we bought them. They had an agreement with JUUL. They were selling JUUL inside their stores, and at one point JUUL represented about 17 percent of their sales. That's the only data that I have that I can speak to. Q. Mr. Wexler, scrutiny around e-vaping, regulatory scrutiny around e-vaping really started to grow in late 2018, right? A. I don't know at what point it I don't know how to measure scrutiny and whether it grew or didn't grow. I've been in the tobacco business, and there's been scrutiny in the tobacco business ever since I've been in it. And yes, there was scrutiny in vape. I don't know when it started growing. I don't know when it influxed. Q. Well, I'm just looking at Paragraph
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	L. WEXLER - CONFIDENTIAL that time, right? MR. FORD: Objection. MR. LEE: Objection to form. A. I can't answer for every consumer. I can say there were a lot of consumers buying the product. Q. I'm sure you're aware of this, but JUUL was first introduced in vape stores, right? A. I cannot speak to whether it was first introduced in vape stores. I do know that Vapor Shark was pretty early in JUUL's evolution, in terms of getting the product, and they had vape shops. Q. You're aware that JUUL saw significant success in vape shops before it saw significant success in convenience stores, right? MR. LEE: Objection to form. MR. FORD: Objection.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	L. WEXLER - CONFIDENTIAL companies that had an agreement with the they had it before we bought them. They had an agreement with JUUL. They were selling JUUL inside their stores, and at one point JUUL represented about 17 percent of their sales. That's the only data that I have that I can speak to. Q. Mr. Wexler, scrutiny around e-vaping, regulatory scrutiny around e-vaping really started to grow in late 2018, right? A. I don't know at what point it I don't know how to measure scrutiny and whether it grew or didn't grow. I've been in the tobacco business, and there's been scrutiny in the tobacco business ever since I've been in it. And yes, there was scrutiny in vape. I don't know when it started growing. I don't know when it influxed. Q. Well, I'm just looking at Paragraph 29 of your Declaration where you say, "at the
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	L. WEXLER - CONFIDENTIAL that time, right? MR. FORD: Objection. MR. LEE: Objection to form. A. I can't answer for every consumer. I can say there were a lot of consumers buying the product. Q. I'm sure you're aware of this, but JUUL was first introduced in vape stores, right? A. I cannot speak to whether it was first introduced in vape stores. I do know that Vapor Shark was pretty early in JUUL's evolution, in terms of getting the product, and they had vape shops. Q. You're aware that JUUL saw significant success in vape shops before it saw significant success in convenience stores, right? MR. LEE: Objection to form. MR. FORD: Objection. A. I can't answer that question.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	L. WEXLER - CONFIDENTIAL companies that had an agreement with the they had it before we bought them. They had an agreement with JUUL. They were selling JUUL inside their stores, and at one point JUUL represented about 17 percent of their sales. That's the only data that I have that I can speak to. Q. Mr. Wexler, scrutiny around e-vaping, regulatory scrutiny around e-vaping really started to grow in late 2018, right? A. I don't know at what point it I don't know how to measure scrutiny and whether it grew or didn't grow. I've been in the tobacco business, and there's been scrutiny in the tobacco business ever since I've been in it. And yes, there was scrutiny in vape. I don't know when it started growing. I don't know when it influxed. Q. Well, I'm just looking at Paragraph 29 of your Declaration where you say, "at the time that JUUL took off there was not much
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	L. WEXLER - CONFIDENTIAL that time, right? MR. FORD: Objection. MR. LEE: Objection to form. A. I can't answer for every consumer. I can say there were a lot of consumers buying the product. Q. I'm sure you're aware of this, but JUUL was first introduced in vape stores, right? A. I cannot speak to whether it was first introduced in vape stores. I do know that Vapor Shark was pretty early in JUUL's evolution, in terms of getting the product, and they had vape shops. Q. You're aware that JUUL saw significant success in vape shops before it saw significant success in convenience stores, right? MR. LEE: Objection to form. MR. FORD: Objection. A. I can't answer that question. Q. Why can't you answer that question?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	L. WEXLER - CONFIDENTIAL companies that had an agreement with the they had it before we bought them. They had an agreement with JUUL. They were selling JUUL inside their stores, and at one point JUUL represented about 17 percent of their sales. That's the only data that I have that I can speak to. Q. Mr. Wexler, scrutiny around e-vaping, regulatory scrutiny around e-vaping really started to grow in late 2018, right? A. I don't know at what point it I don't know how to measure scrutiny and whether it grew or didn't grow. I've been in the tobacco business, and there's been scrutiny in the tobacco business ever since I've been in it. And yes, there was scrutiny in vape. I don't know when it started growing. I don't know when it influxed. Q. Well, I'm just looking at Paragraph 29 of your Declaration where you say, "at the time that JUUL took off there was not much regulatory scrutiny." So, I'm just asking you
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	L. WEXLER - CONFIDENTIAL that time, right? MR. FORD: Objection. MR. LEE: Objection to form. A. I can't answer for every consumer. I can say there were a lot of consumers buying the product. Q. I'm sure you're aware of this, but JUUL was first introduced in vape stores, right? A. I cannot speak to whether it was first introduced in vape stores. I do know that Vapor Shark was pretty early in JUUL's evolution, in terms of getting the product, and they had vape shops. Q. You're aware that JUUL saw significant success in vape shops before it saw significant success in convenience stores, right? MR. LEE: Objection to form. MR. FORD: Objection. A. I can't answer that question. Q. Why can't you answer that question?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	L. WEXLER - CONFIDENTIAL companies that had an agreement with the they had it before we bought them. They had an agreement with JUUL. They were selling JUUL inside their stores, and at one point JUUL represented about 17 percent of their sales. That's the only data that I have that I can speak to. Q. Mr. Wexler, scrutiny around e-vaping, regulatory scrutiny around e-vaping really started to grow in late 2018, right? A. I don't know at what point it I don't know how to measure scrutiny and whether it grew or didn't grow. I've been in the tobacco business, and there's been scrutiny in the tobacco business ever since I've been in it. And yes, there was scrutiny in vape. I don't know when it started growing. I don't know when it influxed. Q. Well, I'm just looking at Paragraph 29 of your Declaration where you say, "at the time that JUUL took off there was not much

	Page 134		Page 136
1	L. WEXLER - CONFIDENTIAL	1	L. WEXLER - CONFIDENTIAL
2	just, you know look, when vape products	2	franchise in some cases almost like an
3	first started, people perceived them as being	3	independent. It wasn't really chain
4	an alternative to cigarettes that had a	4	authorized. It was simply that one of our
5	difference in perceived health. There was not	5	sales reps sold into one franchisee the
6	a lot of history on them.	6	product.
7	I think as they became popular,	7	MR. SOWLATI: I'm just loading a
8	there was some correlation with their	8	document, Wexler Exhibit 10.
9	popularity and the scrutiny that they	9	Q. This is a screenshot of RipTide's
10	received. I don't remember if it was 2018 or	10	website that I actually took this week, two
11	2016 or when. I don't know what thresholds	11	days ago actually. Do you have that open?
12	we're talking about. I'm trying to be	12	A. I'm trying.
13	helpful. I just don't know how to answer that	13	Yes.
14	question.	14	Q. Okay. 5201 Interchange Way,
15	Q. Are you aware that in	15	Louisville, Kentucky is the headquarters of
16	September 2018, Commissioner Scott Gottlieb	16	Turning Point, right?
17 18	sent a letter to various e-vapor manufacturers?	17 18	A. Yes. O. And what I see here is that you were
19	A. I couldn't tell you that it was	19	being sold or RipTide's being sold at
20	September '18. I do remember there was a	20	Circle K and Dollar General, right?
21	letter that was sent out.	21	A. They're on the list, yes.
22	Q. Now, even after that date, we just	22	Q. We can put that document aside.
23	reviewed, you were able to get access to shelf	23	Mr. Wexler, are you familiar with
24	space at major retailers, right?	24	the NJOY product?
25	A. We were able to get access we	25	A. I've heard of it.
	-		
	Page 135		Page 137
1	L. WEXLER - CONFIDENTIAL	1	L. WEXLER - CONFIDENTIAL
2	L. WEXLER - CONFIDENTIAL went through that chart. It was interesting.	2	L. WEXLER - CONFIDENTIAL Q. You're aware that NJOY is not owned
2 3	L. WEXLER - CONFIDENTIAL went through that chart. It was interesting. You skipped through all the other major	2	L. WEXLER - CONFIDENTIAL Q. You're aware that NJOY is not owned by a major tobacco company, right?
2 3 4	L. WEXLER - CONFIDENTIAL went through that chart. It was interesting. You skipped through all the other major retailers that we didn't get access to. But	2 3 4	L. WEXLER - CONFIDENTIAL Q. You're aware that NJOY is not owned by a major tobacco company, right? A. Yes.
2 3 4 5	L. WEXLER - CONFIDENTIAL went through that chart. It was interesting. You skipped through all the other major retailers that we didn't get access to. But yes, there were two major retailers that we	2 3 4 5	L. WEXLER - CONFIDENTIAL Q. You're aware that NJOY is not owned by a major tobacco company, right? A. Yes. Q. And yet it has seen significant
2 3 4 5 6	L. WEXLER - CONFIDENTIAL went through that chart. It was interesting. You skipped through all the other major retailers that we didn't get access to. But yes, there were two major retailers that we were able to get access to. Speedway was a	2 3 4 5 6	L. WEXLER - CONFIDENTIAL Q. You're aware that NJOY is not owned by a major tobacco company, right? A. Yes. Q. And yet it has seen significant success in growth in the last couple of years,
2 3 4 5 6 7	L. WEXLER - CONFIDENTIAL went through that chart. It was interesting. You skipped through all the other major retailers that we didn't get access to. But yes, there were two major retailers that we were able to get access to. Speedway was a very specific example where we had to go to	2 3 4 5 6 7	L. WEXLER - CONFIDENTIAL Q. You're aware that NJOY is not owned by a major tobacco company, right? A. Yes. Q. And yet it has seen significant success in growth in the last couple of years, right?
2 3 4 5 6 7 8	L. WEXLER - CONFIDENTIAL went through that chart. It was interesting. You skipped through all the other major retailers that we didn't get access to. But yes, there were two major retailers that we were able to get access to. Speedway was a very specific example where we had to go to enormous lengths to take care of their problem	2 3 4 5 6 7 8	L. WEXLER - CONFIDENTIAL Q. You're aware that NJOY is not owned by a major tobacco company, right? A. Yes. Q. And yet it has seen significant success in growth in the last couple of years, right? MR. FORD: Objection.
2 3 4 5 6 7 8 9	L. WEXLER - CONFIDENTIAL went through that chart. It was interesting. You skipped through all the other major retailers that we didn't get access to. But yes, there were two major retailers that we were able to get access to. Speedway was a very specific example where we had to go to enormous lengths to take care of their problem in order to get that access.	2 3 4 5 6 7 8 9	L. WEXLER - CONFIDENTIAL Q. You're aware that NJOY is not owned by a major tobacco company, right? A. Yes. Q. And yet it has seen significant success in growth in the last couple of years, right? MR. FORD: Objection. MR. LEE: Objection.
2 3 4 5 6 7 8 9	L. WEXLER - CONFIDENTIAL went through that chart. It was interesting. You skipped through all the other major retailers that we didn't get access to. But yes, there were two major retailers that we were able to get access to. Speedway was a very specific example where we had to go to enormous lengths to take care of their problem in order to get that access. Q. To be clear, you also got access to	2 3 4 5 6 7 8 9	L. WEXLER - CONFIDENTIAL Q. You're aware that NJOY is not owned by a major tobacco company, right? A. Yes. Q. And yet it has seen significant success in growth in the last couple of years, right? MR. FORD: Objection. MR. LEE: Objection. A. I have seen that they've sold
2 3 4 5 6 7 8 9 10	L. WEXLER - CONFIDENTIAL went through that chart. It was interesting. You skipped through all the other major retailers that we didn't get access to. But yes, there were two major retailers that we were able to get access to. Speedway was a very specific example where we had to go to enormous lengths to take care of their problem in order to get that access. Q. To be clear, you also got access to Buc-ee's, in addition to QuikTrip and	2 3 4 5 6 7 8 9 10	L. WEXLER - CONFIDENTIAL Q. You're aware that NJOY is not owned by a major tobacco company, right? A. Yes. Q. And yet it has seen significant success in growth in the last couple of years, right? MR. FORD: Objection. MR. LEE: Objection. A. I have seen that they've sold product over the last couple of years, yes.
2 3 4 5 6 7 8 9 10 11	L. WEXLER - CONFIDENTIAL went through that chart. It was interesting. You skipped through all the other major retailers that we didn't get access to. But yes, there were two major retailers that we were able to get access to. Speedway was a very specific example where we had to go to enormous lengths to take care of their problem in order to get that access. Q. To be clear, you also got access to Buc-ee's, in addition to QuikTrip and Speedway, right?	2 3 4 5 6 7 8 9 10 11	L. WEXLER - CONFIDENTIAL Q. You're aware that NJOY is not owned by a major tobacco company, right? A. Yes. Q. And yet it has seen significant success in growth in the last couple of years, right? MR. FORD: Objection. MR. LEE: Objection. A. I have seen that they've sold product over the last couple of years, yes. Q. At major convenience stores?
2 3 4 5 6 7 8 9 10 11 12 13	L. WEXLER - CONFIDENTIAL went through that chart. It was interesting. You skipped through all the other major retailers that we didn't get access to. But yes, there were two major retailers that we were able to get access to. Speedway was a very specific example where we had to go to enormous lengths to take care of their problem in order to get that access. Q. To be clear, you also got access to Buc-ee's, in addition to QuikTrip and Speedway, right? A. Yeah, we did.	2 3 4 5 6 7 8 9 10 11 12 13	L. WEXLER - CONFIDENTIAL Q. You're aware that NJOY is not owned by a major tobacco company, right? A. Yes. Q. And yet it has seen significant success in growth in the last couple of years, right? MR. FORD: Objection. MR. LEE: Objection. A. I have seen that they've sold product over the last couple of years, yes. Q. At major convenience stores? MR. FORD: Objection.
2 3 4 5 6 7 8 9 10 11 12 13 14	L. WEXLER - CONFIDENTIAL went through that chart. It was interesting. You skipped through all the other major retailers that we didn't get access to. But yes, there were two major retailers that we were able to get access to. Speedway was a very specific example where we had to go to enormous lengths to take care of their problem in order to get that access. Q. To be clear, you also got access to Buc-ee's, in addition to QuikTrip and Speedway, right? A. Yeah, we did. Q. And then we just saw a document	2 3 4 5 6 7 8 9 10 11 12 13 14	L. WEXLER - CONFIDENTIAL Q. You're aware that NJOY is not owned by a major tobacco company, right? A. Yes. Q. And yet it has seen significant success in growth in the last couple of years, right? MR. FORD: Objection. MR. LEE: Objection. A. I have seen that they've sold product over the last couple of years, yes. Q. At major convenience stores? MR. FORD: Objection. A. They show up in the data of selling
2 3 4 5 6 7 8 9 10 11 12 13 14	L. WEXLER - CONFIDENTIAL went through that chart. It was interesting. You skipped through all the other major retailers that we didn't get access to. But yes, there were two major retailers that we were able to get access to. Speedway was a very specific example where we had to go to enormous lengths to take care of their problem in order to get that access. Q. To be clear, you also got access to Buc-ee's, in addition to QuikTrip and Speedway, right? A. Yeah, we did. Q. And then we just saw a document which shows that your products are being sold	2 3 4 5 6 7 8 9 10 11 12 13 14 15	L. WEXLER - CONFIDENTIAL Q. You're aware that NJOY is not owned by a major tobacco company, right? A. Yes. Q. And yet it has seen significant success in growth in the last couple of years, right? MR. FORD: Objection. MR. LEE: Objection. A. I have seen that they've sold product over the last couple of years, yes. Q. At major convenience stores? MR. FORD: Objection. A. They show up in the data of selling product in major convenience stores, yes.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	L. WEXLER - CONFIDENTIAL went through that chart. It was interesting. You skipped through all the other major retailers that we didn't get access to. But yes, there were two major retailers that we were able to get access to. Speedway was a very specific example where we had to go to enormous lengths to take care of their problem in order to get that access. Q. To be clear, you also got access to Buc-ee's, in addition to QuikTrip and Speedway, right? A. Yeah, we did. Q. And then we just saw a document which shows that your products are being sold at a 7-Eleven on the Upper East Side, right?	2 3 4 5 6 7 8 9 10 11 12 13 14	L. WEXLER - CONFIDENTIAL Q. You're aware that NJOY is not owned by a major tobacco company, right? A. Yes. Q. And yet it has seen significant success in growth in the last couple of years, right? MR. FORD: Objection. MR. LEE: Objection. A. I have seen that they've sold product over the last couple of years, yes. Q. At major convenience stores? MR. FORD: Objection. A. They show up in the data of selling product in major convenience stores, yes. Q. Mr. Wexler, you're familiar with the
2 3 4 5 6 7 8 9 10 11 12 13 14	L. WEXLER - CONFIDENTIAL went through that chart. It was interesting. You skipped through all the other major retailers that we didn't get access to. But yes, there were two major retailers that we were able to get access to. Speedway was a very specific example where we had to go to enormous lengths to take care of their problem in order to get that access. Q. To be clear, you also got access to Buc-ee's, in addition to QuikTrip and Speedway, right? A. Yeah, we did. Q. And then we just saw a document which shows that your products are being sold at a 7-Eleven on the Upper East Side, right?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	L. WEXLER - CONFIDENTIAL Q. You're aware that NJOY is not owned by a major tobacco company, right? A. Yes. Q. And yet it has seen significant success in growth in the last couple of years, right? MR. FORD: Objection. MR. LEE: Objection. A. I have seen that they've sold product over the last couple of years, yes. Q. At major convenience stores? MR. FORD: Objection. A. They show up in the data of selling product in major convenience stores, yes.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	L. WEXLER - CONFIDENTIAL went through that chart. It was interesting. You skipped through all the other major retailers that we didn't get access to. But yes, there were two major retailers that we were able to get access to. Speedway was a very specific example where we had to go to enormous lengths to take care of their problem in order to get that access. Q. To be clear, you also got access to Buc-ee's, in addition to QuikTrip and Speedway, right? A. Yeah, we did. Q. And then we just saw a document which shows that your products are being sold at a 7-Eleven on the Upper East Side, right? A. Yeah, but 7-Eleven is kind of	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	L. WEXLER - CONFIDENTIAL Q. You're aware that NJOY is not owned by a major tobacco company, right? A. Yes. Q. And yet it has seen significant success in growth in the last couple of years, right? MR. FORD: Objection. MR. LEE: Objection. A. I have seen that they've sold product over the last couple of years, yes. Q. At major convenience stores? MR. FORD: Objection. A. They show up in the data of selling product in major convenience stores, yes. Q. Mr. Wexler, you're familiar with the Premarket Tobacco Authorization, or PMTA
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	L. WEXLER - CONFIDENTIAL went through that chart. It was interesting. You skipped through all the other major retailers that we didn't get access to. But yes, there were two major retailers that we were able to get access to. Speedway was a very specific example where we had to go to enormous lengths to take care of their problem in order to get that access. Q. To be clear, you also got access to Buc-ee's, in addition to QuikTrip and Speedway, right? A. Yeah, we did. Q. And then we just saw a document which shows that your products are being sold at a 7-Eleven on the Upper East Side, right? A. Yeah, but 7-Eleven is kind of misnomer. We were not authorized at 7-Eleven	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	L. WEXLER - CONFIDENTIAL Q. You're aware that NJOY is not owned by a major tobacco company, right? A. Yes. Q. And yet it has seen significant success in growth in the last couple of years, right? MR. FORD: Objection. MR. LEE: Objection. A. I have seen that they've sold product over the last couple of years, yes. Q. At major convenience stores? MR. FORD: Objection. A. They show up in the data of selling product in major convenience stores, yes. Q. Mr. Wexler, you're familiar with the Premarket Tobacco Authorization, or PMTA process, right?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	L. WEXLER - CONFIDENTIAL went through that chart. It was interesting. You skipped through all the other major retailers that we didn't get access to. But yes, there were two major retailers that we were able to get access to. Speedway was a very specific example where we had to go to enormous lengths to take care of their problem in order to get that access. Q. To be clear, you also got access to Buc-ee's, in addition to QuikTrip and Speedway, right? A. Yeah, we did. Q. And then we just saw a document which shows that your products are being sold at a 7-Eleven on the Upper East Side, right? A. Yeah, but 7-Eleven is kind of misnomer. We were not authorized at 7-Eleven Corporate, and they run a franchise system	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	L. WEXLER - CONFIDENTIAL Q. You're aware that NJOY is not owned by a major tobacco company, right? A. Yes. Q. And yet it has seen significant success in growth in the last couple of years, right? MR. FORD: Objection. MR. LEE: Objection. A. I have seen that they've sold product over the last couple of years, yes. Q. At major convenience stores? MR. FORD: Objection. A. They show up in the data of selling product in major convenience stores, yes. Q. Mr. Wexler, you're familiar with the Premarket Tobacco Authorization, or PMTA process, right? A. Yes.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	L. WEXLER - CONFIDENTIAL went through that chart. It was interesting. You skipped through all the other major retailers that we didn't get access to. But yes, there were two major retailers that we were able to get access to. Speedway was a very specific example where we had to go to enormous lengths to take care of their problem in order to get that access. Q. To be clear, you also got access to Buc-ee's, in addition to QuikTrip and Speedway, right? A. Yeah, we did. Q. And then we just saw a document which shows that your products are being sold at a 7-Eleven on the Upper East Side, right? A. Yeah, but 7-Eleven is kind of misnomer. We were not authorized at 7-Eleven Corporate, and they run a franchise system where the franchises are allowed to take on	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	L. WEXLER - CONFIDENTIAL Q. You're aware that NJOY is not owned by a major tobacco company, right? A. Yes. Q. And yet it has seen significant success in growth in the last couple of years, right? MR. FORD: Objection. MR. LEE: Objection. A. I have seen that they've sold product over the last couple of years, yes. Q. At major convenience stores? MR. FORD: Objection. A. They show up in the data of selling product in major convenience stores, yes. Q. Mr. Wexler, you're familiar with the Premarket Tobacco Authorization, or PMTA process, right? A. Yes. Q. What is the PMTA process?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	L. WEXLER - CONFIDENTIAL went through that chart. It was interesting. You skipped through all the other major retailers that we didn't get access to. But yes, there were two major retailers that we were able to get access to. Speedway was a very specific example where we had to go to enormous lengths to take care of their problem in order to get that access. Q. To be clear, you also got access to Buc-ee's, in addition to QuikTrip and Speedway, right? A. Yeah, we did. Q. And then we just saw a document which shows that your products are being sold at a 7-Eleven on the Upper East Side, right? A. Yeah, but 7-Eleven is kind of misnomer. We were not authorized at 7-Eleven Corporate, and they run a franchise system where the franchises are allowed to take on other products. I think they were allowed to	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	L. WEXLER - CONFIDENTIAL Q. You're aware that NJOY is not owned by a major tobacco company, right? A. Yes. Q. And yet it has seen significant success in growth in the last couple of years, right? MR. FORD: Objection. MR. LEE: Objection. A. I have seen that they've sold product over the last couple of years, yes. Q. At major convenience stores? MR. FORD: Objection. A. They show up in the data of selling product in major convenience stores, yes. Q. Mr. Wexler, you're familiar with the Premarket Tobacco Authorization, or PMTA process, right? A. Yes. Q. What is the PMTA process? A. In 2009, the FDA was given
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	L. WEXLER - CONFIDENTIAL went through that chart. It was interesting. You skipped through all the other major retailers that we didn't get access to. But yes, there were two major retailers that we were able to get access to. Speedway was a very specific example where we had to go to enormous lengths to take care of their problem in order to get that access. Q. To be clear, you also got access to Buc-ee's, in addition to QuikTrip and Speedway, right? A. Yeah, we did. Q. And then we just saw a document which shows that your products are being sold at a 7-Eleven on the Upper East Side, right? A. Yeah, but 7-Eleven is kind of misnomer. We were not authorized at 7-Eleven Corporate, and they run a franchise system where the franchises are allowed to take on other products. I think they were allowed to sell a certain percentage of the products. I	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	L. WEXLER - CONFIDENTIAL Q. You're aware that NJOY is not owned by a major tobacco company, right? A. Yes. Q. And yet it has seen significant success in growth in the last couple of years, right? MR. FORD: Objection. MR. LEE: Objection. A. I have seen that they've sold product over the last couple of years, yes. Q. At major convenience stores? MR. FORD: Objection. A. They show up in the data of selling product in major convenience stores, yes. Q. Mr. Wexler, you're familiar with the Premarket Tobacco Authorization, or PMTA process, right? A. Yes. Q. What is the PMTA process? A. In 2009, the FDA was given jurisdiction by legislation over cigarettes
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	L. WEXLER - CONFIDENTIAL went through that chart. It was interesting. You skipped through all the other major retailers that we didn't get access to. But yes, there were two major retailers that we were able to get access to. Speedway was a very specific example where we had to go to enormous lengths to take care of their problem in order to get that access. Q. To be clear, you also got access to Buc-ee's, in addition to QuikTrip and Speedway, right? A. Yeah, we did. Q. And then we just saw a document which shows that your products are being sold at a 7-Eleven on the Upper East Side, right? A. Yeah, but 7-Eleven is kind of misnomer. We were not authorized at 7-Eleven Corporate, and they run a franchise system where the franchises are allowed to take on other products. I think they were allowed to sell a certain percentage of the products. I don't know what that percentage is anymore.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	L. WEXLER - CONFIDENTIAL Q. You're aware that NJOY is not owned by a major tobacco company, right? A. Yes. Q. And yet it has seen significant success in growth in the last couple of years, right? MR. FORD: Objection. MR. LEE: Objection. A. I have seen that they've sold product over the last couple of years, yes. Q. At major convenience stores? MR. FORD: Objection. A. They show up in the data of selling product in major convenience stores, yes. Q. Mr. Wexler, you're familiar with the Premarket Tobacco Authorization, or PMTA process, right? A. Yes. Q. What is the PMTA process? A. In 2009, the FDA was given jurisdiction by legislation over cigarettes and oral tobacco. And in that legislation,

Page 138 Page 140 1 L. WEXLER - CONFIDENTIAL 1 L. WEXLER - CONFIDENTIAL 2 in 2016. 2 dollars on the PMTA process, including 3 As part of that deeming process, 3 RipTide's PMTA, right? 4 they basically said that any product that 4 That is not correct. We spent a lot wasn't on the market in 2007 in yet what is 5 5 of money -- I believe what we've told to 6 called a grandfather status, had to go through 6 everybody and it's fairly close to what we 7 a process through the FDA in order to get actually spent, I don't know the exact number 7 8 authorization to stay on the market. 8 that we actually spent, it's roughly (Discussion held off the record.) 9 9 \$17 million. RipTide products were not Where was I? So, in 2016, they included in that process. 10 10 11 11 basically said that they deemed the other OTB Sorry. Can you explain a little bit Ο. 12 products, including vape, and that any product 12 more about RipTide not being included in that that wasn't on the market before February 13 13 process? 14 something, 2007 had to go through a process 14 A. We did not submit applications for 15 called a PMTA, Premarket Tobacco 15 RipTide in September of 2020. 16 Authorization, in order to stay in the market. 16 Q. Mr. Wexler, what work have you done 17 And they had a provision that said 17 on that process for RipTide's PMTA? 18 that products that are on the market as of 18 Α. We have done a lot of exploratory 19 this date in August, I think it was 19 work; scoping out what we'd have to do to 20 August 16th, I may be off a couple of days, submit an application for RipTide. 20 21 could stay on the market. And they set a time 21 Okay. Can I show you a document? Ο. 22 period where they had until 2022 to submit 22 Α. Can I just explain something? 23 this application. Through various changes in 23 There is some confusion as to 24 political jockeying, that date moved a couple 24 whether or not we need to put an application 25 of times. Then there was a lawsuit in in for RipTide, and that's part of the dilemma Page 139 Page 141 L. WEXLER - CONFIDENTIAL L. WEXLER - CONFIDENTIAL 1 1 2 Maryland where they established the date as 2 that we had, because the enabling law gave the 3 September 2020 as the date when these 3 FDA jurisdiction over tobacco-based nicotine, 4 applications were due. 4 and RipTide does not use tobacco-based 5 These applications are very nicotine. It uses synthetic nicotine; that's 5 extensive. They require an analysis of a lot part of the NicTech system. 6 6 7 of data, both physical data, which includes 7 So, we did do exploratory work. We 8 the PK tests that I think you mentioned 8 decided not to pursue the PMTA, but certainly 9 earlier, as well as evaluating the vape for 9 scoped out what would be required to do it. 10 potential harmful constituents, as well as 10 So just to confirm, RipTide is still 11 social data in terms of who uses the product. 11 in the market, then, because it is your view 12 You have to do survey work on labels. It's a 12 that you do not need to submit a PMTA? 13 very extensive thing and a very expensive 13 Yeah, it is our view that the FDA 14 process. 14 would not even look at the RipTide because it 15 Thank you for that. Just for 15 doesn't have jurisdiction over it. 16 clarity of the record, I think you said 16 Q. I just submitted a document, Wexler 17 August 16th was the date that products needed 17 Exhibit 12. 18 to be on the market. It's actually 18 Α. Okay. Let me take a look at it. August 8th. MR. SOWLATI: Just for the record, 19 19 20 Okay. I apologize. 20 this is Wexler EX 12. This document is a Α. 21 21 Q. No, no need to I apologize. Turning Point press release dated 22 Α. A lot of dates to keep straight 22 October 27, 2020. 23 23 Can you please let me know when here. 24 No, I mean, you did pretty good. 24 you've had a chance to take a look at it. 25 25 In 2020, you spent millions of Α. Okav.

	- Candary		
	Page 142		Page 144
1	L. WEXLER - CONFIDENTIAL	1	L. WEXLER - CONFIDENTIAL
2	Q. I'm just going to focus you on the	2	Is it Mr. Cushman or Ms. Cushman? I
3	page stamped 12-002, the third paragraph from	3	just want to be precise.
4	the top. You see "On September 8th"?	4	A. I did not say Mr. Cushman.
5	Turning Point says, in its press	5	Q. Okay.
6	release, "On September 8, 2020, TPB announced	6	A. She is not a Mr.
7	that it submitted to the U.S. Food and Drug	7	Q. Okay. Great. I just wanted to
8	Administration premarket tobacco applications	8	clarify.
9	covering 250 products." Then going down, you	9	A. I thought you were saying if she
10	say, "the PMTA covered a broad assortment of	10	wanted to be called Ms. or Mrs., you know, and
11	products in the vapor category, including,"	11	you never know these days the correct
12	and at the end of that sentence, it says, "a	12	terminology.
13	closed system e-cigarette."	13	Q. She notes that, "Turning Point is
14	What is that referring to?	14	just testing the highest nicotine strengths
15	A. Wait, I'm trying to find where it	15	for HPHCs to cut costs."
16	says that.	16	A. Wait, what paragraph are you on?
17	Q. Sure. It's the-second-to-last	17	Q. This is Paragraph 17.
18	sentence of that paragraph.	18	A. Okay. What's the question?
19	A. That's a long sentence, and it's	19	Q. So, she says there, "Turning Point
20	terribly constructed. Hold on.	20	is just testing the highest nicotine strengths
21	Okay. What was your question?	21	for HPHCs to cut costs."
22	Q. It says that the PMTAs that you	22	A. Yes, that's what she says.
23	submitted covered a broad assortment of	23	Q. HPHCs refers to harmful and
24	products in the vapor category, including, at	24	potentially harmful compounds, right?
25	the end of the sentence, it says a closed	25	A. Yes.
	Page 143		Page 145
			Page 143
1	L. WEXLER - CONFIDENTIAL	1	L. WEXLER - CONFIDENTIAL
1 2		1 2	
	L. WEXLER - CONFIDENTIAL		L. WEXLER - CONFIDENTIAL
2	L. WEXLER - CONFIDENTIAL system e-cigarette.	2	L. WEXLER - CONFIDENTIAL Q. Why did you choose to focus on the
2 3	L. WEXLER - CONFIDENTIAL system e-cigarette. I'm just wondering what closed	2	L. WEXLER - CONFIDENTIAL Q. Why did you choose to focus on the highest nicotine strengths?
2 3 4	L. WEXLER - CONFIDENTIAL system e-cigarette. I'm just wondering what closed system e-cigarette you're referring to there.	2 3 4	L. WEXLER - CONFIDENTIAL Q. Why did you choose to focus on the highest nicotine strengths? A. Okay. So, the purpose of this
2 3 4 5	L. WEXLER - CONFIDENTIAL system e-cigarette. I'm just wondering what closed system e-cigarette you're referring to there. A. South Beach Smoke.	2 3 4 5	L. WEXLER - CONFIDENTIAL Q. Why did you choose to focus on the highest nicotine strengths? A. Okay. So, the purpose of this testing is to see what exposure a consumer
2 3 4 5 6	L. WEXLER - CONFIDENTIAL system e-cigarette. I'm just wondering what closed system e-cigarette you're referring to there. A. South Beach Smoke. Q. I am going to load one more	2 3 4 5 6	L. WEXLER - CONFIDENTIAL Q. Why did you choose to focus on the highest nicotine strengths? A. Okay. So, the purpose of this testing is to see what exposure a consumer gets in consuming the products. And there
2 3 4 5 6 7	L. WEXLER - CONFIDENTIAL system e-cigarette. I'm just wondering what closed system e-cigarette you're referring to there. A. South Beach Smoke. Q. I am going to load one more document, and I'm hoping it can be quick, and	2 3 4 5 6 7	L. WEXLER - CONFIDENTIAL Q. Why did you choose to focus on the highest nicotine strengths? A. Okay. So, the purpose of this testing is to see what exposure a consumer gets in consuming the products. And there are as I've talked about particularly with
2 3 4 5 6 7 8	L. WEXLER - CONFIDENTIAL system e-cigarette. I'm just wondering what closed system e-cigarette you're referring to there. A. South Beach Smoke. Q. I am going to load one more document, and I'm hoping it can be quick, and then hopefully we can go on a lunch break.	2 3 4 5 6 7 8	L. WEXLER - CONFIDENTIAL Q. Why did you choose to focus on the highest nicotine strengths? A. Okay. So, the purpose of this testing is to see what exposure a consumer gets in consuming the products. And there are as I've talked about particularly with open systems, there are enormous variety of
2 3 4 5 6 7 8 9	L. WEXLER - CONFIDENTIAL system e-cigarette. I'm just wondering what closed system e-cigarette you're referring to there. A. South Beach Smoke. Q. I am going to load one more document, and I'm hoping it can be quick, and then hopefully we can go on a lunch break. Does that work?	2 3 4 5 6 7 8 9	L. WEXLER - CONFIDENTIAL Q. Why did you choose to focus on the highest nicotine strengths? A. Okay. So, the purpose of this testing is to see what exposure a consumer gets in consuming the products. And there are as I've talked about particularly with open systems, there are enormous variety of flavors and nicotine strengths. We felt that
2 3 4 5 6 7 8 9	L. WEXLER - CONFIDENTIAL system e-cigarette. I'm just wondering what closed system e-cigarette you're referring to there. A. South Beach Smoke. Q. I am going to load one more document, and I'm hoping it can be quick, and then hopefully we can go on a lunch break. Does that work? A. It will work for me.	2 3 4 5 6 7 8 9	L. WEXLER - CONFIDENTIAL Q. Why did you choose to focus on the highest nicotine strengths? A. Okay. So, the purpose of this testing is to see what exposure a consumer gets in consuming the products. And there are as I've talked about particularly with open systems, there are enormous variety of flavors and nicotine strengths. We felt that by testing the highest levels of nicotine
2 3 4 5 6 7 8 9 10	L. WEXLER - CONFIDENTIAL system e-cigarette. I'm just wondering what closed system e-cigarette you're referring to there. A. South Beach Smoke. Q. I am going to load one more document, and I'm hoping it can be quick, and then hopefully we can go on a lunch break. Does that work? A. It will work for me. Q. Mr. Wexler, as we discussed earlier,	2 3 4 5 6 7 8 9 10	L. WEXLER - CONFIDENTIAL Q. Why did you choose to focus on the highest nicotine strengths? A. Okay. So, the purpose of this testing is to see what exposure a consumer gets in consuming the products. And there are as I've talked about particularly with open systems, there are enormous variety of flavors and nicotine strengths. We felt that by testing the highest levels of nicotine strengths, those are the products that have
2 3 4 5 6 7 8 9 10 11	L. WEXLER - CONFIDENTIAL system e-cigarette. I'm just wondering what closed system e-cigarette you're referring to there. A. South Beach Smoke. Q. I am going to load one more document, and I'm hoping it can be quick, and then hopefully we can go on a lunch break. Does that work? A. It will work for me. Q. Mr. Wexler, as we discussed earlier, one of your colleagues, Brittani Cushman,	2 3 4 5 6 7 8 9 10 11 12	L. WEXLER - CONFIDENTIAL Q. Why did you choose to focus on the highest nicotine strengths? A. Okay. So, the purpose of this testing is to see what exposure a consumer gets in consuming the products. And there are as I've talked about particularly with open systems, there are enormous variety of flavors and nicotine strengths. We felt that by testing the highest levels of nicotine strengths, those are the products that have most more of the ingredients than any other
2 3 4 5 6 7 8 9 10 11 12 13	L. WEXLER - CONFIDENTIAL system e-cigarette. I'm just wondering what closed system e-cigarette you're referring to there. A. South Beach Smoke. Q. I am going to load one more document, and I'm hoping it can be quick, and then hopefully we can go on a lunch break. Does that work? A. It will work for me. Q. Mr. Wexler, as we discussed earlier, one of your colleagues, Brittani Cushman, submitted a Declaration, which I've just sent	2 3 4 5 6 7 8 9 10 11 12 13	L. WEXLER - CONFIDENTIAL Q. Why did you choose to focus on the highest nicotine strengths? A. Okay. So, the purpose of this testing is to see what exposure a consumer gets in consuming the products. And there are as I've talked about particularly with open systems, there are enormous variety of flavors and nicotine strengths. We felt that by testing the highest levels of nicotine strengths, those are the products that have most more of the ingredients than any other product. So, it would be sort of a worst-case
2 3 4 5 6 7 8 9 10 11 12 13 14	L. WEXLER - CONFIDENTIAL system e-cigarette. I'm just wondering what closed system e-cigarette you're referring to there. A. South Beach Smoke. Q. I am going to load one more document, and I'm hoping it can be quick, and then hopefully we can go on a lunch break. Does that work? A. It will work for me. Q. Mr. Wexler, as we discussed earlier, one of your colleagues, Brittani Cushman, submitted a Declaration, which I've just sent you by Zoom chat. It's stamped Wexler	2 3 4 5 6 7 8 9 10 11 12 13 14	L. WEXLER - CONFIDENTIAL Q. Why did you choose to focus on the highest nicotine strengths? A. Okay. So, the purpose of this testing is to see what exposure a consumer gets in consuming the products. And there are as I've talked about particularly with open systems, there are enormous variety of flavors and nicotine strengths. We felt that by testing the highest levels of nicotine strengths, those are the products that have most more of the ingredients than any other product. So, it would be sort of a worst-case scenario.
2 3 4 5 6 7 8 9 10 11 12 13 14 15	L. WEXLER - CONFIDENTIAL system e-cigarette. I'm just wondering what closed system e-cigarette you're referring to there. A. South Beach Smoke. Q. I am going to load one more document, and I'm hoping it can be quick, and then hopefully we can go on a lunch break. Does that work? A. It will work for me. Q. Mr. Wexler, as we discussed earlier, one of your colleagues, Brittani Cushman, submitted a Declaration, which I've just sent you by Zoom chat. It's stamped Wexler Exhibit 11. I'm not going to spend a lot of	2 3 4 5 6 7 8 9 10 11 12 13 14 15	L. WEXLER - CONFIDENTIAL Q. Why did you choose to focus on the highest nicotine strengths? A. Okay. So, the purpose of this testing is to see what exposure a consumer gets in consuming the products. And there are as I've talked about particularly with open systems, there are enormous variety of flavors and nicotine strengths. We felt that by testing the highest levels of nicotine strengths, those are the products that have most more of the ingredients than any other product. So, it would be sort of a worst-case scenario. So, if there was going to be the
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	L. WEXLER - CONFIDENTIAL system e-cigarette. I'm just wondering what closed system e-cigarette you're referring to there. A. South Beach Smoke. Q. I am going to load one more document, and I'm hoping it can be quick, and then hopefully we can go on a lunch break. Does that work? A. It will work for me. Q. Mr. Wexler, as we discussed earlier, one of your colleagues, Brittani Cushman, submitted a Declaration, which I've just sent you by Zoom chat. It's stamped Wexler Exhibit 11. I'm not going to spend a lot of time with this. I just have a few questions.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	L. WEXLER - CONFIDENTIAL Q. Why did you choose to focus on the highest nicotine strengths? A. Okay. So, the purpose of this testing is to see what exposure a consumer gets in consuming the products. And there are as I've talked about particularly with open systems, there are enormous variety of flavors and nicotine strengths. We felt that by testing the highest levels of nicotine strengths, those are the products that have most more of the ingredients than any other product. So, it would be sort of a worst-case scenario. So, if there was going to be the presence of things in the products that were
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	L. WEXLER - CONFIDENTIAL system e-cigarette. I'm just wondering what closed system e-cigarette you're referring to there. A. South Beach Smoke. Q. I am going to load one more document, and I'm hoping it can be quick, and then hopefully we can go on a lunch break. Does that work? A. It will work for me. Q. Mr. Wexler, as we discussed earlier, one of your colleagues, Brittani Cushman, submitted a Declaration, which I've just sent you by Zoom chat. It's stamped Wexler Exhibit 11. I'm not going to spend a lot of time with this. I just have a few questions. Can you please let me know when that's loaded?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	L. WEXLER - CONFIDENTIAL Q. Why did you choose to focus on the highest nicotine strengths? A. Okay. So, the purpose of this testing is to see what exposure a consumer gets in consuming the products. And there are as I've talked about particularly with open systems, there are enormous variety of flavors and nicotine strengths. We felt that by testing the highest levels of nicotine strengths, those are the products that have most more of the ingredients than any other product. So, it would be sort of a worst-case scenario. So, if there was going to be the presence of things in the products that were problematic, they were most likely to show up with the highest nicotine products. And so, we felt as though that was the most effective
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	L. WEXLER - CONFIDENTIAL system e-cigarette. I'm just wondering what closed system e-cigarette you're referring to there. A. South Beach Smoke. Q. I am going to load one more document, and I'm hoping it can be quick, and then hopefully we can go on a lunch break. Does that work? A. It will work for me. Q. Mr. Wexler, as we discussed earlier, one of your colleagues, Brittani Cushman, submitted a Declaration, which I've just sent you by Zoom chat. It's stamped Wexler Exhibit 11. I'm not going to spend a lot of time with this. I just have a few questions. Can you please let me know when that's loaded? A. It's loaded.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	L. WEXLER - CONFIDENTIAL Q. Why did you choose to focus on the highest nicotine strengths? A. Okay. So, the purpose of this testing is to see what exposure a consumer gets in consuming the products. And there are as I've talked about particularly with open systems, there are enormous variety of flavors and nicotine strengths. We felt that by testing the highest levels of nicotine strengths, those are the products that have most more of the ingredients than any other product. So, it would be sort of a worst-case scenario. So, if there was going to be the presence of things in the products that were problematic, they were most likely to show up with the highest nicotine products. And so,
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	L. WEXLER - CONFIDENTIAL system e-cigarette. I'm just wondering what closed system e-cigarette you're referring to there. A. South Beach Smoke. Q. I am going to load one more document, and I'm hoping it can be quick, and then hopefully we can go on a lunch break. Does that work? A. It will work for me. Q. Mr. Wexler, as we discussed earlier, one of your colleagues, Brittani Cushman, submitted a Declaration, which I've just sent you by Zoom chat. It's stamped Wexler Exhibit 11. I'm not going to spend a lot of time with this. I just have a few questions. Can you please let me know when that's loaded? A. It's loaded. Q. Mr. Wexler, have you seen this	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	L. WEXLER - CONFIDENTIAL Q. Why did you choose to focus on the highest nicotine strengths? A. Okay. So, the purpose of this testing is to see what exposure a consumer gets in consuming the products. And there are as I've talked about particularly with open systems, there are enormous variety of flavors and nicotine strengths. We felt that by testing the highest levels of nicotine strengths, those are the products that have most more of the ingredients than any other product. So, it would be sort of a worst-case scenario. So, if there was going to be the presence of things in the products that were problematic, they were most likely to show up with the highest nicotine products. And so, we felt as though that was the most effective
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	L. WEXLER - CONFIDENTIAL system e-cigarette. I'm just wondering what closed system e-cigarette you're referring to there. A. South Beach Smoke. Q. I am going to load one more document, and I'm hoping it can be quick, and then hopefully we can go on a lunch break. Does that work? A. It will work for me. Q. Mr. Wexler, as we discussed earlier, one of your colleagues, Brittani Cushman, submitted a Declaration, which I've just sent you by Zoom chat. It's stamped Wexler Exhibit 11. I'm not going to spend a lot of time with this. I just have a few questions. Can you please let me know when that's loaded? A. It's loaded. Q. Mr. Wexler, have you seen this document before?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	L. WEXLER - CONFIDENTIAL Q. Why did you choose to focus on the highest nicotine strengths? A. Okay. So, the purpose of this testing is to see what exposure a consumer gets in consuming the products. And there are as I've talked about particularly with open systems, there are enormous variety of flavors and nicotine strengths. We felt that by testing the highest levels of nicotine strengths, those are the products that have most more of the ingredients than any other product. So, it would be sort of a worst-case scenario. So, if there was going to be the presence of things in the products that were problematic, they were most likely to show up with the highest nicotine products. And so, we felt as though that was the most effective way to get to the answers that the FDA was
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	L. WEXLER - CONFIDENTIAL system e-cigarette. I'm just wondering what closed system e-cigarette you're referring to there. A. South Beach Smoke. Q. I am going to load one more document, and I'm hoping it can be quick, and then hopefully we can go on a lunch break. Does that work? A. It will work for me. Q. Mr. Wexler, as we discussed earlier, one of your colleagues, Brittani Cushman, submitted a Declaration, which I've just sent you by Zoom chat. It's stamped Wexler Exhibit 11. I'm not going to spend a lot of time with this. I just have a few questions. Can you please let me know when that's loaded? A. It's loaded. Q. Mr. Wexler, have you seen this document before? A. I don't remember seeing it.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	L. WEXLER - CONFIDENTIAL Q. Why did you choose to focus on the highest nicotine strengths? A. Okay. So, the purpose of this testing is to see what exposure a consumer gets in consuming the products. And there are as I've talked about particularly with open systems, there are enormous variety of flavors and nicotine strengths. We felt that by testing the highest levels of nicotine strengths, those are the products that have most more of the ingredients than any other product. So, it would be sort of a worst-case scenario. So, if there was going to be the presence of things in the products that were problematic, they were most likely to show up with the highest nicotine products. And so, we felt as though that was the most effective way to get to the answers that the FDA was seeking.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	L. WEXLER - CONFIDENTIAL system e-cigarette. I'm just wondering what closed system e-cigarette you're referring to there. A. South Beach Smoke. Q. I am going to load one more document, and I'm hoping it can be quick, and then hopefully we can go on a lunch break. Does that work? A. It will work for me. Q. Mr. Wexler, as we discussed earlier, one of your colleagues, Brittani Cushman, submitted a Declaration, which I've just sent you by Zoom chat. It's stamped Wexler Exhibit 11. I'm not going to spend a lot of time with this. I just have a few questions. Can you please let me know when that's loaded? A. It's loaded. Q. Mr. Wexler, have you seen this document before? A. I don't remember seeing it. Q. Just to begin, who is Ms. Cushman?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	L. WEXLER - CONFIDENTIAL Q. Why did you choose to focus on the highest nicotine strengths? A. Okay. So, the purpose of this testing is to see what exposure a consumer gets in consuming the products. And there are as I've talked about particularly with open systems, there are enormous variety of flavors and nicotine strengths. We felt that by testing the highest levels of nicotine strengths, those are the products that have most more of the ingredients than any other product. So, it would be sort of a worst-case scenario. So, if there was going to be the presence of things in the products that were problematic, they were most likely to show up with the highest nicotine products. And so, we felt as though that was the most effective way to get to the answers that the FDA was seeking. MR. SOWLATI: Thank you, Mr. Wexler,
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	L. WEXLER - CONFIDENTIAL system e-cigarette. I'm just wondering what closed system e-cigarette you're referring to there. A. South Beach Smoke. Q. I am going to load one more document, and I'm hoping it can be quick, and then hopefully we can go on a lunch break. Does that work? A. It will work for me. Q. Mr. Wexler, as we discussed earlier, one of your colleagues, Brittani Cushman, submitted a Declaration, which I've just sent you by Zoom chat. It's stamped Wexler Exhibit 11. I'm not going to spend a lot of time with this. I just have a few questions. Can you please let me know when that's loaded? A. It's loaded. Q. Mr. Wexler, have you seen this document before? A. I don't remember seeing it. Q. Just to begin, who is Ms. Cushman? A. She is currently my general counsel.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	L. WEXLER - CONFIDENTIAL Q. Why did you choose to focus on the highest nicotine strengths? A. Okay. So, the purpose of this testing is to see what exposure a consumer gets in consuming the products. And there are as I've talked about particularly with open systems, there are enormous variety of flavors and nicotine strengths. We felt that by testing the highest levels of nicotine strengths, those are the products that have most more of the ingredients than any other product. So, it would be sort of a worst-case scenario. So, if there was going to be the presence of things in the products that were problematic, they were most likely to show up with the highest nicotine products. And so, we felt as though that was the most effective way to get to the answers that the FDA was seeking. MR. SOWLATI: Thank you, Mr. Wexler, for your patience and time. For now, I

		2,	
	Page 146		Page 148
1	L. WEXLER - CONFIDENTIAL	1	L. WEXLER - CONFIDENTIAL
2	MR. LEE: Hold on, hold on. I don't	2	A. Yes.
3	think I have that many questions. So, if	3	Q. Can you explain what was the V2
4	Mr. Wexler is okay, not too hungry and can	4	product a little bit?
5	go make another hour, I think maybe we can	5	A. The V2 product was an early form of
6	continue after short break.	6	Cigalike product. It was principally sold
7	THE WITNESS: If it's all right with	7	online by a company called VMR, and they came
8	you	8	to us and asked us if we would be willing to
9	MR. FORD: We should go off the	9	pick up retail distribution for the product
10	record.	10	and take it to retail C-stores, tobacco
11	(Discussion held off the record.)	11	outlets. It was a fairly standard Cigalike
12	(Luncheon recess taken at	12	product.
13	12:30 p.m.)	13	Q. And do you recall when was the time
14		14	frame, approximately, about that discussion?
15		15	A. Well, the discussion went on for a
16 17		16 17	while, and I think we started implementing in
18		18	2013, I think. O. Thank you.
19		19	Q. Thank you. Mr. Wexler, you mentioned that after
20		20	Turning Point had been selling the V2 product
21		21	you just described, the company that
22		22	manufactured V2 product was acquired by
23		23	another company, correct?
24		24	A. Yes.
25		25	Q. Who acquired that company from the
			~
	Page 147		Page 149
1	L. WEXLER - CONFIDENTIAL	1	L. WEXLER - CONFIDENTIAL
2	L. WEXLER - CONFIDENTIAL AFTERNOON SESSION	2	L. WEXLER - CONFIDENTIAL manufacturer V2?
2 3	L. WEXLER - CONFIDENTIAL AFTERNOON SESSION (Time noted: 1:18 p.m.)	2	L. WEXLER - CONFIDENTIAL manufacturer V2? A. JUUL, I don't know if they're called
2 3 4	L. WEXLER - CONFIDENTIAL AFTERNOON SESSION (Time noted: 1:18 p.m.) LARRY WEXLER,	2 3 4	L. WEXLER - CONFIDENTIAL manufacturer V2? A. JUUL, I don't know if they're called JUUL Inc. or JUUL Company, but JUUL purchased
2 3 4 5	L. WEXLER - CONFIDENTIAL AFTERNOON SESSION (Time noted: 1:18 p.m.) LARRY WEXLER, resumed and testified as follows:	2 3 4 5	L. WEXLER - CONFIDENTIAL manufacturer V2? A. JUUL, I don't know if they're called JUUL Inc. or JUUL Company, but JUUL purchased VMR. They bought the whole they didn't
2 3 4 5 6	L. WEXLER - CONFIDENTIAL A F T E R N O O N S E S S I O N (Time noted: 1:18 p.m.) L A R R Y W E X L E R, resumed and testified as follows: EXAMINATION BY	2 3 4 5 6	L. WEXLER - CONFIDENTIAL manufacturer V2? A. JUUL, I don't know if they're called JUUL Inc. or JUUL Company, but JUUL purchased VMR. They bought the whole they didn't just buy the product. I think they bought the
2 3 4 5 6 7	L. WEXLER - CONFIDENTIAL AFTERNOON SESSION (Time noted: 1:18 p.m.) LARRY WEXLER, resumed and testified as follows: EXAMINATION BY MR. LEE:	2 3 4 5 6 7	L. WEXLER - CONFIDENTIAL manufacturer V2? A. JUUL, I don't know if they're called JUUL Inc. or JUUL Company, but JUUL purchased VMR. They bought the whole they didn't just buy the product. I think they bought the whole company.
2 3 4 5 6 7 8	L. WEXLER - CONFIDENTIAL A F T E R N O O N S E S S I O N (Time noted: 1:18 p.m.) L A R R Y W E X L E R, resumed and testified as follows: EXAMINATION BY MR. LEE: Q. Good afternoon, Mr. Wexler. I hope	2 3 4 5 6 7 8	L. WEXLER - CONFIDENTIAL manufacturer V2? A. JUUL, I don't know if they're called JUUL Inc. or JUUL Company, but JUUL purchased VMR. They bought the whole they didn't just buy the product. I think they bought the whole company. Q. Okay. Thank you for that
2 3 4 5 6 7 8	L. WEXLER - CONFIDENTIAL A F T E R N O O N S E S S I O N (Time noted: 1:18 p.m.) L A R R Y W E X L E R, resumed and testified as follows: EXAMINATION BY MR. LEE: Q. Good afternoon, Mr. Wexler. I hope you had a nice lunch.	2 3 4 5 6 7 8	L. WEXLER - CONFIDENTIAL manufacturer V2? A. JUUL, I don't know if they're called JUUL Inc. or JUUL Company, but JUUL purchased VMR. They bought the whole they didn't just buy the product. I think they bought the whole company. Q. Okay. Thank you for that clarification.
2 3 4 5 6 7 8 9	L. WEXLER - CONFIDENTIAL A F T E R N O O N S E S S I O N (Time noted: 1:18 p.m.) L A R R Y W E X L E R, resumed and testified as follows: EXAMINATION BY MR. LEE: Q. Good afternoon, Mr. Wexler. I hope you had a nice lunch. A. I enjoyed my sandwich. Thank you.	2 3 4 5 6 7 8 9	L. WEXLER - CONFIDENTIAL manufacturer V2? A. JUUL, I don't know if they're called JUUL Inc. or JUUL Company, but JUUL purchased VMR. They bought the whole they didn't just buy the product. I think they bought the whole company. Q. Okay. Thank you for that clarification. And you also mentioned earlier today
2 3 4 5 6 7 8 9 10	L. WEXLER - CONFIDENTIAL A F T E R N O O N S E S S I O N (Time noted: 1:18 p.m.) L A R R Y W E X L E R, resumed and testified as follows: EXAMINATION BY MR. LEE: Q. Good afternoon, Mr. Wexler. I hope you had a nice lunch. A. I enjoyed my sandwich. Thank you. Q. Great. My name is Joonsuk Lee, I'm	2 3 4 5 6 7 8 9 10	L. WEXLER - CONFIDENTIAL manufacturer V2? A. JUUL, I don't know if they're called JUUL Inc. or JUUL Company, but JUUL purchased VMR. They bought the whole they didn't just buy the product. I think they bought the whole company. Q. Okay. Thank you for that clarification. And you also mentioned earlier today that after that acquisition by JUUL of the
2 3 4 5 6 7 8 9 10 11	L. WEXLER - CONFIDENTIAL A F T E R N O O N S E S S I O N (Time noted: 1:18 p.m.) L A R R Y W E X L E R, resumed and testified as follows: EXAMINATION BY MR. LEE: Q. Good afternoon, Mr. Wexler. I hope you had a nice lunch. A. I enjoyed my sandwich. Thank you. Q. Great. My name is Joonsuk Lee, I'm an attorney with the Federal Trade Commission,	2 3 4 5 6 7 8 9 10 11	L. WEXLER - CONFIDENTIAL manufacturer V2? A. JUUL, I don't know if they're called JUUL Inc. or JUUL Company, but JUUL purchased VMR. They bought the whole they didn't just buy the product. I think they bought the whole company. Q. Okay. Thank you for that clarification. And you also mentioned earlier today that after that acquisition by JUUL of the company that manufactures V2, Turning Point
2 3 4 5 6 7 8 9 10 11 12 13	L. WEXLER - CONFIDENTIAL A F T E R N O O N S E S S I O N	2 3 4 5 6 7 8 9 10 11 12 13	L. WEXLER - CONFIDENTIAL manufacturer V2? A. JUUL, I don't know if they're called JUUL Inc. or JUUL Company, but JUUL purchased VMR. They bought the whole they didn't just buy the product. I think they bought the whole company. Q. Okay. Thank you for that clarification. And you also mentioned earlier today that after that acquisition by JUUL of the company that manufactures V2, Turning Point Brand was shut off, that was your language, to
2 3 4 5 6 7 8 9 10 11 12 13 14	L. WEXLER - CONFIDENTIAL A F T E R N O O N S E S S I O N (Time noted: 1:18 p.m.) L A R R Y W E X L E R, resumed and testified as follows: EXAMINATION BY MR. LEE: Q. Good afternoon, Mr. Wexler. I hope you had a nice lunch. A. I enjoyed my sandwich. Thank you. Q. Great. My name is Joonsuk Lee, I'm an attorney with the Federal Trade Commission, and I'm going to ask you some questions. I may jump around a little bit because Counsel	2 3 4 5 6 7 8 9 10 11 12 13 14	L. WEXLER - CONFIDENTIAL manufacturer V2? A. JUUL, I don't know if they're called JUUL Inc. or JUUL Company, but JUUL purchased VMR. They bought the whole they didn't just buy the product. I think they bought the whole company. Q. Okay. Thank you for that clarification. And you also mentioned earlier today that after that acquisition by JUUL of the company that manufactures V2, Turning Point Brand was shut off, that was your language, to sell the V2 product, correct?
2 3 4 5 6 7 8 9 10 11 12 13 14 15	L. WEXLER - CONFIDENTIAL A F T E R N O O N S E S S I O N (Time noted: 1:18 p.m.) L A R R Y W E X L E R, resumed and testified as follows: EXAMINATION BY MR. LEE: Q. Good afternoon, Mr. Wexler. I hope you had a nice lunch. A. I enjoyed my sandwich. Thank you. Q. Great. My name is Joonsuk Lee, I'm an attorney with the Federal Trade Commission, and I'm going to ask you some questions. I may jump around a little bit because Counsel has covered a number of areas that I would	2 3 4 5 6 7 8 9 10 11 12 13 14 15	L. WEXLER - CONFIDENTIAL manufacturer V2? A. JUUL, I don't know if they're called JUUL Inc. or JUUL Company, but JUUL purchased VMR. They bought the whole they didn't just buy the product. I think they bought the whole company. Q. Okay. Thank you for that clarification. And you also mentioned earlier today that after that acquisition by JUUL of the company that manufactures V2, Turning Point Brand was shut off, that was your language, to sell the V2 product, correct? MR. SOWLATI: Objection to form.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	L. WEXLER - CONFIDENTIAL A F T E R N O O N S E S S I O N (Time noted: 1:18 p.m.) L A R R Y W E X L E R, resumed and testified as follows: EXAMINATION BY MR. LEE: Q. Good afternoon, Mr. Wexler. I hope you had a nice lunch. A. I enjoyed my sandwich. Thank you. Q. Great. My name is Joonsuk Lee, I'm an attorney with the Federal Trade Commission, and I'm going to ask you some questions. I may jump around a little bit because Counsel has covered a number of areas that I would otherwise cover. So, if you need a frame of	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	L. WEXLER - CONFIDENTIAL manufacturer V2? A. JUUL, I don't know if they're called JUUL Inc. or JUUL Company, but JUUL purchased VMR. They bought the whole they didn't just buy the product. I think they bought the whole company. Q. Okay. Thank you for that clarification. And you also mentioned earlier today that after that acquisition by JUUL of the company that manufactures V2, Turning Point Brand was shut off, that was your language, to sell the V2 product, correct? MR. SOWLATI: Objection to form. A. What does that mean?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	L. WEXLER - CONFIDENTIAL A F T E R N O O N S E S S I O N (Time noted: 1:18 p.m.) L A R R Y W E X L E R, resumed and testified as follows: EXAMINATION BY MR. LEE: Q. Good afternoon, Mr. Wexler. I hope you had a nice lunch. A. I enjoyed my sandwich. Thank you. Q. Great. My name is Joonsuk Lee, I'm an attorney with the Federal Trade Commission, and I'm going to ask you some questions. I may jump around a little bit because Counsel has covered a number of areas that I would otherwise cover. So, if you need a frame of reference for any of my questions, just say,	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	L. WEXLER - CONFIDENTIAL manufacturer V2? A. JUUL, I don't know if they're called JUUL Inc. or JUUL Company, but JUUL purchased VMR. They bought the whole they didn't just buy the product. I think they bought the whole company. Q. Okay. Thank you for that clarification. And you also mentioned earlier today that after that acquisition by JUUL of the company that manufactures V2, Turning Point Brand was shut off, that was your language, to sell the V2 product, correct? MR. SOWLATI: Objection to form. A. What does that mean? MR. FORD: You can go ahead and
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	L. WEXLER - CONFIDENTIAL A F T E R N O O N S E S S I O N (Time noted: 1:18 p.m.) L A R R Y W E X L E R, resumed and testified as follows: EXAMINATION BY MR. LEE: Q. Good afternoon, Mr. Wexler. I hope you had a nice lunch. A. I enjoyed my sandwich. Thank you. Q. Great. My name is Joonsuk Lee, I'm an attorney with the Federal Trade Commission, and I'm going to ask you some questions. I may jump around a little bit because Counsel has covered a number of areas that I would otherwise cover. So, if you need a frame of reference for any of my questions, just say, back up a second, and tell me what we are	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	L. WEXLER - CONFIDENTIAL manufacturer V2? A. JUUL, I don't know if they're called JUUL Inc. or JUUL Company, but JUUL purchased VMR. They bought the whole they didn't just buy the product. I think they bought the whole company. Q. Okay. Thank you for that clarification. And you also mentioned earlier today that after that acquisition by JUUL of the company that manufactures V2, Turning Point Brand was shut off, that was your language, to sell the V2 product, correct? MR. SOWLATI: Objection to form. A. What does that mean? MR. FORD: You can go ahead and answer.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	L. WEXLER - CONFIDENTIAL A F T E R N O O N S E S S I O N	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	L. WEXLER - CONFIDENTIAL manufacturer V2? A. JUUL, I don't know if they're called JUUL Inc. or JUUL Company, but JUUL purchased VMR. They bought the whole they didn't just buy the product. I think they bought the whole company. Q. Okay. Thank you for that clarification. And you also mentioned earlier today that after that acquisition by JUUL of the company that manufactures V2, Turning Point Brand was shut off, that was your language, to sell the V2 product, correct? MR. SOWLATI: Objection to form. A. What does that mean? MR. FORD: You can go ahead and answer. Counsel for Altria is stating an
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	L. WEXLER - CONFIDENTIAL A F T E R N O O N S E S S I O N	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	L. WEXLER - CONFIDENTIAL manufacturer V2? A. JUUL, I don't know if they're called JUUL Inc. or JUUL Company, but JUUL purchased VMR. They bought the whole they didn't just buy the product. I think they bought the whole company. Q. Okay. Thank you for that clarification. And you also mentioned earlier today that after that acquisition by JUUL of the company that manufactures V2, Turning Point Brand was shut off, that was your language, to sell the V2 product, correct? MR. SOWLATI: Objection to form. A. What does that mean? MR. FORD: You can go ahead and answer. Counsel for Altria is stating an objection for the record. That's all.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	L. WEXLER - CONFIDENTIAL A F T E R N O O N S E S S I O N	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	L. WEXLER - CONFIDENTIAL manufacturer V2? A. JUUL, I don't know if they're called JUUL Inc. or JUUL Company, but JUUL purchased VMR. They bought the whole they didn't just buy the product. I think they bought the whole company. Q. Okay. Thank you for that clarification. And you also mentioned earlier today that after that acquisition by JUUL of the company that manufactures V2, Turning Point Brand was shut off, that was your language, to sell the V2 product, correct? MR. SOWLATI: Objection to form. A. What does that mean? MR. FORD: You can go ahead and answer. Counsel for Altria is stating an objection for the record. That's all. A. So, like, in most contracts, the
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	L. WEXLER - CONFIDENTIAL A F T E R N O O N S E S S I O N	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	L. WEXLER - CONFIDENTIAL manufacturer V2? A. JUUL, I don't know if they're called JUUL Inc. or JUUL Company, but JUUL purchased VMR. They bought the whole they didn't just buy the product. I think they bought the whole company. Q. Okay. Thank you for that clarification. And you also mentioned earlier today that after that acquisition by JUUL of the company that manufactures V2, Turning Point Brand was shut off, that was your language, to sell the V2 product, correct? MR. SOWLATI: Objection to form. A. What does that mean? MR. FORD: You can go ahead and answer. Counsel for Altria is stating an objection for the record. That's all. A. So, like, in most contracts, the contract with VMR had divorce provisions.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	L. WEXLER - CONFIDENTIAL A F T E R N O O N S E S S I O N (Time noted: 1:18 p.m.) L A R R Y W E X L E R, resumed and testified as follows: EXAMINATION BY MR. LEE: Q. Good afternoon, Mr. Wexler. I hope you had a nice lunch. A. I enjoyed my sandwich. Thank you. Q. Great. My name is Joonsuk Lee, I'm an attorney with the Federal Trade Commission, and I'm going to ask you some questions. I may jump around a little bit because Counsel has covered a number of areas that I would otherwise cover. So, if you need a frame of reference for any of my questions, just say, back up a second, and tell me what we are talking about here before I jump in. Is that okay? A. Thank you. I appreciate that. Q. Great. Do you recall that earlier in the morning today, you discussed a product	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	L. WEXLER - CONFIDENTIAL manufacturer V2? A. JUUL, I don't know if they're called JUUL Inc. or JUUL Company, but JUUL purchased VMR. They bought the whole they didn't just buy the product. I think they bought the whole company. Q. Okay. Thank you for that clarification. And you also mentioned earlier today that after that acquisition by JUUL of the company that manufactures V2, Turning Point Brand was shut off, that was your language, to sell the V2 product, correct? MR. SOWLATI: Objection to form. A. What does that mean? MR. FORD: You can go ahead and answer. Counsel for Altria is stating an objection for the record. That's all. A. So, like, in most contracts, the contract with VMR had divorce provisions. Sometimes, you spend more time on divorce
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	L. WEXLER - CONFIDENTIAL A F T E R N O O N S E S S I O N	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	L. WEXLER - CONFIDENTIAL manufacturer V2? A. JUUL, I don't know if they're called JUUL Inc. or JUUL Company, but JUUL purchased VMR. They bought the whole they didn't just buy the product. I think they bought the whole company. Q. Okay. Thank you for that clarification. And you also mentioned earlier today that after that acquisition by JUUL of the company that manufactures V2, Turning Point Brand was shut off, that was your language, to sell the V2 product, correct? MR. SOWLATI: Objection to form. A. What does that mean? MR. FORD: You can go ahead and answer. Counsel for Altria is stating an objection for the record. That's all. A. So, like, in most contracts, the contract with VMR had divorce provisions.

Page 150 Page 152 1 L. WEXLER - CONFIDENTIAL L. WEXLER - CONFIDENTIAL 1 2 We were very concerned that we would 2 Vapor Beast, the principal business of Vapor 3 build a retail presence for the product and Beast was distributing products to vape shops. 3 4 then VMR would pull the product from us. So, 4 Before that, we had no business. We didn't 5 there were a number of provisions in there to 5 spend any time in vape shops before 2016. 6 give us time to sell through our inventory and 6 Okay. Thank you. 7 also some provisions that if VMR was sold, 7 Since 2016, Turning Point Brands 8 have been involved in distributing vape that we would get a portion of the proceeds of 8 9 9 the sale. products to vape shops, correct? 10 Shortly after JUUL bought VMR, we 10 Yes. In 2016 we bought Vapor Beast, 11 were given notice by JUUL that we could sell 11 and then shortly thereafter, we bought Vapor 12 out the inventory that we had on hand for a 12 Shark, which had a small distribution 13 certain period and that they would be no 13 business. They were a little more B2C, and 14 longer supplying us with any replenishment. 14 they had retail operations. 15 So, after going out and getting 20, 30,000 15 Then we bought Vapor Supply in 2017, 16 16 and they also had a wholesale business that stores, more, putting displays out, creating a 17 17 consumer base, the product was taken from us. shifted to vape shops. And then we bought 18 Okay. Thank you. When you say 20 18 IVG, which was mostly a B2C, but they also had 19 to 30 stores, what type of stores are you 19 a wholesale business that sold to vape shops. 20 20 referring to? Thank you. 21 21 MR. FORD: Twenty to 30,000. 22 MR. LEE: Sorry about that. Let me 22 23 23 24 When you say, "20 to 30,000 stores," 24 25 what type of stores are you referring to? 25 Page 151 Page 153 1 L. WEXLER - CONFIDENTIAL 1 L. WEXLER - CONFIDENTIAL 2 2 Α. It would be the stores that are 3 normal in our distribution platform. They 3 4 were principally C-stores and tobacco outlets. 4 5 When you say, "C-stores and tobacco 5 6 outlets," they are different from vape shops, 7 correct? 8 Yes. We did not distribute V2 in --8 9 it may have gotten into some vape shops, but 10 we had no program to put them into vape shops. 10 Why not? 11 11 12 Α. They were a closed system product. 12 Ο. Thank you. 13 We believe the markets are somewhat different 13 Based on your experience, how do you 14 and that it was more likely someone, on a 14 describe the demographics of the customers who 15 product like V2, would either buy them online 15 come to Turning Point Brands' vape shops? or buy them in C-stores. The products 16 16 MR. SOWLATI: Objection to form. 17 themselves cannot have -- we talked about this 17 MR. FORD: Objection. 18 earlier. The products themselves didn't 18 In my -- I did not spend a lot of 19 really have the kind of experience that people 19 time inside the retail stores. It was my 20 in open systems were looking for. 20 impression that the demographics of the people 21 Thank you. 21 who came to the stores were older. I know 22 Changing the topic a little here, 22 from our B2C operation, which also deals with 23 Turning Point Brands have been distributing 23 open systems, that the demographics, the 24 vape products to vape shops, correct? 24 average age of our consumers in one of our 25 Beginning in 2016 when we bought product lines is 55; another one is 48. So,

Page 154 Page 156 L. WEXLER - CONFIDENTIAL 1 L. WEXLER - CONFIDENTIAL 1 2 they're somewhere in that age bracket. 2 Again, the specifics of these 3 What I saw in the stores -- they 3 contracts change over time, but this is the 4 didn't do any studies, so this is not speaking kind of general principals. 5 with any explicit data. My impression was 5 In return, the C-store operator or 6 that the consumers were in the age, probably 6 the store operator -- because these contracts 7 average somewhere around 48 to 50. But are also in other channels, the C-store 7 there's not -- I never saw any data on the 8 8 channel basically gives up the facings to the 9 people who came to the stores. 9 manufacturers. And the mechanics of that are sort of interesting. I'll get back to that. 10 Okay. Thank you. 10 11 Again, changing the topic slightly, 11 And in return, they get payments based on 12 when you say, "C-stores," that means 12 their sales, and they also get access to promotional payments -- promotions that, at 13 convenience stores, right? 13 14 Yes. Sorry. It's a bit of industry 14 times, are not available to stores that are Α. 15 15 not under contract. jargon. 16 Q. That's fine. I try to use the same 16 I'll speak a little bit about the 17 language, C-stores, here. 17 impact it has in the moist snuff category 18 Do you recall earlier in the morning 18 because I'm a little bit more familiar with 19 when you were discussing with Counsel for 19 that. So, if you look at -- and at one time, 20 Altria, you were speaking about contracts at I did some analysis on just using national 20 21 C-stores? Do you recall that? 21 shares rather than any specific chain. So 22 22 Α. Yes, I do. Altria has roughly 53 percent of the national 23 So, when you say contracts in the 23 share of moist snuff. Reynolds has about 32 24 24 shares. So, between the two of them, they context of C-stores, do you mean retail 25 contracts between tobacco companies and have about 85 percent share. And moist snuff Page 155 Page 157 L. WEXLER - CONFIDENTIAL L. WEXLER - CONFIDENTIAL 1 1 2 C-store chains? 2 is usually sold in fairly contained -- is 3 MR. SOWLATI: Objection to form. 3 often sold in fairly contained geographies The major tobacco companies in inside the store. It's sort of a display. 4 Α. 4 cigarettes and in moist snuff, that I'm fairly These displays can have 32, 48, or 5 5 familiar with, contract with the stores. 64 -- generally, they have either 32, 48, or 6 6 7 These contracts generally cover a number of 7 64 facings. And so, when you do the math of 8 different parameters. The major companies 8 the 85 percent, I'll focus just on the 64 9 generally ask for shelf space, the share of 9 facing one, Altria and Reynolds would get all the available space, visible space equal to 10 10 but ten of the facings. So, you're talking 11 their market share. That market share could 11 now that there's ten facings available. 12 be the trading area; it could be the specific 12 There's 64 facings in this display, and Altria 13 chain; the chain they share with the specific 13 and Reynolds would get all but ten. So, they 14 chain. They generally ask for the highest 14 would get about 54. And so, three companies, 15 amount whether it's the -- if the trading area 15 Swisher, Swedish Match, and Turning Point, 16 was lower than the chain, they'd ask for the 16 would then have only ten facings in which they 17 17 could display the product. percent of sales they have in the chain, or if 18 the trading area was higher, they would do 18 So, I looked at it. If you were to take -- and I'm using -- this is not a 19 that. 19 20 scientific -- I'm using this just to try to They ask for signage. Generally, 20 21 they get the top signs and any signs embedded 21 describe in principals. You can poke all 22 into the selling area. And they have kinds of holes into this analysis. But if you 23 provisions that if there are other signs put 23 were to use national shares and apply it, if 24 up around the store, they get additional signs 24 you were to rank the top 64 SKUs nationally, 25 as well. if you were to do that, then there would be 20

Page 158 Page 160 L. WEXLER - CONFIDENTIAL 1 L. WEXLER - CONFIDENTIAL 1 2 SKUs from the other three companies that would 2 these products have lower distribution. And 3 rank in the top 64 SKUs. When you look at 3 so, their velocities must be higher in the 4 that, what happens is that the retailer, on points of distribution that they have. So, if 5 average, cannot service as broad a market as 5 you were to take the velocity of the brands 6 they could under the contract. So, let's call 6 where they do sell and apply that velocity to this kind of activity "natural selection." 7 this kind of mythical store that I've just 7 8 8 created with the 64-SKU thing, essentially, This whole process of natural selection, where 9 you actually go and you rank all the SKUs, the 9 the store sales would be -- just by taking out 64 SKUs. I think it stops at 64. The other those ten products and putting in these other 10 10 11 three companies would then get 20 SKUs. 11 ten product, the store sales would be 12 Now, what's interesting about that 12 22 percent higher. Again, you could poke lots of holes in it. But in any case, the 13 is because of these contracts, the 13 14 distribution of these other three companies' 14 implication is that the store gives up some 15 SKUs are somewhat limited. So, for instance, 15 economics by reducing their sales by not 16 I just looked at some data for another purpose 16 having the breadth in the marketplace. 17 the other day, and in the data that we get 17 And what's interesting about it is 18 from MSA, which is an information service that 18 that there is a shift value in the smokeless 19 tracks shipments into retail across 19 category. And the brands, a lot of the SKUs 20 hundreds -- 200-some odd thousand stores. 20 that are being excluded from this rack are 21 We have one particular SKU. Our 21 SKUs that are priced at a lower level. So, 22 can, our Stoker's Wintergreen, would rank in 22 it's basically hurting the consumer because 23 the stop 64. Now, it's ranked in the top 64 23 the consumer's having less access to products 24 nationally, but in the last 13 weeks it only 24 that are at a lower cost. And at least in the 25 had shipments into something, like, 32 percent case of our product, which we've done some Page 159 Page 161 1 L. WEXLER - CONFIDENTIAL 1 L. WEXLER - CONFIDENTIAL 2 of all the stores and 36 percent of the chain 2 testing against some of the major brands, are 3 stores. So that if it had universal 3 at least equivalent, we actually get slight distribution, you could make the presumption preference. We really don't get statistical 4 4 that its share would be higher and all of our 5 preference, but you can say that there are at 6 product share would be higher and that we 6 least -- they are no less than equal in taste 7 would have more products that were in the 64. 7 preference. But because of the difficulty and 8 But if you just look at what the 8 lack of room to put these products into these 9 retailer loses in this, they kind of restrict 9 sets, the consumer's getting prevented, 10 the percent of the market that they can cover 10 preventing access to these products. So 11 because of this constraint that's imposed on 11 there's a number of really important implications of these contracts. And we've 12 them by Altria and Reynolds. And if you do 12 13 it, this analysis I did, I looked at the 13 seen it in cigarettes, you can see it in 14 brands, the SKUs that Altria and Reynolds 14 smokeless. 15 would lose because they'd drop out of the top 15 What's interesting is that when we 16 64, these ten SKUs, and ten SKUs would come 16 were first introducing RipTide, I think it in. And that would increase the coverage of 17 was -- you didn't see a lot of contracted 17 18 the market by one-and-a-half to two percent. 18 space in vape. I did notice, this is in July, call it June, July, August of 2019, I did 19 And that gap is growing because these are 19 20 growing brands in the marketplace. So, the 20 notice the last time I was out, and 21 retailer loses by not having the breadth of 21 unfortunately because of COVID I think we've 22 products that they need to service all the all been inside too much, I haven't been out

in stores very often.

But when I've gone out, I have seen

that the vape section is much more organized

23

24

25

23

24

25

potential consumers that go into their store.

look at the -- now, remember, these brands,

What becomes interesting, when you

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

1

2

3

4

6

8

9

10

11

12

13

14

15

16

17

18

19

20

21

23

24

25

Page 162 L. WEXLER - CONFIDENTIAL 1 2 than it was when we were first introducing 3 RipTide and certainly light years difference 4 than when we introduced V2. When we 5 introduced V2, you can get vape into a lot of 6 different places. You can even get counter 7 displays in there. 8 They've since been regulated out by 9 the FDA. But now when you walk into a store, 10 the stores that I've been in, and quite 11 frankly, it is not a statistical sample 12 because I haven't been in a lot of stores because of COVID, but I have seen some 13 14 pictures that the sales guys sent in, that you 15 tend to see the section that looks just like 16 cigarettes and just like, you know, the moist 17 snuff sort of display section, where JUUL has 18 this big sign on the top. And the only 19 embedded signs you see in the display is 20 Reynolds product and you see that most of the 21 other products are sort of at the bottom. 22 And this has some implications 23 because, for instance, our RipTide product, we 24 had the worst possible -- if you were to pick a time to introduce RipTide, we picked 25 Page 163 L. WEXLER - CONFIDENTIAL 1 2 absolutely the wrong time to do it. Just as 3

L. WEXLER - CONFIDENTIAL there was a lot of political pressure, and the

Page 164

FDA came out and banned flavors in pod systems. Now, what's interesting in sort of demonstrating this totally different consumer base is that when they banned flavors in pod systems, they actually left flavors in open systems. And I think that the reason for that is because the open systems are really ex-cigarette smokers, very little initiation there, and they're just older. And with pod systems, pod systems were popular among populations -- a different type of population, and the FDA was very concerned about -- and, you know, looking at the national surveys that are done on youth usage, you know, you don't see any open systems there. They're just not there. They're pretty high from these pod systems.

So, without the ability to have flavors and with the hangover of all this distribution that we got where we didn't get -- and quite frankly, we didn't get a lot of sales because of all the controversy there on vape, we sort of just said, Okay, we're

we were getting distribution, just as we were starting to get into stores, Vape Gate happened, which I think is what I talked about earlier, which is that marijuana product that caused some issues in the lungs. The FDA and the CDC came out, and their first reaction, since this was a vaping product, even though it was a marijuana product -- well, they found out it was a marijuana product. They didn't know what product was causing it. They came out and they said, "Don't vape, and certainly don't vape anything that you haven't vaped before and hadn't had problems with." So just as RipTide started to get a little pit of traction, as Graham talked about in the Vesser presentations, all of a sudden all the momentum just stopped everything just stopped and it was like we hit a brick wall. One of the consequences of the Vape

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

Gate and the controversy -- now, the CDC and the FDA ultimately came out and said, "This isn't vaping products. It's just a marijuana product." But one of the consequences was,

Page 165

L. WEXLER - CONFIDENTIAL going to de-emphasize RipTide, and we're going to stop going national. We're going to pull back. If you look at our financial statements, we had a very large write-off at the end of 2019 with the inventory that we bought because we were seeing momentum. We started building up our inventory to sell the product, and then we had to write it all off because the market for us just sort of closed.

Now, we did keep RipTide open in some geographies in 2020. We had some geographies where we said, "Okay. Let's see what we could do with RipTide." Just a couple of observations. The hit rates on RipTide were much lower than they were when we first introduced it. I hadn't seen any contracts, but it certainly -- the vape section certainly looked like there were contracts there. I've $\,$ talked to one of our ex-Philip Morris employees, and they say that there are contracts in vape now. As I said, I've never seen one.

I do know that our hit rates, our success rates of sales guys walking into

Page 166 Page 168 L. WEXLER - CONFIDENTIAL 1 L. WEXLER - CONFIDENTIAL 1 2 stores were lower. And it was much more 2 different than V2 and VMR, which was the 3 difficult, the acquisition of shelf space 3 existing product that we entered into a 4 where it was a lot slower in 2020 than it was 4 partnership with VMR. This was a 5 in 2019 before these sections were as well 5 self-developed product. 6 6 organized as they are today. Got it. Thank you. 7 Thank you very much. Do you recall how much of research 7 Ο. 8 You mentioned "hit rates." 8 and development spend was invested in 9 What are hit rates? 9 developing the RipTide product? MR. SOWLATI: Objection to form. 10 Oh, sorry. I'm a creature of our 10 11 11 internal jargon. Hit rates are the number of I don't remember seeing a number on Α. 12 times a salesperson is successful at getting 12 that. I know we did work with our supplier to new distribution divided by the number of help develop the -- they had developed a 13 13 14 times they present the product. So, we 14 number of devices, and we chose one of the basically look at, if this is a priority for 15 15 devices and worked with them to try to improve 16 them, you assume that they made the ask in 16 entire spends, and we created the liquid. 17 every store they go into, and then we 17 What about RipTide device, the Ο. 18 calculate how many stores we got this new 18 RipStick? 19 distribution in, and then we just divide it. 19 Α. That's what we did. We went to some 20 And that's what we call a hit rate. 20 of our suppliers and we picked a product from 21 Thank you. 21 the supplier that they had on their shelf, and 22 So, you covered a lot of ground 22 then we asked them to customize it for us. 23 here, but you also mentioned the RipTide 23 There was very little development effort on 24 product sold by Turning Point Brands. 24 our part. It was really on the supplier's 25 Earlier, you mentioned market shares in the part. Page 167 Page 169 L. WEXLER - CONFIDENTIAL L. WEXLER - CONFIDENTIAL 1 1 2 C-store channel. 2 Since Turning Point developed the 3 Do you have any sense of national 3 RipTide product, has anyone approached you or marshal shares for RipTide in the C-store the company to acquire the product? 4 4 5 5 Not that I know of. channel today? Α. It's minimal. I don't have an exact Would you have sold it, if the price 6 Α. 6 Ο. 7 number, but it's not material. 7 was right? 8 Do you think it's over 5 percent? 8 MR. SOWLATI: Objection to form. Ο. 9 Α. For RipTide in C-stores? 9 MR. FORD: Objection. Yes. 10 I guess you'd have to decide what 10 0. 11 No. 11 the price is right. I think, in general, in Α. 12 12 markets, if someone comes with an offer that Ο. Over 1 percent? 13 I haven't looked at it, but if it 13 has a higher value than the long-term value Α. was 1 percent, I would have looked at it. So, 14 you think you have in a product, you have to 14 15 I will assume it's significantly less than 15 at least consider it. 16 1 percent nationally. 16 Thank you. 17 17 Ο. Thank you. Let's talk about the liquid for the 18 Could you explain a little about how 18 RipTide product. So, if I understand what you Turning Point Brands first acquired the right discussed in the morning correctly, RipTide 19 19 20 to sell RipTide product? liquid does not use nicotine derived out of 21 21 We didn't acquire the right to sell tobacco, correct? 22 RipTide product. We filed for a trademark and 22 Α. That is correct. 23 developed the product. So, we designed the 23 So, RipTide's liquid uses synthetic Ο. 24 product; we created the product. It wasn't a 24 nicotine, correct? 25 preexisting product that we acquired. Very 25 Yes. Α.

Page 170 Page 172 1 L. WEXLER - CONFIDENTIAL 1 L. WEXLER - CONFIDENTIAL 2 Ο. I think you tried to explain this a 2 Α. At peak, we had six or seven people 3 little in the morning, but how is synthetic 3 involved in the R&D in the vape product. It's 4 nicotine different from nicotine salts? 4 embarrassingly small compared to large 5 MR. SOWLATI: Objection to form. 5 companies like Altria and Reynolds. 6 Α. In tobacco-derived nicotine, the 6 Do you have a sense of your annual 7 7 nicotine is extracted from the tobacco plant budget for R&D for vape products? 8 8 and then put into a solution for its use. In Α. I think I need to put this in a 9 synthetic nicotine, there is a chemical 9 little bit of context. With Vape Gate, what reaction -- I'm going to get a little bit out we saw with the CDC and the FDA announcements, 10 10 11 of my skis here because I'm not a chemist. I 11 we saw a fairly significant contraction in the 12 can give you some of my impressions. 12 marketplace. Our run rate of sales in our Essentially, it is -- okay. I know 13 13 vaping area was probably 150, \$160 million 14 there's always a risk of being colorful, but 14 annual run rate going into Vape Gate. After 15 it's a bit Frankensteinian where you have 15 Vape Gate, it came down fairly quickly to 16 these big tubes and reactors and all this 16 somewhere around plus or minus 100 million; 17 stuff, where you put together a series of 17 more minus than plus, I think. 18 chemicals, and there's a forced chemical 18 In response, what we did is, we had 19 reaction to combine them, and it creates a 19 to -- we severely cut back on our investment 20 nicotine. But the nicotine is not exactly the 20 in vape. We consolidated two operating 21 same as a nicotine derived from tobacco, 21 companies that we had, we consolidated four 22 that's extracted from a tobacco plant. It 22 distribution points to one, and we severely 23 actually has -- it actually is just a little 23 cut back on our R&D staff. That was in late 24 bit different. It has different properties November, early December of 2019. We 24 when it's consumed. 25 essentially had to get -- unfortunately, we Page 171 Page 173 L. WEXLER - CONFIDENTIAL L. WEXLER - CONFIDENTIAL 1 1 2 Tobacco-derived nicotine tends to 2 had to layoff about 10 percent of our staff. 3 get a little more immediacy in terms of --3 Thank you. this is from what consumers tell us. Again, I Let's change gears a little here 4 4 5 don't know the physiological -- what happens again. Sorry about that. Let's talk about physiologically or what happens chemically. your product distribution specifically to the 6 6 7 This is what consumers tells us. 7 C-store channel. I understand Turning Point Tobacco-derived nicotine tends to get a faster 8 8 Brands have other products, for example, 9 impact on the body, but synthetic nicotine is 9 Stoker's and moist snuff product that's sold 10 much more longer lasting. It stays active in 10 into the C-store channel. 11 the body for a longer period of time. That's 11 But how do you compare the Turning 12 what consumers have told us. 12 Point Brands' capability of distribution to 13 So, part of the NicTech technology 13 the C-store channel to major tobacco 14 is using the synthetic nicotine kind of 14 companies' distribution capabilities? 15 creates a different experience that, as I said 15 MR. SOWLATI: Objection to form. 16 before earlier this morning, that a subsection 16 MR. FORD: Objection. 17 17 of consumers seek to enjoy. Again, you'd have Α. Okay. So, can you describe what you 18 to talk to one of my scientists to explain why 18 mean by, "distribution capabilities"? Sure. Let me clarify. Your access 19 and how that works. 19 0. 20 20 Fair enough. Thank you. to stores and the spaces inside the stores. 21 21 Does Turning Point Brands have Α. Okay. So, let me take a step back 22 in-house research and development personnel? because I'm still trying to understand what 23 We do. 23 the question is. Α. 24 How many do you have on the R&D of 24 First thing is that, we can walk

into any store that the major guys can walk

25

vape product?

Page 174 Page 176 1 L. WEXLER - CONFIDENTIAL 1 L. WEXLER - CONFIDENTIAL 2 into. We don't have nearly as many people, 2 know, quite frankly, from time to time, we get 3 and so, you know, we have roughly 150 people 3 encroached upon by other companies. There's 4 in our sales department. At the time when I 4 been a couple of times when one of the 5 left Philip Morris, Altria, I think their 5 majors -- you know, we had in situation in one 6 number was something like 3,000, so it was 6 area where one of the majors was actually 7 taking our product and hiding it behind 7 very different. So, we cannot cover as many 8 8 signage in the rack. That's not incredibly 9 9 widespread. So our sales guy goes in, he Now, you know, you need to separate 10 distribution from selling, okay? Because we 10 talks to the store owner, talks about what we 11 11 actually don't deliver to C-stores, and for have to offer, talks about new products, 12 the most part, I did not believe that the 12 checks inventory to see if they have any majors do. They do in some cases, and there 13 13 inventory gaps they can fill. When I say 14 are some retailers that have their own 14 "he," I'm saying generically, this covers both 15 distribution centers, so they may deliver to 15 men and women. We do have women in our sales 16 those distribution centers. 16 force. In these politically-sensitive times, 17 We deliver to a trade class that's 17 I'm always careful about saying things like 18 called tobacco and candy wholesalers, for the 18 that. And they'll straighten out the racks, 19 most part. They're the bulk of our direct 19 they'll put up signage where possible. 20 customers. That's who we ship most of our 20 We also have another group of 21 product to. There are some other trade 21 people -- so we let 100 people go do that. We classes that are some of the other products 22 22 have another group of people that call on 23 that we won't talk about. They perform the 23 chains, and there are large chains and small 24 function of receiving the product, and they chains. That's a very different type of sell. 24 There you go in and you sell to the head of 25 actually ship it into the retail. So the Page 175 Page 177 L. WEXLER - CONFIDENTIAL 1 L. WEXLER - CONFIDENTIAL 1 2 retail actually orders from the tobacco and 2 merchandising, you make your sale, and they 3 candy wholesalers. They don't order directly 3 then planogram you into their store set. And from us. They perform the function of 4 4 in most cases, the store managers are then responsible for putting the product up on the 5 collecting taxes, paying the taxes to the 5 6 state, and collecting the money from the 6 rack. Now, people go in periodically and 7 retailer. 7 check and make sure that we're getting our 8 Now, at the same time, sort of a 8 space we're allowed. But in most chain 9 parallel system, our salespeople go into 9 stores, you can't put up signage. You 10 stores to try to create demand for the 10 actually have to buy the signage; you have to 11 product. So, our sales guys will walk into, 11 contract for the signage. let's say, an independent retailer, and 12 12 I think that $\operatorname{--}$ so when you talk 13 they'll talk to the store manager, talk to the 13 about our capabilities versus the other 14 store owner, explain the features and benefits 14 companies' capabilities, there's a couple of 15 of our products, pricing. They'll also go 15 different things. One is that we have far 16 through and check the dating. Some of our 16 fewer people, so we have far less breadth. I

perform as well.

They will also put up signage and they'll try to straighten out our areas in the stores. So, like, for instance, in the smokeless rack, we have the veins that are —the facings that are assigned to us. You

products are dated and we don't want our

consumers to have products that are dated

because they don't taste as good. They don't

17

18

19

20

21

22

23

24

25

I think that -- so when you talk about our capabilities versus the other companies' capabilities, there's a couple of different things. One is that we have far fewer people, so we have far less breadth. I think my sales force does an excellent job. If one of products is Zig-Zag rolling papers -- I once had a competitor come up to me and say, "How many salespeople do you have? You must have like 300, 400 salespeople because everywhere I go, I see Zig-Zag," and it was one of my proudest moments, this guy acknowledging that my guys do a great job. But we don't, we only have, like, a hundred

17

18

19

21

23

24

25

Page 178 Page 180 L. WEXLER - CONFIDENTIAL 1 L. WEXLER - CONFIDENTIAL 1 2 people on the street. 2 about a concept called weighted distribution, 3 I sort of lost my have track there a 3 which is basically the percent of where the 4 little bit. product is sold. We have been able to, very 5 5 successfully over the last couple of years, So, in any case, sp one difference 6 is the breadth that we can get and the number 6 increase our weight of distribution. So, 7 7 of people. And while we do get a lot of we're now in about 60 percent of the market. 8 breadth, it's very thin on depth, because if 8 But it's a struggle because, you know, 9 we're calling on one store, we can't call 9 remember, when you go back to that rack, another store. We only have X number of there's only a very limited space. And if 10 10 11 thousands of sales calls to allocate in a 11 they create more space, then they've got to 12 year. And if we go to 200,000 stores, which I 12 give more space to Altria and Reynolds. So, it's very self defeating. If we can't get one 13 don't even know if we can get to in a year, 13 14 you know, we can't revisit any other stores. 14 of those ten slots, where if we're in an open 15 So, we're in a constant process of allocating 15 rack where the space has been allocated, if 16 our sales calls among the various stores. 16 they accept four or five of our SKUs and if 17 The other thing we have is, we don't 17 the contracts require them to keep this 18 have that much market leverage and market 18 proportion of space for Reynolds and Philip 19 power. So, while in some segments, like in 19 Morris, it means they've got to give even more 20 space to the other companies which has a papers in the measured universe, in 20 21 principally a C-store area, we have about 35 21 consequence that they can't have as many 22 shares. Zig-Zag is a leading product. Most 22 products on the stores. It's a very 23 of the time, it's the leading product. It's 23 constraining thing for both the retailer and 24 certainly the leading premium brand in papers. 24 for competitors. 25 And in make your own cigar wraps, which is the And as I said, you know, we sell our Page 179 Page 181 L. WEXLER - CONFIDENTIAL 1 1 L. WEXLER - CONFIDENTIAL 2 outer shell of a machine-made cigar, you know, 2 product for about 40 percent less than the 3 we have 60-some-odd share. 3 majors. And so, the consumers are not getting So, in markets where there's free 4 access to a product that is tested as equally 4 5 and fair trade, we do very well. So, in as good and sells at a significant discount to 5 markets, like -- for instance, competitors in the majors because of this arrangement where 6 6 7 papers have been companies that are sort of 7 competition is limited because of the 8 our size and significantly bigger, but not as 8 requirement that Philip Morris and Reynolds 9 big as Altria and Reynolds. As you can see, 9 has. 10 we've done pretty well with our products in 10 Now, it's kind of interesting. I've 11 those particular segments. 11 done -- I was an operations research major in 12 In products like moist snuff, as I 12 college, so I'm sort of a little faster with 13 said, you know, Philip Morris and Reynolds 13 math. And one of my first jobs, which wasn't 14 between them have 85 share. Now, I think 14 on my resume that Adam went through earlier 15 we've done very well. We introduced our 15 this morning, was doing an inventory program 16 product in 2008. It has grown almost on a 16 for a small manufacturer of hand tools. And I 17 straight line since 2008. It actually 17 quickly learned that because of cycle stock 18 accelerated in the last two years. But it's 18 and safety stock and all that, you don't need been a struggle. I mean, we're still -- you 19 19 proportional inventory based on proportion of 20 know, in the last 13 weeks, our products have sales. No rational person has their inventory 21 gotten about 30-some-odd percent -- shipments 21 evenly divided by percent -- you know, percent 22 into 30-some-odd percents of stores. 22 of inventory is not percent of what your sales

are.

So, for instance, you know, one vein

can -- one facing can service, you know, a

23

24

23

24

25

Now, we do focus on the

larger-volume stores. So, you can see in our

earnings calls and things like that, we talk

Page 182 Page 184 L. WEXLER - CONFIDENTIAL 1 L. WEXLER - CONFIDENTIAL 2 Mr. Wexler. I have one more question 2 product that has one share or three share or to ask. Going back to the earlier discussion 3 five shares. You don't need five times as of synthetic nicotine, are you aware of any 4 much space just because something has five other companies that sell synthetic nicotine 5 share versus one share because these racks are products? 6 refilled multiple times during the week and I have heard of some companies that 7 because the turnover is, you know -- you have started using synthetic nicotine 8 either have some depth to them so there's 8 products. I can't name them at this time, but 9 turnover there. 10 I know that my guys have come and told me that 10 So, again, going back to my 11 nomenclature before, if you had natural 11 other companies are starting to sell them. 12 Do you know whether they are in open 12 selection and the retailer had free choice and he really wanted to get breadth and service 13 systems or closed systems? 13 14 The only ones I know of are in open Α. 14 the consumers walking in through the door, 15 systems. 15 they want to have a wider selection of 16 MR. LEE: Thank you. That's all for 16 product, but they can't because the 17 17 opportunity costs of bringing in these other now. I leave it to Mr. Sowlati to finish 18 his questions, and I will reserve $\ensuremath{\mathrm{my}}$ time 18 products and then giving, basically, not to potentially have follow-up questions. 19 useful space to Reynolds and Altria, the 19 Thank you. 20 opportunity cost of other products you can't 21 MR. SOWLATI: I'm just going to 21 put on the shelf, then, is too big an literally need five minutes, so if we can 22 opportunity cost. Not only are you selling 23 get back at 2:25, and I can't imagine I'm 23 against the majors -- first of all, we're 24 selling against the other competitors that are 24 going to have more than a few questions. 25 (Recess was taken.) trying to get the same space. 25 Page 183 Page 185 L. WEXLER - CONFIDENTIAL I. WEXLER - CONFIDENTIAL 1 FURTHER EXAMINATION 2 And then we're going against the 3 majors in trying to get the space carved out BY MR. SOWLATI: Ο. Okay, Mr. Wexler. Just a few more of their rack. We're also being constrained 4 questions, I promise. 5 by the way these contracts are designed from You told Mr. Lee that the reason 6 every other product in the store so that we RipTide lost momentum was because of 7 have to prove that we're going to be controversy around vaping and the FDA flavor 8 profitable enough for the retailer to take ban; is that right? 9 against all of that. 10 So, it's a heavy load. And quite 10 A. No. What I said was that those 11 things happened at the same time, and it's 11 frankly, the reason I'm so proud of my sales 12 sort of unknown what the potential of that 12 guys, I'm so proud of the way the product has 13 product could have been because of all the 13 performed, is that despite that, and I think 14 controversy. And then, certainly, losing the 14 in large part because we came out with a tub flavors made it much more difficult to compete 15 which doesn't fit into this confined space, 16 that we were able to get some distribution 16 with that product. 17 Okay. I'm just reading back your 17 because this is a tub format, that we've been 18 testimony. You said, "suddenly all of the 18 as successful as we are because the hurdle is momentum just stopped." That's what you so incredibly difficult. 19 20 testified happened after the controversy 20 Thank you. 21 around vaping and the flavor ban, right? 21 MR. FORD: Can I interject? Can we 22 Α. I did say that, yes. 22 go off the record for five minutes? I 23 Mr. Wexler, in addition to JUUL and 23 need to take a quick break. 24 Reynolds, Imperial Tobacco through myblu and 24 (Recess was taken.) 25 25 Japan Tobacco through Logic compete in e-vapor BY MR. LEE:

	Page 186		Page 188
1	L. WEXLER - CONFIDENTIAL	1	
2	for shelf space, right?	2	CERTIFICATE
3	A. Yes.	3	
4	MR. SOWLATI: I have no further		STATE OF NEW YORK)
5	questions.	4) SS.:
6	MR. LEE: Thank you. I have no		COUNTY OF SUFFOLK)
7	further questions. I think this concludes	5	
		6	I, KRISTI CRUZ, a Notary Public
8	the deposition. Thank you very much.	7	within and for the State of New York, do
9	MR. SOWLATI: Thank you very much,	8	hereby certify:
10	Mr. Wexler, for your time.	9	That LARRY WEXLER, the witness
11	(Time noted: 2:32 p.m.)	10	whose deposition is hereinbefore set
12		11	forth, was duly sworn by me and that
13		12	such deposition is a true record of the
14		13	testimony given by such witness.
15		14	I further certify that I am not
16		15	related to any of the parties to this
17		16	action by blood or marriage; and that I
		17	am in no way interested in the outcome
18		18	of this matter.
19		19	IN WITNESS WHEREOF, I have
20		20	hereunto set my hand this 1st day of
21		21	February 2021.
22		22	
23		23	Kristi Cress
24		24	KRISTI CRUZ
25		25	KKISII CKUZ
	-	23	
	Page 187		Page 189
1	_	1	Page 189
2	Page 187	2	***ERRATA SHEET***
	_		***ERRATA SHEET*** U.S. LEGAL SUPPORT
2	ACKNOWLEDGMENT	3	***ERRATA SHEET*** U.S. LEGAL SUPPORT 90 Broad Street
3	ACKNOWLEDGMENT	2	***ERRATA SHEET*** U.S. LEGAL SUPPORT 90 Broad Street New York, New York 10004
3	A C K N O W L E D G M E N T STATE OF NEW YORK)	2 3 4	***ERRATA SHEET*** U.S. LEGAL SUPPORT 90 Broad Street New York, New York 10004 212.750.6434
2 3 4 5	A C K N O W L E D G M E N T STATE OF NEW YORK)	3	***ERRATA SHEET*** U.S. LEGAL SUPPORT 90 Broad Street New York, New York 10004 212.750.6434 REF: 338990
2 3 4 5	A C K N O W L E D G M E N T STATE OF NEW YORK) :SS COUNTY OF)	2 3 4 5	***ERRATA SHEET*** U.S. LEGAL SUPPORT 90 Broad Street New York, New York 10004 212.750.6434
2 3 4 5 6 7	A C K N O W L E D G M E N T STATE OF NEW YORK) :SS COUNTY OF) I, LARRY WEXLER, hereby certify that	2 3 4 5	***ERRATA SHEET*** U.S. LEGAL SUPPORT 90 Broad Street New York, New York 10004 212.750.6434 REF: 338990 NAME OF CASE: MATTER OF ALTRIA GROUP AND JUUL LABS
2 3 4 5 6 7 8	A C K N O W L E D G M E N T STATE OF NEW YORK) :SS COUNTY OF) I, LARRY WEXLER, hereby certify that I have read the transcript of my testimony	2 3 4 5 6	***ERRATA SHEET*** U.S. LEGAL SUPPORT 90 Broad Street New York, New York 10004 212.750.6434 REF: 338990 NAME OF CASE: MATTER OF ALTRIA GROUP AND JUUL LABS DATE OF DEPOSITION: JANUARY 29, 2021
2 3 4 5 6 7 8	A C K N O W L E D G M E N T STATE OF NEW YORK) :SS COUNTY OF) I, LARRY WEXLER, hereby certify that I have read the transcript of my testimony taken under oath in my deposition of	2 3 4 5 6	***ERRATA SHEET*** U.S. LEGAL SUPPORT 90 Broad Street New York, New York 10004 212.750.6434 REF: 338990 NAME OF CASE: MATTER OF ALTRIA GROUP AND JUUL LABS DATE OF DEPOSITION: JANUARY 29, 2021 NAME OF WITNESS: LARRY WEXLER
2 3 4 5 6 7 8	A C K N O W L E D G M E N T STATE OF NEW YORK) :SS COUNTY OF) I, LARRY WEXLER, hereby certify that I have read the transcript of my testimony	2 3 4 5 6	***ERRATA SHEET*** U.S. LEGAL SUPPORT 90 Broad Street New York, New York 10004 212.750.6434 REF: 338990 NAME OF CASE: MATTER OF ALTRIA GROUP AND JUUL LABS DATE OF DEPOSITION: JANUARY 29, 2021 NAME OF WITNESS: LARRY WEXLER
2 3 4 5 6 7 8 9	A C K N O W L E D G M E N T STATE OF NEW YORK) :SS COUNTY OF) I, LARRY WEXLER, hereby certify that I have read the transcript of my testimony taken under oath in my deposition of January 29, 2021; that the transcript is a	2 3 4 5 6 7 8	***ERRATA SHEET*** U.S. LEGAL SUPPORT 90 Broad Street New York, New York 10004 212.750.6434 REF: 338990 NAME OF CASE: MATTER OF ALTRIA GROUP AND JUUL LABS DATE OF DEPOSITION: JANUARY 29, 2021 NAME OF WITNESS: LARRY WEXLER
2 3 4 5 6 7 8 9 10 11	A C K N O W L E D G M E N T STATE OF NEW YORK) :SS COUNTY OF) I, LARRY WEXLER, hereby certify that I have read the transcript of my testimony taken under oath in my deposition of January 29, 2021; that the transcript is a true, complete and correct record of my	2 3 4 5 6 7 8 9	***ERRATA SHEET*** U.S. LEGAL SUPPORT 90 Broad Street New York, New York 10004 212.750.6434 REF: 338990 NAME OF CASE: MATTER OF ALTRIA GROUP AND JUUL LABS DATE OF DEPOSITION: JANUARY 29, 2021 NAME OF WITNESS: LARRY WEXLER
2 3 4 5 6 7 8 9 10 11	A C K N O W L E D G M E N T STATE OF NEW YORK) :SS COUNTY OF) I, LARRY WEXLER, hereby certify that I have read the transcript of my testimony taken under oath in my deposition of January 29, 2021; that the transcript is a true, complete and correct record of my testimony, and that the answers on the record	2 3 4 5 6 7 8 9 10 11	***ERRATA SHEET*** U.S. LEGAL SUPPORT 90 Broad Street New York, New York 10004 212.750.6434 REF: 338990 NAME OF CASE: MATTER OF ALTRIA GROUP AND JUUL LABS DATE OF DEPOSITION: JANUARY 29, 2021 NAME OF WITNESS: LARRY WEXLER
2 3 4 5 6 7 8 9 10 11 12 13 14 15	A C K N O W L E D G M E N T STATE OF NEW YORK) :SS COUNTY OF) I, LARRY WEXLER, hereby certify that I have read the transcript of my testimony taken under oath in my deposition of January 29, 2021; that the transcript is a true, complete and correct record of my testimony, and that the answers on the record	2 3 4 5 6 7 8 9 10 11 12	***ERRATA SHEET*** U.S. LEGAL SUPPORT 90 Broad Street New York, New York 10004 212.750.6434 REF: 338990 NAME OF CASE: MATTER OF ALTRIA GROUP AND JUUL LABS DATE OF DEPOSITION: JANUARY 29, 2021 NAME OF WITNESS: LARRY WEXLER
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	A C K N O W L E D G M E N T STATE OF NEW YORK) :SS COUNTY OF) I, LARRY WEXLER, hereby certify that I have read the transcript of my testimony taken under oath in my deposition of January 29, 2021; that the transcript is a true, complete and correct record of my testimony, and that the answers on the record as given by me are true and correct.	2 3 4 5 6 7 8 9 10 11 12 13	***ERRATA SHEET*** U.S. LEGAL SUPPORT 90 Broad Street New York, New York 10004 212.750.6434 REF: 338990 NAME OF CASE: MATTER OF ALTRIA GROUP AND JUUL LABS DATE OF DEPOSITION: JANUARY 29, 2021 NAME OF WITNESS: LARRY WEXLER
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	A C K N O W L E D G M E N T STATE OF NEW YORK) :SS COUNTY OF) I, LARRY WEXLER, hereby certify that I have read the transcript of my testimony taken under oath in my deposition of January 29, 2021; that the transcript is a true, complete and correct record of my testimony, and that the answers on the record	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	***ERRATA SHEET*** U.S. LEGAL SUPPORT 90 Broad Street New York, New York 10004 212.750.6434 REF: 338990 NAME OF CASE: MATTER OF ALTRIA GROUP AND JUUL LABS DATE OF DEPOSITION: JANUARY 29, 2021 NAME OF WITNESS: LARRY WEXLER
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	A C K N O W L E D G M E N T STATE OF NEW YORK) :SS COUNTY OF) I, LARRY WEXLER, hereby certify that I have read the transcript of my testimony taken under oath in my deposition of January 29, 2021; that the transcript is a true, complete and correct record of my testimony, and that the answers on the record as given by me are true and correct.	2 3 4 5 6 7 8 9 10 11 12 13 14 15	***ERRATA SHEET*** U.S. LEGAL SUPPORT 90 Broad Street New York, New York 10004 212.750.6434 REF: 338990 NAME OF CASE: MATTER OF ALTRIA GROUP AND JUUL LABS DATE OF DEPOSITION: JANUARY 29, 2021 NAME OF WITNESS: LARRY WEXLER
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	A C K N O W L E D G M E N T STATE OF NEW YORK) :SS COUNTY OF) I, LARRY WEXLER, hereby certify that I have read the transcript of my testimony taken under oath in my deposition of January 29, 2021; that the transcript is a true, complete and correct record of my testimony, and that the answers on the record as given by me are true and correct. LARRY WEXLER	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	***ERRATA SHEET*** U.S. LEGAL SUPPORT 90 Broad Street New York, New York 10004 212.750.6434 REF: 338990 NAME OF CASE: MATTER OF ALTRIA GROUP AND JUUL LABS DATE OF DEPOSITION: JANUARY 29, 2021 NAME OF WITNESS: LARRY WEXLER
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	A C K N O W L E D G M E N T STATE OF NEW YORK) :SS COUNTY OF) I, LARRY WEXLER, hereby certify that I have read the transcript of my testimony taken under oath in my deposition of January 29, 2021; that the transcript is a true, complete and correct record of my testimony, and that the answers on the record as given by me are true and correct. LARRY WEXLER Signed and subscribed to before	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	***ERRATA SHEET*** U.S. LEGAL SUPPORT 90 Broad Street New York, New York 10004 212.750.6434 REF: 338990 NAME OF CASE: MATTER OF ALTRIA GROUP AND JUUL LABS DATE OF DEPOSITION: JANUARY 29, 2021 NAME OF WITNESS: LARRY WEXLER
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	A C K N O W L E D G M E N T STATE OF NEW YORK) :SS COUNTY OF) I, LARRY WEXLER, hereby certify that I have read the transcript of my testimony taken under oath in my deposition of January 29, 2021; that the transcript is a true, complete and correct record of my testimony, and that the answers on the record as given by me are true and correct. LARRY WEXLER Signed and subscribed to before	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	***ERRATA SHEET*** U.S. LEGAL SUPPORT 90 Broad Street New York, New York 10004 212.750.6434 REF: 338990 NAME OF CASE: MATTER OF ALTRIA GROUP AND JUUL LABS DATE OF DEPOSITION: JANUARY 29, 2021 NAME OF WITNESS: LARRY WEXLER
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	A C K N O W L E D G M E N T STATE OF NEW YORK) :SS COUNTY OF) I, LARRY WEXLER, hereby certify that I have read the transcript of my testimony taken under oath in my deposition of January 29, 2021; that the transcript is a true, complete and correct record of my testimony, and that the answers on the record as given by me are true and correct. LARRY WEXLER Signed and subscribed to before me, this day	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	***ERRATA SHEET*** U.S. LEGAL SUPPORT 90 Broad Street New York, New York 10004 212.750.6434 REF: 338990 NAME OF CASE: MATTER OF ALTRIA GROUP AND JUUL LABS DATE OF DEPOSITION: JANUARY 29, 2021 NAME OF WITNESS: LARRY WEXLER PAGE LINE FROM TO REASON
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	A C K N O W L E D G M E N T STATE OF NEW YORK) :SS COUNTY OF) I, LARRY WEXLER, hereby certify that I have read the transcript of my testimony taken under oath in my deposition of January 29, 2021; that the transcript is a true, complete and correct record of my testimony, and that the answers on the record as given by me are true and correct. LARRY WEXLER Signed and subscribed to before me, this day	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	***ERRATA SHEET*** U.S. LEGAL SUPPORT 90 Broad Street New York, New York 10004 212.750.6434 REF: 338990 NAME OF CASE: MATTER OF ALTRIA GROUP AND JUUL LABS DATE OF DEPOSITION: JANUARY 29, 2021 NAME OF WITNESS: LARRY WEXLER PAGE LINE FROM TO REASON
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	A C K N O W L E D G M E N T STATE OF NEW YORK) :SS COUNTY OF) I, LARRY WEXLER, hereby certify that I have read the transcript of my testimony taken under oath in my deposition of January 29, 2021; that the transcript is a true, complete and correct record of my testimony, and that the answers on the record as given by me are true and correct. LARRY WEXLER Signed and subscribed to before me, this day	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	***ERRATA SHEET*** U.S. LEGAL SUPPORT 90 Broad Street New York, New York 10004 212.750.6434 REF: 338990 NAME OF CASE: MATTER OF ALTRIA GROUP AND JUUL LABS DATE OF DEPOSITION: JANUARY 29, 2021 NAME OF WITNESS: LARRY WEXLER PAGE LINE FROM TO REASON
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	A C K N O W L E D G M E N T STATE OF NEW YORK) :SS COUNTY OF) I, LARRY WEXLER, hereby certify that I have read the transcript of my testimony taken under oath in my deposition of January 29, 2021; that the transcript is a true, complete and correct record of my testimony, and that the answers on the record as given by me are true and correct. LARRY WEXLER Signed and subscribed to before me, this day of , 20	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	***ERRATA SHEET*** U.S. LEGAL SUPPORT 90 Broad Street New York, New York 10004 212.750.6434 REF: 338990 NAME OF CASE: MATTER OF ALTRIA GROUP AND JUUL LABS DATE OF DEPOSITION: JANUARY 29, 2021 NAME OF WITNESS: LARRY WEXLER PAGE LINE FROM TO REASON
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	A C K N O W L E D G M E N T STATE OF NEW YORK) :SS COUNTY OF) I, LARRY WEXLER, hereby certify that I have read the transcript of my testimony taken under oath in my deposition of January 29, 2021; that the transcript is a true, complete and correct record of my testimony, and that the answers on the record as given by me are true and correct. LARRY WEXLER Signed and subscribed to before me, this day of , 20	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	***ERRATA SHEET*** U.S. LEGAL SUPPORT 90 Broad Street New York, New York 10004 212.750.6434 REF: 338990 NAME OF CASE: MATTER OF ALTRIA GROUP AND JUUL LABS DATE OF DEPOSITION: JANUARY 29, 2021 NAME OF WITNESS: LARRY WEXLER PAGE LINE FROM TO REASON

		55:14,22	
Exhibits	\$	143:15	2
<u> </u>		11:20	
EX 0001 Larry	\$160	96:18	2
Wexler 01292	172:13	12	17:22
1	\$17	25:7 55:24	2.4
4:9 13:10	140:9	121:10	35:20,23
EX 0003 Larry	\$35	141:17,20	36:14,24
Wexler 01292	109:11,13	12-002	37:24 126:22
1	\$6	142:3	20
4:10	56:25	12:30	7:13 39:22
EX 0004 Larry		146:13	103:25
Wexler 01292	0	13	150:15,18,24
1		73:8 74:6	157:25
4:12 80:24	009	158:24	158:11
EX 0005 Larry	74:12	179:20	200,000
Wexler 01292		13-009	178:12
1	1	74:7	200-some
4:13		13009	158:20
EX 0007 Larry	1	73:12	2003
Wexler 01292	13:10 15:23	15	17:3
1	16:4 52:18,	88:13	2007
4:14	25 78:8	150	138:5,14
EX 0008 Larry	114:15	172:13 174:3	2008
Wexler 01292	167:12,14,16	16th	61:15
4:15	1.4	138:20	179:16,17
	77:18,20	139:17	2009
EX 0009 Larry Wexler 01292	78:6 95:22	17	61:15,16
wexier 01292	1.8	27:23 123:3	137:21
4:16 129:11	35:19,23	133:6 143:25	2013
EX 0010 Larry	36:13,24	144:17	148:17
Wexler 01292	37:24	18	2014
wexier 01292	10	59:13 62:10	33:2
4:17 136:8	41:12 121:10	134:20	2015
EX 0011 Larry	136:8 173:2	180	33:2
Wexler 01292	100	59:12	2016
1	66:25 67:4	19	134:11
4:19 143:15	71:12 172:16	115:7	138:2,10
EX 0012 Larry	176:21	1998	151:25
Wexler 01292	10128	16:12,15	152:5,7,10
1	129:23	17:3 39:25	2017
4:18 141:17	10:10	106:13	152:15
EX 0013 Larry	52:5	1:18	2018
Wexler 01292	11	147:3	29:5 33:2
1	36:7 42:6	1st	46:16 133:11
4:11	44:18 46:11	75:8	134:10,16
		į	i .

2010	75.7	72.21	F0
2019	75:7	72:21	50
29:6 52:17,	3,000	4.8	29:17 51:13
18,23,24,25	174:6	72:4,21	154:7
53:7 58:16	3.6	40	5201
59:2 61:22	72:5	25:7 116:13	136:14
62:3,20	3.99	181:2	53
75:7,9 81:2,	95:24	400	156:22
8,9,19 83:14	30	177:21	54
114:15,17	51:16 80:3	4005	157:14
123:8 124:2,	150:19	81:24	55
7,14 126:8,			
15 161:19	30,000	4007	51:13 153:25
165:6 166:5	150:15,21,24	85:24	
172:24	30-some-odd	45	6
2020	179:21,22	102:16	
13:11 46:17	300	48	6
127:7 139:3,	109:13	153:25 154:7	30:15 56:14
25 140:15	177:21	157:5,6	76:8
141:22 142:6	3005		6,000
165:12 166:4	53:17,23		55:16 56:3
	3006	5	60
2022	56:13 75:12	5	83:9 180:7
138:22	3007	29:8 36:9,	60-some-odd
22	77:13	-	179:3
39:24 97:13,		12,23 38:2	
15 106:11,14	3010	43:2 70:25	64
110:17,22	79:15,19	72:15,20	157:6,7,8,
111:2 112:22	31	88:19 90:16	12,24 158:3,
113:6 160:12	81:8	97:21,23	10,23 159:7,
23	32	98:2,16	16
106:14 123:7	156:23	101:17	64-SKU
25	157:5,6	103:10 104:6	160:8
80:3 106:4	158:25	126:22	
250	35	135:24 167:8	7
142:9	7:7 178:21	5,000	
26	36	66:10	7
13:11 106:4	159:2	5-002	30:16 34:25
27		91:3	40:18
141:22		5-0021	114:12,15
	4	91:2	7,000
28		5-005	115:14,21
114:2	4	90:2	
29	25:3 80:24,	5-021	7-006
133:21	25 81:7	91:4,5	114:25
	4,000	5.2	7-eleven
3	28:10 55:15,	72:21	130:2
	16 56:3		135:16,17,
3	61:17	5.5	18,25
23:17 52:19	4.6	72:5	7-milliliter

95:20	35:11 44:14 56:3 62:14	accurate 29:25 54:16	addition 45:7 135:11
	164:20	76:16	additional
8	able	ACE	83:18 115:22
	26:23 29:14	28:13 47:13	155:24
8	55:14 60:4	92:14	additive
38:10,12	88:15 108:6	achieve	45:2
123:8 142:6	115:21	55:18	_
8-003	116:15		address
123:23	128:17	acid	14:25 84:6
8-024	129:25	43:3 44:25	adjust
124:22	130:12,17	45:2,7	100:9
8-025	134:23,25	47:12,15,16,	adjusted
125:9	135:6 180:4	20 70:12,15,	66:7
8-026	183:16	17	adjustment
126:19		acknowledge	101:15
8-027	above	5:4,7	administered
127:2	55:7 116:12	acknowledging	5:8
8-029	absolutely	177:24	Administratio
	163:2	acquire	n
127:20	absorption	167:21 169:4	142:8
8-031	43:4	acquired	administrativ
128:20	absurd	19:2 148:22,	
80	105:25	25 153:4	e
29:19	accelerated	167:19,25	8:4
85	179:18	acquisition	adopting
156:25 157:8	accept	7:14 149:11	56:21
179:14	180:16		adult
8th		166:3	77:23,25
139:19 142:4	access	across	79:2
	27:13 105:8,	57:17 58:9	advantage
	15 115:20	158:19	50:10
9	118:23 119:6	active	advantages
	120:24	171:10	42:14
9	134:23,25	actively	advertisement
129:11	135:4,6,9,10	57:3	73:10 126:5
9.99	156:12	activity	advised
95:20,23	160:23	158:7	107:15
99	161:10	acts	
92:5,15	173:19 181:4	70:11	affect
125:16 126:6	accessed		11:23 27:20
	129:13,20	actual	afternoon
	130:8	67:16	147:8
A	accessible	Adam	age
- 1-16	41:22	6:15 181:14	51:11,12,13
a-half-an-	account	adapt	153:24
hour	29:11 49:7	63:14	154:2,6
102:16	51:2 123:7,	add	ago
ability	19 128:25	21:15 38:7	30:17 39:24
11:23 22:10	19 120.23	95:10 116:9	106:11
			100.11

110:17 111:2	59:15,16,17	149:18	appropriate
112:16,23	107:2 113:5,	answered	50:10 119:19
113:20	17 149:19	38:5 112:15	120:14
136:11	154:20	answering	approximately
agree	156:22	120:11	115:14
34:9,16	157:9,12		148:14
57:14 70:23	159:12,14	answers	
	172:5 174:5	10:15 71:10	April
90:21	179:9 180:12	72:19 145:20	128:23
104:10,19	l .	anti-	area
105:6,13	182:19	competitive	60:8 155:12,
agreement	amount	7:9	15,18,22
5:15,16	26:9 30:3,4	anybody	172:13 176:6
27:13 133:2,	35:24 37:10,	39:14	178:21
4	11,16 40:10	anymore	areas
ahead	41:4,6 50:19	16:20 29:3	147:15
13:9 27:11	60:16,17	135:23	175:22
48:23 119:16	61:18 100:9		Argumentative
120:18	109:22	anyone	132:8
149:17	155:15	169:3	
air	amusing	apologize	around
100:9	17:12	139:20,21	36:5 51:17
	analysis	Apparently	78:7 101:24,
align	94:23 139:6	38:24 124:17	25 102:24
109:19	156:20	126:11	133:9,10
allocate	l .	appeal	147:14 154:7
178:11	157:22	46:10	155:24
allocated	159:13		172:16
110:9 180:15	announce	appeared 33:9 59:4	arrangement
allocating	112:9		5:13 127:10
178:15	announced	appears	181:6
allow	142:6	89:19 94:12	asked
33:6 120:6	announcements	122:17	13:17 14:23,
	172:10	apples	24 38:4
allowed	annual	95:18,21	64:23 98:3
45:7 111:21	172:6,14	application	1
135:20,21	,	138:23	105:13
177:8	answer	140:20,24	110:25
alternative	10:10,12,16	applications	111:14
31:23 134:4	11:4,17	139:4,5	132:11 148:8
alternatives	21:14 34:15	140:14 142:8	168:22
41:8 57:4,9,	37:5 48:23		asking
15,17	57:23 69:14	apply	8:7 10:9,25
Alto	90:10 94:8	157:23 160:6	34:14,16
28:6,9 47:13	99:5 104:17	appreciate	37:7 48:25
91:10,24	116:25	6:20 147:21	63:24 84:19
•	117:15	approach	94:10 98:24
Altria	119:14,22	96:7	103:19
6:16 7:4,7,	120:10,19	approached	105:18
8,14 8:5,24	131:5,22,23	13:25 169:3	110:18
14:19,20	134:13	15 25 105 5	133:23
	_		
	I	I	I

assigned	average	basic-	41:9 46:19
175:25	29:22 51:11,	109:2	47:14 51:20
associated	13,17 153:24	basically	58:18 62:5,
32:6,20	154:7 158:5	23:6,13	18 69:2
assortment	aware	40:12 49:15	71:24 72:8
142:10,23	7:16,19,23	50:23 84:21	79:3 82:13
assume	8:2,3,9 9:8	87:3 110:6	84:7 86:14
166:16	11:25 131:8,	116:6 138:4,	95:4 97:25
167:15	16 132:15	11 156:8	140:5 151:13
	134:15 137:2	160:22	174:12
assuming		166:15 180:3	believed
52:15		182:18	61:23 83:14
assured	В	batteries	believer
86:2		33:7,11	62:21
attach	B2c	42:19 100:5	benefits
22:19	26:8 51:12	battery	175:14
attached	152:13,18	_	
22:15	153:22	20:9 22:13,	benzoic
attention	back	16 35:15,24 37:9 40:21	43:3 44:24,
26:9 42:4	22:4 26:21	41:5 60:15	25 45:2,7
attorney	40:18 49:25	71:25 99:20	47:12,14,16,
9:16,17	57:13 58:16,	100:22,25	20 70:12,15,
147:12	25 65:5	-	17
attorneys	67:17 72:18	Beach	Berry
5:2 12:3	75:5,9 93:24	32:13 143:5	126:21
attract	97:10 103:17	bearing	Besides
96:6	111:9 118:10	105:23	20:23
attributed	119:2,9	Beast	best
44:13	120:17	23:20 152:2,	98:18
	122:15	3,10	better
attributes	129:16	Beast's	58:19,22
83:23 84:9, 21	147:18	24:12	62:19,22
	156:10 165:4	began	63:10 65:12
August	172:19,23	133:24	66:15,20,24
127:6	173:21 180:9	begin	67:2 68:9
138:19,20	182:10	30:19 143:22	70:5 71:3,6,
139:17,19 161:19	background	beginning	7,13,14,17
	6:25 39:19	43:19 122:15	130:24
authorization	ballpark	151:25	big
137:17	29:14	behavior	33:16 34:5
138:8,16	banned	99:2	42:3 60:24
authorized	164:3,6	behind	162:18
135:18 136:4	base	59:15 107:9,	170:16 179:9
available	150:17 164:6	12 176:7	182:21
6:18 64:3	based	belief	bigger
129:8 155:10	99:20 153:13	114:5	33:11 53:22
156:14	156:11	believe	54:7 55:8
157:11	181:19	28:4 34:2	59:9 101:22
		70.1 JI.7	179:8

	_		
biggest	box	briefly	152:2,4,13,
40:17	94:11	8:21 30:16	16,19 153:2,
billion	bracket	bright	4
56:25	154:2	107:25	business'
bills			30:12
	brand	bring	
17:14	7:20 83:9	96:10 99:14	businesses
bit	85:5 96:10	bringing	28:20
14:14 23:15,	100:3 104:13	182:17	busy
16 99:12	149:13	Brittani	6:18
106:6 120:21	178:24	7:24 143:12	buy
140:11	branded	broad	22:12,15
147:14 148:4	48:10 59:12	39:19 69:8	40:9 84:24,
154:14	brands	132:22,23	25 93:13,20
156:16,18	6:10 8:7	142:10,23	99:22 100:16
170:10,15,24	17:25 57:5	158:5	105:24 149:6
172:9 178:4	58:13,19,22,		151:15,16
	23 62:19	broad-ranging	177:10
blank 19:13	76:14 85:8	14:10	
	1	broader	buying
bloodstream	151:23	101:7 153:8	100:20 131:6
43:14	152:7,22	broke	
blow	153:5	124:12	С
61:4	159:14,20,25	Buc-ee's	
Blue	160:5,19	127:21,22	C-STORE
126:20	161:2 166:24	128:3,22	39:13 99:21,
body	167:19	-	-
38:21 70:20,	171:21 173:8	135:11	24,25 108:7
-	Brands'	budget	109:2,16
21 171:9,11	153:15	172:7	155:2 156:5,
body's	173:12	build	7 167:2,4
43:3	breadth	150:3	173:7,10,13
bottle	1	building	178:21
101:24	159:21	117:8 165:8	C-STORES
bottles	160:16	builds	13:19 14:14
74:14 102:2	177:16	43:20	34:7 46:23
bottom	178:6,8		47:6,8 62:8
53:17,21,25	182:13	bulk	100:18
76:10,21	break	18:8 174:19	106:22 114:5
81:25 85:19	11:15,16,18	bunch	116:15 121:6
1	51:25 96:15	87:8	132:13,24
117:5 162:21	130:12,17	bushel	148:10
bought	143:8 145:25	86:13	151:4,5,16
23:11 59:18	146:6 183:23	business	154:12,17,
86:23 133:3	breaking	13:18 14:12,	21,24 167:9
149:5,6	121:17,18	13 24:12,13,	174:11
150:10	Breakthrough	16,17 27:2	
151:25		28:11,18	cable
152:10,11,	74:9,16	32:12 39:16	17:8
15,17 165:7	brick	111:11 112:7	calculate
	25:14,24		166:18
	163:20	133:15,16	

calculated	63:8	CBD	changed
29:21	capsule	54:11 117:24	15:15 61:13
calculation	22:9	CBDS	66:8 107:7
25:12	capture	80:4	changes
calculations	15:23	CDC	103:18
106:14	card	163:8,22	138:23
calendar	17:14	172:10	changing
113:24	care	centers	57:2 151:22
call	135:8	174:15,16	154:11
14:16 18:19	careful	cents	channel
22:13 23:4	176:17	92:5,16	17:10,12
24:7 42:4		125:16 126:6	156:8 167:2,
52:17,25	carries	CEO	5 173:7,10,
53:8,11	35:16	6:12 53:12	13
59:23 75:8	carry		channels
79:17 103:7	31:9 32:6	certain	48:12 156:7
109:7	61:16	10:24 43:24	charging
114:14,17	101:23,25	50:19 104:3	50:17,18
115:7 130:22	102:3,24	111:19	chart
153:9 158:6	carrying	135:22 150:13	93:4 124:3,4
161:19	126:20		1
166:20	cartridge	certainly	135:2
176:22 178:9	22:14,15	34:6,7 55:10	chases
called	cartridges	78:19 121:22	61:4
5:20 17:17	87:14	141:8 162:3	chat
21:8 32:12	carve	163:13	11:10 12:4,
59:18 61:3	106:20	165:18	16,19 52:9
86:23	carved	178:24	114:11
108:12,13	183:3	certainty	143:14
138:6,15	case	28:14	check
144:10 148:7	7:3,17 8:5	chain	175:16 177:7
149:3 174:18	124:17	86:17 116:18	checks
180:2	160:13,25	124:19,25	176:12
	178:5	125:6 127:24	chemical
calling	cases	136:3	170:9,18
178:9	49:17 136:2	155:13,14,	chemically
calls	174:13 177:4	16,17 156:21	171:6
53:13 76:17	categories	159:2 177:8	chemicals
178:11,16	59:24	chains	70:4 170:18
179:25	category	115:15 155:2	chemist
candy	61:13	176:23,24	69:17,20
174:18 175:3	142:11,24	chance	170:11
capabilities	156:17	53:2 141:24	chemistry
173:14,18	160:19	change	70:14,20,21
177:13,14		15:12 101:17	chew
capability	caused	109:18 156:3	121:7
173:12	163:7	173:4	
capable	causing		Chief
	163:12		114:25
t			



Chinese	137:22 155:5	close	college
19:14,18	161:13	13:3 25:24	16:6,7
62:25	162:16	27:22 44:21	181:12
choice	Circle	62:3 140:6	colloquy
182:12	136:20	152:23	120:21
choices	circling	closed	colorful
32:18	125:13	18:22,24,25	170:14
		21:4,5,7,10,	
choose	Ciro	19,24 22:2,	combination
145:2	128:10,16,19	5,7,8 24:24	37:9,10
chose	clarification	25:8 26:17,	69:24 71:24
41:8 68:3	149:9	19 29:10,16	72:8,22,24,
168:14	clarified	30:3,5,9	25 77:9,10
Cigalike	66:23	41:13 47:3	83:22 84:22
30:20,21	clarify	56:24 57:18	combinations
32:12 34:3	48:13 144:8	99:10,15,16	100:4
51:7,10,11	173:19	100:14	combine
59:5 148:6,	clarity	101:8,19,22	170:19
11	139:16	102:17,21,24	combined
Cigalikes	class	142:13,25	35:24 41:5
23:4,16	132:22,23	143:3 151:12	71:25 106:20
30:17 31:3,6	174:17	165:10	combining
32:5,9,13,22	classes	closely	70:3,7
33:5,9,19,	118:8 174:22	43:16	come
22,25 34:3,	classic	closer	13:14 14:21
5,8 35:2,7,	96:7	43:4,7 44:8	47:8 109:4
12 38:17	classificatio	45:12,14	117:11
40:20 42:18	n	closest	153:15
47:3,9 51:3,	23:4	45:22	159:16
5 57:18	classify		177:19
60:15	24:25	club	comes
cigar	clause	108:10,14,	11:14 39:21
178:25 179:2	105:22	18,22 110:9,	68:24 72:14
cigarette	clear	10,11 111:12	74:25 78:4,
23:5,7	10:22 15:15	clubs	12,13,14
30:23,24	20:13 21:17	61:3	169:12
31:2,7,14,17	25:10 48:8	coaching	comfortable
32:10,18	49:4 61:22	120:13	32:9,15
43:5,8,13,	62:17 67:11	code	103:16
17,25 44:9,	95:2 106:10,	129:22	comments
15,21 45:12,	12 119:17	coils	114:22
15,17,23,24	135:10	100:6 101:4	118:20
113:11		colleague	commercial
cigarettes	clearly 40:24	7:24	40:4 44:7
31:10,13		colleagues	57:5 58:13
32:3,7,17	clerk	143:12	104:21
45:18 60:3	102:17	collecting	Commission
111:12,15	click	175:5,6	7:4 147:12
112:8 134:4	99:23		, 1 11, 12

Gandary 25, 2021				
Commissioner	compare	complete	33:1 34:1	
134:16	62:9 95:5,21	11:24 21:14	35:1 36:1	
commitment	173:11	110:19 111:4	37:1 38:1	
127:5 128:23	compared	complex	39:1 40:1	
commodity	42:14,18	85:8,9	41:1 42:1	
17:19	54:10 90:22	component	43:1 44:1	
communicate	172:4	19:21 40:8	45:1 46:1	
68:2,4	compares	compounds	47:1 48:1	
communication	95:24	144:24	49:1 50:1	
12:3	comparing	computer	51:1 52:1	
communication	35:7 94:22	129:14	53:1 54:1	
s	95:18	concentrated	55:1 56:1	
107:20	comparison	60:22	57:1 58:1	
compact	92:8,12	concentration	59:1 60:1	
42:15	compelling	35:3,6,20	61:1 62:1	
companies	78:21,22	36:23 70:25	63:1 64:1	
16:10 55:11	79:5,9 86:7,	concentration	65:1 66:1	
64:7 108:5	9 92:18		67:1 68:1	
114:4 133:2	compensating	s 36:12	69:1,13 70:1	
154:25	109:20		71:1 72:1	
155:4,8	compete	concept 108:11 180:2	73:1 74:1	
157:14	60:9 91:15,		75:1 76:1	
158:2,11	22 106:17	concern	77:1 78:1	
172:5,21	competing	115:19	79:1 80:1	
176:3 179:7	91:16,25	concerned	81:1 82:1	
180:20	competition	150:2 164:14	83:1 84:1 85:1 86:1	
companies'	49:17,18	concerns	87:1 88:1	
158:14	92:3 181:7	116:20	89:1 90:1	
173:14	competitions	120:23	91:1 92:1	
177:14	61:3	conducted	93:1 94:1	
company		7:17 13:20	95:1 94:1	
6:19 16:6	competitive	104:2	97:1 98:1	
17:8,11,13,	57:20,25	confidence	99:1 100:1	
18,25 21:8	63:13,15,23, 24	66:18	101:1 102:1	
23:11 54:2		confidential	103:1 102:1	
64:4 68:15	competitively	5:1 6:1 7:1	105:1 104:1	
109:4 111:20	82:23	8:1 9:1 10:1	107:1 108:1	
137:3 148:7,	competitor	11:1 12:1	109:1 110:1	
21,23,25	112:9 177:19	13:1 14:1	111:1 112:1	
149:4,7,12	competitors	15:1 16:1	113:1 114:1	
169:4	9:5 54:10	17:1 18:1	115:1 116:1	
company-	55:10 59:8	19:1 20:1	117:1 118:1	
operated	83:18 91:13	21:1 22:1	119:1 120:1	
152:23	109:14 114:9	23:1 24:1	121:1 122:1	
comparable	121:20 179:6	25:1,21 26:1	123:1 124:1	
94:19	180:24	27:1 28:1	125:1 126:1	
	182:24	29:1 30:1	127:1 128:1	
		31:1 32:1	129:1 130:1	
	•	· '		

131:1 132:1 133:1 134:1	connotation 31:17	100:14 105:3 118:20 131:5	130:20,22 154:24 172:9
135:1 134:1	consent	145:5 150:17	continue
137:1 138:1	5:13,17	160:22 164:5	128:25 146:6
139:1 140:1	· ·		
141:1 142:1	consequence	consumer's	continuing
143:1 144:1	180:21	160:23 161:9	120:2
145:1 146:1	consequences	consumers	continuous
147:1 148:1	163:21,25	34:22 37:17,	59:3
149:1 150:1	consider	19 39:3	continuously
151:1 152:1	35:19,23	41:7,15,18	121:9
153:1 154:1	47:25 98:4,	42:21 43:23	contract
155:1 154:1	25 169:15	46:9 56:20	19:9,12
157:1 158:1	considered	57:3 63:14	20:22 107:8
159:1 160:1	16:16	65:14,16,23	112:2,22,25
161:1 162:1	consistently	66:9,10,19,	113:4,8,14,
163:1 164:1	66:3	25 67:4	17 127:16
165:1 166:1	consolidated	68:17 70:21	149:22 155:6
167:1 168:1	172:20,21	71:16 72:6,	156:15 158:6
169:1 170:1	constant	11,23 83:17,	177:11
171:1 172:1	178:15	25 84:8,9, 10,14,16,20,	contracted
173:1 174:1	constantly	24 91:16	121:19
175:1 176:1	13:4	92:19,22	161:17
177:1 178:1	constituents	96:6 102:13	contraction
179:1 180:1	139:10	103:14	172:11
181:1 182:1	constrained	105:7,14	contractor
183:1	183:4	130:25 131:6	20:25
confined	constraining	153:24 154:6	contracts
183:15	180:23	159:23	60:2,8 62:7
confirm	constraint	171:4,7,12,	106:7,8,18,
17:24 124:2,	159:11	17 175:18	19 107:6,7,
10,13 141:10	constructed	181:3 182:14	12 108:11,13
conflicts	142:20	consuming	111:24 112:6
26:7		145:6	113:3,11,12
confused	consultant	consumption	114:7 149:21
54:4	16:10 17:2	65:10	154:20,23,25
confusing	consume	contained	155:7 156:3,
132:10	65:2	22:18 157:2,	6 158:13
confusion	consumed	3	161:12
67:13,18	170:25	container	165:17,19,22
140:23	consumer	22:10	180:17 183:5
	20:11 22:23		contribute
congregate 103:15	35:13,17,22	78:23 79:11	35:21
connected	41:3 45:7	80:18 81:12,	contributed
20:10	64:10 70:6,8	14 83:7 93:9	34:10,17,20
	71:7 77:23	99:5 119:10,	41:2
connection 8:19 12:7	78:3 79:2 83:20 84:23	15 121:4,22	controversy
0.13 17.1	91:6 93:13	122:23	163:22
	71.0 73.13		
	<u> </u>		

164:24	182:20,22	covers	104:4 153:14
convenience	costs	72:9 176:14	174:20
30:3,10	50:21	COVID	customize
55:16 78:15	144:15,21	161:21	168:22
114:2 115:15	182:17	162:13	customizing
118:7	counsel	create	33:12
124:19,25	5:12 6:16	33:16 42:3	cut
125:6 131:18	7:21 8:6	43:7 45:11	120:5,8
132:5,17	10:23 11:2	175:10	144:15,21
137:12,15	14:2 15:8	180:11	172:19,23
154:13	111:7 120:3,	created	cycle
convenient	4 143:23	35:15 67:13	181:17
99:21	147:14	107:3 108:10	cylinder
conversation	149:19	126:14 160:8	30:23
10:6 14:9,10	154:19	167:24	30.23
conversations	counselors	168:16	
107:21,23	120:15	creates	D
COO	counter	84:22 170:19	_
76:13	109:9,10	171:15	data
cooperate	162:6	creating	131:24,25
9:10	counters	43:4 113:2	132:21 133:7
Copenhagen	109:16	150:16	137:14
73:5	couple	creature	139:7,11
	8:13 45:21	166:10	154:5,8
corner	56:18 137:6,	credit	158:16,17
53:18	11 138:20,24	17:14	database
corporate	165:14 176:4		51:16
25:7 82:18	177:14 180:5	crossed 73:19	date
135:19	coupled		29:4 113:15,
correct	79:3	crumbs	23 117:7,9,
31:10 58:24	course	121:20	21 126:13
140:4 144:11	78:25	Crunch	133:25
148:23		126:21	134:22
149:14	court	curious	138:19,24
151:7,24	5:2 10:2,7,	39:10 111:19	139:2,3,17
152:9,24	14	current	dated
153:6	cover	6:11	52:17,25
169:21,22,24	14:21 122:16	curve	75:8 81:8
correctly	147:16 155:7	43:11,16,17	114:14 123:7
15:23 27:24	159:10 174:7	44:4 45:14	141:21
78:7 169:19	coverage	Cushman	175:17,18
correlation	159:17	7:24 143:12,	dates
134:8	covered	22 144:2,4	139:22
cost	142:10,23	Cushman's	dating
62:15 86:19	147:15	143:25	175:16
103:6,7,9	166:22	customers	day
112:12 116:4	covering	50:3,11	58:3 121:16
160:24	142:9	97:20 98:13	158:17

days 136:11	declare 5:9	demonstrating	develop 19:17,24
138:20	decline	department	67:6 168:13
144:11	33:8	174:4	developed
de-emphasize	declined	depending	19:2,18
165:2	34:4	95:15 106:13	167:23
deals	decorated	deposition	168:13 169:2
153:22	30:25	5:3,5,6 8:16	developing
December	decrease	9:9,14 11:9,	168:9
172:24	32:23	13 83:20	development
decent	dedicated	99:13 119:21	86:3 168:8,
62:13	101:11	120:15	23 171:22
decide	deem	depositions	device
100:21 102:7	137:24	9:23	20:8 67:14,
169:10	deemed	depth	16 75:14,21
decided	138:11	178:8 182:8	76:22 92:5,
16:19,22	deeming	derive	15 93:10,13,
64:19 129:22	138:3	119:9	15,16 94:11
141:8	deeper	derived	99:22 100:20
deciding	109:25	169:20	168:17
127:15	defeating	170:21	devices
decision	180:13	describe	33:15 93:19,
25:23	definitely	8:21 30:22	22 94:2,3
decisions	123:10	113:11	95:13 101:22
100:19	deliver	153:14	168:14,15
deck	33:7 35:12	157:21	dictated
88:21 89:4,	60:24	173:17	49:16
18,21,23	174:11,15,17	described	dictates
90:6,14	delivered	148:21	50:23
Declaration	41:6 60:23	designate	difference
7:20,25	67:19 86:6	25:20	21:23 24:20
12:7,11	93:21	designated	134:5 162:3
13:10,11	deliveries	69:12	178:5
14:22 15:2,	99:20	designed	different
5,7,9,17,20	delivering	167:23 183:5	24:12,16
17:22 23:18	60:22	desire	33:14 50:15
25:4 29:9	delivers	32:4 42:22	51:7,19,21
30:16 38:10,	65:12	desires	54:4 59:5,8 65:7,8,15
12 41:12	delivery	83:21	67:10 70:8,9
42:7,24	63:13,22	desk	72:6,7,9,23
44:18 46:17 55:13 56:4	demand	12:14 13:6	76:4,5 78:4,
97:9 98:11	49:15,20	details	12 83:22
103:21 106:4	50:16 175:10	107:6	86:18 91:10
115:20	demographics	determine	94:20 95:14
133:21	51:10,19,21	49:11 104:3	98:6,8 99:11
143:13,25	153:14,20,23	determining	100:2,3,5,7,
	, ,	40:3	12,16,17,24

101:3,4 102:6 112:2,	discreet 41:14,16,20	distribute	122:25 123:3,17,21
4 151:6,13	46:3 76:3	distributed	129:5,8,10
155:8 162:6	99:18	91:17 147:24	130:6,11
164:5,13	discreetness	distributing	135:14
168:2 170:4,	41:18 101:23	151:23	136:8,22
24 171:15	discuss	152:3,8	140:21
174:7 176:24	14:9 18:13	distribution	141:16,20
177:15	discussed	24:13,16	143:7,20
differentiate	12:6 14:11	48:12 54:12	documents
67:14	28:8 30:16	55:18 62:12,	8:7,10 11:8,
differentiate	143:11	16 86:12,14	12 12:10
d	147:23	87:10 88:4	81:11 89:25
65:6,11	169:19	101:9 118:20	doing
differentiate	discusses	130:21 148:9	25:11 83:9
s	90:4	151:3 152:12	125:12
55:10	discussing	158:14 159:4	181:15
differentiati	154:19	160:2,4	Dollar
on	discussion	163:3 164:22	136:20
54:9	12:11 90:13	166:13,19	dollars
differently	107:13 138:9	172:22	65:22 110:4,
72:23 83:21	146:11	173:6,12,14,	8 116:5
difficult	148:14,15	18 174:10,	140:2
26:5 108:21	discussions	15,16 180:2,	door
110:11	15:16	6 183:16	125:24 126:5
111:10 166:3	107:16,17	distributor	182:14
183:19	display	23:25	downloaded
difficulty	109:4,7	divide	81:3 123:13
36:14,25	157:4,12,17	95:11 166:19	draft
37:25 119:6	162:17,19	divided	15:6 73:22,
161:7	displayed	166:13	23
digesting	109:8	181:21	drafted
107:19	displays	division	112:24
dilemma	60:4 150:16	18:18	drafting
140:25	157:5 162:7	divorce	112:22
direct	disposable	149:22,23	dramatic
39:15 119:22	22:11,13	document	61:12
174:19	36:4	13:21 52:9,	dramatically
direct-type	disposables	13,14,16,18,	32:23
18:12	61:9	20 53:3,7,9	draw
directly	disposal	73:7,18	64:18 67:20
107:20 175:3	12:3 87:6	74:11 75:6,	103:7
disbelieve	dispose	10,11 79:14 80:21,23	drawbacks
44:15	116:3	81:6 88:11,	31:4 33:6
discount	dispute	12,16,19	40:19
181:5	6:20 9:4	89:20 97:5	drawing
		114:10,11	19:13
	<u> </u>	<u> </u>	I

drive	152:21	efficient	end
98:12	154:18 163:6	6:22 9:12	99:19
driven	166:25	70:2	142:12,25
127:11	171:16	effort	165:6
	181:14	168:23	endurance
drop	earliest		11:14
159:15	26:22	efforts	
Drug		82:18	energy
142:7	early	either	26:11 33:16
Duane	86:17 90:6,	8:15 16:23	engage
130:2	14 118:13	19:2 20:24	27:15
due	122:19	22:10 47:11	engine
130:13,17	131:13	106:14	23:21 24:3
139:4	132:11 148:5	151:15 157:6	enjoy
duly	172:24	182:8	69:3 72:11
5:20	earning	element	102:22
	53:13	40:14 72:19	171:17
dynamic	earnings	78:18 107:8	enjoyed
61:19,23	52:17,24	elements	
	53:8 54:18	14:11 40:15	147:10
E	63:21 75:8	70:7 71:25	enjoyment
	79:16 81:2,		70:22
e-cigarette	8,19 88:10	72:10,22,24,	enormous
56:24 142:13	T	25 78:15	135:8 145:8
143:2,4	114:14,17	92:2 112:2,4	enter
e-cigs	179:25	embarrassed	58:23 64:20
23:3	easier	41:24 42:2	entered
	10:9 14:17	embarrassingl	66:4 168:3
e-commerce	42:15,16	Y	enthusiasm
23:21 24:3	126:18	172:4	117:8
e-liquid	east	embedded	
62:25 73:9	128:2 129:23	22:9 155:21	enthusiastic
e-vaping	135:16	162:19	68:5
133:10	econometric	emerging	entire
e-vapor	104:7	17:11	54:20 72:2
18:23 22:5	economic		168:16
23:3 25:9	50:5,12	employees	entirety
26:17,20	109:25	89:11 165:21	15:24
40:3 58:10		employer	entitled
59:3 112:19	economics	6:9	119:14,21
127:16	160:15	employers	120:4,8
134:17	edit	16:2	entries
	13:22	enabling	63:14,15,23,
earlier	effect	141:2	24
42:9 62:23	117:3	encouraging	
116:11	effective	87:12	entry
122:16 132:4	42:19,20	117:10,22	59:6 76:23
139:9 143:11	54:8 55:3		77:2,6
147:22	145:19	encroached	environment
149:10	113:17	176:3	51:12 57:6
151:18			58:14
	1	1	1

equal	exactly	expensive	express
37:23 70:24	45:10 77:5	62:13 139:13	115:19
111:15	86:15 112:3	experience	expression
155:10 161:6	113:9	13:18 14:15	38:19
equally	118:18,21	15:24 33:13	extensive
181:4	170:20	40:12 42:22	64:16 139:6,
equivalent	EXAMINATION	47:20 48:3	13
161:3	5:23 147:6	62:9,11	extent
ergonomics	examined	67:21,24	48:24
75:25	5:21	68:10,19,23	extra
essentially	excellent	69:5,11 70:8	102:3
24:4 43:20	177:17	71:3,17	extract
69:22 93:18	exceptional	72:2,10,14,	50:4,11
108:9,14	77:23,25	19 87:5	extracted
109:18 160:8	79:2	96:11 99:12	170:7,22
170:13	exceptionally	100:12	extraordinary
172:25	54:8 55:2	102:6,14,22	116:2
establish	excited	116:10 132:5	
49:2	64:13 117:6	151:19	extremely 62:13 116:4
established	118:4	153:13	
59:25 139:2	excluded	171:15	eyesight
evaluating	160:20	experienced	125:21
139:9	exclusive	9:23 82:17	
		experiences	F
evenly	19:15	71:9	
181:21	Excuse	expert	face
eventually	33:23 89:22	47:25 70:18	24:5
59:18	Exhibit	expertise	facility
everybody	13:10 80:24	26:6 106:25	14:5
140:6	129:11 136:8	explain	facing
evolution	141:17	35:14 47:17	157:9 181:25
59:4 60:12	143:15	99:5 140:11,	facings
131:14	exhibits	22 148:3	156:8 157:7,
EX	11:8	167:18 170:2	10,11,12,16
52:19 73:8	exist	171:18	175:25
75:7 80:25	80:10 112:19	175:14	fact
		_ 	
81:7 88:19	existence		
81:7 88:19 90:2 114:15		explained	26:21 32:11
81:7 88:19 90:2 114:15 123:8 141:20	existence	explained 98:19	26:21 32:11 64:22 72:14
81:7 88:19 90:2 114:15 123:8 141:20 ex-cigarette	existence 121:11	explained 98:19 explicit	26:21 32:11 64:22 72:14 93:4 116:21
81:7 88:19 90:2 114:15 123:8 141:20	existence 121:11 existing	explained 98:19 explicit 154:5	26:21 32:11 64:22 72:14 93:4 116:21 117:4 121:4,
81:7 88:19 90:2 114:15 123:8 141:20 ex-cigarette	existence 121:11 existing 168:3	explained 98:19 explicit 154:5 exploratory	26:21 32:11 64:22 72:14 93:4 116:21 117:4 121:4, 6,14 122:19
81:7 88:19 90:2 114:15 123:8 141:20 ex-cigarette 164:10	existence 121:11 existing 168:3 exited 25:12	explained 98:19 explicit 154:5 exploratory 140:18 141:7	26:21 32:11 64:22 72:14 93:4 116:21 117:4 121:4, 6,14 122:19 factor
81:7 88:19 90:2 114:15 123:8 141:20 ex-cigarette 164:10 ex-philip	existence 121:11 existing 168:3 exited	explained 98:19 explicit 154:5 exploratory 140:18 141:7 exposure	26:21 32:11 64:22 72:14 93:4 116:21 117:4 121:4, 6,14 122:19 factor 34:9,17,21,
81:7 88:19 90:2 114:15 123:8 141:20 ex-cigarette 164:10 ex-philip 165:20	existence 121:11 existing 168:3 exited 25:12 expanded 115:13	explained 98:19 explicit 154:5 exploratory 140:18 141:7 exposure 145:5	26:21 32:11 64:22 72:14 93:4 116:21 117:4 121:4, 6,14 122:19 factor 34:9,17,21, 23 75:14,22,
81:7 88:19 90:2 114:15 123:8 141:20 ex-cigarette 164:10 ex-philip 165:20 exact	existence 121:11 existing 168:3 exited 25:12 expanded 115:13 expect	explained 98:19 explicit 154:5 exploratory 140:18 141:7 exposure 145:5 expound	26:21 32:11 64:22 72:14 93:4 116:21 117:4 121:4, 6,14 122:19 factor 34:9,17,21, 23 75:14,22, 24 104:23
81:7 88:19 90:2 114:15 123:8 141:20 ex-cigarette 164:10 ex-philip 165:20 exact 45:4 70:14	existence 121:11 existing 168:3 exited 25:12 expanded 115:13 expect 54:8 80:20	explained 98:19 explicit 154:5 exploratory 140:18 141:7 exposure 145:5	26:21 32:11 64:22 72:14 93:4 116:21 117:4 121:4, 6,14 122:19 factor 34:9,17,21, 23 75:14,22, 24 104:23 factors
81:7 88:19 90:2 114:15 123:8 141:20 ex-cigarette 164:10 ex-philip 165:20 exact 45:4 70:14 83:4 107:6	existence 121:11 existing 168:3 exited 25:12 expanded 115:13 expect	explained 98:19 explicit 154:5 exploratory 140:18 141:7 exposure 145:5 expound	26:21 32:11 64:22 72:14 93:4 116:21 117:4 121:4, 6,14 122:19 factor 34:9,17,21, 23 75:14,22, 24 104:23 factors 40:10,25
81:7 88:19 90:2 114:15 123:8 141:20 ex-cigarette 164:10 ex-philip 165:20 exact 45:4 70:14 83:4 107:6 128:9 140:7	existence 121:11 existing 168:3 exited 25:12 expanded 115:13 expect 54:8 80:20	explained 98:19 explicit 154:5 exploratory 140:18 141:7 exposure 145:5 expound	26:21 32:11 64:22 72:14 93:4 116:21 117:4 121:4, 6,14 122:19 factor 34:9,17,21, 23 75:14,22, 24 104:23 factors

	- Januar y		
104:12,22	100:24	67:3 100:17	78:14 101:8
fair	175:14	142:15	145:9 164:3,
			6,7,21
10:13 29:20	February	fine	
49:17 80:11	138:13	52:3 154:16	flexibility
106:2 171:20	Federal	finish	100:24
179:5	7:3 147:12	10:9,11	flow
fair-priced	feedback	finished	80:5
50:2	65:17 68:6	73:18	flows
fairer	feel	first	80:18
60:9	38:20 39:6	9:3,16 15:6,	fluctuates
fairly	73:13 76:4,5	20 27:14	29:20
43:14 57:19	81:11 85:7	_	
		33:18 34:5	focus
61:13,20	99:6	44:20,22	65:20 85:20
66:3 68:4	feels	53:11 56:17	86:4 88:23
90:14	65:12	59:6 61:14	97:12 142:2
116:16,21	felt	67:9 75:16	145:2 157:8
117:18 140:6	32:9 78:10	76:20 79:5	179:23
148:11 155:5	83:17,23	81:3 85:25	focused
157:2,3	145:9,19	93:12 104:15	54:5 82:19
172:11,15	fewer	130:20	focusing
familiar	177:16	131:9,12	93:10
47:10 123:16	fiction	134:3 161:16	following
136:23		162:2 163:8	_
137:16 155:6	17:10,11	165:16	85:23 127:10
156:18	fiercely	167:19	follows
family	56:21	173:24	5:22 147:5
_	fighting	181:13	Food
16:21	121:19	182:23	142:7
far	figure		footprint
32:16 108:3	113:23	fit	115:13
125:20,23	figures	183:15	force
177:15,16	29:10	fits	54:7,9 55:2,
faster		76:2	5,8,17 56:2,
34:3 45:8	file	five	
171:8 181:12	89:15	59:14,15,20	7,10 116:11
fastest	filed	62:10 180:16	176:16
121:8	7:16 167:22	182:3,4	177:17
favor	files	183:22	forced
	73:20 88:21	fix	170:18
10:11	filing	87:3	forces
FDA	54:19	fixtures	86:11
137:21 138:7	fill		FORD
141:3,13	176:13	59:25	21:13 25:19
145:20 162:9		flavor	27:7,11 30:7
163:7,23	final	63:12,22	31:18,24
164:3,14	73:22	85:6 100:21	34:12 36:18
172:10	financial	flavors	37:3 38:4
features	165:4	33:11,15	39:18 44:10
63:5 77:9,11	find	40:11,22	48:7,16,21
	16:24 17:12		40.1,10,41

		<u> </u>	
49:8,24 52:2	149:15	164:23 176:2	gave
55:23 57:21	153:16 155:3	183:11	7:21 8:22,23
61:25 68:12	168:10 169:8	free	9:2 33:12
69:12 71:4	170:5 173:15	17:15 49:18	66:8,10,13
72:17 73:13,	format	73:14 81:11	68:7 87:8
17,25 77:4	46:3 81:21	99:6 179:4	141:2
80:15 81:10	183:17	182:12	geared
82:25 84:5,	formed		60:22
18 87:19	108:14	frequent 39:9	
89:3,13 90:7			gears
92:11,21	forms	fresh	173:4
93:7 94:7	78:4,12	82:2	general
96:16,19	forth	front	13:25 15:8
98:7 99:4	65:5 103:17	122:2,11	45:21 49:10
110:19 111:3	found	130:15	58:10 136:20
116:23	45:23 65:15	FTC	143:23 156:4
110.23	66:12 72:10	7:6,11,16,	169:11
117:13,19	73:10 163:10	21,25 8:4	generally
118.25	foundation	9:17 13:16,	29:25 30:9
-	90:8 104:16	23 14:4,24	41:19 48:15
120:3,18,25	116:24	15:17	51:6 84:25
122:6,13	four	fulfillment	99:19 100:17
131:3,21	172:21	50:20	102:23
132:7,18	180:16	full	116:12
137:8,13		6:2 85:25	127:24
146:9 149:17	fourth	86:13	155:7,9,14,
150:21	63:20 75:13		20 157:6
153:17 169:9	81:25	function	generate
173:16	frame	11:11 12:4	24:8
183:21	73:16 147:16	32:10 50:16	generation
forgetting	148:14	174:24 175:4	18:19
14:6	framing	functions	
form	77:6	47:16	generically 176:14
12:2 30:6	franchise	fund	
32:11 34:9,	25:7 135:19	17:20	geographies
17,21,23	136:2	future	157:3
36:17 40:5	franchisee	125:4	165:12,13
45:19 55:20	136:5		gesture
71:4,5	franchisees		10:18
75:14,22,24	153:9	G	get all
85:14 92:20	franchises	gaining	157:9,13
105:9,17	25:17,25	121:12	getting
114:20	135:20		26:14 53:22
117:14	Frankensteini	gap	54:6 55:8
118:17		159:19	62:15 65:4,
119:23	an 170.15	gaps	16 86:12,17
120:13 121:2	170:15	176:13	97:17 111:9
122:5 131:4,	frankly	Gate	113:22
20 148:5	102:12	163:4,22	116:14,20
-55 5	162:11	172:9,14,15	-,
	•	•	-

118:23 119:6	69:19 71:3	grew	183:12
120:9,24	76:8 80:5,	34:7 59:9	
121:5,13	12,22 81:6	133:14	H
131:14	85:19 88:13,	ground	
150:15 153:2	23,24 93:24	9:22 11:21	half
161:9 163:3	95:21 96:14	166:22	115:23
166:12 177:7	97:8 100:13,	grounds	
181:3	14 105:24	48:22	halt 61:12
give	106:3 110:20	group	
7:2 11:23	113:25	24:7 64:21	hand
13:17 29:3,	114:10	176:20,22	76:2 116:3
14 52:19	119:14 120:6	-	150:12
56:17 66:7	123:2,3,6,9	groups	181:16
67:4 69:14	130:5 142:2,	65:20	handful
70:21 71:3	9 143:6,15	grow	45:25
75:9 76:5,16	145:15	133:11,14	handling
78:3 88:10,	147:13	growing	87:5
24 96:12	150:15	47:5 66:3	hands
103:22	165:2,3	83:16 121:8,	93:22
112:10	170:10	9 133:18	handy
114:3,6	172:14	159:19,20	12:13,15
121:3 150:6	182:10	grown	handy-store
170:12	183:2,7	34:3 179:16	129:21
180:12,19	good	growth	_
· ·	5:25 13:6	46:12,21	hangover
given	52:2 57:5	137:6	164:21
8:18 16:18	58:13 63:11	guess	happen
36:11,21	68:6 76:2	14:16 19:23	9:14 67:5
83:23 103:10	84:9 96:16	22:3 70:4	happened
137:21	118:14	87:17 106:13	33:2 58:17
150:11	122:20	169:10	60:11 163:5
giving	139:24 147:8	guidance	hard
8:14 42:21	175:19 181:5	80:2	59:16 101:25
65:16,17			harmful
87:10 182:18	Gottlieb	guidelines	139:10
glasses	134:16	107:24	144:23,24
125:19	Graham	guy	harsh
glitches	76:9 163:17	16:17 39:10	70:5
9:11	grandfather	117:18 176:9	hat
goes	138:6	177:23	67:25 68:21
38:21 176:9	great	guys	head
going	12:12 53:5	123:19	176:25
6:21 9:13,	78:11 96:21	125:19	
15,21 11:7	116:4 144:7	129:21	headquarters
12:18 13:9	147:11,22	162:14	136:15
23:15 49:25	177:24	165:25	headway
50:9 51:23	greater	173:25	86:11
52:8,10 61:7	33:14 78:3	175:11	health
63:18 65:3,5		100.04	1 1 1 1 1 · F
OJ.TO OJ.J.	110:2	177:24	134:5
03.10 03.3,3	110:2	1//:24	134:5

health-	74:22 102:11	hoping	implication
conscious	110:3 155:18	143:7	160:14
31:16	159:5,6	hour	implications
healthier	160:3,12	51:24 96:14	161:12
31:23	169:13	146:5	162:22
hear	highest	HPHCS	implied
69:18 70:6	40:16	144:15,21,23	66:22
122:7	144:14,20	hundred	importance
heard	145:3,10,18	177:25	41:15 94:15
70:16 104:18	155:14	hundreds	important
119:13	highlight	101:12	38:22 40:3,
136:25	90:5	158:20	8,13 41:2
heavy	highly	hungry	43:6 44:6
183:10	127:10	146:4	67:22 80:9
hedge	hilarious	hurdle	82:10 85:12
17:20	61:5	102:17	90:5,12
heightened	his/her	183:18	104:23
90:18,23	5:9	hurdles	109:10 110:5
held	history	101:20 102:4	161:11
138:9 146:11	8:14 134:6	103:10	importantly
help	hit	hurting	86:21
45:11 69:4	34:5 38:17,	33:19 160:22	imposed
107:10	18,22 40:2,7		159:11
168:13	116:13		impression
helped	163:20	I	153:20 154:5
46:8 55:17	165:15,24	idea	impressions
56:2 69:3	166:8,9,11,	13:6 61:18	170:12
87:7,9	20	identify	improve
helpful	hold	85:20	168:15
107:11 132:9	23:19 34:12	imagine	in-house
134:13	38:13 52:21	32:8 34:22	19:2,25 63:8
helps	77:15 79:21	121:22	66:6 71:18
72:2	80:6 119:12		171:22
hiding	122:14 129:9	imitate	inaudible
176:7	142:20 146:2	44:14	55:12
high	holes	immediacy 171:3	include
36:8,9 42:25	157:22	_	18:22 29:10
43:2,19	160:13	impact	included
62:16 64:16	home	35:13 63:13,	140:10,12
99:19 116:4	102:23	22 64:9	includes
164:18	honest	156:17 171:9	139:7
high-level	125:18	impacts	including
69:14	honestly	72:23	6:4 22:12
high-volume	107:5	Imperial	34:21 84:2
127:24	hope	59:20	91:23 101:21
higher	147:8	implementing	106:7 115:14
37:18 50:22		148:16	118:7 138:12
	1	<u> </u>	1

140:2 142:11,24 incomparable	initially 13:24 initiation	181:10 interestingly 17:9	investigation 7:17 investment
67:20,24	82:15 164:10	interject	7:8 172:19
68:19,23	innovation	111:3 183:21	investors
69:5,11	44:19 60:21	internal	53:14 54:17,
72:13 73:2,3	61:12,19	166:11	23 62:18
increase	63:8 109:17	international	67:23 80:12
42:11 43:3	innovations	16:21,24	involved
97:22 98:12	58:8	internet	7:11 21:10
104:6 159:17	innovative	17:7 24:6	101:21 107:5
180:6	130:13,18,	interrupt	112:21,25
incredibly	19,23	119:12	152:8 172:3
109:10 176:8	inside	interview	IP
183:19	110:9 111:12	13:20	19:17,20,21
independent	133:5 153:19	interviewed	isolating
60:4 86:24	157:4 161:22	13:16	37:6 40:6
136:3 175:12	173:20	intro	issue
indicate	insights	92:6,15	35:11
5:15	13:17	introduce	issues
individual	instance	84:13 108:6	7:11 27:17
33:12 34:24	49:11 158:15	162:25	34:19 163:7
individual's	162:23	introduced	IVG
32:4	175:23 179:6	59:11 61:16	152:18
individuals	181:24	104:15	153:10
31:21	instrumental	131:9,12	
inducement	56:8	162:4,5	
96:12	INTENSE	165:17	
industry	28:13	179:15	Japan
114:9 154:14	intention	introducing	17:9,10,12
infinite	108:2	115:24	59:19
100:11	Interchange	161:16 162:2	jargon
influxed	136:14	introductions	154:15
133:19	interchangeab	61:19	166:11
information	le	invented	job
6:14 9:7	93:14	65:7,8	10:8 16:2,
11:2 43:9	interest	inventory	16,18
76:17 158:18	109:19,20	49:13 86:25	177:17,24
ingredients	interested	150:6,12	jobs
69:25 145:12	14:12	165:6,8	16:5,9
inherent	interesting	176:12,13	181:13
60:14	111:17 135:2	181:15,19,	jockeying
inhibit	156:10	20,22	138:24
108:5	158:12	invest	join
initial	159:24	26:14	108:18
88:4	160:17	invested	joining
00.4	161:15 164:4	168:8	108:15,16
		100.0	100.13,10

	l		1 _ •
Joonsuk	JUULS	19 99:17,25	Lacks
147:11	99:17	102:5,6	90:7 116:23
July		103:16	lanes
81:8 161:18,	K	105:21	101:9
19		110:23	language
jump	keep	113:10	15:15 149:13
36:5 147:14,	12:10,12	117:23	154:17
19	13:6 28:12	118:18,19,21	large
June	40:6 76:3	119:4,20	30:2 33:7
161:19	109:9 121:12	120:15	86:12 88:12
jurisdiction	139:22	122:23	89:4,15
137:22,25	165:11	123:12	101:13,18
141:3,15	180:17	131:12	102:13
JUUL	Kentucky	132:12,25	115:15 123:2
7:4,7,8,15	136:15	133:12,13,	165:5 172:4
23:11 26:23,	kind	18,19 134:2,	176:23
24 27:3,13,	61:5 66:17	11,13 135:23	183:14
15 28:22,23,	100:21,22	140:7 141:23	larger
24 35:8	105:25	143:17	22:17 29:12,
36:11,15,22	107:11	144:10,11	13 33:10
37:2 43:10,	135:17	149:3 153:21	34:8 37:16
11,16 44:12	151:19 156:4	162:16	38:17 40:14
45:3,22 46:4	158:7 159:9	163:12	42:18 78:5
49:12,13,14,	160:7 171:14	164:15,16	89:12
22 57:10	181:10	165:24	larger-volume
64:6,7 68:10	kinds	168:12 169:5	179:24
78:7 82:23	37:20 50:14	170:13 171:5	largest
83:11 91:10,	101:3 157:22	174:3,9	91:17
23 92:10,25	kit	176:2,5	Larry
93:3,6,15	92:15	178:13,14	21:13 73:13
94:5,13,21	know	179:2,13,20	74:4 89:14
95:3,9,20,23	6:18 10:21	180:8,25	99:4 110:20
104:14	11:15 15:10	181:21,24,25	111:5 116:25
130:12,15,	27:12 29:5,	182:7	120:19
17,20 131:9,	18 31:14	knowledge	lasting
16 132:11,	32:25 38:7	39:16,21	171:10
15,21 133:4,	44:12,22	69:7	lasts
5,6,22	45:9 49:15		70:9
149:3,4,11	50:8 52:12	L	
150:10,11	56:18 62:12		late
162:17	64:14 69:6,	L-A-W-R-E-N-	133:11 172:23
JUUL's	10 70:15,18	C-E	
8:5 36:7	71:11 72:4,	6:7	launch
42:24 43:6,	20 73:21	labels	78:20 79:5,9
25 44:2	74:3,15	139:12	88:20
83:13 94:17	76:16 81:16	lack	law
131:13	84:6 85:8	70:5 161:8	120:6 141:2
	91:14 94:18,		
)		
	l		I

	_ _		
Lawrence	left	180:10 181:7	loading
6:6	16:11 39:25	line	80:22 89:7
lawsuit	114:8 125:23	23:22 24:10	136:7
138:25	128:8,15	94:11 117:24	loads
lawyers	164:7 174:5	179:17	123:5
107:14,18,	legal	lines	located
19,21,23	7:3,10	107:25	127:25
layoff	legislation	153:25	locator
173:2	137:22,23	liquid	129:21
leading	length	19:23,24	Logic
83:9 115:15	30:24 70:9	20:2 22:9,17	59:18
124:18,24	lengths	37:10 42:20	
125:6	135:8	83:5 95:3,14	long
178:22,23,24		168:16	73:8 142:19
	letter	169:17,20,23	long-term
Leap	134:17,21	liquids	50:7 80:2
91:11	letters	20:5,6 37:14	169:13
learned	125:15	100:6,7	longer
181:17	letting	100:6,7	25:14 65:13
learning	10:11	list	150:14
14:13	level	95:17 136:21	171:10,11
lease	35:21,25		look
109:10	36:2 43:24	little	10:6 11:7
leasing	69:21 70:3,8	14:14 23:15	13:12,13
109:3,21	108:23	42:16 49:4	36:6 39:4,5
leave	110:3,12	99:12 128:2	49:9,22
16:14,22	128:9,16	140:11 147:14 148:4	51:4,9 73:14
106:12	160:21	151:22	77:12 82:2
Lee	levels	151:22	89:10 92:14
9:17 30:6	36:8 37:13,	152:13	93:9 99:9
31:19 36:17	14,18 42:25	163:16	113:23 117:4
37:4 38:6	50:15 116:5,	164:10	123:14 128:6
40:5 45:19	17 145:10	167:18	134:2
55:19 57:22	leverage	168:23	141:14,18,24
71:5 80:16	178:18	170:3,10,23	156:19 158:3
85:14 90:9	licensed	171:3 172:9	159:8,25
92:20 94:6	19:3,6	173:4 178:4	165:4 166:15
96:20	lieu	181:12	looked
104:16,25	5:8	live	157:18
105:9,17	life	121:16	158:16
117:14	54:21	load	159:13
118:17 121:2	light		165:19
122:5 131:4,	162:3	88:14,15	167:13,14
20 132:19	limitations	114:10 123:2 130:5 143:6	looking
137:9 146:2	60:15	183:10	20:12 31:12,
147:7,11	limited		21,22 37:17
150:22	62:14 101:10	loaded	45:17,18
183:25	153:8 158:15	143:17,18	54:2 56:15
	133:0 130:13		63:5 67:17

	-		
71:9 74:10	164:2,23	magazines	26:10
75:20 81:24	166:4,22	17:15	manager
93:4 94:10,	178:7	magic	175:13
22 95:19	lots	72:5,20	managers
121:25	160:12	mainstream	177:4
128:12,13	Louisville	54:11	Mango
133:20	136:15	maintain	126:21
151:20	love	80:13	Manhattan
164:15	64:21 69:18	maintaining	129:24
looks	low	50:6	manner
23:5 30:22	35:2,6,21,25	major	5:14
93:5 95:6	41:2 108:7	19:14 86:17	
123:18	lower	116:18	manufacture
162:15	35:25 37:13,	134:24	18:6 20:17, 19
lose	14 92:9,24	135:3,5	
101:23	93:2 94:3,5,	137:3,12,15	manufactured
159:15	13,16 95:7,	157:3,12,15	20:21,24
loses	17 102:9	161:2	148:22
159:9,21	103:8 155:16	173:13,25	manufacturer
lost	160:2,21,24	181:11	19:9,12,19
178:3	165:16 166:2	majority	62:25 86:24
lot	lunch	39:21 82:14	149:2 181:16
14:11 16:5	143:8 145:25	majors	manufacturers
24:14 28:11,	147:9	60:7 62:4	19:14 47:23
23 32:18,19,	lunched	174:13	134:18 156:9
20 43:9	66:16	176:5,6	manufactures
44:13 45:3,	luncheon	181:3,6	20:15 149:12
16 46:9	146:12	182:23 183:3	March
49:17 58:7,		make	13:11 46:17
17 60:20	lungs 163:7	6:21 10:8	margin
63:4 64:17	163.7	11:5 18:11,	50:19 80:3
66:6 71:18		12 20:10	103:3
86:25 89:24	M	21:20 25:23	marginal
90:22 100:8		32:17 37:21	103:17
101:22	machine-made	40:17 50:21	margins
102:4,8,15	179:2	73:25 89:8,	80:5 99:11
104:14	made	11 122:15	marijuana
107:13,14,22	7:8 12:24	146:5 159:4	163:6,10,11,
116:16	13:21 15:11	177:2,7	24
130:24 131:6	18:9 20:2	178:25	mark
132:13 134:6	41:25 77:24	makes	13:9
139:6,22	78:4 79:11	11:4 39:5	marked
140:4,18	86:24 116:6	69:25	11:8
143:15	126:17	making	market
153:18	166:16	6:17 10:17	22:21 27:18
160:19	magazine	11:2 86:11	33:10 35:10
161:17	17:15	management	44:21,22
162:5,12		management	46:22 49:10
	1	I	I

50:2,3,13,23	masters	meet	millions
56:24 57:20	108:12,13,25	6:14 82:8,11	65:22 139:25
58:23 59:3,	Match	megabytes	minimal
4,7,13,21	157:15	88:13 123:3	167:6
60:8,10,12	material	member	minor
61:20,21,23	103:10 167:7	108:22	15:14
62:2,5 64:20	materially	men	Mint
65:22 66:4,	27:20	176:15	126:21
16,25 71:15	math	mention	minus
77:2 82:15	157:7 181:13	16:7 40:20,	172:16,17
83:2,15	matter	21,22 41:12	minute
108:21	5:10 6:17	42:24 44:24	52:19 63:6
111:16	12:8 39:13	67:9 118:22	97:12 123:4
130:15,25	matters	119:5 120:23	minutes
138:5,8,13,	104:11,20	121:14,21,23	102:16
16,18,21	127:17	122:17	183:22
139:18		mentioned	misnomer
141:11	mean 27:5 46:21	16:4 22:24	135:18
155:11 158:5	47:17 48:10	27:3 28:7	
159:10,18	54:25 57:25	42:9 60:13	misspoke
165:10	64:9 90:11	94:14 139:8	91:4
166:25	95:15 96:9	148:19	mix
178:18 180:7	104:18 132:4	149:10	30:13
marketing	l .	152:22	moist
24:4 67:25	139:24	166:8,23,25	18:11 60:3
68:21 96:7	149:16	merchandising	64:19,20,22
110:13	154:24 173:18	59:25 109:2	65:2,9 73:4
marketplace	173:18	177:2	113:12
49:12 76:23			121:8,9
159:20	meaning	messaging	155:5
160:16	8:5 80:19		156:17,23,25
172:12	meaningful	methodology	162:16 173:9
markets	54:9 83:15	65:9	179:12
14:14 98:6,8	means	middle	moments
101:16	154:12	6:4,7 79:25	177:23
151:13	180:19	83:14 115:3,	momentum
169:12	meant	8 124:5	117:8 163:19
179:4,6	87:20 103:20	126:4	165:7
markups	measure	Mike	money
49:2	133:13	16:18	86:13,20
Marlboro	measured	milliliter	87:9 116:16
108:18,21	46:22 178:20	78:8	140:5 175:6
110:13	mechanics	milliliters	monitor
marshal	156:9	77:18,20	88:6
167:4	mechanism	78:6 95:22	month
Maryland	45:4 49:9	million	57:17 83:10
139:2	56:5	83:9 140:9	109:11,14
137.2		172:13,16	
			

months	multipacks	128:24	22 90:18,23
51:14 59:14	94:21 95:9	139:21	94:21 95:11
62:10 65:3	multiple	140:24	99:19 102:9,
morning	182:6	141:12	11,25 141:3,
5:25 147:23	myblu	147:16	5 144:14,20
154:18	28:13,20	159:22 172:8	145:3,9,10,
169:19 170:3	47:13 91:11,	174:9 181:18	18 169:20,24
171:16	24 93:16	182:3 183:23	170:4,6,7,9,
181:15	myriad	needed	20,21 171:2,
Morris	86:2	139:17	8,9,14
7:12,14 8:24	Mystic	negative	nicotine-
9:3 14:15,	86:23	31:17	uptake
16,17 16:9,	mythical	never	43:11
11,14,17	160:7	26:2 28:7,8	Nictech
39:23 59:17	100.7	29:21 51:4	68:24 69:4,
65:19,20		53:9 81:20	22 70:20,25
106:6,11,13	N	112:24	71:2,23 72:9
107:2 108:2		114:20 120:6	74:19,25
110:6,17	name	131:25	75:3 77:3
111:13,24	5:16 6:2,4,	144:11 154:8	85:11 86:6
112:10,17,	7,8,15 14:6	165:22	90:4,6,13,
18,22,25	113:10	Newgen	17,23 141:6
165:20 174:5	147:11	18:5,15,17,	171:13
179:13	named	22 19:2 80:3	NJOY
180:19 181:8	16:17 147:24	nice	28:13 47:13,
Morris'	national	6:14 67:6	14 92:14
106:18	123:7,18	147:9	93:16 136:24
109:17,18	156:20,22	nicotine	137:2
mortar	157:23	18:20 33:14	NJOYS
25:15,24	164:15 165:3	35:3,5,12,	99:17
motivate	167:3	16,20 36:8,	nodding
101:18	nationally	12,14,22,25	10:17
mouth	91:17 157:24	37:7,11,13,	nomenclature
65:12	158:24	15,18,20	44:5 182:11
104:10,14	167:16	38:17,18,21,	nontobacco
-	natural	22 39:20	18:19,21
move 16:21 111:6	158:7,8	40:2,7,16,	
	182:11	22,24 41:4	normal
moved	nature	43:2,3,15,24	121:5 151:3
138:24	87:7	45:8 47:12	Notary
moves	necessarily	60:23,25	5:21
128:2	37:18 40:17	65:13 67:20,	note
Moving	necessary	24 68:9,19,	24:9 36:7
115:4,10	46:4,6	23 69:5,11,	44:17 56:4
118:11	need	23,24 70:3,	82:7 128:22
MSA	11:15 26:13	4,7,12,24	noted
158:18	105:21	71:21 72:13,	147:3
	125:18	15 74:9,17,	
	123,10		
•			

notes	119:23	occur	64:24 69:22
78:20 144:13	objection	9:11 51:4	70:23 73:21
notice	11:3,5 30:6,	October	74:5,12,14,
17:16 150:11	7 31:18,19,	123:7 124:13	22 75:5,15,
161:18,20	24 34:13	126:8,15	19 77:5,12,
November	36:17 37:3,4	141:22	15,21 79:7,
114:15 115:7	38:4,6 39:18		13,21,24
	40:5 44:10	odd	81:17 85:17
172:24	45:19 48:7	105:12 158:20	87:24 88:22
Nu-x	49:8,24		89:16 90:3
58:20 82:2	55:19 57:21,	offer	91:5 93:24
85:21 117:7	22 61:25	55:15 56:3	94:9 95:19,
number	68:12 71:4,5	116:4 169:12	22 96:3
9:15 17:6	72:17 77:4	176:11	97:10,11,18
31:3 42:10,	80:15,16	offered	98:10,17,24
13 51:14	82:25 84:5,	16:20 55:16	99:9,25
57:5,15	18 85:14	offering	103:25
58:13 59:7,	90:7,9	72:15	103:23
14,15,20	90:7,9	offers	105:2,18
61:15 62:10	93:7 94:6,7	17:15	111:8 112:21
72:5,9 91:9	98:7 104:16,	office	113:4,25
97:19,24	25 105:9,17	15:9	114:23 118:3
98:13	116:23	Officer	119:2
101:10,18	117:13,14,19	115:2	123:15,22,24
102:13		offsetting	124:10
103:22	118:17,25	60:6	125:23
111:19	119:4,8	okay	126:12,16
114:12 140:7	120:13,25	6:13,24	127:3,19
147:15 150:5	121:2 122:5,	8:13,21,25	128:6,21
153:6 155:7	6,13 131:3,	9:7,21 10:4,	129:6,17
161:11	4,20,21	18 12:21,22	130:9 136:14
166:11,13	132:7,18,19	13:23 15:11,	139:20
167:7	137:8,9,13	22 16:11,23	140:21
168:11,14	149:15,20	17:21,23	141:18,25
174:6 178:6,	153:16,17 155:3 168:10	18:10 19:8,	142:21
10	l .	15 20:18,20	144:5,7,18
numbers	169:8,9	21:16 22:3	145:4 146:4
109:5,6	170:5 173:15,16	23:19 24:15	147:20 149:8
nutraceutical		26:12 29:23	150:18 152:6
21:6	objections	31:12 37:6	154:10
	5:14 119:19	38:9,13,15	164:25
	obligatory	42:8,23 46:2	165:13
<u> </u>	17:7	47:2 48:16,	170:13
oath	observations	25 49:21	173:17,21
5:8 9:25	165:15	51:6,22	173:17,21
10:2	obvious	52:21 53:5,	older
	93:2	12,19 54:15,	153:21
object	obviously	25 55:13	
10:24 48:21	40:8 85:15	57:14 58:25	164:11
		21.14 20.72	
	I	I	I

13:2 47:24 177:19 one 6:15 9:5 13:21 14:14 15:11 19:4, 14 20:10 22:11 23:2 22:11 23:2 26:22 27:14 28:19,23 38:11 39:4 40:13, 32:3 38:11 25 41:9,18 42:23 64:7 67:6 71:7 67:6 71:7 67:6 71:7 67:6 71:7 67:2 71:1 104:15 104:15,20 132:2 99:24 102:13,118:8 104:12,22 112:13 118:8 104:14 105:14 00:15 110:10 110:10:10 110:10:10 110:10:10 110:10:10 110:10:10 110:10:10 110:10:	once	ones	operation	outer
one online 148:7 151:15 open 153:22 operations 148:11 151:4,6 outside 6:15 9:5 13:21 14:14 15:11 19:4, 14:14 15:11 19:4, 13:3,6,8 18:24 20:5 open 152:14 181:11 operator 152:14 181:11 operator 156:5,6 outside outside 22:11 23:2 22:1 24:23, 26:22 7:14 25:29:10,11, 28:19,23 38:14 39:4 40:13, 25 41:9,18 38:16 41:14 42:23 64:7 67:6 71:7 43:17 47:6 50:2 52:15 84:15 88:11 57:17 58:9 60:20 50:2 52:15 41:21:13 118:8 81:15 7:17 58:9 90:2 99:24 60:10,13,18 61:21 62:2 12:12:13 118:8 88:17 89:9 97:21 98:14 130:5,20 130:2,3,8, 136:4,5 143:6,12 100:2,3,8, 136:4,5 123:22 100:2,3,8, 136:4,5 123:22 102:7,14,20, 22 103:5,7, 158:21 103:2,2 103:5,7, 158:21 103:2,2 103:5,7, 158:21 104:5 165:20,23 168:14 155:20 116:8 132:2 166:2,3 oral 177:15,18,23 168:14 155:20 116:8 135:2 116:8 135:9 18 one—and—ahalf 159:18 one—and—ahalf 159:18 one—and—ahalf 159:18 one—and—one 94:19 153:24 50 50:2 50:2 50:15 50:2 50:2 50:2 50:2 50:2 50:2 50:2 50:	13:2 47:24	101:13	17:9 25:13	179:2
one online 148:7 151:15 operations 153:21 14:14 15:11 19:4, 13:3,6,8 152:14 15:11 19:4, 15:11 19:4, 13:3,6,8 15:24 20:5 operations 15:14 6 outside 8:5 66:8 outside 8:5 66:8 outside 8:5 66:8 outside 8:5 66:8 off:6 99:24 100:10 110:10 100:10 110:10 100:10 110:10 110:10 110:10 110:10 110:10 <	177:19	102:10	26:3,7,8	outlets
13:21 14:14 15:11 19:4, 13:3,3,6,8 14:20:10 18:24 20:5 22:21 24:23, 26:22 27:14 25:29:10,11, 28:19,23 38:11 37:20 34:6 39:4 40:13, 25:41,17 43:17 47:6 76:6 71:7 74:2 78:18 84:15 88:11 92:2 99:24 100:10 13:20 13:21 13:18:8 104:12,22 12:13 118:8 120:4 125:14 130:5,20 132:25 133:5 136:4,5 13:24,25 165:20,23 165:20,23 165:20,23 165:20,23 165:20,23 165:20 17:518 17:20 10:20 17:518 165:20 17:518 17:20 10:20 17:518 17:20 10:20 17:518 17:20 10:20	one	online	153:22	148:11
13:21 14:14 15:11 19:4, 13:3,6,8 13:3,6,8 14:20:10 18:24 20:5 22:21 24:23, 26:22 27:14 25:29:10,11, 28:19,23 38:11 17,20 34:6 39:4 40:13, 25:41,17 43:17 47:6 76:76 71:7 74:27 78:18 44:15 88:11 92:2 99:24 100:10 10:20 1	6:15 9:5	148:7 151:15	operations	151:4,6
15:11 19:4, 14 20:10	13:21 14:14	open	152:14	outside
14 20:10 18:24 20:5 operator 76:6 99:24 22:11 23:2 22:21 24:23, 15:5:5,6 100:10 28:19,23 15:33:9,10, 15:3,20 86:3 operatinities 39:4 40:13, 36:3 37:12 operatinity 50:20 25:41:9,18 42:14,17 43:17 47:6 67:6 71:7 43:17 47:6 67:6 71:7 43:17 47:6 50:2 52:15 83:15:137:24 107:5 74:2 78:18 50:2 52:15 50:2 52:15 0pportunity 107:5 84:15 88:11 57:17:58:9 60:10,13,18 16:23 108:15 0ption 10:2:2 99:24 60:10,13,18 16:23 108:15 0ptions 130:5,20 97:21 98:14 99:2,9 132:25 133:5 10:2,3,8, 137:23 0ral 133:24,25 10:27,14,20, 22:103:5,7, 11:04:5 95:18 165:20,23 136:11 145:8 15:20 95:18 0ranges 17:18 15:3:23 10:14:25:21 50:19 69:9 86:13 88:5 166:42,5 16:21 59:6 99:5 95:20,23 176:4,5,6 177:15,18,23 178:5,9 16:3 16:6:6 99:5 18:13,24,25 16:22 0perate 12:11 0rganize 0rganize 56:12,13	15:11 19:4,	. –	181:11	
22:11 23:2 26:22 27:14 28:19,23 38:11 37:20 34:6 39:4 40:13, 25:41:9,18 42:23 64:7 67:6 71:7 67:6 71:7 74:2 78:18 84:15 88:11 92:2 99:24 104:12,22 112:13 118:8 120:4 125:14 130:5,20 132:25 133:5 136:4,5 143:6,12 153:24,25 163:21,25 163:21,25 163:21,25 163:21,25 165:5,6 110:10,11 overhead 50:20 overly 107:5 0med 137:2 153:5, 0momer 16:23 108:15 0momer 35:10 36:2,3 0momer 175:14 176:10 0momer 175:14 176:	14 20:10	1	operator	
26:22 27:14 28:19,23 15 33:9,10, 32:3 38:11 39:4 40:13, 25 41:9,18 42:23 64:7 67:6 71:7 74:2 78:18 84:15 88:11 92:2 99:24 104:12,22 112:13 118:8 104:2,2 112:13 118:8 130:4,5 130:2,9 132:25 133:5 136:4,5 133:2,9 100:2,3,8, 136:4,5 143:6,12 103:20,7,14,20, 156:19 157:9 158:21 163:21,25 163:21,25 163:21,25 163:21,25 163:21,25 163:21,25 163:22,23 178:5,9 188:13,24,25 188:14 171:18 171:10 110:10,11 00corently 114:18 111:10 16:24 25:20 0posed 30:11 0potion 16:23 108:15 0ptions 35:10 36:2,3 0ral 137:22 0posed 30:11 0ptions 35:10 36:2,3 0ral 177:23 0ranges 95:18 0ranges 114:25:21 177:18 175:14 176:10 0rene 177:12 170:10 0rene 175:14 176:10 177:12 176:10 0rene 175:14 176:10 177:12 176:10 0rene 175:14 176:10 177:12 176:10 177:12 176:10 177:12 176:10 177:12 176:10 177:12 176:10 177:12 176:10 177:12 176:10 177	22:11 23:2	1	_	100:10
28:19,23 32:3 38:11 32:3 38:11 33:4 40:13, 25 41:9,18 42:23 64:7 42:14,17 67:6 71:7 74:2 78:18 84:15 88:11 92:2 99:24 100:12,12 112:13 118:8 120:4 125:14 130:5,20 132:25 133:5 136:4,5 143:6,12 153:24,25 153:24,25 153:24,25 163:21,25 165:20,23 177:18 153:23 168:14 177:18 153:23 168:14 177:15,18 175:14 175:3 0ral 176:1,20 0ranges 95:20,23 110:2,8 95:20,23 110	26:22 27:14	1		110:10,11
32:3 38:11 39:4 40:13, 36:3 37:12 38:16 41:14 42:23 64:7 67:6 71:7 74:2 78:18 84:15 88:11 92:2 99:24 104:12,22 112:13 118:8 120:14 125:14 130:5,20 132:25 133:5 136:4,5 136:4,5 136:4,5 136:4,5 136:3,24,25 156:19 157:9 158:21 17:20 158:21 17:20 158:21 17:20 160:20 175:18 160:20 175:18 177:20 176:4,5,6 177:15,18,23 178:18 177:20 176:4,5,6 177:15,18,23 178:5,9 180:13 181:13,24,25 180:13 181:13,24,25 180:13 181:13,24,25 180:13 181:13,24,25 180:13 181:13,24,25 180:13 181:13,24,25 180:13 181:13,24,25 180:13 181:13,24,25 180:13 180:14 One-and-a-half 159:18 One-and-one 94:19 114:25 149:24 114:25 153:21 105:20 177:12,13,19 176:8,15 Other's 105:20 0verly 116:2425:20 0verly 110:25 0vmed 137:2 153:5, 0vmed 137:2 153:5, 0vmer 177:14 180:14 176:10 0verly 107:5 0verly 107:5 0verly 107:5 0verly 107:5 0verly 107:5 0vered 137:2 153:5, 0vmer 177:14 176:23 108:15 0ptions 16:23 108:15 0ptions 1	28:19,23	1		-
39:4 40:13, 25 41:9,18 38:16 41:14 42:23 64:7 42:14,17 67:6 71:7 43:17 47:6 182:17,20,22 opposed 30:11 options 16:23 108:15 options 25:10 36:2,3 oral 137:24 16:23 108:15 options 25:10 36:2,3 oral 137:24 176:10 options 25:14 10:20 10:27,14,20, 156:19 157:9 120:27,14,20, 156:19 157:9 120:27,14,20, 156:19 157:9 120:27,14,20, 166:20,23 136:11 120:20 153:24,25 168:14 151:20 168:14 151:20 168:14 176:20 177:15,18 153:23 168:14 151:20 168:14 176:20 177:15,18 153:23 168:14 151:20 168:14 176:20 176:4,5,6 177:15,18,23 178:5,9 180:13 181:13,24,25 182:2,5 one's 120:7,10 one-and-a-half 159:18 one-and-one 94:19 100:24 other's 138:11 79:14,25 11.59:18 one-and-one 94:19 100:24 other's 138:11 79:14,25 11.59:18 one-and-one 94:19 100:24 other's 138:11 79:14,25 11.59:18 one-and-one 94:19 100:24 other's 138:11 79:14,25 11.50 other's 138:11 79:14,25 11.50 other's 158:23 15:10 other's 158:28 11.50 other's 100:27 other 158:12 other's 179:14,25 11.50 other's 158:23 85:17,	32:3 38:11			
25 41:9,18 42:23 64:7 42:23 64:7 67:6 71:7 74:2 78:18 84:15 88:11 92:2 99:24 104:12,22 112:13 118:8 120:4 125:14 130:5,20 133:25 133:5 136:4,5 143:6,12 153:24,25 156:19 157:9 158:21 163:21,25 166:20,23 156:14 177:15,18,23 177:15,18,23 177:22 176:4,5,6 177:15,18,23 177:15,18,23 177:15,18,23 177:15,18,23 177:15,18,23 177:15,18,23 178:5,9 180:13 181:13,24,25 180:13 181:13,24,25 180:13 177:15,18,23 178:5,9 180:13 178:5,9 180:13 178:5,9 180:13 178:5,9 180:13 178:5,9 180:13 178:5,9 180:14 179:14 175:18 175:18 175:18 180:14 175:18 180:14 175:18 180:14 175:18 180:14 175:18 180:14 175:30 176:20 177:50 178:18 179:14,25 179:14,20, 179:14,20, 179:14,20, 179:14,20, 179:14,20, 179:14,20, 179:14,20, 179:14,20, 179:14,20, 179:14,20, 179:14,20, 179:14,20, 179:14,20, 179:14,20, 179:14,20, 179:14,20, 179:14,20, 179:14,20, 179:14,20, 179:14,25 179:14,25 179:14,25 179:14,25 179:14,25 179:14,25 179:14,25 179:14,25 179:14,25 179:14,25 179:14,25 179:14,25 179:14,25 179:14,25 179:14,25 179:14,25 179:14,25 179:14,25 179:14,25 170:10 175:14 182:17,20,22 183:15 137:24 182:17,20,22 137:2 153:5, 7 0wned 137:2 153:5, 7 0wmed 137:2 153:5, 7 0wmer 175:14 176:10 0operate 16:23 108:15 0ption 16:24,25 0ption 16:23 108:15 0ption 16:24,25 10:21,3 137:21 175:14 176:10 0ption 16:23 108:15 0ption 16:23 108:15 0ption 16:24,25 0ption 16:23 108:15 0ption 16:24 20:23 0ption 16:23 108:15 0ption 16:24 20:23 0ption 16:23 108:15 0ption 16:24 20:24 0ption 16:24	39:4 40:13,			
42:23 64:7 67:6 71:7 74:2 78:18 84:15 88:11 92:2 99:24 104:12,22 112:13 118:8 120:4 125:14 130:5,20 133:25 133:5 136:4,5 136:4,5 136:4,5 153:24,25 163:21,25 163:21,25 163:21,25 163:21,25 163:21,25 163:21,25 163:21,25 163:21,25 163:21,25 163:21,25 168:14 171:18 153:23 177:122 177:15,18,23 176:5,9 180:13 177:15,18,23 177:5,18 180:13 180:13 180:13 180:13 180:13 180:13 180:14 coperate 120:7,10 cone-and-a-half none-and-one 14:25 149:24 94:19 42:14,17 43:17 47:6 182:17,20,22 opposed 30:11 0ption 16:23 108:15 options 35:10 36:2,3 options 35:10 36:2,3 options 35:10 36:2,3 options 35:10 36:2,3 options 175:14 176:10 0ptions 35:10 36:2,3 options 175:14 176:10 0ptions 35:10 36:2,3 options 146:13 147:3 poptions 146:13 147:3 poptions 146:13 147:3 poptions 137:2 153:5, options 16:23 108:15 options 16:23 108:15 options 35:10 36:2,3 options 35:10 36:2,3 options 35:10 36:2,3 options 16:23 108:15 options 16:23 108:15 options 16:23 108:15 options 35:10 36:2,3 options 146:13 147:3 pack 95:20,23 110:2,8 package 40:15 83:22 84:8 packaging 85:4 packs 109:8,9,12, 13 111:11,15 112:8 page 53:16,19 56:12,13 73:11 74:6, original 12:11 00TB 175:14 176:10 Options 35:10 36:2,3 options 136:2,3 options 136:2,3 options 136:2,3 options 146:23 108:15 options 16:23 108:15 options 16:23 108:15 options 16:23 108:15 options 16:23 108:15 options 137:2 153:5, options 16:23 108:15 options 16:23 108:15 options 146:13 147:3 pack 95:20,23 110:2,8 pack 95:20,23 110:2,8 pack 95:20,23 110:2,8 pack 11:25 11:28 page 53:16,19 56:12,13 73:11 74:6, original 23:2 108:11 76:8,10 77:12,13,19 79:14,25 138:11 other's	25 41:9,18	1		_
67:6 71:7 74:2 78:18 43:17 47:6 182:17,20,22 137:2 153:5, 84:15 88:11 50:2 52:15 opposed 30:11 owner 92:2 99:24 60:10,13,18 61:21 62:2 ntile 10 16:23 108:15 option 104:12,22 112:13 118:8 88:17 89:9 option 16:23 108:15 options 130:5,20 99:2,9 35:10 36:2,3 ptions 35:10 36:2,3 p.m. 133:4,5 101:20 oranges p5:18 pc.m. 153:24,25 102:7,14,20, p5:18 pc.m. 146:13 147:3 153:21,25 129:15,16 10:14 25:21 10:14 25:21 10:2,8 165:20,23 136:11 145:8 86:13 88:5 pack 171:18 153:23 116:8 135:9 138:7,16 40:15 83:22 177:22 164:7,9,17 175:3 packs 109:8,9,12 13:11:11,15 180:13 180:14 orders 109:8,9,12 13:11:11,15 11:28 181:13,24,25 166:22 organize 109:8,9,12 13:11:11,15 11:28 182:2,5 organized 59:23 161	42:23 64:7	42:14,17		
74:2 78:18 50:2 52:15 opposed 7 84:15 88:11 57:17 58:9 30:11 owner 104:12,22 61:21 62:2 16:23 108:15 option 120:4 125:14 88:17 89:9 options 16:23 108:15 options 130:5,20 99:2,9 35:10 36:2,3 p 136:4,5 10:20 137:23 oranges 143:6,12 101:20 95:18 ps:18 153:24,25 102:7,14,20, ps:18 ps:20,23 166:91 157:9 22 103:5,7, 10:14 25:21 pack 163:21,25 129:15,16 50:19 69:9 package 165:20,23 136:11 145:8 86:13 88:5 pc:69:9 168:14 151:20 116:8 135:9 package 177:15,18,23 164:7,9,17 138:7,16 packs 177:15,18,23 164:7,9,17 138:7,16 packs 177:15,18,23 166:11 175:3 packs 18:13,24,25 166:21 0perate 12:11 packs 106:22 organize 12:11 packs 106:22 organize 59:23 161:25 13:11:11,15 12:8 12:11 packs 10:14 25:21 12:11 12:11 <	67:6 71:7			
84:15 88:11 92:2 99:24 60:10,13,18 30:11 option 175:14 175:14 176:10 owner 176:11 176:11 176:11 176:11 176:11 176:11 176:11 176:11 176:11 176:11 176:11 176	74:2 78:18	1		· ·
99:2 99:24 104:12,22 112:13 118:8 120:4 125:14 130:5,20 132:25 133:5 136:4,5 143:6,12 153:24,25 156:19 157:9 158:21 163:21,25 163:21 175:14 176:10 175:14 176:10 175:14 176:10 175:14 176:10 175:14 176:10 175:14 176:10 175:14 176:10 175:14 176:10 176:10 175:14 176:10 17	84:15 88:11	1		
104:12,22 112:13 118:8 120:4 125:14 130:5,20 132:25 133:5 136:4,5 11,15,18 143:6,12 153:24,25 156:19 157:9 158:21 163:21,25 163:21,25 163:21,25 163:21,25 163:21,25 163:21,25 163:21,25 163:21 175:18 177:15 180:14 175:3 177:15,18,23 177:15,18,23 177:15,18,23 178:5,9 180:13 178:5,9 180:13 178:5,9 180:13 178:5,0 179:18 0ne-and-a- half 159:18 0ne-and-one 94:19 61:21 62:2 88:17 89:9 97:21 98:14 16:23 108:15 177:23 0ranges 95:18 0rder 10:14 25:21 10:14 25:21 10:14 25:21 10:14 25:21 10:14 25:21 10:14 25:21 10:14 25:21 10:14 25:21 10:14 25:21 10:14 25:21 110:2,8 110:	92:2 99:24	1		
12:13 118:8 88:17 89:9 97:21 98:14 30:5,20 99:2,9 100:2,3,8, 136:4,5 101:20 102:7,14,20, 153:24,25 129:15,16 163:21,25 129:15,16 165:20,23 136:11 145:8 168:14 151:20 168:14 171:18 153:23 172:22 176:4,5,6 177:15,18,23 178:5,9 180:13 178:5,9 180:13 181:13,24,25 180:2 120:7,10 120:7,10 120:7,10 120:7,10 159:18 0ne-and-ane 94:19 14:25 149:24 0ther's 138:11 79:14,25 149:24 0ther's 81:23 85:17, 149:24 0ther's 149:24 0ther's 149:24 0ther's 149:24 0ther's 149:24 0ther's 149:24 0ther's 149:24 0the	104:12,22		_	
130:5,20	112:13 118:8	88:17 89:9		1/0.10
130:3,20 99:2,9 100:2,3,8, 136:4,5 11,15,18 137:23 p.m. 146:13 147:3 p	120:4 125:14	97:21 98:14		
136:4,5	130:5,20	99:2,9		P
143:6,12	132:25 133:5	100:2,3,8,		
153:24,25 102:7,14,20, 95:18 pack 156:19 157:9 22 103:5,7, 10:14 25:21 95:20,23 163:21,25 129:15,16 50:19 69:9 package 165:20,23 136:11 145:8 86:13 88:5 package 168:14 151:20 96:6 99:5 84:8 171:18 153:23 116:8 135:9 packaging 172:22 164:7,9,17 138:7,16 85:4 177:15,18,23 180:14 orders 109:8,9,12, 178:5,9 opened 24:8 175:2 109:8,9,12, 180:13 22:22 organize 109:8,9,12, 181:13,24,25 166:22 organized 59:23 161:25 56:12,13 120:7,10 153:5,8 166:6 73:11 74:6, one-and-a-half 18:3 25:6 original 15,17 75:12 159:18 operates 138:11 79:14,25 0ne-and-one 14:25 138:11 79:14,25 94:19 149:24 other's 81:23 85:17,		11,15,18		=
156:19 157:9 158:21 163:21,25 165:20,23 168:14 171:18 172:22 176:4,5,6 177:15,18,23 178:5,9 180:13 181:13,24,25 182:2,5 cone's 120:7,10 cone-and-a-half 159:18 cone-and-one 94:19 10:14 25:21 10:12,8 10:14 25:21 110:2,8 11	143:6,12	101:20	_	146:13 147:3
158:21 11 104:5 10:14 25:21 110:2,8 163:21,25 129:15,16 50:19 69:9 package 165:20,23 136:11 145:8 86:13 88:5 40:15 83:22 168:14 151:20 116:8 135:9 86:6 99:5 84:8 171:18 153:23 116:8 135:9 packaging 172:22 164:7,9,17 138:7,16 85:4 176:4,5,6 165:11 175:3 packs 177:15,18,23 180:14 orders 109:8,9,12, 180:13 22:22 organize 109:8,9,12, 181:13,24,25 166:22 organized 12:11 page 106:22 operated 59:23 161:25 56:12,13 120:7,10 153:5,8 166:6 73:11 74:6, one-and-a-half 18:3 25:6 original 15,17 75:12 159:18 operating 138:11 76:8,10 one-and-one 114:25 138:11 79:14,25 94:19 149:24 other's 81:23 85:17,	1	102:7,14,20,		pack
163:21,25 129:15,16 50:19 69:9 package 165:20,23 136:11 145:8 86:13 88:5 40:15 83:22 168:14 151:20 96:6 99:5 84:8 171:18 153:23 116:8 135:9 packaging 172:22 164:7,9,17 138:7,16 packaging 176:4,5,6 165:11 175:3 packs 177:15,18,23 180:14 orders 109:8,9,12, 180:13 22:22 organize 109:8,9,12, 181:13,24,25 166:22 organized 53:16,19 120:7,10 59:23 161:25 56:12,13 159:18 operates 18:3 25:6 original 77:12,13,19 159:18 operating 14:25 138:11 79:14,25 94:19 149:24 other's 81:23 85:17,	156:19 157:9	22 103:5,7,		95:20,23
165:20,23 136:11 145:8 86:13 88:5 40:15 83:22 168:14 151:20 96:6 99:5 84:8 171:18 153:23 116:8 135:9 packaging 172:22 164:7,9,17 138:7,16 85:4 176:4,5,6 165:11 175:3 packs 177:15,18,23 180:14 orders 109:8,9,12, 180:13 22:22 organize 109:8,9,12, 181:13,24,25 22:22 organize 12:11 page 182:2,5 operate 106:22 organized 53:16,19 56:12,13 120:7,10 153:5,8 operates 166:6 73:11 74:6, 75:12 159:18 operates 23:2 108:11 76:8,10 77:12,13,19 159:18 operating 138:11 79:14,25 94:19 149:24 other's 81:23 85:17,		11 104:5		110:2,8
168:14 151:20 96:6 99:5 84:8 171:18 153:23 116:8 135:9 85:4 172:22 164:7,9,17 138:7,16 85:4 176:4,5,6 165:11 175:3 packs 177:15,18,23 180:14 orders 109:8,9,12, 180:13 22:22 organize 12:11 page 181:13,24,25 106:22 operate 12:11 page 106:22 operated 59:23 161:25 56:12,13 12:11 56:12,13 73:11 74:6, one-and-a-half 18:3 25:6 original 15,17 75:12 159:18 operating 138:11 76:8,10 one-and-one 114:25 138:11 79:14,25 94:19 149:24 other's 81:23 85:17,	-	129:15,16		package
171:18 153:23 116:8 135:9 packaging 172:22 164:7,9,17 138:7,16 85:4 176:4,5,6 165:11 175:3 packs 177:15,18,23 180:14 orders 109:8,9,12, 180:13 22:22 organize 12:11 page 181:13,24,25 operate 12:11 page 182:2,5 operated 59:23 161:25 56:12,13 120:7,10 153:5,8 operated 59:23 161:25 56:12,13 159:18 operates original 15,17 75:12 159:18 operating 0TB 77:12,13,19 one-and-one 14:25 138:11 79:14,25 94:19 149:24 other's 81:23 85:17,	-	136:11 145:8		40:15 83:22
172:22 164:7,9,17 138:7,16 85:4 176:4,5,6 165:11 175:3 packs 177:15,18,23 180:14 orders 109:8,9,12, 180:13 22:22 organize 112:8 181:13,24,25 operate 12:11 page 182:2,5 operated 59:23 161:25 56:12,13 120:7,10 153:5,8 166:6 73:11 74:6, one-and-a-half 18:3 25:6 original 15,17 75:12 159:18 operating 0TB 77:12,13,19 one-and-one 14:25 138:11 79:14,25 94:19 149:24 other's 81:23 85:17,		151:20		84:8
172:22 164:7,9,17 138:7,16 85:4 176:4,5,6 165:11 175:3 packs 177:15,18,23 180:14 orders 109:8,9,12, 180:13 22:22 organize 13 111:11,15 181:13,24,25 operate 12:11 page 182:2,5 operated 59:23 161:25 56:12,13 120:7,10 operated 59:23 161:25 56:12,13 153:5,8 operates 166:6 73:11 74:6, one-and-a-half operating 0TB 15,17 75:12 159:18 operating 138:11 79:14,25 one-and-one 14:25 149:24 other's 81:23 85:17,				packaging
177:15,18,23 180:14 orders 109:8,9,12, 178:5,9 opened 24:8 175:2 13 111:11,15 180:13 22:22 organize 112:8 181:13,24,25 operate 12:11 page 182:2,5 operated 59:23 161:25 56:12,13 120:7,10 153:5,8 original 73:11 74:6, one-and-a- operates 0riginal 15,17 75:12 159:18 operating 0TB 77:12,13,19 one-and-one 114:25 138:11 79:14,25 94:19 149:24 other's 81:23 85:17,		164:7,9,17	-	
177:15,18,23 180:14 orders 109:8,9,12, 178:5,9 opened 24:8 175:2 13 111:11,15 180:13 22:22 organize 112:8 181:13,24,25 operate 106:22 organized one's 106:22 operated 59:23 161:25 56:12,13 120:7,10 153:5,8 operated 59:23 161:25 56:12,13 153:5,8 operates 73:11 74:6, 75:12 159:18 operating 0TB 77:12,13,19 one-and-one 114:25 138:11 79:14,25 94:19 149:24 other's 81:23 85:17,				packs
178:5,9 opened 24:8 175:2 13 111:11,15 180:13 22:22 organize 112:8 181:13,24,25 operate 12:11 page 182:2,5 operated 59:23 161:25 56:12,13 120:7,10 153:5,8 original 73:11 74:6, one-and-a-half 18:3 25:6 operating 0TB 77:12,13,19 one-and-one 114:25 138:11 79:14,25 94:19 149:24 other's 81:23 85:17,		180:14		
180:13 22:22 organize 112:8 181:13,24,25 operate 12:11 page 182:2,5 one's 59:23 161:25 56:12,13 120:7,10 153:5,8 166:6 73:11 74:6, one-and-a- operates original 15,17 75:12 159:18 18:3 25:6 23:2 108:11 76:8,10 one-and-one 114:25 138:11 79:14,25 94:19 149:24 other's 81:23 85:17,	-	opened	24:8 175:2	
181:13,24,25 operate 12:11 page 182:2,5 one's 59:23 161:25 56:12,13 120:7,10 153:5,8 166:6 73:11 74:6, one-and-a-half 159:18 operating 0TB 77:12,13,19 one-and-one 14:25 138:11 79:14,25 94:19 149:24 other's 81:23 85:17,		22:22	organize	,
182:2,5 106:22 organized 53:16,19 one's 59:23 161:25 56:12,13 120:7,10 153:5,8 166:6 73:11 74:6, one-and-a-half 18:3 25:6 23:2 108:11 76:8,10 159:18 operating OTB 77:12,13,19 one-and-one 114:25 138:11 79:14,25 94:19 149:24 other's 81:23 85:17,		operate	12:11	
one's 120:7,10 59:23 161:25 56:12,13 one-and-a- 153:5,8 166:6 73:11 74:6, one-and-a- operates original 15,17 75:12 159:18 23:2 108:11 76:8,10 one-and-one 0TB 77:12,13,19 one-and-one 114:25 138:11 79:14,25 94:19 149:24 other's 81:23 85:17,	•	. –	organized	
120:7,10 one-and-a- half 153:5,8 operates 18:3 25:6 166:6 original 15,17 75:12 76:8,10 77:12,13,19 one-and-one 94:19 153:5,8 operates 18:3 25:6 166:6 OTB 15,17 75:12 76:8,10 77:12,13,19 79:14,25 149:24 other's 138:11 79:14,25 81:23 85:17,		operated	59:23 161:25	· ·
one-and-a-half operates original 15,17 75:12 159:18 00erating 0TB 77:12,13,19 one-and-one 114:25 138:11 79:14,25 94:19 149:24 0ther's 81:23 85:17,	•	. –	166:6	· ·
half 18:3 25:6 23:2 108:11 76:8,10 159:18 operating OTB 77:12,13,19 one-and-one 114:25 138:11 79:14,25 94:19 149:24 other's 81:23 85:17,	one-and-a-	· ·	original	· ·
159:18 operating OTB 77:12,13,19 one-and-one 94:19 operating 138:11 79:14,25 81:23 85:17,		· -	_	I
one-and-one 94:19 114:25 138:11 79:14,25 149:24 other's 81:23 85:17,	159:18		OTB	•
94:19 149:24 other's 81:23 85:17,	one-and-one		_	1
	94:19			,
		1		

16,25 94:4,	56:19 68:24	peak	98:2,16
10 114:24	71:20,22	172:2	101:17
115:8 123:22	75:3 77:3	penalty	103:10,25
124:5,21	111:13	5:10	104:6 116:13
125:8,9	130:13,17	pending	126:22 133:6
126:4,18,19,	138:3 140:25	11:17 110:16	135:24
25 127:2,19	141:6		155:17
142:3	168:24,25	people 27:14 31:16	156:22,25
painless	171:13	32:2,6,8,14,	157:8 158:25
6:22	174:12,19	15,16,19	159:2,10,18
papers	183:14	33:20 40:9	160:12
177:19	participate	41:23 45:21	167:8,12,14,
178:20,24	53:13	58:7 64:21,	16 173:2
179:7	participated	24,25 66:6	179:21
	107:3	68:7 69:3	180:3,7
paragraph 15:21,23	participating	70:2 71:9,	181:2,21,22
■	5:3	12,18 73:4	percentage
16:4 17:22 23:17 25:3		82:16 83:21,	104:4
29:8 34:25	particular	23 93:19	135:22,23
36:6 38:10,	14:22 51:16 64:4 68:14	96:9 101:19	percents
12 40:18		102:20	179:22
41:12 42:6	84:22 88:8	102:20	perform
44:17 46:11	92:12 106:25	107:21 110:9	52:11 174:23
53:20,24	158:21	125:12,21	175:4,20
55:14,22,23	179:11	134:3 151:19	· ·
56:15,23	parties	153:20 154:9	<pre>performance 83:13</pre>
63:20 75:16	5:12,17 6:19	172:2 174:2,	
76:20 80:2	18:9 26:23	3 176:21,22	127:11,17
81:24 83:8	partners	177:6,16	performed
85:25 97:13,	117:9 118:4,	178:2,7	183:13
14 114:2	5	people's	performs
115:3,9	partnership	93:22	85:8
117:5 118:2,	21:9 23:12,		period
10,11 133:20	14 168:4	per-draw 103:7,9	28:20 33:3
142:3,18	party	·	65:13 138:22
143:24	39:13	perceived	150:13
144:16,17	past	134:3,5	171:11
paragraphs	21:2 25:11	percent	periodically
30:15 106:4,	86:19	7:7 27:23	177:6
5	patience	29:15,17,19	perjury
parallel	145:23	35:19,20	5:11
64:18 175:9	pay	36:9,12,13,	person
	50:4,19	14,23,24	5:8 102:18
parameters 155:8	109:11	37:7,24 38:2	119:20
	paying	43:2 66:11,	181:20
part	175:5	25 67:4	personnel
26:25 29:12,	payments	70:25 71:12	171:22
13 35:7,9	156:11,13	72:15 80:3	
40:14 47:7		97:21,24	
L			

	-	20, 2021	
phase	pictures	PMTA	97:22
59:6 60:12	125:20	58:6 61:11	point
phases	162:14	137:17,20	6:10 7:20
59:5	pipeline	138:15	8:6,9,19 9:5
Philip	86:4	140:2,3,17	17:25 18:3,6
7:12,13 8:24	pit	141:8,12	20:14,23
9:2 14:15,	163:16	142:10	25:6 48:5,9,
16,17 16:9,	PK	PMTAS	10 53:12
11,14,17	44:3 45:14	142:22	62:7,24 72:3
39:22 59:16	139:8	pocket	75:8 76:13
65:19,20	place	41:21 102:2,	82:9,21
106:6,11,13,	43:23 54:10	3	104:2 113:22
18 107:2	58:6 100:17	pod	114:4,7
108:2 109:17	places	20:4,7,8,14,	115:2,3,18,
110:6,17	162:6	16 21:24,25	21 122:3
111:13,24	plan	22:16,20,22	133:5,12
112:10,16,	12:8	23:6 36:4	136:16
18,22,25		42:13,16	141:21 142:5
174:5 179:13	planned 152:23	46:3,23 49:6	144:13,19
180:18 181:8		50:14,17,25	147:24
phone	planogram	51:7,15	148:20
12:5	177:3	57:10 61:8	149:12
photo	plant	67:15 76:22	151:23
128:7	170:7,22	77:7 91:6,17	152:7,22
phrase	platform	93:11,15,16	153:5,15
55:4,6	151:3	94:16,17	157:15
physical	player	95:2,6,16,20	166:24
139:7	59:14 62:11	102:3 103:9	167:19 169:2
physically	players	104:4,6	171:21
5:4 25:12	58:3	130:20	173:7,12
physiological	playing	164:3,6,11,	Point's
171:5	12:25	12,18	52:17,24
physiological	please	pod-based	53:7 81:7
ly	5:15 6:2	20:25 28:2,5	114:17 125:14
171:6	10:16,21	47:11 48:4,	_
pick	11:17 30:8	9,19 49:7,23	points
47:24 148:9	36:20 52:12	51:2 75:17	160:4 172:22
162:24	81:15 123:11	82:23 91:23	poke
picked	141:23	pods	157:21
162:25	143:17	20:9 33:21,	160:12
168:20	plenty	24 34:2,6,7,	political
picking	73:4	10,17,20	138:24 164:2
100:20	plethora	35:7 42:10	politically-
picture	60:20	46:12 58:9	sensitive
125:24	plumes	78:5 83:5,9	176:16
128:12,13	33:16,17	87:14 93:14,	popular
120.12,13	42:4 60:25	20,23 94:14,	27:16 134:7
		15 95:9	164:12

	-	1 1 1 1 1 1 1	
popularity	preference	131:13	principally
42:11 134:9	66:11 67:5	139:24	23:24 148:6
population	96:10 103:4	164:18	151:4 178:21
164:13	161:4,5,7	179:10	principals
populations	preferences	prevented	156:4 157:21
164:13	82:8,12	161:9	principles
portable	premarket	preventing	107:4,9,12
41:20	137:17	161:10	113:2
portfolio	138:15 142:8	previous	priority
82:2 153:9	premium	71:10	166:15
portion	178:24	price	privileged
7:15 72:11	prepare	48:6 49:7,	10:25 107:16
150:8	13:14 65:9	14,22,23	probably
position	prepared	50:22,24,25	25:10 50:9
66:21 108:4	12:7 13:21	51:3,5	51:12 56:10
114:6	15:6	78:13,17,18	66:23 69:17,
positioned	prescription	82:9,21	20 89:24
82:8,11	125:19	83:4,5 92:2,	95:15 105:4
positioning	presence	6,18 93:6	113:19 154:6
85:5	28:9 145:16	94:12,13,15,	172:13
	150:3	16,17 95:6,	problem
positive	present	11,16,17	13:2 63:20
80:13	5:5 166:14	97:22	81:15 86:22
117:12,17,18		101:15,17	87:4,8,9
118:15	presentation	103:18	89:2 135:8
possible	92:4	169:6,11	problematic
6:23 9:12	presentations	priced	145:17
32:17 93:23	123:20	64:16 82:22	problems
108:3 162:24	163:18	91:22 92:5,9	163:15
176:19	President	93:18 94:2,	
possibly	6:12 85:21	4,16 108:7	proceed 111:7
116:7	press	160:21	
potential	54:18 96:25	prices	PROCEEDINGS
139:10	141:21 142:5	49:5,10	5:1
159:23	pressure	50:14 94:13,	proceeds
potentially	164:2	22 96:5	150:8
95:13 144:24	presume	103:6 104:6	process
power	26:2 83:12	pricing	8:11 25:16
100:23	presumption	49:16,19	66:5 93:12
178:19	159:4	50:5 91:7	100:3,16,18
practice	pretty	93:9,10	137:18,20
11:10 54:16	7:14 15:14	94:25 95:5	138:3,7,14
preceded	24:19 27:24	108:19	139:14
59:13	32:23 43:22	175:15	140:2,10,13,
precise	51:18 63:11	primarily	17 152:25
144:3	64:12 68:6	30:10	158:8 178:15
preexisting	75:25 76:3	principal	produced
167:25	92:18 117:12	19:4 152:2	8:10 18:14
10,125		17.1 192.2	
		<u> </u>	I

35:25 37:11	151:12,15	20,22 59:7,	116:7
41:6 60:16	153:25	9,10,12	profitable
produces	157:17 159:6	60:20,21	183:8
19:10	160:11,25	62:19,22	program
product	162:20,23	64:2,22	109:3 151:10
19:21 20:25	163:6,9,10,	66:15 68:10,	181:15
21:7 22:24,	11,12,25	17 80:4,9	programs
25 23:2	165:9	82:3,24	108:25
30:22 32:12	166:14,24	84:25 85:9	109:24 124:5
33:5 36:13,	167:20,22,	87:5 90:23	
24 37:24	23,24,25	91:10,12,15,	promo 123:25 124:7
38:2 39:5,7	168:3,5,9,20	23 93:5 94:4	
40:3,16	169:3,4,14,	104:4 105:19	promotion
41:5,16 44:7	18 171:25	106:21	108:20
49:23 59:17,	172:3 173:6,	108:3,5,6,8	promotional
19 62:15	9 174:21,24	110:13	96:5 110:3,8
64:11 65:5,	175:11 176:7	112:19	116:5 156:13
10,24 66:2,	177:5	116:13 117:7	promotions
19,24 67:2,3	178:22,23	125:14	60:5 156:13
68:5,14 69:3	179:16 180:4	127:11	properties
71:2,15 72:7	181:2,4	128:25	170:24
73:22 77:10	182:2,16	130:14,18	proportion
78:13 83:25	183:6,12	134:2	180:18
84:2,13,24	product's	135:15,21,22	181:19
86:3,16,23	104:11	137:25	proportional
88:5,20	127:17	138:12,18	181:19
93:21 95:15	production	139:17 140:9	proposition
96:5 99:18	73:11	142:9,11,24	77:23,25
104:20	products	145:6,11,16,	79:2
105:3,6,14,	13:19 18:4,	18 151:16,	proprietary
24 109:22,24	5,7,8,13,16,	18,24 152:3,	24:21,23,24
112:10	17,18,20,21,	9 159:7,22	69:6 75:17
116:2,20	22,23,25	160:2,10,23	protective
121:7,8	21:6,19 22:6	161:8,10	25:21 69:9
127:16	23:3,25	162:21	
128:10,14,19	24:22,23,24	163:24 172:7	<pre>proud 55:5 183:11,</pre>
130:24	25:9 26:17,	173:8 174:22	12
131:7,14	20 28:18	175:15,17,18	
136:6,24	30:13 36:7,	176:11	proudest 177:23
137:11,15	11,15,22	177:18	
138:4,12	37:2 40:9	179:10,12,20	prove
139:11	41:9 42:25	180:22	183:7
145:13	43:12,18	182:18,20	proven
147:23	47:11 48:5,	profit	79:4
148:4,5,6,9,	6,9,11,15,	50:21	provide
12,20,22	18,20 49:3,	profitability	38:16 47:20
149:6,14	14 50:14	80:8,13	54:9 69:5
150:3,4,17	56:21 58:11,	110:7,12	86:8 119:15

	Ualidary	•	
provided	pursue	95:14	quickly
40:2 62:24	120:9 141:8	quantity	172:15
67:23 68:9	put	61:2 95:10	181:17
84:3	12:16 18:18	quarter	Quiktrip
provides	22:18 25:11	53:11 79:6	125:5 126:9,
68:18 69:10	58:6 59:19	81:22 86:7	20 127:5,15
90:18,23	61:11 72:22	115:6,16,22	135:11
102:8	80:17,21	quarterly	quite
proving	84:7 88:4,9	53:13	102:12 106:6
87:12	96:25 97:7	question	112:15
provision	99:23 108:3,	10:12,20,25	120:21
138:17	25 125:12	11:4,16,18	162:10
provisions	129:4,22	30:8 36:20	164:23 176:2
149:22,24,25	130:10	37:8 48:21	183:10
150:5,7	133:25	63:17 71:11	quote
155:23	136:22	79:7,8 84:7	44:19
public	140:24	93:25 94:9	quoting
5:21 9:5	151:10	97:2 98:22	84:3
17:25 54:19	155:23 161:8	99:6 104:9	
published	170:8,17	105:11,12,	
43:10	172:8 175:21	22,25 110:16	R
puffs	176:19 177:9	112:15,17	Ded
40:21	182:21	117:16	R&d
	putting	119:3,13	171:24
pull 150:4 165:3	78:11 150:16	120:9,10,20,	172:3,7,23
	160:10 177:5	22 125:5	rack
punches 55:6 116:12		130:16	109:7 160:20 175:24 176:8
	Q	131:22,23	177:6 180:9,
purchased		132:14	15 183:4
149:4	Q1	134:14	racks
purchases	52:17,23,24	142:21	109:16
87:13	53:7 75:7	144:18	121:17
Purdy	Q2	173:23	176:18 182:5
76:10,11,12,	81:2,8,19	questions	raise
15 77:22	Q3	8:13 9:16,18	49:13
78:20 85:21 87:11 114:25	114:17	10:10,24	
115:9,12	Q32019	12:9 14:23	range 33:11 34:11
116:19	114:14	30:18 89:8	35:9 36:13,
117:17	quality	98:20	23 37:19,25
118:12	78:13 104:20	119:22,24	38:2 40:11
120:22	105:4	143:16	60:20 64:2
120:22	quant	145:24 146:3	71:8 83:20
Purdy's	65:21 66:9	147:13,17	84:21 85:3
76:21 77:14	quantitative	quick	101:7
85:18 86:5	64:16	6:22 11:16	rank
purpose	quantities	36:6 97:2	157:24
145:4 158:16	78:14 94:20	143:7 183:23	158:3,9,22
113:1 130:10			

ranked	realized	141:19	release
158:23	57:5 58:13	146:10,11	54:18 97:2
rapid	reason	149:20	141:21 142:6
43:25 44:2	44:15 68:3	183:22	reluctant
46:12,21	75:3 97:25	reducing	114:3
rapidly	164:8 183:11	160:15	remark
61:13 83:17	reasons	reference	79:11
rate	32:2,21	147:17	remarks
43:4 116:13	41:17 42:10	referred	56:13 76:9,
166:20	rebates	97:19	21 77:14
172:12,14	116:5	referring	85:18 86:5
rates	recall	12:10 13:4	remember
87:11,13,15,	26:19 28:6,	44:3 46:15,	15:3,13,18
		16 48:14	16:25 21:3
16,22,25 165:15,24,25	17 147:22,25 148:13	57:10 58:12	27:24 28:21
		63:16,25	29:4 58:15
166:8,9,11	154:18,21 168:7	64:6,8 74:19	59:2 62:6
rational		83:11 98:10	76:7 78:6
181:20	received	142:14 143:4	
Razz	52:13,14		83:2,6 108:12 109:5
126:20	134:10	150:20,25	113:15
re-supplying	receiving	refers	
42:16,17	174:24	87:13 144:23	114:22
reach	recent	refill	123:21
13:23	32:23,25	101:25	134:10,20
reaction	recently	refilled	143:21
68:16 163:8	56:20 130:7	22:22 182:6	159:25
170:10,19	153:3	reflect	168:11 180:9
reactions	recess	30:13	remind
66:7	52:6 96:23	reflected	89:11
reactors	146:12	14:25	reminds
170:16	183:24	regimen	89:11
read	recognize	108:19,20	remote
44:12 78:23	53:6 81:18	regulated	9:9
89:5,12	89:17 114:16	162:8	remotely
114:21	Recognizing	regulatory	5:7
122:14	14:18	133:10,23	renew
125:21	reconvene	relate	127:16
Reade	96:17	65:24,25	rent
130:2	record	relating	50:5,12
ready	5:16 6:3	72:7	reorder
63:14 88:12	11:3 48:8,13		87:11,13,15,
89:13 103:2	50:8 52:5	relationships	16,22,24
	55:24 81:5	50:7	repeat
real	88:18 96:22	relative	30:8 36:19
35:11	98:22 114:13	49:14 94:24	63:17 105:11
reality	123:6 129:10	95:12 103:5	117:15 119:3
103:6	138:9 139:16	108:4	120:20
121:15,24	120.7 123.10		120-20

129:18 132:14 65:17 70:2 21 175:7,12 30:11 31:4, repeating responds 64:10 180:23 7,17,23 182:12 183:8 32:24 33:22, retailers 25:34:10,18 36:16 37:2, 175:5 108:15,21 36:16 37:2, 175:5 108:15,21 36:16 37:2, 175:5 108:15,21 36:16 37:2, 175:5 108:15,21 36:16 37:2, 175:5 108:15,21 36:16 37:2, 175:5 108:15,21 36:16 37:2, 175:5 118:6,23 39:9,15,17, 284 109:11 36:16 37:2, 175:5 118:6,23 39:9,15,17, 284 109:11 36:16 37:2, 175:5 118:6,23 39:9,15,17, 284 109:12 118:6,23 39:9,15,17, 284 109:12 109:11 136:16 37:2, 174:14 44:3,4,19 109:19 restrict to 159:9 restrict to 159:9 restricted 133:6 87:6 result				
repeating responds 180:23 7,17,23 32:24 33:22, 33:20, 33:20, 33:20, 33:20, 33:20, 33:20, 33:20, 33:20, 33:20, 33:20, 33:20, 33:3, 35:8, 22 36:16, 37:2, 35:8, 22 33:3, 33:3, 33:3, 33:3, 33:3, 33:3, 33:3, 33:3, 33:3, 33:3, 33:3, 33:3, 33:3, 33:3, 33:3, 33:3, 33:3, 33:3, 33:1, 31:5, 37:1, 34:10, 43:10, 43:10, 43:10, 43:10, 43:10, 43:10, 43:10, 43:10, 43:10, 43:10,		_	- 1	
70:19 64:10 182:12 183:8 32:24 33:22, replaced 34:6 response 66:17 172:18 retailers 25:34:10,18 replenishment 150:14 responsible 177:5 108:15,21 35:8,22 36:16 37:2, reporter 5:2 10:7,15 rest 134:24 39:9,15,17, 24 40:4 41:3 represent 128:18 10:21 98:21 retailers' 24 40:4 41:3 39:9,15,17, represent 128:18 10:21 98:21 retailers' 45:10,13,18 46:18 47:4 44:3,4,19 representation 159:29 restrict return 10:11 52:4 45:10,13,18 46:18 47:4 48:14 52:9, 43:15 74:14 44:3 45:10,13,18 46:18 47:4 48:14 52:9, 43:15 74:11 74:14 44:13 44:14:3 45:10,13,18 46:18 47:4 48:14 52:9, 43:15 72:15:14 72:15:14 72:15:14 72:15:14 72:15:14 72:15:14 72:15:14 72:15:14 72:15:14 72:15:14 72:15:14 72:15:14 72:17:14 <t< td=""><th></th><td></td><td>I - I</td><td>-</td></t<>			I - I	-
replaced 34:6 response 66:17 172:18 108:15,21 35:8,22 replenishment 150:14 responsible 109:11 36:16 37:2,8 35:8,22 reporter 5:2 10:7,15 74:10 85:25 138:424 39:9,15,77 39:15,77 reporting 5:6,14 150:23 restate 133:4,5 24 40:4 41:3 44:3,4,19 represent 128:18 10:21 98:21 retailers' 45:10,13,18 45:10,13,18 represent 129:12,19 restate 10:21 98:21 retreatilers' 45:10,13,18 47:4 48:14 52:9, representation 159:9 restricted 10:11 52:4 55:14,18,24 55:14,18,24 representing 6:16 9:17 results 10:15 52:4 55:19,57:11, 72:0 53:24 63:2 68:11, 72:16 74:15,23 required 136:5 resume 134:17 reviewed 27:16 74:15,23 76:18 77:3, 19 80:9,14 requirements 147:5 55:2 56:25 76:18 77:3, 19 80:9,14 76:18 77:3, 19 80:9,14 <t< th=""><th>repeating</th><th>responds</th><th>I .</th><th></th></t<>	repeating	responds	I .	
34:6 66:17 172:18 108:15,21 35:8,22 replenishment 150:14 177:5 109:11 36:16 37:2, 18:6:16 37:2, 18:6:23 reporter 5:2 10:7,15 rest 134:24 39:9,15,17, 24:41:3 39:9,15,17, 24:41:3 39:9,15,17, 24:41:3 39:9,15,17, 24:41:3 40:4 41:3 40:14 41:3 40:4 41:3 40:4 41:3 40:4 41:3 40:4 41:3 40:14 41:3 40:14 41:3 40:14 41:3 40:14 41:3 40:14 41:3 40:14 41:3 40:14 41:3 40:14 41:3 40:14 41:3 40:14 41:3 40:14 41:3 40:14 41:3 40:14 41:3 40:14 4	70:19	64:10	182:12 183:8	
replenishment 150:14 reporter 5:2 10:77,15 reporting 5:6,14 represent 128:18 129:12,19 representatio n 74:2 represented 133:6 result 8:10 31:9 representing 6:16 9:17 reporting 6:16 9:17 required 139:6 180:17 required 60:7 106:8 141:9 requirements 87:6 requirements 87:6 requirements 87:6 requirements 87:6 requirements 87:6 resumed 147:5 requirements 87:6 resumed 128:13 129:12,19 restricted 8:10 31:9 results 10:11 52:4 156:5,11 review 10:11 52:4 156:10 19:23 113:4,17 review 10:11 52:4 156:5,11 review 10:11 52:4 156:13 11:13 12:3:7 review 10:11 52:4 156:5,11 19:20:18 28:10 52:19 53:3 113:13 25:71:23 72:16 74:15, 70:18 70:18 70:18 70:18 70:19 70:19 70:19 70:19 70:19 70:10 70:19 70:10 70:19 70:10 70:19 70:10 70:19 70:10 70:19 70:10 70:19 70:10 70:19 70:10 70:19 70:10 70:19 70:10 70:19 70:10 70:19 70:10 70:19 70:10 70:1	replaced	response	retailers	•
150:14	34:6	66:17 172:18	108:15,21	•
Teporter First Test Te	replenishment	responsible	109:11	
Test	_	_	118:6,23	•
5:2 10:7,15 74:10 85:25 135:4,5 24 40:4 41:3 4,19 represent 150:23 retailers' 45:10,13,18 represent 128:18 10:21 98:21 retrailers' 46:18 47:4 representation restrict 159:9 retreating 43:15 53:14,18,24 represented 133:6 87:6 result 10:11 52:4 56:19,57:11, 56:19,57:11, representing 6:16 9:17 86:7,9 117:9,21 review 28:10 52:19 63:2 68:1, 72:16 74:15, require 139:6 180:17 resume 113:4,17 76:18 77:3, 72:16 74:15, 72:16 7	reporter	rest	134:24	
reporting f:6,14 restart 150:23 retailers' 44:3,4,19 44:3,4,19 represent 128:18 109:19 46:18 47:4 48:14,52:9 45:10,13,18 46:18 47:4 48:14,52:9 46:18 47:4 48:14,52:9 46:18,47:4 48:14,52:9 43:15 retreating 48:14,52:9 12,15,23 53:14,18,24 48:14,52:9 12,15,23 53:14,18,24 48:14,52:9 12,15,23 53:14,18,24 48:14,52:9 12,15,23 53:14,18,24 48:14,52:9 12,15,23 53:14,18,24 48:14,52:9 12,15,23 53:14,18,24 54:19,23 53:14,18,24 54:19,23 56:19,57:11 56:19,57:11 57:11 19,20,58:2,4 66:24,62:20 66:24,62:20 66:24,62:20 66:24,62:20 66:24,62:20 66:24,62:20 66:24,62:20 66:24,62:20 66:24,62:20 66:24,62:20 70:216,74:15 72:23 72:16,74:15 72:23 72:16,74:15 72:23 72:16,74:15 72:23 72:16,74:15 72:23 72:16,74:15 72:23 72:16,74:15 72:23 72:16,74:15 72:23 72:16,74:15 72:16,74:15	_			
5:6,14 150:23 retailers' 45:10,13,18 45:10,13,18 45:11,13,18 45:12,13,18 46:18 47:4 48:14 52:9 48:14 52:9 48:14 52:9 48:14 52:9 48:14 52:9 48:14 52:9 12,15,23 12,15,23 12,15,23 53:14,18,24 48:19,23 53:14,18,24 48:19,23 53:14,18,24 56:19,57:11 56:19,57:11 56:19,57:11 56:19,57:11 19,20,58:2,4 66:19,57:11 19,20,58:2,4 66:19,57:11 19,20,58:2,4 66:19,57:11 19,20,58:2,4 66:19,57:11 19,20,58:2,4 66:19,57:11 19,20,58:2,4 66:19,57:11 19,20,58:2,4 66:19,57:11 19,20,58:2,4 66:19,57:11 19,20,58:2,4 66:19,57:11 19,20,58:2,4 66:19,57:11 19,20,58:2,4 66:19,57:11 19,20,58:2,4 66:19,57:11 19,20,58:2,4 66:19,57:11 19,20,58:2,4 66:19,57:11 71,24 60:2,20 63:2,4 66:19,57:11 72:16,74:15 72:16,74:15 72:16,74:15 72:16,74:15 72:16,74:15 72:16,74:15 72:16,74:15 72:16,74:15 72:16,74:15 72:16,74:15 72:16,74:15 72:16,74:15 72:16,74:15 <t< th=""><th></th><th></th><th>174:14</th><th></th></t<>			174:14	
represent 109:19 46:18 47:4 128:18 10:21 98:21 retreating 48:14 52:9 129:12,19 restrict 159:9 return 12,15,23 74:2 87:6 result 53:14,18,24 133:6 8:10 31:9 28:10 52:19 66:19 57:11, representing 8:10 31:9 28:10 52:19 63:2 68:11, representing 86:7,9 17:9,21 review 63:2 68:11, representing 16:14 results 28:10 52:19 63:2 68:11, representing results 28:10 52:19 63:2 68:11, representing results 23:13 25:71:23 66:16 9:17 results 123:7 72:16 74:15, representing 16:24 62:20 63:2 68:11, representing results 123:7 72:16 74:15, representing 117:9,21 reviewed 13:4,17 76:18 77:3, represide 147:5 resume 13:4,17 76:18 77:3, 76:18 77:3, 19:80:9,14 82:6 83:11, <th></th> <th></th> <th>retailers'</th> <th></th>			retailers'	
128:18			109:19	
129:12,19 restrict 43:15 123,23 123	_		retreating	
representation 159:9 return 10:11 52:4 156:5,11 54:19,23 56:19 57:11, 19,20 58:2,4 56:19 57:11, 19,20 58:2,4 56:19 57:11, 19,20 58:2,4 66:19 57:11, 19,20 58:2,4 61:24 62:20 63:2 68:11, 25:14 61:24 62:20 63:2 68:11, 25:14 63:2 68:11, 25:14 72:16 74:15, 20			43:15	
Taylor Testricted 10:11 52:4 54:19,23 56:19 57:11, 19,20 58:2,4 56:19 57:11, 19,20 58:2,4 56:19 57:11, 19,20 58:2,4 61:24 62:20 63:2 68:11, 19,20 58:2,4 61:24 62:20 63:2 68:11, 25:33 71:23 63:2 68:11, 25:33 71:23 71:23 71:23 71:23 71:23 71:23 71:23 71:23 71:23 71:23 71:24 71:34:23 19 80:9,14 71:34:23 19 80:9,14 71:34:23 19 80:9,14 71:34:23 19 80:9,14 71:34:23 19 80:9,14 71:34:23 19 80:9,14 71:34:23 19 80:9,14 71:34:23 19 80:9,14 71:34:23 19 80:9,14 71:34:23 19 80:9,14 71:34:23 19 80:9,14 71:34:23 19 80:9,14 71:34:23 19 80:9,14 71:34:23 19 80:9,14 71:34:23 19 80:9,14 71:34:23 71:34:23 19 80:9,14 71:34:23 19 80:9,14 71:34:23 19 90:21 71:12,17 71:12,17 71:12,17 71:12,17 71:12,17 71:12,17 71:12,17 71:12,17 71:12,17 71:12,17 71:12,17 71:12,17 71:12,17 <t< td=""><th><u> </u></th><td></td><td>return</td><td></td></t<>	<u> </u>		return	
74:2 restricted 156:5,11 56:19 57:11, represented result 28:10 52:19 53:3 113:13 125 71:23 representing 6:16 9:17 86:7,9 117:9,21 review 23:3 113:13 25 71:23 reps 117:9,21 reviewed 13:4,17 76:18 77:3, 139:6 180:17 resume 134:23 76:18 77:3, required 147:5 rewards 178:14 15 85:10,13 60:7 106:8 147:5 rewards 109:25 199:13,24 141:9 25:13 26:2, Reynolds 87:14 90:6, 111:13 181:8 55:2 56:25 199:13,24 requirements 91:7 110:14 111:22,25 99:33,7,19,25 87:6 150:3 150:3 156:23 169:21 159:12,14 104:11,15, 87:6 150:3 150:3 156:23 159:12,14 104:11,15, 87:6 150:3 150:3 156:23 159:12,14 104:11,15, 17:22 148:9,10 156:23 157:9,13 110:17 17:22 154:24 159:12,14 162:20 172:5 115:22,23 18:16 158:19 17:12,17,122 154:24 158:19 17:12,17 124:19,25	_		I .	
represented result 8:10 31:9 review 28:10 52:19 61:24 62:20 63:2 68:11, 61:24 62:20 63:2 68:11, 63:2 68:11, 72:16 74:15, 72:16			156:5,11	
Testife 8:10 31:9 28:10 52:19 63:2 68:11 representing results 25 71:23 6:16 9:17 86:7,9 17:9,21 reviewed 20 75:2 136:5 resume 13:4,17 70:18 77:3 19 80:9,14 require 181:14 reviewed 13:4:23 19 80:9,14 required resumed 147:5 revisit 15 85:10,13 60:7 106:8 retail 147:5 rewards 87:14 90:6 141:9 25:13 26:2 Reynolds 92:10,16,25 requirement 8,13 54:7 55:2 56:25 59:17 93:6 94:5,17 11:13 181:8 55:2 56:25 91:7 110:14 11:22,25 93:6 94:5,17 87:6 12:5,22 12:11 99:23 research 150:3 156:23 104:11,15, 65:23 168:7 150:3 156:23 104:11,15, 171:22 152:14,24 159:12,14 159:12,14 18:19 154:24 159:12,14 15:22,23 resemble 174:25 175:2 Reynolds' 11:2,17,22 18:19 174:25 175:2 Reynolds' 122:2,211,21 resemble 16:19 122:2,11,21 resumed 106:19 122:2,11,2			·	
representing 8.10 31.9 53:3 113:13 63:2 68:17 feesults 86:7,9 72:16 74:15 reps 117:9,21 reviewed 72:16 74:15 require 181:14 reviewed 20 75:2 139:6 180:17 resume 134:23 19 80:9,14 required 147:5 resumed 178:14 15 85:10,13 fequired 147:5 retail 178:14 15 85:10,13 requirement 111:13 181:8 retail rewards 87:14 90:6 19 91:13,24 requirements 87:6 87:10 90:6 79:17 93:6 94:5,17 95:3,7,19,25 99:210,16,25 99:210,16,25 99:23 112:21 99:23 122:11 99:23 123:7 99:23 123:2	_		I .	
6:16 9:17 86:7,9 117:9,21 reviewed 20 75:2 136:5 resume 134:23 19 80:9,14 require 181:14 resime 134:23 19 80:9,14 required 147:5 revisit 82:6 83:11,158:14 178:14 15 85:10,13 requirement 147:5 rewards 87:14 90:6,19 19 91:13,24 requirement 25:13 26:2,8 Reynolds 92:10,16,25 requirements 91:7 110:14 11:22,25 95:3,7,19,25 87:6 12:5,22 148:9,10 156:23 104:11,15,11 65:23 168:7 150:3 156:23 104:11,15,11 17:9:11 156:23 104:11,15,11 10:17 resemble 154:24 159:12,14 110:17 31:6 158:19 174:25 175:2 180:12,18 115:12,17,22 resembles 15:12 180:12,18 117:12,17,22 18:18 18:2:19 122:2,11,21 124:19,25 resources 106:19 125:6,11,15 64:15 65:18 11:10,24 16:12 18:23 128:4,7,14 11:10,24 11:26 113:5,18 126:10 127:17 106:12 18:23 128:4,7,14 11:10,24 126:10 127:17 <th></th> <td></td> <td>1</td> <td>-</td>			1	-
reps 117:9,21 reviewed 20 75:2 136:5 resume 113:4,17 134:23 76:18 77:3,19 80:9,14 require 181:14 resumed 178:14 82:6 83:11,15 82:6 83:11,15 85:10,13 required 147:5 rewards 15 85:10,13 87:14 90:6,13 141:9 8,13 54:7 rewards 109:25 19 91:13,24 requirement 8,13 54:7 55:2 56:25 59:17 93:6 94:5,17 111:13 181:8 87:6 12:5,22 111:22,25 95:3,7,19,25 87:6 12:5,22 12:11 99:23 research 65:23 168:7 150:3 156:23 104:11,15,21 65:23 168:7 150:3 157:9,13 104:11,15,21 171:22 153:2,4,19 159:12,14 16:220 172:5 115:22,23 158:19 174:25 175:2 180:12,18 181:16 122:19,23 158:19 174:25 175:2 180:12,18 181:81 122:2,11,21 resembles 15:12 16:12 18:23 124:19,25			123:7	
reps 117.9,21 113:4,17 76:18 77:3, require 181:14 resume 134:23 76:18 77:3, required 147:5 resumed 178:14 15 85:10,13 60:7 106:8 141:9 retail rewards 87:14 90:6, requirement 8,13 54:7 respolds 112:13 181:8 requirements 87:6 requirements 91:7 110:14 111:22,25 93:6 94:5,17 research 91:7 110:14 12:5,22 112:11 99:23 resemble 150:3 156:23 104:11,15, 171:22 153:2,4,19 156:23 104:11,15, 181:11 153:2,4,19 159:12,14 110:17 resemble 154:24 159:12,14 112:19,23 158:19 174:25 175:2 179:9,13 117:12,17,22 181:8 182:19 174:25 175:2 retail's 181:8 182:19 122:2,11,21 resembles 15:12 retailer 109:21 124:19,25 resources 64:15 65:18 11:10,24 12:6 113:5, 16:12 18:23 128:4,77,14 64:15 65:18 18 127:14 16:12 18:23 128:4,77,14 19:13,16,24 130:3,14,16,		=	reviewed	
require	_	· ·		
require 181:14 resumed 178:14 revisit 178:14 178:14 178:14 15 85:10,13 87:14 90:6, 19 91:13,24 required 141:9 25:13 26:2, Reynolds 19 91:13,24 90:6, 19 91:13,24 requirement 111:13 181:8 55:2 56:25 79:17 111:22,25 93:6 94:5,17			· ·	
required 60:7 106:8 141:9 requirement 111:13 181:8 requirements 87:6 research 65:23 168:7 171:22 181:11 resemble 31:6 resembled 43:16 resembles 23:7 resources 64:15 65:18 required 147:5 retail 147:5 retail 109:25 Reynolds 109:25 19 91:13,24 Reynolds 92:10,16,25 93:6 94:5,17 111:22,25 111:22,25 112:11 99:23 104:11,15, 156:23 157:9,13 150:17 159:12,14 153:2,4,19 162:20 172:5 179:9,13 117:12,17,22 181:8 181:8 182:19 retail's 115:12 retailer 109:21 retailer 109:21 retailer 109:21 111:10,24 112:6 113:5, 18:16,24 112:6 113:5, 19:13,16,24 130:3,14,16,	_			
required 147:5 rewards 87:14 90:6, 141:9 25:13 26:2, Reynolds 92:10,16,25 requirement 55:2 56:25 59:17 93:6 94:5,17 111:13 181:8 91:7 110:14 11:22,25 95:3,7,19,25 requirements 91:7 110:14 11:22,25 95:3,7,19,25 research 148:9,10 156:23 21,24 106:11 65:23 168:7 150:3 157:9,13 110:17 171:22 152:14,24 153:2,4,19 159:12,14 110:17 resemble 31:6 158:19 174:25 175:2 180:12,18 117:12,17,22 resembles 155:12 Reynolds' 122:2,11,21 resembles 155:12 16:12 18:23 125:6,11,15 resources 64:15 65:18 111:10,24 16:12 18:23 128:4,7,14 64:15 65:18 12:6 113:5, 18 127:14 16:12 18:23 128:4,7,14 respect 18 127:14 19:13,16,24 130:3,14,16,				
col: 7 106:8 retail 109:25 19 91:13,24 requirement 8,13 54:7 Reynolds 92:10,16,25 requirements 91:7 110:14 111:22,25 93:6 94:5,17 87:6 12:5,22 12:11 99:23 research 150:3 156:23 104:11,15, 21,24 100:17 171:22 152:14,24 153:2,4,19 159:12,14 110:17 12:19,23 181:11 153:2,4,19 162:20 172:5 175:9,13 117:12,17,22 181:6 158:19 179:9,13 117:12,17,22 181:6 181:8 182:19 122:2,11,21 resembles 15:12 Reynolds 122:2,11,21 16:19 12:56,11,15 12:56,11,15 18:16 12:10,24 12:18 12:10,14 18:18 182:19 12:56,11,15 18:19 11:10,24 16:12 18:23 128:4,7,14 19:13,16,24 130:3,14,16,	_			
requirement 111:13 181:8 requirements 87:6 research 65:23 168:7 171:22 181:11 resemble 31:6 resembled 43:16 resembles 23:7 resources 64:15 65:18 respect 25:13 26:2, 8,13 54:7 55:2 56:25 59:17 111:22,25 111:12,21 112:11 128:10 128:10 128:10 128:10 128:10 128:10 128:10 128:10 128:10 128:10 128:10 128:10 128:10 128:10 156:23 157:9,13 157:9,13 159:12,14 162:20 172:5 179:9,13 117:12,17,22 180:12,18 181:8 182:19 174:25 175:2 180:12,18 181:8 182:19 122:2,11,21 126:10 127:17 16:12 18:23 128:4,7,14 16:12 18:23 19:13,16,24 130:3,14,16,				
Fequirements 111:13 181:8 55:2 56:25 59:17 93:6 94:5,17 requirements 91:7 110:14 11:22,25 99:23 research 148:9,10 156:23 104:11,15, 65:23 168:7 150:3 156:23 21,24 106:11 171:22 152:14,24 153:2,4,19 159:12,14 110:17 181:11 153:2,4,19 162:20 172:5 115:22,23 resemble 158:19 179:9,13 117:12,17,22 158:19 174:25 175:2 180:12,18 118:16 resembles 115:12 Reynolds' 122:2,11,21 resources 109:21 106:19 125:6,11,15 126:10 7:4,9 12:18 127:17 126:10 127:17 126:10 respect 18 127:14 16:12 18:23 128:4,7,14				-
requirements 87:6 research 65:23 168:7 171:22 181:11 resemble 31:6 resembled 43:16 resembles 23:7 resources 64:15 65:18 requirements 91:7 110:14 112:5,22 148:9,10 150:3 150:3 152:14,24 153:2,4,19 154:24 158:19 174:25 175:2 retail's 111:22,25 112:11 99:23 104:11,15, 21,24 106:11 110:17 110:10:11 110:17 110:17 110:17 110:11 110:17 110:17 110:10:11 110:17 110:10:11 110:17 110:10:11 110:17 110:10:10 110:10:10 110:10:10 110:10:10 110:10:10 110:10:10 1	_			
87:6 112:5,22 128:10 104:11,15, research 148:9,10 156:23 104:11,15, 65:23 168:7 150:3 157:9,13 110:17 171:22 181:11 153:2,4,19 159:12,14 112:19,23 181:11 153:2,4,19 162:20 172:5 115:22,23 158:19 174:25 175:2 180:12,18 117:12,17,22 181:8 182:19 122:2,11,21 124:19,25 resembles 115:12 Reynolds' 124:19,25 resources 106:19 125:6,11,15 64:15 65:18 11:10,24 16:12 18:23 128:4,7,14 11:10,24 16:12 18:23 128:4,7,14 11:10,24 16:12 18:23 128:4,7,14 11:10,24 11:10,24 16:12 18:23 128:4,7,14 11:10,24 11:10,24 11:10,24 11:10,24 11:10,24 11:10,24 11:10,24 11:10,24 11:10,24 11:10,24 11:10,24 11:10,24 11:10,24 11:10,24 11:10,24 11:10,24 11:10,24 11:10,24 11:10,24 11:10,24 11:10,24 11:10,24 </td <th></th> <td></td> <td></td> <td>•</td>				•
research 65:23 168:7 171:22 181:11 153:2,4,19 154:24 158:19 174:25 175:2 resembled 43:16 resembles 23:7 resources 64:15 65:18 respect 112:5,22 148:9,10 156:23 157:9,13 159:12,14 159:12,14 162:20 172:5 179:9,13 117:12,17,22 180:12,18 181:8 182:19 Reynolds' 124:19,25 126:10 126:10 127:17 16:12 18:23 128:10 104:11,15, 21,24 106:11 110:17	_		-	
research 148.9,10 156:23 21,24 106:11 65:23 168:7 150:3 157:9,13 110:17 171:22 153:2,4,19 159:12,14 112:19,23 181:11 154:24 162:20 172:5 115:22,23 158:19 179:9,13 117:12,17,22 158:19 179:9,13 117:12,17,22 181:8 182:19 122:2,11,21 Reynolds' 124:19,25 106:19 125:6,11,15 106:19 125:6,11,15 106:10 127:17 11:10,24 16:12 18:23 128:4,7,14 11:10,24 16:12 18:23 128:4,7,14 11:10,24 19:13,16,24 130:3,14,16,	87:6	-		
65:23 168:7 150.3 157:9,13 110:17 171:22 153:2,4,19 159:12,14 112:19,23 181:11 154:24 162:20 172:5 115:22,23 158:19 174:25 175:2 180:12,18 118:16 181:8 182:19 122:2,11,21 124:19,25 15:12 106:19 125:6,11,15 106:19 125:6,11,15 126:10 11:10,24 12:6 113:5, 16:12 18:23 128:4,7,14 18 127:14 19:13,16,24 130:3,14,16,	research	-		
171:22 181:11 resemble 31:6 resembled 43:16 resembles 23:7 resources 64:15 65:18 respect 152:14,24 153:2,4,19 162:20 172:5 179:9,13 117:12,17,22 180:12,18 180:12,18 181:8 182:19 122:2,11,21 Reynolds' 106:19 right 7:4,9 12:18 16:12 18:23 179:9,13 177:12,17,22 180:12,18 181:8 182:19 122:2,11,21 123:14,24 123:15:22,23 179:9,13 117:12,17,22 180:12,18 181:8 182:19 122:2,11,21 123:14,24 123:15:22,23 179:9,13 110:12,17 180:12,18 181:8 182:19 122:2,11,21 123:14,24 123:15:22,23 179:9,13 110:12,17 110:12,17 123:14,16 112:19,23 115:22,23 179:9,13 117:12,17,22 118:16 123:14,16 123:14 113:15,16 123:14 113:15,16 123:14 113:15,16 123:14 113:15,16 123:14 113:15,16 123:14 113:15,16 123:14 113:15,16 123:14 113:15,16 123:14 113:15,16 123:14 113:15,16 123:14 113:15,16 123:14 113:	65:23 168:7			
181:11 153:2,4,19 162:20 172:5 115:22,23 resemble 158:19 179:9,13 117:12,17,22 resembled 174:25 175:2 180:12,18 118:16 resembles 115:12 Reynolds' 122:2,11,21 resources 106:19 125:6,11,15 64:15 65:18 11:10,24 16:12 18:23 127:17 18 127:14 19:13,16,24 130:3,14,16,	171:22	-	· · ·	
resemble 154.24 179:9,13 117:12,17,22 31:6 174:25 175:2 180:12,18 118:16 resembled 181:8 182:19 122:2,11,21 resembles 15:12 Reynolds' 124:19,25 resources 106:19 125:6,11,15 64:15 65:18 11:10,24 16:12 18:23 127:17 respect 18 127:14 19:13,16,24 130:3,14,16,	181:11		1	
31:6 158:19 174:25 175:2 180:12,18 118:16 resembled 43:16 115:12 Reynolds' 122:2,11,21 resembles 115:12 106:19 125:6,11,15 resources 111:10,24 7:4,9 12:18 127:17 64:15 65:18 112:6 113:5, 16:12 18:23 128:4,7,14 respect 18 127:14 19:13,16,24 130:3,14,16,	resemble		1	
resembled 174.25 175.2 181:8 182:19 122:2,11,21 43:16 retail's Reynolds' 124:19,25 resembles 106:19 125:6,11,15 resources 111:10,24 7:4,9 12:18 127:17 64:15 65:18 112:6 113:5, 16:12 18:23 128:4,7,14 respect 18 127:14 19:13,16,24 130:3,14,16,	31:6		· · ·	
43:16 retail's 115:12 Reynolds' 124:19,25 resembles 106:19 125:6,11,15 resources 111:10,24 7:4,9 12:18 127:17 64:15 65:18 112:6 113:5, 16:12 18:23 128:4,7,14 respect 18 127:14 19:13,16,24 130:3,14,16,	resembled		1	
resembles 23:7 resources 64:15 65:18 respect 115:12 106:19 125:6,11,15 126:10 7:4,9 12:18 127:17 16:12 18:23 19:13,16,24 130:3,14,16,				
23:7 resources 64:15 65:18 respect 109:21 11:10,24 112:6 113:5, 18 127:14 right 7:4,9 12:18 16:12 18:23 19:13,16,24 130:3,14,16,				
resources 64:15 65:18 respect 109:21 111:10,24 112:6 113:5, 18 127:14 109:21 7:4,9 12:18 127:17 128:4,7,14 130:3,14,16,				
64:15 65:18				
respect 112:6 113:5,		-		
	_	18 127:14	17.13,10,24	
	100.0			/ /
		ı	ı	

19 132:6,17	162:3,23,25		162:11
133:11	163:16	s	samples
134:24	165:2,11,14,		65:4
135:12,16	15 166:23	S-T-U-A-R-T	sandwich
136:16,20	167:4,9,20,	6:8	147:10
137:3,7,18	22 168:9,17		sat
140:3 144:24	169:3,18,19	safety	64:20
146:7 152:22	Riptide's	181:18	
154:13	72:13 94:15,	sale	satisfaction
167:19,21	16 95:6	110:7,14	35:18,22 36:2 41:3,7
169:7,11	129:12,19	150:9 177:2	· ·
Ripstick	136:9,19	sales	43:4,7 44:8 45:12 60:18
67:10,16	140:3,17	23:21 24:3	70:9 74:23
68:9 75:13,	169:23	27:21,23	79:4 84:4,
21,23 76:22	Riptides	29:15 30:13	17,23 85:12
92:5 168:18	99:17	33:19 34:2,4	
Riptide	rise	54:7,8 55:2,	90:18,24
19:4,5,17	36:11,21	5,8,17 56:2,	satisfied
20:4,13,23	42:10 43:6,	7,9 86:10	83:21 85:2
54:11 55:15	14	88:20 89:19,	saying
56:3 58:20	risk	25 90:14	7:7 10:8
62:12,19	170:14	97:5 102:16	47:21 68:8,
63:2,4,12,22	rolling	116:10,11	15 77:7,8
64:13 65:25	177:18	125:19 133:7	87:16,25
66:6 67:11,		136:5 155:17	108:17
15 69:4 73:9	room	156:12	110:21
75:17 76:22,	5:5 12:16	160:9,11,15 162:14	119:25 132:20 144:9
25 77:11,22,	58:19,21 62:18,22	164:24	176:14,17
24 78:21	83:24 161:8	165:25	·
80:4,12,20		172:12 174:4	says
82:7,10,20	rooms	175:11	12:22 74:8,
83:25 86:5	58:23	176:9,15	16,21,22
87:10 88:20	roughly	177:17	76:22 77:22 78:25 86:5
91:10,19,22,	30:24 140:8	178:11,16	87:11 90:17,
25 92:9	156:22 174:3	181:20,22	20 94:11
93:15 95:2,	rule	183:11	105:21
25 115:4,10,	120:5	salespeople	115:2,9,12
13,21 116:8,	rules	24:7 175:9	117:4,5
14 118:12,13	9:22 11:21	177:20,21	118:3,13
123:25	58:6	salesperson	122:21
124:7,11,14,	rumor	166:12	123:25
24 125:2,3,	27:16		124:5,7
16 126:4,9,	run	salt	125:15
20 127:5	26:2 135:19	70:13	126:3,19
128:3,8,14	172:12,14	salts	127:4,9
140:9,12,15,	running	47:12 170:4	128:22 130:4
20,25 141:4,	16:17 124:6	sample	131:24
10,14 161:16		45:24,25	142:5,12,16,
			_ = = = -, == , - = ,

22,25	section	segment	114:11 129:7
144:19,22	161:25	56:25 61:10	sense
scale	162:15,17	83:16	11:5 50:3
26:13,15	165:18	segments	167:3 172:6
scan	sections	18:4,7	sentence
123:11	166:5	178:19	38:16 54:4,5
scenario	secure	179:11	75:21 82:7
145:14	130:2	select	142:12,18,
SCHWARTZ	see	57:4 58:12	19,25
119:17 120:7	12:24 21:22	selection	separate
	23:22 32:5	158:7,8	174:9
science	35:3 36:9	182:12,15	_
17:10,11	39:11 40:4	-	separately 20:10
scientific	46:4,13	self-	
45:25 157:20	53:17,25	developed	September
scientist	53:17,25	168:5	134:16,20
45:3,9	69:14 70:11	sell	139:3 140:15
scientists	73:18 74:8,	18:8 21:6,	142:4,6
45:6 171:18	23 80:6 82:4	18,21 23:8	series
scoped	85:18 88:3	25:8 26:16,	70:16 170:17
141:9	89:24 92:6	23 28:2,22	served
scoping	99:10 103:10	30:2,4	8:6
140:19	115:5,10,16	106:21	service
Scott	124:8	108:18 118:9	158:5,18
134:16	125:17,25	135:22	159:22
screen	126:3,23	149:14	181:25
12:17	120:3,23	150:6,11	182:13
	128:7,10,11,	160:6 165:8	set
screens 12:25	14,16,17	167:20,21	48:6 49:5,19
	129:2,16	176:24,25	78:11 107:23
screenshot	136:18 142:4	180:25	108:19
129:13,20	145:5	selling	138:21 153:8
136:9	161:13,17	13:19 17:9,	177:3
scroll	162:15,19,20	11 23:10	sets
114:21	164:17	27:19 28:24	161:9
scrutiny	165:13	50:21 93:12	setting
133:9,10,13,	176:12	110:13	8:16 49:10,
15,17,23,24	177:22	111:11,14	21 50:25
134:9	179:9,24	112:8 128:3	seven
searching	seeing	133:4 137:14	172:2
57:3	36:15,25	148:20	severely
second	37:25 143:21	155:22	172:19,22
30:17 38:15	165:7 168:11	174:10	shadow
54:5 60:11	seek	182:22,24	117:10
75:9 81:22	seek 43:23 44:7	sells	
88:11,13,24		28:18 32:13	shame
105:22 124:6	171:17	181:5	32:11
147:18	seeking	send	shape
	41:18 145:21	12:15 52:8	31:7,13 46:3

_			1 1 5 5 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6
share	shift	135:15	155:21,23,24
11:11 12:18	103:4 160:18	shut	162:19
32:22 33:22,	shifted	26:24 27:3,	similar
24 46:22,23	152:17	6,7,9 149:13	30:25 47:20
47:2,5,8	ship	side	111:25
62:5 111:14,	174:20,25	80:22 88:10	similarly
16 121:12		129:5,23	10:14 70:12
128:24	shipments	I -	
155:9,11,13	88:2 158:19,	130:11	simply
	25 179:21	135:16	20:11 136:4
156:23,25	shipped	sign	single
159:5,6	88:6	13:14	22:11 72:3
179:3,14	shipping	111:21,23	122:3
182:2,5	50:20	112:9,11,13	singles
shareholders		162:18	94:22
85:11,13	shoddy	signage	
116:19	105:4	60:5,6	sit
117:21	shop	I -	61:4
120:23	39:12	155:20	situation
shares	101:10,11	175:21	83:3 176:5
	153:4	176:8,19	size
156:21,24	shops	177:9,10,11	31:7 33:6
157:23	23:22 24:2,	signed	41:13 78:5
166:25 167:4	7,10 30:2,	7:19 13:11,	85:7 100:22
178:22 182:3	11,14 39:9,	22 15:17	179:8
Shark		46:17 111:24	
24:9,21	17,22 61:17	significance	skim
26:22,24	131:15,17	15:4 28:22	81:11 89:3,
27:4,6,13,19	132:12,22		5,14
131:13	151:6,9,10,	97:23 98:17	skipped
132:25	24 152:3,5,	significant	135:3
152:12	9,17,19,24	26:25 27:25	skis
153:10	153:6,15	29:24 30:4	170:11
	short	33:21,24	SKU
Shark's	146:6	97:19 98:4,	158:21
24:11 26:25	shortage	5,13,25	
27:23	27:18 49:12	101:17	SKUS
sharp		103:20,21	28:10 61:15,
43:14	shortly	131:17,18	17 101:10,12
shelf	150:10	132:15,16	157:24
105:8,15	152:11	137:5 172:11	158:2,3,9,
106:8,21	show	181:5	10,11,15
119:6 121:6,	12:9 128:24		159:14,16
13 122:4,11,	137:14	significantly	160:19,21
18 128:9,15	140:21	29:17 46:24,	180:16
II	145:17	25 51:15	slide
134:23 155:9	showed	55:9 92:24	89:5 90:17,
166:3 168:21	43:11 61:14	94:3,5	_
182:21		167:15 179:8	20 127:4,9
shell	shows	signs	slides
179:2	91:9 92:4,13	111:19	88:24 89:10
	128:8 129:25	112:12	123:10
	I	I	I



slight	snuff	156:10 157:4	122:4,11,18
161:3	18:11 60:3	162:17,21	128:9 130:2
slightly	64:19,20,23	164:4,25	134:24
154:11	65:2,10 73:4	165:10 175:8	155:9,10
slip	113:12 121:9	178:3 179:7	161:18 166:3
7:13 41:20	155:5	181:12	177:8
slots	156:17,23,25	sorts	180:10,11,
180:14	162:17 173:9	78:15	12,15,18,20
slower	179:12	sounds	182:4,19,25
	social	51:18 52:2	183:3,15
116:14 166:4	139:11	63:4,7 64:12	spaces
slowly	society	68:8 70:5	173:20
61:11	41:25	96:16	speak
small	soft	117:12,17	7:10 10:4
13:21 15:12		-	31:11 32:3
33:17 35:15	78:20 79:5,9	source 67:18	34:23 39:8
41:13 53:21	softer		45:4,20 48:2
54:6 55:7	65:11	South	54:17 70:14,
75:14,22,24	sold	32:13 143:5	17 86:15
101:15	20:9 21:7	Sowlati	87:20 91:20
125:15,20	28:6,9,15,20	5:24 6:15	92:22,23
152:12 172:4	30:10,14	25:22 27:9	105:2 106:5,
176:23	47:6 48:5,	48:14 51:23	16 107:8,9,
181:16	10,12 49:3	52:4,7 73:6	15 117:24
smaller	94:21 95:9	81:5,15	122:8,24
23:6 41:19	109:12,13,22	88:18 96:13,	-
42:15 55:9,	110:2 124:14	17,21,24	131:11 132:24 133:8
11 99:18	126:9 135:15	120:17 122:7	
smoke	136:5,19	136:7 141:19	156:16
32:13 33:17	137:10 148:6	145:22	speaking
42:4 43:12	150:7 152:19	149:15	54:22 68:16
60:25 61:4	157:2,3	153:16 155:3	85:22 119:18
82:17 143:5	166:24 169:6	168:10 169:8	120:12
smokeless	173:9 180:4	170:5 173:15	154:4,20
18:4 160:18	solution	sp	specific
161:14	170:8	178:5	7:10 26:6
175:24	solve	space	112:24
smoker	87:9	57:4,16	123:21 135:7
42:3 82:8,11	solved	58:3,9	153:7
smokers	87:8	105:8,16	155:12,13
31:12 32:19	someone's	106:9,21	156:21
	50:18	108:7 109:2,	specifically
38:23,25	someplace	10,21 111:14	34:14 85:10
45:17,20 82:14 164:10	63:18	112:12	173:6
		114:3,6,8	specification
smoking	sort	115:20	s
18:5 31:22	55:18 66:5	118:23 119:6	20:3 21:21
smoother	76:4,5	120:24	62:24
67:20	145:13	121:6,13,19	
	<u> </u>	1	1

specifics	90:25	statements	156:6 157:4
83:6 156:2	114:15,25	165:5	159:23
specify	123:8,23	stating	160:7,9,11,
16:8,9 57:24	124:21 125:9	5:15 149:19	14 162:9
specifying	126:19	statistical	166:17
64:4 68:14	127:2,20	161:4 162:11	173:25
speculate	129:11 142:3	status	175:13,14
29:7 87:19	143:14	138:6	176:10
speculating	stamps	stay	177:3,4
87:17	53:17	80:4 138:8,	178:9,10
	standard	16,21	183:6
Speedway	148:11	-	stores
86:14,22	start	stays	25:7,8,15,
115:25	15:19 82:2	171:10	17,24 26:16
116:17,21	85:18 102:14	step	27:2 28:4
124:11,14,	start-up	22:4 99:24	30:4,10
16,18 135:6,	17:7	116:2 173:21	55:16 56:4,
12		stepped	6,11 88:2
spell	start-ups	87:7	102:14 114:3
6:2	17:4,5	stick	115:14,22,24
spend	started	76:8 79:13	118:7 121:18
102:15	8:4 16:6	stigma	127:6 131:9,
143:15	18:18 33:9,	31:9 32:6	12,18 132:5,
149:23 152:5	19,20 54:3	stipulation	16,17 133:5
153:18 168:8	61:7,8	5:18	137:12,15
spending	109:20	stock	150:16,19,
116:16	118:11	127:15	24,25 151:2
spends	133:11,18	181:17,18	153:19,21
168:16	134:3 148:16	Stoker's	154:3,9,13
spent	163:16 165:8	73:2 121:7	155:6 156:14
39:22 64:17	starting	127:6 158:22	158:20
65:3,22	17:8 62:3,4,	173:9	159:2,3
86:12 139:25	7 86:10	stood	161:23
140:4,7,8	118:11 163:4	118:21	162:10,12
spike	starts		163:4 166:2,
43:19,21	43:15 53:25	stop 23:10 28:24	18 173:20
spoke	76:10 77:18,	110:15	174:8
14:3 45:3	20 80:2	110:13	175:10,23
staff	81:25 85:25	120:11	177:9
172:23 173:2	115:4	158:23 165:3	178:12,14,16
stamp	state		179:22,24
73:23	6:2 81:6	stopped 27:18 163:19	180:22
	123:6 175:6		story
stamped 52:18 53:16	stated	stops	65:24
56:12 73:12	58:18	158:10	straight
75:12 79:14	statement	store	139:22
80:25 81:23	37:22 64:5	88:5 115:15	179:17
85:24 88:19	118:15 122:3	124:19,25	
03.74 00.13		125:6 155:24	

straighten 175:22	subscriptions	75:14,22,24 79:3 108:4	Synapse
176:18	subsection	supplier	synthetic
streams	171:16	168:12,21	141:5 169:23
60:22	subsegment	supplier's	170:3,9
street	66:13 71:16	168:24	171:9,14
39:12 178:2	84:10	suppliers	system
strength	subsegments	168:20	18:23,25
40:23,24	37:21	supply	20:4,7,8,14,
72:16	subset	23:21 24:10	16 21:24
strengths	22:2 66:19	27:17 49:15,	22:5,8,14,16
33:14 100:7	subsidiary	19 50:15	23:6 24:24
144:14,20	113:5	152:15	25:2,8
145:3,9,11	subsidizing	supplying	26:17,19
strike	110:7	150:14	42:16,17
19:16 31:14	substances	sure	43:17 45:8
47:18 71:21	47:19	6:5 36:21	47:3 50:17
111:6 125:3,	success	89:8 90:11	56:24 60:17
4	34:10,18,20	96:20 98:23	75:18 76:22 77:7 87:2
strong	36:15 37:2	122:16 131:8	91:6 93:11
128:24	38:2 40:4,17	142:17	100:14,15,25
struggle	44:7,14 46:4	173:19 177:7	100:14,15,25
179:19 180:8	57:6 58:14	surprise	102:7,18,22,
Stuart	104:11,13,21	28:15	25 103:5,9
6:6,7	131:17,18 -	surprising	135:19 141:6
studies	132:11,15,16	96:8	142:13
43:10 44:12	137:6 165:25	survey	143:2,4
64:16 65:21	successful	139:12	151:12
66:9 104:3	24:14 37:14,	surveys	153:10,11
154:4	15 105:7,15,	164:15	175:9
study	20 132:22,23	Swedish	systems
104:8	166:12	157:15	21:4,6,7,10,
stuff	183:18	Swisher	19 22:2,7,
170:17	successfully	157:15	20,21 28:3,5
subjects	12:23 180:5	switch	29:10,11,15
14:22	sudden	31:13,21,22	30:3,5,9
submit	60:19 163:18	32:2 45:18	33:9,10,18,
138:22	sued	97:20 98:13	20 34:6
140:14,20	7:7	100:13,15	36:3,4 37:12
141:12	suggest	101:19	38:16 41:14
submitted	13:3	102:18 104:5	42:13,14 46:23 47:6
7:24 141:16	suing	switching	49:6,7 51:2,
142:7,23	7:12	33:20 99:2	15 57:10,17,
143:13	summer	103:17	18 58:9
subpoena 8:6	16:5	sworn	60:13,18
0.0	superior	5:21	61:8 77:8
	63:13,23		

91:18 97:21	talk	175:19	tense
98:14 99:3,	23:15 39:4,	tastes	25:11
10,15,16	14 40:19	72:6	term
100:2,4,8,	41:24 55:4	taxes	22:7 88:7
11,18 101:8	63:6 69:8	175:5	terminate
102:15,20,21	107:17	team	25:25
103:8,12	169:17	63:8	terminated
104:5 130:21	171:18 173:5	technical	23:13
145:8 151:20	174:23	9:11 69:15,	terminating
153:23	175:13	16	25:16
164:4,7,8,9,	177:12		terminology
12,17,19	179:25	technological 52:11	24:20 30:21
Szymanczyk	talked		144:12
16:18	21:18 45:21	technology	
	46:9 83:24	57:2 67:14	terms
	99:12 145:7	69:2,23,24	69:8 70:2
T	151:17	74:9,17 78:9	99:2 118:19
take	163:5,17	86:6 171:13	131:14
10:15 11:7,	165:20	tell	139:11 171:3
15,18 13:12	talking	8:25 14:3,8	terribly
22:3 25:19	19:20,22	45:6 58:11	142:20
36:6 49:6,22	38:25 48:17	64:13 67:22,	test
50:10 51:2,	58:8 69:21	23 75:15	11:14 12:21
24 73:7	86:15 98:16,	85:13 95:12	tested
88:13 96:14	17 99:16	116:19	181:4
100:19	117:24,25	134:19	testified
115:25	118:12,19	147:18 171:4	5:22 8:15
123:3,14	134:12	telling	62:23 132:4
135:8,20	147:19	65:24 80:11	147:5
141:18,24	157:10	110:23	testify
148:10	talks	117:20	74:3
157:19 160:5	45:5 87:15	tells	testifying
173:21	107:14	132:21 171:7	9:25 10:2
183:8,23	176:10,11	temperatures	testimony
•	tank	100:10	5:10 7:3
33:21,24	20:5 97:21	ten	8:14,18,22,
47:2 52:6	98:14 99:2	157:10,11,	23 9:2 11:24
96:23 146:12	104:5	13,16 159:16	testing
150:17	tanks	160:10,11	144:14,20
183:24	100:6 101:2,	180:14	145:5,10
takes	3	ten-minute	161:2
26:5 28:11	target	51:25 96:15	tests
94:23	82:16	tend	139:8
	targets	30:2,4 43:23	Texas
taking	80:13,20	50:22 102:8	127:25
10:7 42:20 47:7 116:2		103:14 105:4	text
119:20 160:9	taste	125:20	12:4
176:7	40:11 73:3	162:15	14.4
1/0./	85:6 161:6		

	_		
texture	179:25	third	91:21 102:15
76:4,6	think	6:19 18:9	107:7 109:8
thank	21:5 24:20	26:23 53:20,	111:10
6:13,17	27:7,22	24 56:15	123:19,20
27:10 99:8	28:19,25	115:6 117:5	124:11 126:8
112:14	30:12 31:25	142:3	128:4 131:2
120:16	32:15,18	third-party	133:22
139:15	33:8 34:4,	21:18 23:25	138:21
145:22	11,19 35:10	27:14 48:11,	143:16
147:10,21	41:17 44:11	15,17,19	145:23 147:3
148:18 149:8	46:2,8 47:15	49:3,6	148:13
150:18	49:25 51:9,	thought	149:23 150:6
151:21	13 55:21,23	13:5 40:25	152:5 153:19
152:6,20	61:6,14 62:3	63:18 65:6	156:3,19
153:12	64:3 66:21	66:25 75:25	161:20
154:10	67:2,7,16,	84:15 85:12	162:25 163:2
166:7,21	17,25 68:13,	94:23 98:15	171:11 174:4
167:17 168:6	15,20 69:20	111:4 121:23	175:8 176:2
169:16	72:18 73:2	132:3 144:9	178:23
171:20 173:3	80:17 84:13,	thousand	times
183:20	19,20 93:8	158:20	10:5 26:6
Thanks	96:13 105:20	thousands	41:24 83:19
9:7	106:16,24	178:11	138:25
the-second-	107:11	three	156:14
to-last	108:11 109:3	18:4,7 40:25	166:12,14
142:17	112:15	109:12	176:4,16
thin	116:11 122:9	112:12	182:3,6
178:8	125:11,18	157:14	tinkering
thing	127:25 134:7	158:2,11,14	65:4
24:18,20	135:21,25	182:2	title
28:21 33:18	138:19	thresholds	6:11
40:13 41:23	139:8,16	98:9 134:11	tobacco
45:23 73:14	146:3,5	tie	9:6 13:18
109:15	148:16,17	108:17	18:4 39:20
111:20	149:6 158:10	tiers	59:19,24
132:24	161:16,21		65:9 106:17
139:13 160:8	163:5 164:8	109:23,25	133:15,16
173:24	167:8	time	137:3,17,23,
178:17	169:11,14	10:23 11:14	24 138:15
180:23	170:2 172:8,	26:9,10	142:8 148:10
things	17 174:5	27:22 28:11,	151:4,5
39:4 40:21	177:12,17	20,23 29:21,	154:25 155:4
61:10 70:16	179:14	22 43:15,20,	169:21
73:19 84:15	183:13	24 57:15	170:7,21,22
85:4,9 87:6	thinking	58:16 59:22 61:20 64:3,	173:13
100:5 145:16	21:25 46:19		174:18 175:2
176:17	57:13 58:16	17 65:13 70:10 76:25	tobacco-based
177:15	107:3	78:8 80:19	141:3,4
		70.0 00.13	
	<u> </u>		

tobacco-	tougher	trouble	114:24
derived	62:8	121:12,16,17	120:17
170:6 171:2,	TPB	troubles	123:22
8	117:6 142:6	118:23 121:5	124:21 125:8
			127:19
today	track	true	128:20
6:18,21 7:2	178:3	58:5 95:4	
9:14,25 10:5	tracks	116:10	143:24
11:24 12:11	158:19	trust	turning
25:12 51:10	traction	76:15	6:10 7:20
57:12 147:23	118:13	truthful	8:6,9,19 9:4
149:10	122:19	11:23 54:16,	17:24 18:3,6
152:21 166:6		1	20:14,23
167:5	163:17	20 76:16	25:6 42:21
	trade	try	48:5,9,10
Today's	7:4 117:9	6:21 9:10	
11:13	118:3,5,8	10:4,10,21	52:17,24
told	147:12	50:4,8,10,11	53:7,12
14:6 29:2	174:17,21	54:20 93:23	62:24 75:8
62:17 84:8,	179:5	99:13 121:3	76:13 81:7
10 85:10	trademark	154:16	97:8 104:2
107:19 140:5	167:22	157:20	114:4,7,17
171:12		168:15	115:2,18,20
ton	trading	175:10,22	125:14
86:19 100:19	155:12,15,18	-	136:16
	traditional	trying	141:21 142:5
tools	53:22 54:7	59:15 68:2,3	144:13,19
181:16	training	78:2 96:9	147:24
top	88:21 89:19,	98:19 106:17	148:20
15:19 56:16	25 90:14	120:7,10	149:12
63:21 74:17	97:5,7	132:9 134:12	151:23
75:13 77:13,	transcript	136:12	152:7,22
17 91:7	25:20 52:22	142:15	=
102:5 124:6	1	173:22	153:5,15
142:4 155:21	53:8,10	182:25 183:3	157:15
157:24	54:18 63:21	tub	166:24
158:3,23	69:13 81:2,	183:14,17	167:19 169:2
159:15	8,19,22		171:21
162:18	88:10 97:7	tubes	173:7,11
	114:14,18	170:16	turnover
topic	122:2,11	turn	182:7,9
151:22	transcripts	17:21 23:17	Twenty
154:11	114:20	25:3 29:8	150:21
topics	transport	30:15 38:9	two
14:24	42:15	41:11 42:6	12:25 21:20
total	trial	53:16 56:12	
29:15 95:22,		73:11 75:5	41:17 46:13,
23	8:16 10:2	76:9 79:14	16 95:6,20
totally	trials	81:23 85:17,	113:21
65:8 100:2,	65:4	23 86:10	115:14 135:5
3,15 164:5	Tropical	90:2,25	136:10
3,13 104.3	126:21	106:3 113:25	156:24
		100.3 113.23	
	<u> </u>		<u> </u>

159:18	26:16	Vague	165:18,22
172:20	unique	30:7 34:13	171:25
179:18	66:2 77:9	36:18 39:18	172:3,7,9,
two-step	unit	57:22 61:25	14,15,20
93:11	20:11 22:11,	68:12 80:16	vaped
tying	12	82:25 84:18	163:14
93:21	universal	90:7 92:11,	vaper
type	37:21 159:3	21 93:7 94:7	39:2,11
17:5 150:19,	universe	98:7 117:13	41:25 42:2
25 164:13	178:20	118:25	47:23 48:2
176:24	unpack	vagueness	66:13
typeface	105:10	48:22	vapers
89:12		value	38:19,25
	unprofitable	77:23,25	39:8,9 63:5
types	116:16,22	78:3,11,16,	82:14
	unrealistic	18 79:2	vaping
typical	67:8	82:9,21	33:13 39:20
91:6	unusual	83:4,6 95:12	42:5 99:25
	96:4 121:4	160:18	163:9,24
υ	Upper	169:13	172:13
	129:23	vape	vapor
U.S.	135:16	14:12,13	20:8,12
115:12 142:7	uptake	19:14 20:11	23:20,21
ultimately	43:25 44:2	23:22,25	24:9,11,12,
163:23	USA	24:7,10	21 26:21,22,
unbelievable	16:17	30:2,11,14	24,25 27:4,
14:5	usage	32:20 35:10,	6,12,19,23
unclear	164:16	16,25 39:9,	33:8 37:11,
10:20	user	12,17,22	16,17 40:9,
uncompromised	51:11 99:11	45:22 47:24	10,17 40.5,
84:3,16	users	60:12 61:5,	42:21 43:12,
85:11	51:7,8,10	17 71:8 87:5	18 56:21
undercutting	103:13	101:10,11	57:4 60:16,
93:6	utilize	102:13	23 75:18
understand	47:11	103:13,14	82:18 102:8
7:2,6,11	I T T	131:9,12,15,	131:13
9:13,19,24		17 132:11,	132:25
11:9 65:23	V	16,22 133:17	142:11,24
87:22		134:2 138:12	152:2,10,11,
106:18,23	V2	139:9 151:6,	15 153:10
100:18,23	21:8 22:24,	9,10,24	variety
169:18	25 23:2,8,10	152:3,5,8,9,	31:25 33:15
173:7,22	59:12 62:9	17,19,24	100:11 101:7
•	147:24	153:4,6,15	145:8
understanding 9:22 101:14	148:3,5,20,	161:18,25	various
	22 149:2,12,	162:5 163:4,	134:17
Understood	14 151:8,15	13,14,21	134.17
10:19 11:6,	162:4,5	164:25	178:16
20 25:22	168:2		1,0.10
L			

vast	waive	65:7,15	34:1,25 35:1
82:13 100:4	5:13	70:11 74:2	36:1 37:1
vein	walk	76:2 78:22	38:1 39:1
181:24	99:21,23	79:8 86:8,21	40:1,19
veins	102:13 162:9	106:19	41:1,11 42:1
175:24	173:24,25	136:14	43:1 44:1,24
velocities	175:11	145:20	45:1 46:1,11
160:3	walked	183:5,12	47:1,10
velocity	15:8	ways	48:1,4,24
<u> </u>	walking	72:7	49:1 50:1
160:5,6	102:24	website	51:1 52:1,8,
Ventures	165:25	24:6 129:12,	16,18 53:1,
85:22	182:14	19 136:10	2,6 54:1,15
verbally		week	55:1,25 56:1
5:9 10:16	wall	129:13,20	57:1,9 58:1
versus	109:15	-	59:1 60:1
29:16 43:12	163:20	130:8 136:10	61:1 62:1,23
48:11 70:15	want	182:6	63:1 64:1
72:20,21	16:19,21	weeks	65:1 66:1
177:13 182:5	21:17 32:2,	158:24	67:1 68:1
Vesser	16 36:5	179:20	69:1 70:1
163:17	40:18 42:3	weight	71:1 72:1
view	48:7 51:24	55:7 116:12	73:1,8 74:1
44:6 141:11,	52:15 64:24	180:6	75:1,7 76:1,
13	69:16 74:6	weighted	11 77:1 78:1
visible	76:9 81:13	180:2	79:1 80:1,8,
155:10	82:17 83:17	went	21,25 81:1,
VMR	85:23	46:24 66:8	7,18 82:1
21:8,9	100:22,23,24	71:11 109:18	83:1 84:1
23:11,13	101:24	135:2 148:15	85:1 86:1
	105:10	168:19	87:1 88:1,9,
148:7 149:5,	110:14 111:6	181:14	19 89:1,17
22 150:4,7,	118:10 144:3	Wexler	90:1,2 91:1
10 168:2,4	175:17	5:25 6:1,6,	92:1 93:1
volume	182:15	8,15 7:1,23	94:1 95:1
46:24	wanted	8:1,3 9:1	96:1,25 97:1
Vuse	85:20 86:4	10:1 11:1,22	98:1 99:1
28:6,9 47:12	112:7 144:7,	12:1,6 13:1,	100:1 101:1
91:10,24	10 182:13	10 14:1	100:1 101:1
128:19	watched	15:1,20 16:1	19 104:1,9
	102:12	17:1,21	105:1 106:1,
W	watching	18:1,15 19:1	3,5 107:1
	64:25	20:1 21:1	108:1 109:1
W-E-X-L-E-R	way	22:1 23:1	110:1,15
6:8	6:25 11:22	24:1 25:1	111:1 112:1,
wait	21:25 22:7	26:1 27:1	14 113:1,16,
97:4 142:15	33:12 38:20,	28:1 29:1	25 114:1,15,
144:16	24 39:5 45:5	30:1,19 31:1	16,24 115:1,
111,10	60:16 64:10	32:1 33:1	18 116:1
	00.10 04.10	22.1 22.1	10 110.1

117:1 118:1	wholesaler	140:16,19	130:22			
119:1,16	23:22 24:10	141:7 143:9,	135:13,17			
120:1 121:1,	wholesalers	10 168:12	141:13			
25 122:1,3	118:6 174:18	worked	152:25 153:7			
123:1,8,16	175:3	7:12 16:10	year			
124:1,24	wider	17:4,7,13,	113:16,19			
125:1 126:1	182:15	17,19 106:10	128:22			
127:1,14		110:16,25	178:12,13			
128:1 129:1,	widespread	112:16,18	-			
4,11 130:1,	130:21 176:9	168:15	years			
10,12 131:1	wind		7:13 32:23,			
132:1,3	43:22	works	25 39:22,24			
133:1,9	Wintergreen	12:20 45:5	46:13,16			
134:1 135:1	158:22	49:16 70:19,	106:11,15			
136:1,8,23	wire	20 76:12	110:17,22			
137:1,16	109:7	171:19	111:2 112:23			
137:1,10	witness	worst	113:6,21			
140:1,16	5:9,20 21:16	162:24	121:10			
1	27:10 52:3	worst-case	137:6,11			
141:1,16,20	73:15 74:5	145:13	162:3 179:18			
142:1 143:1,	81:13,17	worth	180:5			
11,14,19	88:22 89:15	26:10 70:18	yellow			
144:1 145:1,	99:8 111:8	wraps	125:13			
22 146:1,4	119:22	178:25	yields			
147:1,8	120:5,8	write	85:11			
148:1,19	122:8 146:7	165:9	York			
149:1 150:1		write-off	129:22			
151:1 152:1	women 176:15	165:5	younger			
153:1 154:1			51:15			
155:1 156:1	wonderful	writing	youth			
157:1 158:1	67:7	107:6	164:16			
159:1 160:1	wondering	wrong	104.10			
161:1 162:1	143:3	109:6 163:2				
163:1 164:1	word		Z			
165:1 166:1	50:9 70:5	Y				
167:1 168:1	103:20		Zig-zag			
169:1 170:1	104:10,14	yeah	177:18,22			
171:1 172:1	words	13:8 15:13	178:22			
173:1 174:1	40:15 50:7	16:5 23:24	zip			
175:1 176:1	56:18 66:22	42:13 44:11,	129:22			
177:1 178:1	68:3 75:16	20 56:9 58:5	Zoom			
179:1 180:1	79:12 85:15,	62:2 64:14	11:10 12:19			
181:1 182:1	16 111:23	66:14,18	52:9 114:11			
183:1	117:2 122:22	74:10 78:19	143:14			
wholesale	work	80:17 81:13				
24:11,17	8:19 11:19	84:12 88:25				
26:7 28:17,	13:7 15:24	90:22 91:14,				
19 29:9	16:19 106:7	16 94:18				
30:12	139:12	117:23 126:2				
152:16,19	_ 	11, 20 120 2				